

2024

Formulario Integral (Lista de Medicamentos Cubiertos)

wellcare

TM

Wellcare No Premium (HMO) y

Wellcare TexanPlus Classic No Premium (HMO)

15



IMPORTANTE: ESTE DOCUMENTO CONTIENE INFORMACIÓN ACERCA DE LOS MEDICAMENTOS QUE TIENEN COBERTURA CON ESTE PLAN

Lista de Medicamentos Aprobados por HPMS, ID del Archivo Presentado 24183, Número de Versión 13

Esta lista de medicamentos se actualizó el 06/01/2024. Para obtener información más reciente o realizar otras preguntas, comuníquese con Servicios para Miembros de Wellcare al número de teléfono o mediante el sitio web de su plan que aparecen en la portada y la contraportada de este formulario. Entre el 1 de octubre y el 31 de marzo, los representantes están disponibles los siete días de la semana, de 8 a.m. a 8 p.m. Entre el 1 de abril y el 30 de septiembre, los representantes están disponibles de lunes a viernes, de 8 a.m. a 8 p.m.

NEVADA

HMO

1-800-977-7522 (TTY: 711)

[wellcare.com/allwellNV](https://www.wellcare.com/allwellNV)

TEXAS

HMO

1-833-444-9088 (TTY: 711)

[wellcare.com/medicare](https://www.wellcare.com/medicare)

Nota para los miembros actuales: Este formulario presenta cambios en relación con el del año pasado. Revise este documento para asegurarse de que aún contenga los medicamentos que usted toma.

Cuando en esta lista de medicamentos (formulario) se usan los términos “nosotros”, “nos” o “nuestro”, se hace referencia a Wellcare. Cuando se refiere al “plan” o a “nuestro plan”, significa Wellcare No Premium (HMO) y Wellcare TexanPlus Classic No Premium (HMO).

Este documento incluye una lista de los medicamentos para nuestro plan que se actualizó por última vez el 06/01/2024. Para obtener una lista de medicamentos más reciente, comuníquese con nosotros. Nuestra información de contacto, junto con la fecha de la última actualización de la lista de medicamentos, aparece en el interior de la portada y la contraportada.

Por lo general, usted debe usar farmacias de la red para poder usar sus beneficios de medicamentos recetados. Los beneficios, el formulario, la red de farmacias y/o los copagos/el coseguro pueden cambiar el 1 de enero del 2024 y, de vez en cuando, durante el año.

¿Qué es la Lista de Medicamentos de Wellcare No Premium (HMO) y Wellcare TexanPlus Classic No Premium (HMO)?

Una lista de medicamentos es una lista de los medicamentos cubiertos y seleccionados por nuestro plan en consulta con un equipo de proveedores de atención médica, que representa las terapias recetadas que se consideran una parte necesaria de un programa de tratamiento de calidad. Por lo general, nuestro plan cubre los medicamentos que figuran en nuestra lista de medicamentos, siempre y cuando el medicamento sea médicamente necesario, la receta se surta en una farmacia de la red del plan, y se cumplan otras reglas del plan. Para obtener más información sobre cómo surtir sus recetas, revise su Evidencia de cobertura.

¿El Formulario (lista de medicamentos) puede cambiar?

La mayoría de los cambios en la cobertura de medicamentos ocurren el 1 de enero, pero podemos agregar o eliminar medicamentos en la Lista de Medicamentos durante el año, cambiarlos a diferentes niveles de costos compartidos o agregar nuevas restricciones. Al hacer estos cambios debemos seguir las normas de Medicare.

Cambios que pueden afectarle este año: En los siguientes casos, usted se verá afectado por cambios en la cobertura durante el año:

- **Medicamentos genéricos nuevos.** Es posible que eliminemos de inmediato un medicamento de marca de nuestra Lista de Medicamentos si lo reemplazamos con un medicamento genérico nuevo, el cual aparecerá en el mismo nivel de distribución de costos o en un nivel inferior y con las mismas restricciones o menos. Además, al agregar el nuevo medicamento genérico, es posible que decidamos mantener el medicamento de marca en nuestra Lista de Medicamentos, pero moverlo inmediatamente a un nivel de distribución de costos diferente o agregar nuevas restricciones. Si actualmente toma ese medicamento de marca, puede que no le informemos con anticipación antes de hacer dicho cambio, pero le proporcionaremos información más adelante sobre los cambios específicos que realizamos.
 - Si realizamos un cambio de este tipo, usted o quien emite sus recetas médicas pueden solicitarnos hacer una excepción para que continuemos cubriendo el medicamento de marca para usted. El aviso que le proporcionamos también incluirá información sobre cómo solicitar una excepción. Asimismo, puede encontrar información en la siguiente sección titulada “¿Cómo solicito una excepción a la Lista de Medicamentos de Wellcare No Premium (HMO) y Wellcare TexanPlus Classic No Premium (HMO)?”

Medicamentos retirados del mercado. Si la Administración de Alimentos y Medicamentos considera que un medicamento incluido en nuestra lista de medicamentos es inseguro o si el fabricante del medicamento lo retira del mercado, eliminaremos inmediatamente el medicamento de nuestra lista de medicamentos e informaremos a los miembros que toman el medicamento.

- **Otros cambios.** Es posible que hagamos otros cambios que afecten a miembros que actualmente tomen un medicamento. Por ejemplo, podemos agregar un medicamento genérico que no es nuevo en el mercado para reemplazar un medicamento de marca que está incluido actualmente en la lista de medicamentos. También podemos agregar restricciones nuevas al medicamento de marca o pasarlo a otro nivel de distribución de costos, o hacer ambas cosas. También podemos hacer cambios con base en las nuevas pautas clínicas. Si eliminamos medicamentos de nuestra lista de medicamentos, o agregamos con autorización previa, límites de cantidad y/o restricciones de terapia escalonada a un medicamento o movemos un medicamento a un nivel de distribución de costos mayor, debemos notificar el cambio a los miembros afectados, al menos, 30 días antes de que el cambio entre en vigencia, o en el momento en que el miembro solicite una nueva recarga del medicamento, en cuya ocasión el miembro recibirá un suministro de 30 días del medicamento.
 - Si realizamos un cambio de ese tipo, usted o quien emite sus recetas pueden solicitar que hagamos una excepción para que continuemos cubriendo el medicamento de marca para usted. El aviso que le proporcionamos también incluirá información sobre cómo solicitar una excepción. Asimismo, puede encontrar información en la siguiente sección titulada “¿Cómo solicito una excepción a la Lista de Medicamentos de Wellcare No Premium (HMO) y Wellcare TexanPlus Classic No Premium (HMO)?”

Cambios que no le afectarán si actualmente está tomando el medicamento. En general, si usted está tomando un medicamento de nuestra lista de medicamentos para 2024 que estaba cubierto a principio del año, no suspenderemos ni reduciremos su cobertura durante el año de cobertura 2024, excepto los casos descritos anteriormente. Esto significa que estos medicamentos seguirán estando disponibles con la misma distribución de costos y sin nuevas restricciones para los miembros que los tomen durante el resto del año de cobertura. Este año no recibirá un aviso directo sobre los cambios que no le afectan. Sin embargo, el 1 de enero del próximo año, dichos cambios podrían afectarlo y es importante revisar la Lista de medicamentos del nuevo año de beneficio para ver si hay algún cambio con respecto a los medicamentos.

La lista de medicamentos adjunta está actualizada al 06/01/2024. Si desea obtener información actualizada sobre los medicamentos cubiertos por nuestro plan, comuníquese con nosotros. Nuestra información de contacto aparece en el interior de la portada y la contraportada.

La lista de medicamentos se actualizará mensualmente y se publicará en nuestro sitio web. Para obtener una versión impresa de la lista de medicamentos actualizada o para obtener información sobre los medicamentos cubiertos en nuestro plan, visite nuestro sitio web o llame a Servicios para Miembros a nuestro número de contacto que aparece en el interior de la portada y la contraportada.

¿Cómo se utiliza la Lista de Medicamentos?

Existen dos formas de buscar los medicamentos en la lista de medicamentos:

Afección Médica

La lista de medicamentos empieza en la página 1. Los medicamentos en esta lista de medicamentos se agrupan en categorías según el tipo de condición médica a tratar. Por ejemplo, los medicamentos que se utilizan para tratar afecciones cardíacas se encuentran en la categoría “Cardiovascular, Hipertensión/ Lípidos”. Si conoce el uso de su medicamento, busque el nombre de la categoría en la lista que empieza en la página 1. Luego, busque su medicamento bajo el nombre de esa categoría.

Listado por Orden Alfabético

Si no está seguro en qué categoría buscar, debe buscar su medicamento en el Índice que comienza en la página INDEX-1. El Índice proporciona una lista en orden alfabético de todos los medicamentos que se incluyen en este documento. Los medicamentos de marca y los medicamentos genéricos están enumerados en el índice. Busque en el Índice y encuentre su medicamento. Al lado de su medicamento, verá el número de página en donde puede encontrar información sobre la cobertura. Diríjase a la página indicada en el índice y busque el nombre de su medicamento en la primera columna de la lista.

¿Qué son los medicamentos genéricos?

Nuestro plan cubre tanto medicamentos de marca como medicamentos genéricos. Un medicamento genérico es aprobado por la FDA por contener el mismo ingrediente activo que el medicamento de marca. Generalmente, los medicamentos genéricos cuestan menos que los medicamentos de marca.

¿Hay alguna restricción en mi cobertura?

Algunos medicamentos cubiertos pueden tener requisitos adicionales o límites dentro de la cobertura. Estos requisitos y límites pueden incluir:

- **Autorización Previa:** Nuestro plan requiere que usted o su médico obtengan una autorización previa para ciertos medicamentos. Esto significa que deberá obtener la aprobación de nuestro plan antes de surtir sus recetas. Si no obtiene aprobación, es posible que nuestro plan no cubra el medicamento.
- **Límites de Cantidad:** En el caso de ciertos medicamentos, nuestro plan limita la cantidad del medicamento que será cubierto. Por ejemplo, nuestro plan proporciona 18 tabletas por receta para rizatriptán de 5 mg. Esto además del suministro regular mensual o trimestral.
- **Terapia Escalonada:** En algunos casos, nuestro plan requiere que primero pruebe ciertos medicamentos para tratar su afección médica antes de que cubramos otro medicamento para esa afección. Por ejemplo, si tanto el medicamento A como el medicamento B se utilizan para tratar su afección médica, es posible que nuestro plan no cubra el medicamento B si usted no prueba primero el medicamento A. Si el medicamento A no funciona en su caso, entonces nuestro plan cubrirá el medicamento B.

Para enterarse si su medicamento tiene algún requisito o límite adicional, debe buscar en la lista de medicamentos que comienza en la página 1. También puede obtener más información acerca de las restricciones aplicadas a los medicamentos específicos cubiertos visitando nuestro sitio web. Hemos publicado documentos en línea en los que se explica nuestra autorización previa y las restricciones de la terapia escalonada. También puede pedirnos que le enviemos una copia. Nuestra información de contacto, junto con la fecha de la última actualización de la lista de medicamentos, aparece en el interior de la portada y la contraportada.

Puede solicitar que nuestro plan haga una excepción a estas restricciones o límites, o solicitar una lista de otros medicamentos similares que pueden utilizarse para tratar su afección médica. Consulte la sección “¿Cómo solicito una excepción a la Lista de Medicamentos de Wellcare No Premium (HMO) y Wellcare TexanPlus Classic No Premium (HMO)?” en la página V para obtener información sobre cómo solicitar una excepción.

¿Qué sucede si mi medicamento no está en la Lista de Medicamentos?

Si su medicamento no está incluido en este formulario (lista de medicamentos cubiertos), primero deberá comunicarse con Servicios para Miembros y preguntar por la cobertura de su medicamento.

Si le informan que nuestro plan no cubre su medicamento, tiene dos opciones:

- Puede solicitar a Servicios para Miembros una lista de medicamentos similares que estén cubiertos por nuestro plan. Cuando reciba la lista, muéstresela a su médico y pídale que le recete un medicamento similar que esté cubierto en nuestro plan.
- Puede solicitar que nuestro plan haga una excepción y cubra su medicamento. Véase más adelante para obtener más información sobre la solicitud de excepciones.

¿Cómo solicito una excepción a la Lista de Medicamentos de Wellcare No Premium (HMO) y Wellcare TexanPlus Classic No Premium (HMO)?

Puede solicitar que nuestro plan haga una excepción a sus normas de cobertura. Hay varios tipos de excepciones que puede solicitarnos.

- Puede solicitarnos que cubramos un medicamento incluso si no se incluye en nuestra lista de medicamentos. Si se aprueba, recibirá cobertura para este medicamento en un nivel de distribución de costos predeterminado, y no podrá solicitarnos que le proporcionemos el medicamento en un nivel de distribución de costos menor.
- Puede solicitar que cubramos un medicamento de la lista con un nivel de distribución de costos menor, a menos que el medicamento esté en el nivel de especialidad. Si es aprobado, esto reducirá el monto que usted debe pagar por su medicamento.
- Puede solicitar la exoneración de las restricciones de cobertura o de los límites de su fármaco. Por ejemplo, para ciertos medicamentos, nuestro plan limita la cantidad de medicamento que cubriremos. Si su medicamento tiene un límite de cantidad, puede solicitarnos que no apliquemos ese límite y que cubramos una cantidad mayor.

Por lo general, nuestro plan aprobará su solicitud de excepción únicamente si los medicamentos alternativos que se incluyen en la lista de medicamentos del plan, el medicamento con una distribución de costos menor o las restricciones de uso adicionales no serían tan eficaces para tratar su afección y/o causarían que usted tuviera efectos médicos adversos.

Debe comunicarse con nosotros para solicitarnos una excepción a la decisión de cobertura inicial sobre la lista de medicamentos, los niveles o las restricciones de uso. **Cuando solicite una excepción a la lista de medicamentos, nivel o restricción de utilización, debe enviar una declaración del profesional que extiende la receta o del médico para respaldar su solicitud.** Por lo general, debemos tomar nuestra decisión en un plazo de 72 horas desde que recibimos la declaración de apoyo de quien emite sus recetas. Puede solicitar una excepción acelerada (rápida) si usted o su médico consideran que podría haber daños graves a su salud si esperan hasta 72 horas por una decisión. Si se acepta su solicitud para acelerar el proceso, debemos darle una respuesta en menos de 24 horas después de haber recibido la declaración de apoyo de su médico o de quien emite sus recetas.

¿Qué debo hacer antes de poder hablar con mi médico sobre un cambio en mis medicamentos o la solicitud de una excepción?

Como miembro nuevo o permanente de nuestro plan es posible que tome medicamentos que no estén en nuestra lista de medicamentos. O también puede que esté tomando un medicamento que está en nuestra lista de medicamentos, pero su capacidad para obtenerlo es limitada. Por ejemplo, puede que necesite nuestra autorización previa para poder surtir sus recetas. Debe hablar con su médico para decidir si debe cambiar a un medicamento adecuado que esté dentro de nuestra cobertura o si debe solicitar una excepción a nuestra lista de medicamentos para que cubramos el medicamento que usted toma. Mientras consulta con su médico para determinar cuál es la decisión correcta para usted, es posible que, en ciertos casos, incluyamos el medicamento en su cobertura durante los primeros 90 días de su membresía en el plan.

Para cada uno de sus medicamentos que no esté en nuestra lista de medicamentos, o si su capacidad para obtener sus medicamentos es limitada, cubriremos un suministro temporal de 30 días. Si su receta es para menos días, permitiremos recargas para proporcionar, como máximo, un suministro de 30 días del medicamento. Después de su primer suministro de 30 días, no pagaremos por estos medicamentos, incluso si es miembro del plan hace menos de 90 días.

Si reside en un centro de cuidados a largo plazo y necesita un medicamento que no está en nuestra lista de medicamentos o si su capacidad para obtener sus medicamentos es limitada, pero ya pasaron más de 90 días desde que inició su membresía en nuestro plan, cubriremos un suministro de emergencia de 31 días de ese medicamento mientras usted solicita una excepción a la lista de medicamentos.

Si experimenta un cambio en el nivel de atención (como que le den el alta o lo internen en un centro de cuidados a largo plazo), su médico o su farmacia pueden llamar a nuestro Centro de servicios para proveedores y solicitar una anulación única. Esta anulación única será para un suministro de 30 días como máximo (a menos que tenga una receta por menos días).

Para obtener más información

Para obtener información más detallada sobre su cobertura de medicamentos recetados del plan, revise su Evidencia de cobertura y demás materiales del plan.

Si tiene alguna pregunta sobre nuestro plan, comuníquese con nosotros. Nuestra información de contacto, junto con la fecha de la última actualización de la lista de medicamentos, aparece en el interior de la portada y la contraportada.

Si tiene preguntas generales sobre la cobertura de medicamentos con receta de Medicare, llame a Medicare al 1-800-MEDICARE (**1-800-633-4227**) las 24 horas del día, los 7 días de la semana. Los usuarios de TTY deben llamar al **1-877-486-2048**. También puede visitar <http://www.medicare.gov>.

La Lista de Medicamentos de nuestro plan

La lista de medicamentos, que se muestra a continuación, proporciona información sobre la cobertura de los medicamentos cubiertos en nuestro plan. Si tiene problemas para encontrar su medicamento en la lista, vaya al índice que comienza en la página INDEX-1.

La primera columna de la tabla enumera los nombres de los medicamentos. Los medicamentos de marca están en **mayúscula** (p. ej., **ELIQUIS**) y los medicamentos genéricos están en minúscula cursiva (p. ej., *simvastatin*).

La información en la columna de Requisitos/Límites le indica si hay algún requisito especial para la cobertura de su medicamento en nuestro plan.

- **GC** significa Intervalo Sin Cobertura: proporcionamos cobertura adicional de este medicamento recetado en el intervalo sin cobertura. Para obtener más información sobre esta cobertura, consulte su Evidencia de Cobertura.
- **NT** significa No Cubierto por la Part D: este medicamento recetado normalmente no está cubierto en un plan Medicare Prescription Drug Plan. El monto que paga cuando surte una receta para este medicamento no cuenta hacia sus costos totales de medicamentos (es decir, el monto que paga no lo ayuda a calificar para obtener cobertura ante catástrofes). Además, si recibe Ayuda Adicional para pagar sus recetas, no recibirá ninguna Ayuda Adicional para pagar por este medicamento.
- **NM** significa que el medicamento no está disponible a través de su beneficio mensual de servicio por correo. Esto se indica en la columna Requisitos/Límites de su formulario. Puede recibir un suministro de más de un mes para la mayoría de los medicamentos de su lista de medicamentos a través del servicio por correo con una distribución de costos reducida. Consulte el Capítulo 5 de su Evidencia de Cobertura para obtener más información.
- **PA** significa Autorización Previa: consulte la página IV para obtener más información.
- **PA-NS** significa Autorización Previa para Comenzar a Utilizar un Nuevo Medicamento: Esto significa que si este medicamento es nuevo para usted, deberá obtener nuestra aprobación antes de surtir su receta. Si está tomando este medicamento en el momento de la inscripción, no se le pedirá cumplir con los criterios de aprobación.
- **B/D** significa Cubierto por la Part B o la Part D de Medicare: Puede que este medicamento cumpla con los requisitos para la cobertura de las Part B o Part D de Medicare: Usted (o su médico) debe obtener nuestra autorización previa para determinar si este medicamento está cubierto por la Parte D de Medicare antes de surtir su receta de este medicamento. Sin aprobación previa, es posible que no cubramos este medicamento.
- **QL** significa Límites de Cantidad: Consulte la página IV para obtener más información.

- **LA** significa medicamento de Acceso Limitado. Esta receta puede estar disponible solamente en determinadas farmacias. Para obtener más información, consulte el Directorio de Farmacias o llame a Servicios para Miembros al número de teléfono o mediante el sitio web de su plan que aparecen en la portada y la contraportada de este formulario. Entre el 1 de octubre y el 31 de marzo, los representantes están disponibles los siete días de la semana, de 8 a.m. a 8 p.m. Entre el 1 de abril y el 30 de septiembre, los representantes están disponibles de lunes a viernes, de 8 a.m. a 8 p.m.
- **ST** significa Terapia Escalonada: Consulte la página IV para obtener más información.
- **^** significa que el Medicamento puede estar disponible solo para un suministro de hasta 30 días.

Montos de copago/coseguro correspondientes al nivel del medicamento

Los medicamentos recetados están agrupados en uno de seis niveles. Para saber en qué nivel se encuentra su medicamento, busque en la columna de Nivel del Medicamento de la lista de medicamentos que empieza en la página 1. Para obtener información más detallada sobre sus gastos de bolsillo para las recetas, incluidos los deducibles que se pueden aplicar, consulte su Evidencia de Cobertura y otros materiales del plan.

- **Nivel 1 (Medicamentos Genéricos Preferidos)**: incluye los medicamentos genéricos preferidos y puede incluir algunos medicamentos de marca.

- Copago **Preferido**: \$0
- Copago **Estándar**: \$5

- **Nivel 2 (Medicamentos Genéricos)**: incluye medicamentos genéricos y puede incluir algunos medicamentos de marca.

- Copago **Preferido**: \$0
- Copago **Estándar**: \$10

- **Nivel 3 (Medicamentos de Marca Preferidos)**: incluye medicamentos de marca preferidos y puede incluir algunos medicamentos genéricos.

Usted no deberá pagar más de \$35 por un suministro de un mes de cada producto de insulina cubierto en este nivel. Si la distribución de costos del nivel es inferior a \$35, usted pagará el costo más bajo por el producto de insulina.

- Copago **Preferido**: \$42
- Copago **Estándar**: \$47

- **Nivel 4 (Medicamentos No Preferidos)**: incluye medicamentos de marca no preferidos y medicamentos genéricos no preferidos.

Usted no deberá pagar más de \$35 por un suministro de un mes de cada producto de insulina cubierto en este nivel. Si la distribución de costos del nivel es inferior a \$35, usted pagará el costo más bajo por el producto de insulina.

- Rango de Coseguro **Preferido**: del 48% al 49%
- Rango de Coseguro **Estándar**: del 48% al 49%

- **Nivel 5 (Nivel de Especialidad)** incluye medicamentos genéricos y de marca de alto costo. Los medicamentos de este nivel no son elegibles para excepciones de pago en un nivel inferior.

Usted no deberá pagar más de \$35 por un suministro de un mes de cada producto de insulina cubierto en este nivel. Si la distribución de costos del nivel es inferior a \$35, usted pagará el costo más bajo por el producto de insulina.

- Coseguro **Preferido**: 33%
- Coseguro **Estándar**: 33%

- **Nivel 6 (Medicamentos de Cuidado Seleccionados)** incluye algunos medicamentos genéricos y de marca que se utilizan con frecuencia para tratar afecciones crónicas específicas o para prevenir enfermedades (vacunas).

- Copago **Preferido**: \$0
- Copago **Estándar**: \$0

Consulte la Evidencia de Cobertura o el Resumen de Beneficios para ver sus copagos/coseguros y sus montos aplicables.

Table of Contents

| | |
|--|----|
| AGENTES DE DIAGNÓSTICO/VARIOS..... | 3 |
| ANTIINFECCIOSOS..... | 5 |
| CARDIOVASCULAR, HIPERTENSIÓN/LÍPIDOS..... | 17 |
| ENFERMEDADES RESPIRATORIAS Y ALERGIA..... | 26 |
| GASTROENTEROLOGÍA..... | 30 |
| INMUNOLOGÍA, VACUNAS/BIOTECNOLOGÍA..... | 34 |
| MEDICAMENTOS ANTINEOPLÁSICOS/INMUNOSUPRESORES..... | 38 |
| MEDICAMENTOS AUTONÓMICOS/PARA EL SISTEMA NERVIOSO CENTRAL, NEUROLOGÍA/PSIQUIATRÍA..... | 48 |
| MEDICAMENTOS PARA EL OÍDO, LA NARIZ/LA GARGANTA..... | 65 |
| MEDICAMENTOS UROLÓGICOS..... | 66 |
| MUSCULOESQUELÉTICO/REUMATOLOGÍA..... | 67 |
| OBSTETRICIA/GINECOLOGÍA..... | 69 |
| OFTALMOLOGÍA..... | 75 |
| SISTEMA ENDOCRINO/DIABETES..... | 78 |
| SUMINISTROS VARIOS..... | 84 |
| TRATAMIENTOS DERMATOLÓGICOS/TÓPICOS..... | 85 |
| VITAMINAS, MINERALES/ELECTROLITOS..... | 90 |

| Nombre del medicamento | Nivel del med. | Requisitos / Limitaciones |
|---|----------------|---------------------------|
| AGENTES DE DIAGNÓSTICO/VARIOS | | |
| AGENTES VARIOS | | |
| <i>acamprosate oral tablet, delayed release (dr/ec) 333 mg</i> | 2 | GC |
| <i>acetic acid irrigation solution 0.25 %</i> | 2 | GC |
| <i>anagrelide oral capsule 0.5 mg, 1 mg</i> | 2 | GC |
| ARALAST NP INTRAVENOUS RECON SOLN 1,000 MG, 500 MG | 5^ | PA; LA |
| <i>carglumic acid oral tablet, dispersible 200 mg</i> | 5^ | PA; LA |
| <i>cevimeline oral capsule 30 mg</i> | 2 | GC |
| CHEMET ORAL CAPSULE 100 MG | 4 | |
| CLINIMIX 4.25%/D5W SULFIT FREE INTRAVENOUS PARENTERAL SOLUTION 4.25 % | 4 | B/D |
| <i>d10 %-0.45 % sodium chloride intravenous parenteral solution</i> | 2 | GC |
| <i>d2.5 %-0.45 % sodium chloride intravenous parenteral solution</i> | 4 | |
| <i>d5 % and 0.9 % sodium chloride intravenous parenteral solution</i> | 2 | GC |
| <i>d5 %-0.45 % sodium chloride intravenous parenteral solution</i> | 2 | GC |
| <i>deferasirox oral granules in packet 180 mg, 360 mg, 90 mg</i> | 5^ | PA |
| <i>deferasirox oral tablet 180 mg, 360 mg</i> | 5^ | PA |
| <i>deferasirox oral tablet 90 mg</i> | 2 | PA; GC |
| <i>deferasirox oral tablet, dispersible 125 mg</i> | 4 | PA |
| <i>deferasirox oral tablet, dispersible 250 mg, 500 mg</i> | 5^ | PA |
| <i>dextrose 10 % and 0.2 % nacl intravenous parenteral solution</i> | 3 | |
| <i>dextrose 10 % in water (d10w) intravenous parenteral solution 10 %</i> | 2 | GC |
| <i>dextrose 5 % in water (d5w) intravenous parenteral solution</i> | 2 | GC |
| <i>dextrose 5 % in water (d5w) intravenous piggyback 5 %</i> | 2 | GC |
| <i>dextrose 5 %-lactated ringers intravenous parenteral solution</i> | 4 | |
| <i>dextrose 5%-0.2 % sod chloride intravenous parenteral solution</i> | 2 | GC |

Puede encontrar información sobre lo que significan los símbolos y las abreviaturas de esta tabla al principio de esta.

06/01/2024

| Nombre del medicamento | Nivel del med. | Requisitos / Limitaciones |
|---|----------------|-----------------------------|
| <i>dextrose 5%-0.3 % sod.chloride intravenous parenteral solution</i> | 4 | |
| <i>dextrose 50 % in water (d50w) intravenous parenteral solution</i> | 2 | B/D; GC |
| <i>dextrose 50 % in water (d50w) intravenous syringe</i> | 2 | B/D; GC |
| <i>dextrose 70 % in water (d70w) intravenous parenteral solution</i> | 4 | B/D |
| <i>disulfiram oral tablet 250 mg, 500 mg</i> | 2 | GC |
| <i>droxidopa oral capsule 100 mg</i> | 4 | PA; QL (90 EA per 30 days) |
| <i>droxidopa oral capsule 200 mg, 300 mg</i> | 4 | PA; QL (180 EA per 30 days) |
| ENDARI ORAL POWDER IN PACKET 5 GRAM | 5^ | PA; LA |
| INCRELEX SUBCUTANEOUS SOLUTION 10 MG/ML | 5^ | PA; LA |
| <i>levocarnitine (with sugar) oral solution 100 mg/ml</i> | 2 | B/D; GC |
| <i>levocarnitine oral solution 100 mg/ml</i> | 2 | GC |
| <i>levocarnitine oral tablet 330 mg</i> | 2 | B/D; GC |
| LOKELMA ORAL POWDER IN PACKET 10 GRAM, 5 GRAM | 3 | |
| <i>midodrine oral tablet 10 mg, 2.5 mg, 5 mg</i> | 2 | GC |
| <i>nitisinone oral capsule 10 mg, 2 mg, 20 mg, 5 mg</i> | 5^ | PA |
| <i>pilocarpine hcl oral tablet 5 mg, 7.5 mg</i> | 2 | GC |
| PROLASTIN-C INTRAVENOUS RECON SOLN 1,000 MG | 5^ | PA; LA |
| PROLASTIN-C INTRAVENOUS SOLUTION 1,000 MG (+/-)/20 ML | 5^ | PA; LA |
| <i>riluzole oral tablet 50 mg</i> | 2 | GC |
| <i>risedronate oral tablet 30 mg</i> | 2 | QL (30 EA per 30 days); GC |
| <i>sevelamer carbonate oral powder in packet 0.8 gram</i> | 4 | QL (540 EA per 30 days) |
| <i>sevelamer carbonate oral powder in packet 2.4 gram</i> | 4 | QL (180 EA per 30 days) |
| <i>sevelamer carbonate oral tablet 800 mg</i> | 3 | QL (540 EA per 30 days) |
| <i>sodium chloride 0.9 % intravenous parenteral solution</i> | 2 | GC |
| <i>sodium chloride 0.9 % intravenous piggyback</i> | 2 | GC |
| <i>sodium chloride irrigation solution 0.9 %</i> | 2 | GC |
| <i>sodium phenylbutyrate oral powder 0.94 gram/gram</i> | 5^ | PA |
| <i>sodium phenylbutyrate oral tablet 500 mg</i> | 5^ | PA |
| <i>sodium polystyrene sulfonate oral powder</i> | 2 | GC |
| <i>sps (with sorbitol) oral suspension 15-20 gram/60 ml</i> | 2 | GC |

Puede encontrar información sobre lo que significan los símbolos y las abreviaturas de esta tabla al principio de esta.

06/01/2024

| Nombre del medicamento | Nivel del med. | Requisitos / Limitaciones |
|--|----------------|-----------------------------|
| <i>sps (with sorbitol) rectal enema 30-40 gram/120 ml</i> | 2 | GC |
| <i>trientine oral capsule 250 mg</i> | 5^ | PA |
| VELPHORO ORAL TABLET,CHEWABLE 500 MG | 4 | QL (180 EA per 30 days) |
| VELTASSA ORAL POWDER IN PACKET 16.8 GRAM, 25.2 GRAM, 8.4 GRAM | 3 | |
| <i>water for irrigation, sterile irrigation solution</i> | 4 | |
| ZEMAIRA INTRAVENOUS RECON SOLN 1,000 MG, 4,000 MG, 5,000 MG | 5^ | PA; LA |
| <i>zoledronic acid-mannitol-water intravenous piggyback 5 mg/100 ml</i> | 2 | B/D; GC |
| DISUASIVOS PARA FUMADORES | | |
| <i>bupropion hcl (smoking deter) oral tablet extended release 12 hr 150 mg</i> | 2 | GC |
| NICOTROL INHALATION CARTRIDGE 10 MG | 4 | |
| NICOTROL NS NASAL SPRAY, NON-AEROSOL 10 MG/ML | 4 | |
| <i>varenicline oral tablet 0.5 mg, 1 mg</i> | 2 | QL (56 EA per 28 days); GC |
| <i>varenicline oral tablets, dose pack 0.5 mg (11)- 1 mg (42)</i> | 2 | GC |
| ANTIINFECCIOSOS | | |
| AGENTES ANTIFÚNGICOS | | |
| ABELCET INTRAVENOUS SUSPENSION 5 MG/ML | 4 | B/D |
| <i>amphotericin b injection recon soln 50 mg</i> | 2 | B/D; GC |
| <i>casprofungin intravenous recon soln 50 mg, 70 mg</i> | 2 | GC |
| <i>clotrimazole mucous membrane troche 10 mg</i> | 2 | QL (150 EA per 30 days); GC |
| CRESEMBA ORAL CAPSULE 186 MG, 74.5 MG | 5^ | PA |
| <i>fluconazole in nacl (iso-osm) intravenous piggyback 200 mg/100 ml</i> | 4 | |
| <i>fluconazole in nacl (iso-osm) intravenous piggyback 400 mg/200 ml</i> | 2 | GC |
| <i>fluconazole oral suspension for reconstitution 10 mg/ml, 40 mg/ml</i> | 2 | GC |
| <i>fluconazole oral tablet 100 mg, 150 mg, 200 mg, 50 mg</i> | 2 | GC |
| <i>flucytosine oral capsule 250 mg, 500 mg</i> | 5^ | PA |
| <i>griseofulvin microsize oral suspension 125 mg/5 ml</i> | 3 | |
| <i>griseofulvin microsize oral tablet 500 mg</i> | 4 | |
| <i>griseofulvin ultramicrosize oral tablet 125 mg, 250 mg</i> | 4 | |

Puede encontrar información sobre lo que significan los símbolos y las abreviaturas de esta tabla al principio de esta.

06/01/2024

| Nombre del medicamento | Nivel del med. | Requisitos / Limitaciones |
|---|----------------|-----------------------------|
| <i>itraconazole oral capsule 100 mg</i> | 4 | PA |
| <i>ketoconazole oral tablet 200 mg</i> | 2 | PA; GC |
| <i>micafungin intravenous recon soln 100 mg, 50 mg</i> | 5^ | |
| NOXAFIL ORAL SUSPENSION 200 MG/5 ML (40 MG/ML) | 5^ | PA; QL (630 ML per 30 days) |
| <i>nystatin oral suspension 100,000 unit/ml</i> | 2 | GC |
| <i>nystatin oral tablet 500,000 unit</i> | 2 | GC |
| <i>posaconazole oral suspension 200 mg/5 ml (40 mg/ml)</i> | 5^ | PA; QL (630 EA per 30 days) |
| <i>posaconazole oral tablet, delayed release (dr/ec) 100 mg</i> | 5^ | PA; QL (96 EA per 30 days) |
| <i>terbinafine hcl oral tablet 250 mg</i> | 1 | GC |
| <i>voriconazole intravenous recon soln 200 mg</i> | 5^ | PA |
| <i>voriconazole oral suspension for reconstitution 200 mg/5 ml (40 mg/ml)</i> | 5^ | PA |
| <i>voriconazole oral tablet 200 mg</i> | 4 | PA; QL (120 EA per 30 days) |
| <i>voriconazole oral tablet 50 mg</i> | 4 | PA; QL (480 EA per 30 days) |
| AGENTES PARA EL TRACTO URINARIO | | |
| <i>methenamine hippurate oral tablet 1 gram</i> | 3 | |
| <i>nitrofurantoin macrocrystal oral capsule 100 mg, 50 mg</i> | 3 | |
| <i>nitrofurantoin monohyd/m-cryst oral capsule 100 mg</i> | 3 | |
| <i>trimethoprim oral tablet 100 mg</i> | 2 | GC |
| AGENTES RELACIONADOS CON LA SULFANILAMIDA | | |
| <i>sulfadiazine oral tablet 500 mg</i> | 4 | |
| <i>sulfamethoxazole-trimethoprim intravenous solution 400-80 mg/5 ml</i> | 4 | |
| <i>sulfamethoxazole-trimethoprim oral suspension 200-40 mg/5 ml</i> | 2 | GC |
| <i>sulfamethoxazole-trimethoprim oral tablet 400-80 mg, 800-160 mg</i> | 1 | GC |
| ANTIVIRALES | | |
| <i>abacavir oral solution 20 mg/ml</i> | 2 | GC |
| <i>abacavir oral tablet 300 mg</i> | 2 | GC |
| <i>abacavir-lamivudine oral tablet 600-300 mg</i> | 2 | GC |
| <i>acyclovir oral capsule 200 mg</i> | 1 | GC |
| <i>acyclovir oral suspension 200 mg/5 ml</i> | 4 | |
| <i>acyclovir oral tablet 400 mg, 800 mg</i> | 1 | GC |

Puede encontrar información sobre lo que significan los símbolos y las abreviaturas de esta tabla al principio de esta.

06/01/2024

| Nombre del medicamento | Nivel del med. | Requisitos / Limitaciones |
|---|----------------|----------------------------|
| <i>acyclovir sodium intravenous solution 50 mg/ml</i> | 4 | B/D |
| <i>adefovir oral tablet 10 mg</i> | 4 | |
| <i>amantadine hcl oral capsule 100 mg</i> | 2 | GC |
| <i>amantadine hcl oral solution 50 mg/5 ml</i> | 2 | GC |
| <i>amantadine hcl oral tablet 100 mg</i> | 2 | GC |
| APTIVUS ORAL CAPSULE 250 MG | 5^ | |
| <i>atazanavir oral capsule 150 mg, 200 mg, 300 mg</i> | 2 | GC |
| BARACLUDGE ORAL SOLUTION 0.05 MG/ML | 5^ | |
| BIKTARVY ORAL TABLET 30-120-15 MG, 50-200-25 MG | 5^ | |
| CIMDUO ORAL TABLET 300-300 MG | 5^ | |
| COMPLERA ORAL TABLET 200-25-300 MG | 5^ | |
| <i>darunavir oral tablet 600 mg</i> | 5^ | QL (60 EA per 30 days) |
| <i>darunavir oral tablet 800 mg</i> | 5^ | QL (30 EA per 30 days) |
| DELSTRIGO ORAL TABLET 100-300-300 MG | 5^ | |
| DESCOVY ORAL TABLET 120-15 MG, 200-25 MG | 5^ | QL (30 EA per 30 days) |
| DOVATO ORAL TABLET 50-300 MG | 5^ | |
| EDURANT ORAL TABLET 25 MG | 5^ | |
| <i>efavirenz oral capsule 200 mg, 50 mg</i> | 2 | GC |
| <i>efavirenz oral tablet 600 mg</i> | 2 | GC |
| <i>efavirenz-emtricitabin-tenofovir oral tablet 600-200-300 mg</i> | 5^ | |
| <i>efavirenz-lamivu-tenofovir disop oral tablet 400-300-300 mg, 600-300-300 mg</i> | 5^ | |
| <i>emtricitabine oral capsule 200 mg</i> | 2 | GC |
| <i>emtricitabine-tenofovir (tdf) oral tablet 100-150 mg, 133-200 mg, 167-250 mg</i> | 5^ | QL (30 EA per 30 days) |
| <i>emtricitabine-tenofovir (tdf) oral tablet 200-300 mg</i> | 4 | QL (30 EA per 30 days) |
| EMTRIVA ORAL SOLUTION 10 MG/ML | 4 | |
| <i>entecavir oral tablet 0.5 mg, 1 mg</i> | 2 | GC |
| EPCLUSA ORAL PELLETS IN PACKET 150-37.5 MG | 5^ | PA; QL (28 EA per 28 days) |
| EPCLUSA ORAL PELLETS IN PACKET 200-50 MG | 5^ | PA; QL (56 EA per 28 days) |
| EPCLUSA ORAL TABLET 200-50 MG | 5^ | PA; QL (56 EA per 28 days) |
| EPCLUSA ORAL TABLET 400-100 MG | 5^ | PA; QL (28 EA per 28 days) |
| EPIVIR HBV ORAL SOLUTION 25 MG/5 ML (5 MG/ML) | 4 | |
| <i>etravirine oral tablet 100 mg, 200 mg</i> | 5^ | |

Puede encontrar información sobre lo que significan los símbolos y las abreviaturas de esta tabla al principio de esta.

06/01/2024

| Nombre del medicamento | Nivel del med. | Requisitos / Limitaciones |
|---|----------------|-------------------------------|
| EVOTAZ ORAL TABLET 300-150 MG | 5^ | |
| <i>famciclovir oral tablet 125 mg, 250 mg, 500 mg</i> | 2 | GC |
| <i>fosamprenavir oral tablet 700 mg</i> | 4 | |
| FUZEON SUBCUTANEOUS RECON SOLN 90 MG | 5^ | |
| <i>ganciclovir sodium intravenous recon soln 500 mg</i> | 2 | GC |
| GENVOYA ORAL TABLET 150-150-200-10 MG | 5^ | |
| HARVONI ORAL PELLETS IN PACKET 33.75-150 MG | 5^ | PA; QL (28 EA per 28 days) |
| HARVONI ORAL PELLETS IN PACKET 45-200 MG | 5^ | PA; QL (56 EA per 28 days) |
| HARVONI ORAL TABLET 45-200 MG | 5^ | PA; QL (60 EA per 30 days) |
| HARVONI ORAL TABLET 90-400 MG | 5^ | PA; QL (28 EA per 28 days) |
| INTELENCE ORAL TABLET 25 MG | 4 | |
| ISENTRESS HD ORAL TABLET 600 MG | 5^ | |
| ISENTRESS ORAL POWDER IN PACKET 100 MG | 5^ | |
| ISENTRESS ORAL TABLET 400 MG | 5^ | |
| ISENTRESS ORAL TABLET,CHEWABLE 100 MG | 5^ | |
| ISENTRESS ORAL TABLET,CHEWABLE 25 MG | 4 | |
| JULUCA ORAL TABLET 50-25 MG | 5^ | |
| LAGEVRIO (EUA) ORAL CAPSULE 200 MG | 6 | QL (40 EA per 180 days) |
| <i>lamivudine oral solution 10 mg/ml</i> | 2 | GC |
| <i>lamivudine oral tablet 100 mg, 150 mg, 300 mg</i> | 2 | GC |
| <i>lamivudine-zidovudine oral tablet 150-300 mg</i> | 2 | GC |
| LEXIVA ORAL SUSPENSION 50 MG/ML | 4 | |
| <i>lopinavir-ritonavir oral solution 400-100 mg/5 ml</i> | 2 | GC |
| <i>lopinavir-ritonavir oral tablet 100-25 mg, 200-50 mg</i> | 2 | GC |
| <i>maraviroc oral tablet 150 mg, 300 mg</i> | 5^ | |
| <i>nevirapine oral suspension 50 mg/5 ml</i> | 2 | GC |
| <i>nevirapine oral tablet 200 mg</i> | 2 | GC |
| <i>nevirapine oral tablet extended release 24 hr 100 mg, 400 mg</i> | 2 | GC |
| NORVIR ORAL POWDER IN PACKET 100 MG | 4 | |
| ODEFSEY ORAL TABLET 200-25-25 MG | 5^ | |
| <i>oseltamivir oral capsule 30 mg</i> | 2 | QL (168 EA per 365 days); GC |
| <i>oseltamivir oral capsule 45 mg, 75 mg</i> | 2 | QL (84 EA per 365 days); GC |
| <i>oseltamivir oral suspension for reconstitution 6 mg/ml</i> | 2 | QL (1080 ML per 365 days); GC |

Puede encontrar información sobre lo que significan los símbolos y las abreviaturas de esta tabla al principio de esta.

06/01/2024

| Nombre del medicamento | Nivel del med. | Requisitos / Limitaciones |
|---|----------------|---|
| PAXLOVID ORAL TABLETS,DOSE PACK 150-100 MG | 6 | \$0 Cost Sharing; QL (20 EA per 180 days) |
| PAXLOVID ORAL TABLETS,DOSE PACK 300 MG (150 MG X 2)-100 MG | 6 | \$0 Cost Sharing; QL (30 EA per 180 days) |
| PIFELTRO ORAL TABLET 100 MG | 5^ | |
| PREVYMIS ORAL TABLET 240 MG, 480 MG | 5^ | PA; QL (30 EA per 30 days) |
| PREZCOBIX ORAL TABLET 800-150 MG-MG | 5^ | |
| PREZISTA ORAL SUSPENSION 100 MG/ML | 5^ | QL (400 ML per 30 days) |
| PREZISTA ORAL TABLET 150 MG | 5^ | QL (240 EA per 30 days) |
| PREZISTA ORAL TABLET 600 MG | 5^ | QL (60 EA per 30 days) |
| PREZISTA ORAL TABLET 75 MG | 4 | QL (480 EA per 30 days) |
| PREZISTA ORAL TABLET 800 MG | 5^ | QL (30 EA per 30 days) |
| RELENZA DISKHALER INHALATION BLISTER WITH DEVICE 5 MG/ACTUATION | 3 | QL (120 EA per 365 days) |
| REYATAZ ORAL POWDER IN PACKET 50 MG | 5^ | |
| <i>ribavirin oral capsule 200 mg</i> | 2 | GC |
| <i>ribavirin oral tablet 200 mg</i> | 2 | GC |
| <i>rimantadine oral tablet 100 mg</i> | 4 | |
| <i>ritonavir oral tablet 100 mg</i> | 2 | GC |
| RUKOBIA ORAL TABLET EXTENDED RELEASE 12 HR 600 MG | 5^ | |
| SELZENTRY ORAL SOLUTION 20 MG/ML | 5^ | |
| SELZENTRY ORAL TABLET 25 MG | 4 | |
| SELZENTRY ORAL TABLET 75 MG | 5^ | |
| STRIBILD ORAL TABLET 150-150-200-300 MG | 5^ | |
| SUNLENCA ORAL TABLET 300 MG, 300 MG (4-TABLET PACK) | 5^ | |
| SYM TUZA ORAL TABLET 800-150-200-10 MG | 4 | |
| <i>tenofovir disoproxil fumarate oral tablet 300 mg</i> | 2 | GC |
| TIVICAY ORAL TABLET 10 MG | 3 | |
| TIVICAY ORAL TABLET 25 MG, 50 MG | 5^ | |
| TIVICAY PD ORAL TABLET FOR SUSPENSION 5 MG | 5^ | |
| TRIUMEQ ORAL TABLET 600-50-300 MG | 5^ | |
| TRIUMEQ PD ORAL TABLET FOR SUSPENSION 60-5-30 MG | 5^ | |
| TRIZIVIR ORAL TABLET 300-150-300 MG | 5^ | |

Puede encontrar información sobre lo que significan los símbolos y las abreviaturas de esta tabla al principio de esta.

06/01/2024

| Nombre del medicamento | Nivel del med. | Requisitos / Limitaciones |
|--|----------------|----------------------------|
| TROGARZO INTRAVENOUS SOLUTION 200 MG/1.33 ML (150 MG/ML) | 5 [^] | |
| TYBOST ORAL TABLET 150 MG | 3 | |
| <i>valacyclovir oral tablet 1 gram, 500 mg</i> | 2 | GC |
| <i>valganciclovir oral recon soln 50 mg/ml</i> | 5 [^] | |
| <i>valganciclovir oral tablet 450 mg</i> | 3 | |
| VEMLIDY ORAL TABLET 25 MG | 5 [^] | |
| VIRACEPT ORAL TABLET 250 MG, 625 MG | 5 [^] | |
| VIREAD ORAL POWDER 40 MG/SCOOP (40 MG/GRAM) | 5 [^] | |
| VIREAD ORAL TABLET 150 MG, 250 MG | 5 [^] | |
| VIREAD ORAL TABLET 200 MG | 4 | |
| VOSEVI ORAL TABLET 400-100-100 MG | 5 [^] | PA; QL (28 EA per 28 days) |
| <i>zidovudine oral capsule 100 mg</i> | 2 | GC |
| <i>zidovudine oral syrup 10 mg/ml</i> | 2 | GC |
| <i>zidovudine oral tablet 300 mg</i> | 2 | GC |
| CEFALOSPORINAS | | |
| <i>cefaclor oral capsule 250 mg, 500 mg</i> | 2 | GC |
| <i>cefaclor oral suspension for reconstitution 125 mg/5 ml, 250 mg/5 ml, 375 mg/5 ml</i> | 2 | GC |
| <i>cefaclor oral tablet extended release 12 hr 500 mg</i> | 4 | |
| <i>cefadroxil oral capsule 500 mg</i> | 1 | GC |
| <i>cefadroxil oral suspension for reconstitution 250 mg/5 ml</i> | 3 | |
| <i>cefadroxil oral suspension for reconstitution 500 mg/5 ml</i> | 2 | GC |
| <i>cefazolin in dextrose (iso-os) intravenous piggyback 1 gram/50 ml</i> | 3 | |
| CEFAZOLIN IN DEXTROSE (ISO-OS) INTRAVENOUS PIGGYBACK 2 GRAM/100 ML | 4 | |
| <i>cefazolin injection recon soln 1 gram</i> | 3 | |
| <i>cefazolin injection recon soln 10 gram, 100 gram, 300 g</i> | 4 | |
| <i>cefazolin injection recon soln 500 mg</i> | 2 | GC |
| <i>cefazolin intravenous recon soln 1 gram</i> | 3 | |
| <i>cefdinir oral capsule 300 mg</i> | 2 | GC |
| <i>cefdinir oral suspension for reconstitution 125 mg/5 ml, 250 mg/5 ml</i> | 2 | GC |

Puede encontrar información sobre lo que significan los símbolos y las abreviaturas de esta tabla al principio de esta.

06/01/2024

| Nombre del medicamento | Nivel del med. | Requisitos / Limitaciones |
|---|----------------|---------------------------|
| CEFEPIME IN DEXTROSE 5 % INTRAVENOUS PIGGYBACK 1 GRAM/50 ML, 2 GRAM/50 ML | 4 | |
| <i>cefepime in dextrose, iso-osm intravenous piggyback 1 gram/50 ml, 2 gram/100 ml</i> | 4 | |
| <i>cefepime injection recon soln 1 gram, 2 gram</i> | 4 | |
| <i>cefixime oral capsule 400 mg</i> | 2 | GC |
| <i>cefixime oral suspension for reconstitution 100 mg/5 ml, 200 mg/5 ml</i> | 4 | |
| <i>cefoxitin in dextrose, iso-osm intravenous piggyback 1 gram/50 ml, 2 gram/50 ml</i> | 2 | GC |
| <i>cefoxitin intravenous recon soln 1 gram, 10 gram, 2 gram</i> | 2 | GC |
| <i>cefpodoxime oral suspension for reconstitution 100 mg/5 ml</i> | 4 | |
| <i>cefpodoxime oral suspension for reconstitution 50 mg/5 ml</i> | 2 | GC |
| <i>cefpodoxime oral tablet 100 mg, 200 mg</i> | 3 | |
| <i>cefprozil oral suspension for reconstitution 125 mg/5 ml</i> | 2 | GC |
| <i>cefprozil oral suspension for reconstitution 250 mg/5 ml</i> | 3 | |
| <i>cefprozil oral tablet 250 mg, 500 mg</i> | 2 | GC |
| <i>ceftazidime injection recon soln 1 gram</i> | 4 | |
| <i>ceftazidime injection recon soln 2 gram</i> | 2 | GC |
| <i>ceftazidime injection recon soln 6 gram</i> | 3 | |
| <i>ceftriaxone in dextrose, iso-os intravenous piggyback 1 gram/50 ml, 2 gram/50 ml</i> | 4 | |
| <i>ceftriaxone injection recon soln 1 gram, 10 gram, 2 gram</i> | 4 | |
| CEFTRIAZONE INJECTION RECON SOLN 100 GRAM | 4 | |
| <i>ceftriaxone injection recon soln 250 mg, 500 mg</i> | 2 | GC |
| <i>ceftriaxone intravenous recon soln 1 gram, 2 gram</i> | 4 | |
| <i>cefuroxime axetil oral tablet 250 mg, 500 mg</i> | 2 | GC |
| <i>cefuroxime sodium injection recon soln 750 mg</i> | 2 | GC |
| <i>cefuroxime sodium intravenous recon soln 1.5 gram</i> | 2 | GC |
| <i>cephalexin oral capsule 250 mg, 500 mg</i> | 1 | GC |
| <i>cephalexin oral suspension for reconstitution 125 mg/5 ml, 250 mg/5 ml</i> | 2 | GC |
| <i>tazicef injection recon soln 1 gram, 6 gram</i> | 2 | GC |
| <i>tazicef injection recon soln 2 gram</i> | 4 | |
| <i>tazicef intravenous recon soln 1 gram</i> | 2 | GC |

Puede encontrar información sobre lo que significan los símbolos y las abreviaturas de esta tabla al principio de esta.

06/01/2024

| Nombre del medicamento | Nivel del med. | Requisitos / Limitaciones |
|--|----------------|---------------------------|
| <i>tazicef intravenous recon soln 2 gram</i> | 4 | |
| TEFLARO INTRAVENOUS RECON SOLN 400 MG, 600 MG | 5^ | |
| ERITROMICINAS/OTROS MACRÓLIDOS | | |
| <i>azithromycin intravenous recon soln 500 mg</i> | 3 | |
| <i>azithromycin oral packet 1 gram</i> | 3 | |
| <i>azithromycin oral suspension for reconstitution 100 mg/5 ml, 200 mg/5 ml</i> | 2 | GC |
| <i>azithromycin oral tablet 250 mg, 250 mg (6 pack), 500 mg, 500 mg (3 pack), 600 mg</i> | 1 | GC |
| <i>clarithromycin oral suspension for reconstitution 125 mg/5 ml</i> | 2 | GC |
| <i>clarithromycin oral suspension for reconstitution 250 mg/5 ml</i> | 4 | |
| <i>clarithromycin oral tablet 250 mg, 500 mg</i> | 2 | GC |
| <i>clarithromycin oral tablet extended release 24 hr 500 mg</i> | 2 | GC |
| DIFICID ORAL TABLET 200 MG | 5^ | QL (20 EA per 10 days) |
| <i>e.e.s. 400 oral tablet 400 mg</i> | 2 | GC |
| <i>ery-tab oral tablet, delayed release (dr/ec) 250 mg, 333 mg</i> | 2 | GC |
| <i>erythrocin (as stearate) oral tablet 250 mg</i> | 2 | GC |
| ERYTHROCIN INTRAVENOUS RECON SOLN 500 MG | 4 | |
| <i>erythromycin ethylsuccinate oral tablet 400 mg</i> | 4 | |
| <i>erythromycin oral capsule, delayed release (dr/ec) 250 mg</i> | 4 | |
| <i>erythromycin oral tablet 250 mg, 500 mg</i> | 4 | |
| <i>erythromycin oral tablet, delayed release (dr/ec) 250 mg, 333 mg, 500 mg</i> | 2 | GC |
| MEDICAMENTOS ANTIINFECCIOSOS DIVERSOS | | |
| <i>albendazole oral tablet 200 mg</i> | 5^ | |
| <i>amikacin injection solution 1,000 mg/4 ml, 500 mg/2 ml</i> | 4 | |
| ARIKAYCE INHALATION SUSPENSION FOR NEBULIZATION 590 MG/8.4 ML | 5^ | PA; LA |
| <i>atovaquone oral suspension 750 mg/5 ml</i> | 2 | GC |
| <i>atovaquone-proguanil oral tablet 250-100 mg</i> | 4 | |
| <i>atovaquone-proguanil oral tablet 62.5-25 mg</i> | 2 | GC |
| <i>aztreonam injection recon soln 1 gram, 2 gram</i> | 4 | |

Puede encontrar información sobre lo que significan los símbolos y las abreviaturas de esta tabla al principio de esta.

06/01/2024

| Nombre del medicamento | Nivel del med. | Requisitos / Limitaciones |
|---|----------------|--------------------------------|
| CAYSTON INHALATION SOLUTION FOR NEBULIZATION 75 MG/ML | 5^ | PA; LA; QL (84 ML per 56 days) |
| <i>chloroquine phosphate oral tablet 250 mg, 500 mg</i> | 4 | |
| <i>clindamycin hcl oral capsule 150 mg, 300 mg, 75 mg</i> | 1 | GC |
| CLINDAMYCIN IN 0.9 % SOD CHLOR INTRAVENOUS PIGGYBACK 300 MG/50 ML, 900 MG/50 ML | 2 | GC |
| CLINDAMYCIN IN 0.9 % SOD CHLOR INTRAVENOUS PIGGYBACK 600 MG/50 ML | 4 | |
| <i>clindamycin in 5 % dextrose intravenous piggyback 300 mg/50 ml, 900 mg/50 ml</i> | 2 | GC |
| <i>clindamycin in 5 % dextrose intravenous piggyback 600 mg/50 ml</i> | 4 | |
| <i>clindamycin phosphate injection solution 150 mg/ml</i> | 2 | GC |
| COARTEM ORAL TABLET 20-120 MG | 4 | |
| <i>colistin (colistimethate na) injection recon soln 150 mg</i> | 4 | QL (30 EA per 10 days) |
| <i>dapsone oral tablet 100 mg, 25 mg</i> | 2 | GC |
| <i>daptomycin intravenous recon soln 500 mg</i> | 5^ | |
| EMVERM ORAL TABLET,CHEWABLE 100 MG | 5^ | QL (12 EA per 365 days) |
| <i>ertapenem injection recon soln 1 gram</i> | 4 | |
| <i>ethambutol oral tablet 100 mg, 400 mg</i> | 2 | GC |
| <i>gentamicin in nacl (iso-osm) intravenous piggyback 100 mg/100 ml, 60 mg/50 ml, 80 mg/100 ml, 80 mg/50 ml</i> | 2 | GC |
| <i>gentamicin injection solution 40 mg/ml</i> | 2 | GC |
| <i>gentamicin sulfate (ped) (pf) injection solution 20 mg/2 ml</i> | 4 | |
| <i>hydroxychloroquine oral tablet 200 mg</i> | 2 | GC |
| <i>imipenem-cilastatin intravenous recon soln 250 mg</i> | 2 | GC |
| <i>imipenem-cilastatin intravenous recon soln 500 mg</i> | 4 | |
| <i>isoniazid oral solution 50 mg/5 ml</i> | 2 | GC |
| <i>isoniazid oral tablet 100 mg, 300 mg</i> | 1 | GC |
| <i>ivermectin oral tablet 3 mg</i> | 3 | PA; QL (20 EA per 30 days) |
| <i>linezolid 600 mg/300 ml-0.9% nacl single-use</i> | 4 | |
| <i>linezolid in dextrose 5% intravenous piggyback 600 mg/300 ml</i> | 4 | |
| <i>linezolid oral suspension for reconstitution 100 mg/5 ml</i> | 5^ | QL (1800 ML per 30 days) |
| <i>linezolid oral tablet 600 mg</i> | 3 | QL (60 EA per 30 days) |

Puede encontrar información sobre lo que significan los símbolos y las abreviaturas de esta tabla al principio de esta.

06/01/2024

| Nombre del medicamento | Nivel del med. | Requisitos / Limitaciones |
|--|----------------|--------------------------------|
| LINEZOLID-0.9% SODIUM CHLORIDE INTRAVENOUS PARENTERAL SOLUTION 600 MG/300 ML | 4 | |
| <i>mefloquine oral tablet 250 mg</i> | 2 | GC |
| <i>meropenem intravenous recon soln 1 gram, 500 mg</i> | 4 | |
| MEROPENEM-0.9% SODIUM CHLORIDE INTRAVENOUS PIGGYBACK 1 GRAM/50 ML, 500 MG/50 ML | 4 | |
| <i>metro i.v. intravenous piggyback 500 mg/100 ml</i> | 2 | GC |
| <i>metronidazole in nacl (iso-os) intravenous piggyback 500 mg/100 ml</i> | 2 | GC |
| <i>metronidazole oral tablet 250 mg, 500 mg</i> | 1 | GC |
| <i>neomycin oral tablet 500 mg</i> | 2 | GC |
| <i>nitazoxanide oral tablet 500 mg</i> | 5 [^] | QL (6 EA per 30 days) |
| <i>paromomycin oral capsule 250 mg</i> | 4 | |
| <i>pentamidine inhalation recon soln 300 mg</i> | 2 | B/D; QL (1 EA per 28 days); GC |
| <i>pentamidine injection recon soln 300 mg</i> | 2 | GC |
| <i>praziquantel oral tablet 600 mg</i> | 4 | |
| PRIFTIN ORAL TABLET 150 MG | 4 | |
| PRIMAQUINE ORAL TABLET 26.3 MG | 4 | |
| <i>pyrazinamide oral tablet 500 mg</i> | 2 | GC |
| <i>quinine sulfate oral capsule 324 mg</i> | 3 | PA |
| <i>rifabutin oral capsule 150 mg</i> | 2 | GC |
| <i>rifampin intravenous recon soln 600 mg</i> | 2 | GC |
| <i>rifampin oral capsule 150 mg, 300 mg</i> | 2 | GC |
| SIRTURO ORAL TABLET 100 MG, 20 MG | 5 [^] | PA; LA |
| STREPTOMYCIN INTRAMUSCULAR RECON SOLN 1 GRAM | 2 | GC |
| SYNERCID INTRAVENOUS RECON SOLN 500 MG | 5 [^] | |
| <i>tigecycline intravenous recon soln 50 mg</i> | 5 [^] | |
| <i>tinidazole oral tablet 250 mg, 500 mg</i> | 2 | GC |
| <i>tobramycin in 0.225 % nacl inhalation solution for nebulization 300 mg/5 ml</i> | 5 [^] | PA; QL (280 ML per 28 days) |
| <i>tobramycin sulfate injection recon soln 1.2 gram</i> | 2 | GC |
| <i>tobramycin sulfate injection solution 10 mg/ml, 40 mg/ml</i> | 2 | GC |
| TRECTOR ORAL TABLET 250 MG | 4 | |
| <i>vancomycin hcl 1.25 gram vial outer, suv</i> | 4 | |

Puede encontrar información sobre lo que significan los símbolos y las abreviaturas de esta tabla al principio de esta.

06/01/2024

| Nombre del medicamento | Nivel del med. | Requisitos / Limitaciones |
|--|----------------|----------------------------|
| <i>vancomycin hcl 1.5 gram vial outer, suv</i> | 4 | |
| VANCOMYCIN IN 0.9 % SODIUM CHL INTRAVENOUS PIGGYBACK 1 GRAM/200 ML, 500 MG/100 ML, 750 MG/150 ML | 4 | |
| VANCOMYCIN INJECTION RECON SOLN 100 GRAM | 4 | |
| <i>vancomycin intravenous recon soln 1,000 mg, 10 gram, 5 gram</i> | 4 | |
| VANCOMYCIN INTRAVENOUS RECON SOLN 1.25 GRAM, 1.5 GRAM | 4 | |
| <i>vancomycin intravenous recon soln 500 mg</i> | 2 | GC |
| <i>vancomycin intravenous recon soln 750 mg</i> | 3 | |
| <i>vancomycin oral capsule 125 mg</i> | 4 | QL (80 EA per 180 days) |
| <i>vancomycin oral capsule 250 mg</i> | 4 | QL (160 EA per 180 days) |
| XIFAXAN ORAL TABLET 550 MG | 5^ | PA; QL (90 EA per 30 days) |
| PENICILINAS | | |
| <i>amoxicillin oral capsule 250 mg, 500 mg</i> | 1 | GC |
| <i>amoxicillin oral suspension for reconstitution 125 mg/5 ml, 200 mg/5 ml, 250 mg/5 ml, 400 mg/5 ml</i> | 1 | GC |
| <i>amoxicillin oral tablet 500 mg, 875 mg</i> | 1 | GC |
| <i>amoxicillin oral tablet, chewable 125 mg, 250 mg</i> | 2 | GC |
| <i>amoxicillin-pot clavulanate oral suspension for reconstitution 200-28.5 mg/5 ml, 250-62.5 mg/5 ml, 400-57 mg/5 ml, 600-42.9 mg/5 ml</i> | 2 | GC |
| <i>amoxicillin-pot clavulanate oral tablet 250-125 mg, 500-125 mg, 875-125 mg</i> | 2 | GC |
| <i>amoxicillin-pot clavulanate oral tablet extended release 12 hr 1,000-62.5 mg</i> | 2 | GC |
| <i>amoxicillin-pot clavulanate oral tablet, chewable 200-28.5 mg, 400-57 mg</i> | 2 | GC |
| <i>ampicillin oral capsule 500 mg</i> | 1 | GC |
| <i>ampicillin sodium injection recon soln 1 gram, 2 gram, 250 mg, 500 mg</i> | 4 | |
| <i>ampicillin sodium injection recon soln 10 gram, 125 mg</i> | 2 | GC |
| <i>ampicillin sodium intravenous recon soln 1 gram</i> | 4 | |
| <i>ampicillin sodium intravenous recon soln 2 gram</i> | 2 | GC |

Puede encontrar información sobre lo que significan los símbolos y las abreviaturas de esta tabla al principio de esta.

06/01/2024

| Nombre del medicamento | Nivel del med. | Requisitos / Limitaciones |
|--|----------------|---------------------------|
| <i>ampicillin-sulbactam injection recon soln 1.5 gram, 15 gram, 3 gram</i> | 2 | GC |
| <i>ampicillin-sulbactam intravenous recon soln 1.5 gram, 3 gram</i> | 2 | GC |
| BICILLIN L-A INTRAMUSCULAR SYRINGE 1,200,000 UNIT/2 ML, 2,400,000 UNIT/4 ML, 600,000 UNIT/ML | 4 | |
| <i>dicloxacillin oral capsule 250 mg, 500 mg</i> | 2 | GC |
| <i>nafcillin in dextrose iso-osm intravenous piggyback 1 gram/50 ml, 2 gram/100 ml</i> | 2 | GC |
| <i>nafcillin injection recon soln 1 gram, 2 gram</i> | 2 | GC |
| <i>nafcillin injection recon soln 10 gram</i> | 5^ | |
| <i>oxacillin injection recon soln 1 gram</i> | 2 | GC |
| <i>oxacillin injection recon soln 10 gram, 2 gram</i> | 4 | |
| PENICILLIN G POT IN DEXTROSE INTRAVENOUS PIGGYBACK 2 MILLION UNIT/50 ML, 3 MILLION UNIT/50 ML | 4 | |
| <i>penicillin g potassium injection recon soln 20 million unit, 5 million unit</i> | 4 | |
| <i>penicillin g procaine intramuscular syringe 1.2 million unit/2 ml</i> | 4 | |
| <i>penicillin g sodium injection recon soln 5 million unit</i> | 2 | GC |
| <i>penicillin v potassium oral recon soln 125 mg/5 ml, 250 mg/5 ml</i> | 2 | GC |
| <i>penicillin v potassium oral tablet 250 mg, 500 mg</i> | 1 | GC |
| <i>pfizerpen-g injection recon soln 20 million unit, 5 million unit</i> | 4 | |
| PIPERACILLIN-TAZOBACTAM INTRAVENOUS RECON SOLN 13.5 GRAM | 4 | |
| <i>piperacillin-tazobactam intravenous recon soln 2.25 gram, 3.375 gram, 4.5 gram, 40.5 gram</i> | 4 | |
| <i>piperacil-tazobact 13.5 gm vl inner, muv, p/f 13.5 gram</i> | 4 | |
| QUINOLONAS | | |
| CIPRO ORAL SUSPENSION, MICROCAPSULE RECON 500 MG/5 ML | 4 | |
| <i>ciprofloxacin hcl oral tablet 100 mg</i> | 4 | |
| <i>ciprofloxacin hcl oral tablet 250 mg, 500 mg, 750 mg</i> | 1 | GC |
| <i>ciprofloxacin in 5 % dextrose intravenous piggyback 200 mg/100 ml</i> | 2 | GC |

Puede encontrar información sobre lo que significan los símbolos y las abreviaturas de esta tabla al principio de esta.

06/01/2024

| Nombre del medicamento | Nivel del med. | Requisitos / Limitaciones |
|---|----------------|---------------------------|
| <i>ciprofloxacin in 5 % dextrose intravenous piggyback 400 mg/200 ml</i> | 4 | |
| <i>ciprofloxacin oral suspension,microcapsule recon 500 mg/5 ml</i> | 4 | |
| <i>levofloxacin in d5w intravenous piggyback 250 mg/50 ml</i> | 4 | |
| <i>levofloxacin in d5w intravenous piggyback 500 mg/100 ml, 750 mg/150 ml</i> | 2 | GC |
| <i>levofloxacin intravenous solution 25 mg/ml</i> | 2 | GC |
| <i>levofloxacin oral solution 250 mg/10 ml</i> | 4 | |
| <i>levofloxacin oral tablet 250 mg, 500 mg, 750 mg</i> | 1 | GC |
| <i>moxifloxacin oral tablet 400 mg</i> | 2 | GC |
| MOXIFLOXACIN-SOD.ACE,SUL-WATER INTRAVENOUS PIGGYBACK 400 MG/250 ML | 2 | GC |
| <i>moxifloxacin-sod.chloride(iso) intravenous piggyback 400 mg/250 ml</i> | 2 | GC |
| TETRACICLINAS | | |
| <i>doxy-100 intravenous recon soln 100 mg</i> | 2 | GC |
| <i>doxycycline hyclate intravenous recon soln 100 mg</i> | 2 | GC |
| <i>doxycycline hyclate oral capsule 100 mg, 50 mg</i> | 2 | GC |
| <i>doxycycline hyclate oral tablet 100 mg, 20 mg</i> | 2 | GC |
| <i>doxycycline monohydrate oral capsule 100 mg, 50 mg</i> | 2 | GC |
| <i>doxycycline monohydrate oral tablet 100 mg, 50 mg, 75 mg</i> | 2 | GC |
| <i>minocycline oral capsule 100 mg, 50 mg, 75 mg</i> | 2 | GC |
| <i>tetracycline oral capsule 250 mg</i> | 3 | PA |
| <i>tetracycline oral capsule 500 mg</i> | 4 | PA |
| CARDIOVASCULAR, HIPERTENSIÓN/LÍPIDOS | | |
| AGENTES ANTIARRÍTMICOS | | |
| <i>amiodarone intravenous solution 50 mg/ml</i> | 2 | GC |
| <i>amiodarone intravenous syringe 150 mg/3 ml</i> | 2 | GC |
| <i>amiodarone oral tablet 100 mg, 400 mg</i> | 2 | GC |
| <i>amiodarone oral tablet 200 mg</i> | 1 | GC |
| <i>disopyramide phosphate oral capsule 100 mg, 150 mg</i> | 4 | |
| <i>dofetilide oral capsule 125 mcg, 250 mcg, 500 mcg</i> | 2 | GC |
| <i>flecainide oral tablet 100 mg, 150 mg, 50 mg</i> | 2 | GC |
| MULTAQ ORAL TABLET 400 MG | 4 | |

Puede encontrar información sobre lo que significan los símbolos y las abreviaturas de esta tabla al principio de esta.

06/01/2024

| Nombre del medicamento | Nivel del med. | Requisitos / Limitaciones |
|--|----------------|----------------------------|
| NORPACE CR ORAL CAPSULE, EXTENDED RELEASE 100 MG, 150 MG | 4 | |
| <i>pacerone oral tablet 100 mg, 400 mg</i> | 2 | GC |
| <i>pacerone oral tablet 200 mg</i> | 1 | GC |
| <i>propafenone oral capsule, extended release 12 hr 225 mg, 325 mg, 425 mg</i> | 2 | GC |
| <i>propafenone oral tablet 150 mg, 225 mg, 300 mg</i> | 2 | GC |
| <i>quinidine sulfate oral tablet 200 mg, 300 mg</i> | 2 | GC |
| <i>sorine oral tablet 120 mg, 160 mg, 240 mg, 80 mg</i> | 1 | GC |
| <i>sotalol af oral tablet 120 mg, 160 mg, 80 mg</i> | 2 | GC |
| <i>sotalol oral tablet 120 mg, 160 mg, 240 mg, 80 mg</i> | 1 | GC |
| AGENTES CARDIOVASCULARES DIVERSOS | | |
| CORLANOR ORAL SOLUTION 5 MG/5 ML | 4 | QL (450 ML per 30 days) |
| CORLANOR ORAL TABLET 5 MG, 7.5 MG | 4 | QL (60 EA per 30 days) |
| <i>digoxin oral solution 50 mcg/ml (0.05 mg/ml)</i> | 2 | GC |
| <i>digoxin oral tablet 125 mcg (0.125 mg), 250 mcg (0.25 mg)</i> | 2 | QL (30 EA per 30 days); GC |
| ENTRESTO ORAL TABLET 24-26 MG, 49-51 MG, 97-103 MG | 3 | QL (60 EA per 30 days) |
| <i>ranolazine oral tablet extended release 12 hr 1,000 mg, 500 mg</i> | 4 | |
| VERQUVO ORAL TABLET 10 MG, 2.5 MG, 5 MG | 4 | QL (30 EA per 30 days) |
| VYNDAQEL ORAL CAPSULE 20 MG | 4 | PA |
| AGENTES REDUCTORES DE LÍPIDOS/COLESTEROL | | |
| ALTOPREV ORAL TABLET EXTENDED RELEASE 24 HR 20 MG, 40 MG, 60 MG | 5^ | ST; QL (30 EA per 30 days) |
| <i>amlodipine-atorvastatin oral tablet 10-10 mg, 10-20 mg, 10-40 mg, 10-80 mg, 2.5-10 mg, 2.5-20 mg, 2.5-40 mg, 5-10 mg, 5-20 mg, 5-40 mg, 5-80 mg</i> | 6 | QL (30 EA per 30 days); GC |
| <i>atorvastatin oral tablet 10 mg, 20 mg, 40 mg, 80 mg</i> | 6 | QL (30 EA per 30 days); GC |
| <i>cholestyramine (with sugar) oral powder 4 gram</i> | 3 | |
| <i>cholestyramine (with sugar) oral powder in packet 4 gram</i> | 3 | |
| <i>cholestyramine light oral powder 4 gram</i> | 2 | GC |
| <i>cholestyramine light oral powder in packet 4 gram</i> | 2 | GC |
| <i>cholestyramine-aspartame oral powder in packet 4 gram</i> | 2 | GC |
| <i>colesevelam oral powder in packet 3.75 gram</i> | 2 | GC |
| <i>colesevelam oral tablet 625 mg</i> | 2 | GC |

Puede encontrar información sobre lo que significan los símbolos y las abreviaturas de esta tabla al principio de esta.

06/01/2024

| Nombre del medicamento | Nivel del med. | Requisitos / Limitaciones |
|---|----------------|----------------------------|
| <i>colestipol oral granules 5 gram</i> | 2 | GC |
| <i>colestipol oral packet 5 gram</i> | 2 | GC |
| <i>colestipol oral tablet 1 gram</i> | 2 | GC |
| EZALLOR SPRINKLE ORAL CAPSULE, SPRINKLE 10 MG, 20 MG, 40 MG, 5 MG | 4 | ST; QL (30 EA per 30 days) |
| <i>ezetimibe oral tablet 10 mg</i> | 1 | GC |
| <i>ezetimibe-simvastatin oral tablet 10-10 mg, 10-20 mg, 10-40 mg, 10-80 mg</i> | 6 | QL (30 EA per 30 days); GC |
| <i>fenofibrate micronized oral capsule 134 mg, 200 mg, 67 mg</i> | 2 | GC |
| <i>fenofibrate nanocrystallized oral tablet 145 mg, 48 mg</i> | 2 | GC |
| <i>fenofibrate oral tablet 160 mg, 54 mg</i> | 2 | GC |
| <i>fenofibric acid (choline) oral capsule, delayed release(dr/ec) 135 mg, 45 mg</i> | 2 | GC |
| <i>fluvastatin oral capsule 20 mg, 40 mg</i> | 6 | QL (60 EA per 30 days); GC |
| <i>fluvastatin oral tablet extended release 24 hr 80 mg</i> | 6 | QL (30 EA per 30 days); GC |
| <i>gemfibrozil oral tablet 600 mg</i> | 1 | GC |
| LIVALO ORAL TABLET 1 MG, 2 MG, 4 MG | 4 | QL (30 EA per 30 days) |
| <i>lovastatin oral tablet 10 mg, 20 mg, 40 mg</i> | 6 | QL (60 EA per 30 days); GC |
| <i>niacin oral tablet extended release 24 hr 1,000 mg, 500 mg, 750 mg</i> | 2 | QL (60 EA per 30 days); GC |
| PRALUENT PEN SUBCUTANEOUS PEN INJECTOR 150 MG/ML, 75 MG/ML | 3 | PA |
| <i>pravastatin oral tablet 10 mg, 20 mg, 40 mg, 80 mg</i> | 6 | QL (30 EA per 30 days); GC |
| <i>prevalite oral powder 4 gram</i> | 2 | GC |
| <i>prevalite oral powder in packet 4 gram</i> | 2 | GC |
| <i>rosuvastatin oral tablet 10 mg, 20 mg, 40 mg, 5 mg</i> | 6 | QL (30 EA per 30 days); GC |
| <i>simvastatin oral tablet 10 mg, 20 mg, 40 mg, 5 mg, 80 mg</i> | 6 | QL (30 EA per 30 days); GC |
| VASCEPA ORAL CAPSULE 0.5 GRAM, 1 GRAM | 4 | |
| ZYPITAMAG ORAL TABLET 2 MG, 4 MG | 4 | ST; QL (30 EA per 30 days) |
| NITRATOS | | |
| <i>isosorbide dinitrate oral tablet 10 mg, 20 mg, 30 mg, 5 mg</i> | 2 | GC |
| <i>isosorbide mononitrate oral tablet 10 mg, 20 mg</i> | 1 | GC |
| <i>isosorbide mononitrate oral tablet extended release 24 hr 120 mg, 30 mg, 60 mg</i> | 1 | GC |
| <i>nitro-bid transdermal ointment 2 %</i> | 3 | |

Puede encontrar información sobre lo que significan los símbolos y las abreviaturas de esta tabla al principio de esta.

06/01/2024

| Nombre del medicamento | Nivel del med. | Requisitos / Limitaciones |
|--|----------------|----------------------------|
| <i>nitroglycerin sublingual tablet 0.3 mg, 0.4 mg, 0.6 mg</i> | 2 | GC |
| <i>nitroglycerin transdermal patch 24 hour 0.1 mg/hr, 0.2 mg/hr, 0.4 mg/hr, 0.6 mg/hr</i> | 2 | GC |
| TRATAMIENTO CONTRA LA HIPERTENSIÓN | | |
| <i>acebutolol oral capsule 200 mg, 400 mg</i> | 2 | GC |
| <i>aliskiren oral tablet 150 mg, 300 mg</i> | 2 | GC |
| <i>amiloride oral tablet 5 mg</i> | 1 | GC |
| <i>amiloride-hydrochlorothiazide oral tablet 5-50 mg</i> | 1 | GC |
| <i>amlodipine oral tablet 10 mg, 2.5 mg, 5 mg</i> | 1 | GC |
| <i>amlodipine-benazepril oral capsule 10-20 mg, 10-40 mg, 2.5-10 mg, 5-10 mg, 5-20 mg, 5-40 mg</i> | 6 | QL (30 EA per 30 days); GC |
| <i>amlodipine-olmesartan oral tablet 10-20 mg, 10-40 mg, 5-20 mg, 5-40 mg</i> | 6 | QL (30 EA per 30 days); GC |
| <i>amlodipine-valsartan oral tablet 10-160 mg, 10-320 mg, 5-160 mg, 5-320 mg</i> | 6 | QL (30 EA per 30 days); GC |
| <i>amlodipine-valsartan-hcthiazyd oral tablet 10-160-12.5 mg, 10-160-25 mg, 10-320-25 mg, 5-160-12.5 mg, 5-160-25 mg</i> | 6 | GC |
| <i>atenolol oral tablet 100 mg, 25 mg, 50 mg</i> | 1 | GC |
| <i>atenolol-chlorthalidone oral tablet 100-25 mg, 50-25 mg</i> | 1 | GC |
| <i>benazepril oral tablet 10 mg, 20 mg, 40 mg, 5 mg</i> | 6 | GC |
| <i>benazepril-hydrochlorothiazide oral tablet 10-12.5 mg, 20-12.5 mg, 20-25 mg, 5-6.25 mg</i> | 6 | GC |
| <i>bisoprolol fumarate oral tablet 10 mg, 5 mg</i> | 1 | GC |
| <i>bisoprolol-hydrochlorothiazide oral tablet 10-6.25 mg, 2.5-6.25 mg, 5-6.25 mg</i> | 1 | GC |
| <i>bumetanide injection solution 0.25 mg/ml</i> | 2 | GC |
| <i>bumetanide oral tablet 0.5 mg, 1 mg, 2 mg</i> | 2 | GC |
| <i>candesartan oral tablet 16 mg, 4 mg, 8 mg</i> | 6 | QL (60 EA per 30 days); GC |
| <i>candesartan oral tablet 32 mg</i> | 6 | QL (30 EA per 30 days); GC |
| <i>candesartan-hydrochlorothiazid oral tablet 16-12.5 mg</i> | 6 | QL (60 EA per 30 days); GC |
| <i>candesartan-hydrochlorothiazid oral tablet 32-12.5 mg, 32-25 mg</i> | 6 | QL (30 EA per 30 days); GC |
| <i>captopril oral tablet 100 mg, 12.5 mg, 25 mg, 50 mg</i> | 6 | GC |
| <i>captopril-hydrochlorothiazide oral tablet 25-15 mg, 25-25 mg, 50-15 mg, 50-25 mg</i> | 6 | GC |

Puede encontrar información sobre lo que significan los símbolos y las abreviaturas de esta tabla al principio de esta.

06/01/2024

| Nombre del medicamento | Nivel del med. | Requisitos / Limitaciones |
|---|-----------------------|----------------------------------|
| <i>cartia xt oral capsule,extended release 24hr 120 mg, 180 mg, 240 mg, 300 mg</i> | 2 | GC |
| <i>carvedilol oral tablet 12.5 mg, 25 mg, 3.125 mg, 6.25 mg</i> | 1 | GC |
| <i>chlorthalidone oral tablet 25 mg, 50 mg</i> | 2 | GC |
| <i>clonidine hcl oral tablet 0.1 mg, 0.2 mg, 0.3 mg</i> | 1 | GC |
| <i>clonidine transdermal patch weekly 0.1 mg/24 hr, 0.2 mg/24 hr, 0.3 mg/24 hr</i> | 2 | GC |
| <i>diltiazem hcl intravenous solution 5 mg/ml</i> | 2 | GC |
| <i>diltiazem hcl oral capsule,ext.rel 24h degradable 120 mg, 180 mg, 240 mg</i> | 2 | GC |
| <i>diltiazem hcl oral capsule,extended release 12 hr 120 mg, 60 mg, 90 mg</i> | 2 | GC |
| <i>diltiazem hcl oral capsule,extended release 24 hr 120 mg, 180 mg, 240 mg, 300 mg, 360 mg, 420 mg</i> | 2 | GC |
| <i>diltiazem hcl oral capsule,extended release 24hr 120 mg, 180 mg, 240 mg, 300 mg, 360 mg</i> | 2 | GC |
| <i>diltiazem hcl oral tablet 120 mg, 30 mg, 60 mg, 90 mg</i> | 1 | GC |
| <i>diltiazem hcl oral tablet extended release 24 hr 120 mg, 180 mg, 240 mg, 300 mg, 360 mg, 420 mg</i> | 2 | GC |
| <i>dilt-xr oral capsule,ext.rel 24h degradable 120 mg, 180 mg, 240 mg</i> | 2 | GC |
| <i>doxazosin oral tablet 1 mg, 2 mg, 4 mg, 8 mg</i> | 1 | GC |
| EDARBI ORAL TABLET 40 MG, 80 MG | 4 | QL (30 EA per 30 days) |
| EDARBYCLOR ORAL TABLET 40-12.5 MG, 40-25 MG | 4 | QL (30 EA per 30 days) |
| <i>enalapril maleate oral tablet 10 mg, 2.5 mg, 20 mg, 5 mg</i> | 6 | GC |
| <i>enalapril-hydrochlorothiazide oral tablet 10-25 mg, 5-12.5 mg</i> | 6 | GC |
| <i>eplerenone oral tablet 25 mg, 50 mg</i> | 2 | GC |
| <i>felodipine oral tablet extended release 24 hr 10 mg, 2.5 mg, 5 mg</i> | 2 | GC |
| <i>fosinopril oral tablet 10 mg, 20 mg, 40 mg</i> | 6 | GC |
| <i>fosinopril-hydrochlorothiazide oral tablet 10-12.5 mg, 20-12.5 mg</i> | 6 | GC |
| <i>furosemide injection solution 10 mg/ml</i> | 2 | GC |
| <i>furosemide oral solution 10 mg/ml, 40 mg/5 ml (8 mg/ml)</i> | 1 | GC |
| <i>furosemide oral tablet 20 mg, 40 mg, 80 mg</i> | 1 | GC |

Puede encontrar información sobre lo que significan los símbolos y las abreviaturas de esta tabla al principio de esta.

06/01/2024

| Nombre del medicamento | Nivel del med. | Requisitos / Limitaciones |
|---|----------------|----------------------------|
| <i>guanfacine oral tablet 1 mg, 2 mg</i> | 3 | PA |
| <i>hydralazine injection solution 20 mg/ml</i> | 2 | GC |
| <i>hydralazine oral tablet 10 mg, 100 mg, 25 mg, 50 mg</i> | 2 | GC |
| <i>hydrochlorothiazide oral capsule 12.5 mg</i> | 1 | GC |
| <i>hydrochlorothiazide oral tablet 12.5 mg, 25 mg, 50 mg</i> | 1 | GC |
| <i>indapamide oral tablet 1.25 mg, 2.5 mg</i> | 1 | GC |
| <i>irbesartan oral tablet 150 mg, 300 mg, 75 mg</i> | 6 | QL (30 EA per 30 days); GC |
| <i>irbesartan-hydrochlorothiazide oral tablet 150-12.5 mg</i> | 6 | QL (60 EA per 30 days); GC |
| <i>irbesartan-hydrochlorothiazide oral tablet 300-12.5 mg</i> | 6 | QL (30 EA per 30 days); GC |
| <i>isradipine oral capsule 2.5 mg, 5 mg</i> | 2 | GC |
| KERENDIA ORAL TABLET 10 MG, 20 MG | 3 | QL (30 EA per 30 days) |
| <i>labetalol oral tablet 100 mg, 200 mg, 300 mg</i> | 2 | GC |
| <i>lisinopril oral tablet 10 mg, 2.5 mg, 20 mg, 30 mg, 40 mg, 5 mg</i> | 6 | GC |
| <i>lisinopril-hydrochlorothiazide oral tablet 10-12.5 mg, 20-12.5 mg, 20-25 mg</i> | 6 | GC |
| <i>losartan oral tablet 100 mg, 25 mg, 50 mg</i> | 6 | GC |
| <i>losartan-hydrochlorothiazide oral tablet 100-12.5 mg, 100-25 mg, 50-12.5 mg</i> | 6 | GC |
| <i>matzim la oral tablet extended release 24 hr 180 mg, 240 mg, 300 mg, 360 mg, 420 mg</i> | 2 | GC |
| <i>metolazone oral tablet 10 mg, 2.5 mg, 5 mg</i> | 2 | GC |
| <i>metoprolol succinate oral tablet extended release 24 hr 100 mg, 200 mg, 25 mg, 50 mg</i> | 1 | GC |
| <i>metoprolol ta-hydrochlorothiaz oral tablet 100-25 mg, 100-50 mg, 50-25 mg</i> | 2 | GC |
| <i>metoprolol tartrate intravenous solution 5 mg/5 ml</i> | 2 | GC |
| <i>metoprolol tartrate oral tablet 100 mg, 25 mg, 50 mg</i> | 1 | GC |
| <i>metyrosine oral capsule 250 mg</i> | 5^ | PA |
| <i>minoxidil oral tablet 10 mg, 2.5 mg</i> | 2 | GC |
| <i>moexipril oral tablet 15 mg, 7.5 mg</i> | 6 | GC |
| <i>nadolol oral tablet 20 mg, 40 mg, 80 mg</i> | 2 | GC |
| <i>nebivolol oral tablet 10 mg, 2.5 mg, 5 mg</i> | 2 | QL (30 EA per 30 days); GC |
| <i>nebivolol oral tablet 20 mg</i> | 2 | QL (60 EA per 30 days); GC |
| <i>nicardipine oral capsule 20 mg, 30 mg</i> | 2 | GC |

Puede encontrar información sobre lo que significan los símbolos y las abreviaturas de esta tabla al principio de esta.

06/01/2024

| Nombre del medicamento | Nivel del med. | Requisitos / Limitaciones |
|--|----------------|----------------------------|
| <i>nifedipine oral tablet extended release 24hr 30 mg, 60 mg, 90 mg</i> | 2 | GC |
| <i>nifedipine oral tablet extended release 30 mg, 60 mg, 90 mg</i> | 2 | GC |
| <i>nimodipine oral capsule 30 mg</i> | 2 | GC |
| <i>nisoldipine oral tablet extended release 24 hr 17 mg, 20 mg, 25.5 mg, 30 mg, 34 mg, 40 mg, 8.5 mg</i> | 2 | GC |
| NYMALIZE ORAL SOLUTION 60 MG/10 ML | 5 [^] | |
| NYMALIZE ORAL SYRINGE 30 MG/5 ML, 60 MG/10 ML | 5 [^] | |
| <i>olmesartan oral tablet 20 mg, 40 mg</i> | 6 | QL (30 EA per 30 days); GC |
| <i>olmesartan oral tablet 5 mg</i> | 6 | QL (60 EA per 30 days); GC |
| <i>olmesartan-amlodipin-hcthiazyd oral tablet 20-5-12.5 mg, 40-10-12.5 mg, 40-10-25 mg, 40-5-12.5 mg, 40-5-25 mg</i> | 6 | QL (30 EA per 30 days); GC |
| <i>olmesartan-hydrochlorothiazide oral tablet 20-12.5 mg, 40-12.5 mg, 40-25 mg</i> | 6 | QL (30 EA per 30 days); GC |
| <i>perindopril erbumine oral tablet 2 mg, 4 mg, 8 mg</i> | 6 | GC |
| <i>pindolol oral tablet 10 mg, 5 mg</i> | 2 | GC |
| <i>prazosin oral capsule 1 mg, 2 mg, 5 mg</i> | 2 | GC |
| <i>propranolol oral capsule, extended release 24 hr 120 mg, 160 mg, 60 mg, 80 mg</i> | 2 | GC |
| <i>propranolol oral solution 20 mg/5 ml (4 mg/ml), 40 mg/5 ml (8 mg/ml)</i> | 2 | GC |
| <i>propranolol oral tablet 10 mg, 20 mg, 40 mg, 60 mg, 80 mg</i> | 2 | GC |
| <i>quinapril oral tablet 10 mg, 20 mg, 40 mg, 5 mg</i> | 6 | GC |
| <i>quinapril-hydrochlorothiazide oral tablet 10-12.5 mg, 20-12.5 mg, 20-25 mg</i> | 6 | GC |
| <i>ramipril oral capsule 1.25 mg, 10 mg, 2.5 mg, 5 mg</i> | 6 | GC |
| <i>spironolactone oral tablet 100 mg, 25 mg, 50 mg</i> | 1 | GC |
| <i>spironolacton-hydrochlorothiaz oral tablet 25-25 mg</i> | 2 | GC |
| <i>taztia xt oral capsule, extended release 24 hr 120 mg, 180 mg, 240 mg, 300 mg, 360 mg</i> | 2 | GC |
| <i>telmisartan oral tablet 20 mg, 40 mg, 80 mg</i> | 6 | QL (30 EA per 30 days); GC |
| <i>telmisartan-amlodipine oral tablet 40-10 mg, 40-5 mg, 80-10 mg, 80-5 mg</i> | 6 | QL (30 EA per 30 days); GC |
| <i>telmisartan-hydrochlorothiazid oral tablet 40-12.5 mg, 80-25 mg</i> | 6 | QL (30 EA per 30 days); GC |
| <i>telmisartan-hydrochlorothiazid oral tablet 80-12.5 mg</i> | 6 | QL (60 EA per 30 days); GC |

Puede encontrar información sobre lo que significan los símbolos y las abreviaturas de esta tabla al principio de esta.

06/01/2024

| Nombre del medicamento | Nivel del med. | Requisitos / Limitaciones |
|---|----------------|----------------------------|
| <i>terazosin oral capsule 1 mg, 10 mg, 2 mg, 5 mg</i> | 1 | GC |
| <i>tiadylt er oral capsule,extended release 24 hr 120 mg, 180 mg, 240 mg, 300 mg, 360 mg, 420 mg</i> | 2 | GC |
| <i>timolol maleate oral tablet 10 mg, 20 mg, 5 mg</i> | 2 | GC |
| <i>torse mide oral tablet 10 mg, 100 mg, 20 mg, 5 mg</i> | 1 | GC |
| <i>trandolapril oral tablet 1 mg, 2 mg, 4 mg</i> | 6 | GC |
| <i>treprostinil sodium injection solution 1 mg/ml, 10 mg/ml, 2.5 mg/ml, 5 mg/ml</i> | 5^ | PA-NS |
| <i>triamterene-hydrochlorothiazid oral capsule 37.5-25 mg</i> | 1 | GC |
| <i>triamterene-hydrochlorothiazid oral tablet 37.5-25 mg, 75-50 mg</i> | 1 | GC |
| <i>valsartan oral tablet 160 mg, 40 mg, 80 mg</i> | 6 | QL (60 EA per 30 days); GC |
| <i>valsartan oral tablet 320 mg</i> | 6 | QL (30 EA per 30 days); GC |
| <i>valsartan-hydrochlorothiazide oral tablet 160-12.5 mg, 160-25 mg, 320-12.5 mg, 320-25 mg, 80-12.5 mg</i> | 6 | QL (30 EA per 30 days); GC |
| <i>verapamil intravenous solution 2.5 mg/ml</i> | 2 | GC |
| <i>verapamil intravenous syringe 2.5 mg/ml</i> | 2 | GC |
| <i>verapamil oral capsule, 24 hr er pellet ct 100 mg, 200 mg, 300 mg</i> | 2 | GC |
| <i>verapamil oral capsule,ext rel. pellets 24 hr 120 mg, 180 mg, 240 mg, 360 mg</i> | 2 | GC |
| <i>verapamil oral tablet 120 mg, 40 mg, 80 mg</i> | 1 | GC |
| <i>verapamil oral tablet extended release 120 mg, 180 mg, 240 mg</i> | 1 | GC |
| TRATAMIENTO PARA LA COAGULACIÓN | | |
| <i>aspirin-dipyridamole oral capsule, er multiphase 12 hr 25-200 mg</i> | 2 | GC |
| BRILINTA ORAL TABLET 60 MG, 90 MG | 3 | |
| <i>cilostazol oral tablet 100 mg, 50 mg</i> | 1 | GC |
| <i>clopidogrel oral tablet 75 mg</i> | 1 | GC |
| <i>dabigatran etexilate oral capsule 110 mg</i> | 4 | QL (120 EA per 30 days) |
| <i>dabigatran etexilate oral capsule 150 mg, 75 mg</i> | 4 | QL (60 EA per 30 days) |
| <i>dipyridamole oral tablet 25 mg, 50 mg, 75 mg</i> | 3 | PA |
| DOPTELET (10 TAB PACK) ORAL TABLET 20 MG | 5^ | PA; LA |
| DOPTELET (15 TAB PACK) ORAL TABLET 20 MG | 5^ | PA; LA |

Puede encontrar información sobre lo que significan los símbolos y las abreviaturas de esta tabla al principio de esta.

06/01/2024

| Nombre del medicamento | Nivel del med. | Requisitos / Limitaciones |
|---|----------------|---------------------------------|
| DOPTELET (30 TAB PACK) ORAL TABLET 20 MG | 5^ | PA; LA |
| ELIQUIS DVT-PE TREAT 30D START ORAL TABLETS,DOSE PACK 5 MG (74 TABS) | 3 | QL (74 EA per 30 days) |
| ELIQUIS ORAL TABLET 2.5 MG | 3 | QL (60 EA per 30 days) |
| ELIQUIS ORAL TABLET 5 MG | 3 | QL (74 EA per 30 days) |
| <i>enoxaparin subcutaneous solution 300 mg/3 ml</i> | 4 | |
| <i>enoxaparin subcutaneous syringe 100 mg/ml, 120 mg/0.8 ml, 150 mg/ml, 30 mg/0.3 ml, 40 mg/0.4 ml, 60 mg/0.6 ml, 80 mg/0.8 ml</i> | 4 | |
| <i>fondaparinux subcutaneous syringe 10 mg/0.8 ml, 5 mg/0.4 ml, 7.5 mg/0.6 ml</i> | 5^ | |
| <i>fondaparinux subcutaneous syringe 2.5 mg/0.5 ml</i> | 2 | GC |
| <i>heparin (porcine) in 5 % dex intravenous parenteral solution 20,000 unit/500 ml (40 unit/ml), 25,000 unit/250 ml(100 unit/ml), 25,000 unit/500 ml (50 unit/ml)</i> | 2 | GC |
| <i>heparin (porcine) injection solution 1,000 unit/ml, 10,000 unit/ml, 20,000 unit/ml, 5,000 unit/ml</i> | 2 | B/D; GC |
| HEPARIN(PORCINE) IN 0.45% NAACL INTRAVENOUS PARENTERAL SOLUTION 12,500 UNIT/250 ML | 3 | |
| <i>heparin(porcine) in 0.45% nacl intravenous parenteral solution 25,000 unit/250 ml, 25,000 unit/500 ml</i> | 3 | |
| <i>jantoven oral tablet 1 mg, 10 mg, 2 mg, 2.5 mg, 3 mg, 4 mg, 5 mg, 6 mg, 7.5 mg</i> | 1 | GC |
| <i>pentoxifylline oral tablet extended release 400 mg</i> | 1 | GC |
| PRADAXA ORAL CAPSULE 110 MG | 4 | QL (120 EA per 30 days) |
| PRADAXA ORAL CAPSULE 150 MG, 75 MG | 4 | QL (60 EA per 30 days) |
| <i>prasugrel oral tablet 10 mg, 5 mg</i> | 2 | GC |
| PROMACTA ORAL POWDER IN PACKET 12.5 MG | 5^ | PA; LA; QL (360 EA per 30 days) |
| PROMACTA ORAL POWDER IN PACKET 25 MG | 5^ | PA; LA; QL (180 EA per 30 days) |
| PROMACTA ORAL TABLET 12.5 MG, 25 MG | 5^ | PA; LA; QL (30 EA per 30 days) |
| PROMACTA ORAL TABLET 50 MG, 75 MG | 5^ | PA; LA; QL (60 EA per 30 days) |
| <i>warfarin oral tablet 1 mg, 10 mg, 2 mg, 2.5 mg, 3 mg, 4 mg, 5 mg, 6 mg, 7.5 mg</i> | 1 | GC |
| XARELTO DVT-PE TREAT 30D START ORAL TABLETS,DOSE PACK 15 MG (42)- 20 MG (9) | 3 | QL (51 EA per 30 days) |
| XARELTO ORAL SUSPENSION FOR RECONSTITUTION 1 MG/ML | 3 | QL (620 ML per 30 days) |

Puede encontrar información sobre lo que significan los símbolos y las abreviaturas de esta tabla al principio de esta.

06/01/2024

| Nombre del medicamento | Nivel del med. | Requisitos / Limitaciones |
|---|----------------|--|
| XARELTO ORAL TABLET 10 MG, 20 MG | 3 | QL (30 EA per 30 days) |
| XARELTO ORAL TABLET 15 MG, 2.5 MG | 3 | QL (60 EA per 30 days) |
| ENFERMEDADES RESPIRATORIAS Y ALERGIA | | |
| AGENTES ANTIHISTAMÍNICOS/ANTIALERGÉNICOS | | |
| <i>adrenalin injection solution 1 mg/ml (1 ml)</i> | 4 | |
| <i>cetirizine oral solution 1 mg/ml</i> | 1 | GC |
| <i>cyproheptadine oral tablet 4 mg</i> | 3 | PA |
| <i>desloratadine oral tablet 5 mg</i> | 2 | GC |
| <i>diphenhydramine hcl injection solution 50 mg/ml</i> | 2 | GC |
| <i>diphenhydramine hcl injection syringe 50 mg/ml</i> | 2 | GC |
| <i>epinephrine injection auto-injector 0.15 mg/0.3 ml, 0.3 mg/0.3 ml</i> | 2 | GC |
| EPINEPHRINE INJECTION AUTO-INJECTOR 0.3 MG/0.3 ML | 2 | GC |
| <i>hydroxyzine hcl oral tablet 10 mg, 25 mg, 50 mg</i> | 3 | PA |
| <i>hydroxyzine pamoate oral capsule 25 mg, 50 mg</i> | 3 | PA |
| <i>levocetirizine oral solution 2.5 mg/5 ml</i> | 2 | GC |
| <i>levocetirizine oral tablet 5 mg</i> | 2 | GC |
| <i>promethazine injection solution 25 mg/ml, 50 mg/ml</i> | 4 | PA |
| <i>promethazine oral syrup 6.25 mg/5 ml</i> | 2 | PA; GC |
| <i>promethazine oral tablet 12.5 mg, 25 mg, 50 mg</i> | 2 | PA; GC |
| AGENTES PULMONARES | | |
| <i>acetylcysteine solution 100 mg/ml (10 %), 200 mg/ml (20 %)</i> | 2 | B/D; GC |
| ADEMPAS ORAL TABLET 0.5 MG, 1 MG, 1.5 MG, 2 MG, 2.5 MG | 5 [^] | PA-NS; LA; QL (90 EA per 30 days) |
| ADVAIR HFA INHALATION HFA AEROSOL INHALER 115-21 MCG/ACTUATION, 230-21 MCG/ACTUATION, 45-21 MCG/ACTUATION | 3 | QL (12 GM per 30 days) |
| <i>albuterol sulfate inhalation hfa aerosol inhaler 90 mcg/actuation</i> | 2 | 8.5 gm inhaler; QL (17 GM per 30 days); GC |
| <i>albuterol sulfate inhalation hfa aerosol inhaler 90 mcg/actuation (nda020503)</i> | 2 | 6.7 gm inhaler; QL (13.4 GM per 30 days); GC |
| ALBUTEROL SULFATE INHALATION HFA AEROSOL INHALER 90 MCG/ACTUATION (NDA020983) | 2 | 18 gm inhaler; QL (36 GM per 30 days); GC |
| <i>albuterol sulfate inhalation solution for nebulization 0.63 mg/3 ml, 1.25 mg/3 ml, 2.5 mg /3 ml (0.083 %), 2.5 mg/0.5 ml</i> | 2 | B/D; GC |

Puede encontrar información sobre lo que significan los símbolos y las abreviaturas de esta tabla al principio de esta.

06/01/2024

| Nombre del medicamento | Nivel del med. | Requisitos / Limitaciones |
|---|----------------|---|
| <i>albuterol sulfate inhalation solution for nebulization 5 mg/ml</i> | 2 | GC |
| <i>albuterol sulfate oral syrup 2 mg/5 ml</i> | 2 | GC |
| <i>albuterol sulfate oral tablet 2 mg, 4 mg</i> | 2 | GC |
| <i>alyq oral tablet 20 mg</i> | 5^ | PA-NS; QL (60 EA per 30 days) |
| <i>ambrisentan oral tablet 10 mg, 5 mg</i> | 5^ | PA-NS; LA; QL (30 EA per 30 days) |
| ANORO ELLIPTA INHALATION BLISTER WITH DEVICE 62.5-25 MCG/ACTUATION | 3 | QL (60 EA per 30 days) |
| <i>arformoterol inhalation solution for nebulization 15 mcg/2 ml</i> | 4 | B/D; QL (120 ML per 30 days) |
| ARNUITY ELLIPTA INHALATION BLISTER WITH DEVICE 100 MCG/ACTUATION, 200 MCG/ACTUATION, 50 MCG/ACTUATION | 3 | QL (30 EA per 30 days) |
| ATROVENT HFA INHALATION HFA AEROSOL INHALER 17 MCG/ACTUATION | 4 | QL (25.8 GM per 30 days) |
| BERINERT INTRAVENOUS KIT 500 UNIT (10 ML) | 5^ | PA; LA; QL (24 EA per 30 days) |
| BEVESPI AEROSPHERE INHALATION HFA AEROSOL INHALER 9-4.8 MCG | 3 | QL (10.7 GM per 30 days) |
| <i>bosentan oral tablet 125 mg, 62.5 mg</i> | 5^ | PA-NS; LA; QL (60 EA per 30 days) |
| BREO ELLIPTA INHALATION BLISTER WITH DEVICE 100-25 MCG/DOSE, 200-25 MCG/DOSE, 50-25 MCG/DOSE | 3 | QL (60 EA per 30 days) |
| <i>breynga inhalation hfa aerosol inhaler 160-4.5 mcg/actuation, 80-4.5 mcg/actuation</i> | 3 | QL (30.9 GM per 30 days) |
| BREZTRI AEROSPHERE INHALATION HFA AEROSOL INHALER 160-9-4.8 MCG/ACTUATION | 3 | Retail Inhalation Canister (10.7g inhaler containing 120 inhalations); QL (10.7 GM per 30 days) |
| <i>budesonide inhalation suspension for nebulization 0.25 mg/2 ml</i> | 4 | B/D |
| <i>budesonide inhalation suspension for nebulization 0.5 mg/2 ml</i> | 3 | B/D |
| COMBIVENT RESPIMAT INHALATION MIST 20-100 MCG/ACTUATION | 4 | QL (8 GM per 30 days) |
| <i>cromolyn inhalation solution for nebulization 20 mg/2 ml</i> | 4 | B/D |
| FASENRA PEN SUBCUTANEOUS AUTO-INJECTOR 30 MG/ML | 5^ | PA; LA; QL (1 ML per 28 days) |
| FASENRA SUBCUTANEOUS SYRINGE 30 MG/ML | 5^ | PA; LA; QL (1 ML per 28 days) |
| <i>flunisolide nasal spray, non-aerosol 25 mcg (0.025 %)</i> | 2 | QL (75 ML per 30 days); GC |

Puede encontrar información sobre lo que significan los símbolos y las abreviaturas de esta tabla al principio de esta.

06/01/2024

| Nombre del medicamento | Nivel del med. | Requisitos / Limitaciones |
|--|----------------|-----------------------------------|
| <i>fluticasone propionate nasal spray,suspension 50 mcg/actuation</i> | 2 | QL (16 GM per 30 days); GC |
| <i>fluticasone propion-salmeterol inhalation blister with device 100-50 mcg/dose, 250-50 mcg/dose, 500-50 mcg/dose</i> | 3 | QL (60 EA per 30 days) |
| <i>formoterol fumarate inhalation solution for nebulization 20 mcg/2 ml</i> | 4 | B/D; QL (120 ML per 30 days) |
| HAEGARDA SUBCUTANEOUS RECON SOLN 2,000 UNIT | 5^ | PA; LA; QL (30 EA per 30 days) |
| HAEGARDA SUBCUTANEOUS RECON SOLN 3,000 UNIT | 5^ | PA; LA; QL (20 EA per 30 days) |
| <i>icatibant subcutaneous syringe 30 mg/3 ml</i> | 5^ | PA; QL (27 ML per 30 days) |
| INCRUSE ELLIPTA INHALATION BLISTER WITH DEVICE 62.5 MCG/ACTUATION | 3 | QL (30 EA per 30 days) |
| <i>ipratropium bromide inhalation solution 0.02 %</i> | 2 | B/D; GC |
| <i>ipratropium-albuterol inhalation solution for nebulization 0.5 mg-3 mg(2.5 mg base)/3 ml</i> | 2 | B/D; GC |
| KALYDECO ORAL GRANULES IN PACKET 13.4 MG, 5.8 MG | 5^ | PA; QL (56 EA per 28 days) |
| KALYDECO ORAL GRANULES IN PACKET 25 MG, 50 MG, 75 MG | 5^ | PA; LA; QL (56 EA per 28 days) |
| KALYDECO ORAL TABLET 150 MG | 5^ | PA; LA; QL (56 EA per 28 days) |
| <i>levalbuterol hcl inhalation solution for nebulization 0.31 mg/3 ml, 0.63 mg/3 ml, 1.25 mg/0.5 ml, 1.25 mg/3 ml</i> | 2 | B/D; GC |
| LEVALBUTEROL TARTRATE INHALATION HFA AEROSOL INHALER 45 MCG/ACTUATION | 3 | QL (30 GM per 30 days) |
| <i>mometasone nasal spray,non-aerosol 50 mcg/actuation</i> | 2 | QL (34 GM per 30 days); GC |
| <i>montelukast oral granules in packet 4 mg</i> | 2 | GC |
| <i>montelukast oral tablet 10 mg</i> | 1 | GC |
| <i>montelukast oral tablet,chewable 4 mg, 5 mg</i> | 2 | GC |
| OFEV ORAL CAPSULE 100 MG, 150 MG | 5^ | PA; LA; QL (60 EA per 30 days) |
| OPSUMIT ORAL TABLET 10 MG | 5^ | PA-NS; LA; QL (30 EA per 30 days) |
| ORKAMBI ORAL GRANULES IN PACKET 100-125 MG, 150-188 MG, 75-94 MG | 5^ | PA; LA; QL (56 EA per 28 days) |
| ORKAMBI ORAL TABLET 100-125 MG, 200-125 MG | 5^ | PA; LA; QL (112 EA per 28 days) |
| <i>pirfenidone oral capsule 267 mg</i> | 5^ | PA; QL (270 EA per 30 days) |
| <i>pirfenidone oral tablet 267 mg</i> | 5^ | PA; QL (270 EA per 30 days) |
| PIRFENIDONE ORAL TABLET 534 MG | 5^ | PA; QL (90 EA per 30 days) |
| <i>pirfenidone oral tablet 801 mg</i> | 5^ | PA; QL (90 EA per 30 days) |

Puede encontrar información sobre lo que significan los símbolos y las abreviaturas de esta tabla al principio de esta.

06/01/2024

| Nombre del medicamento | Nivel del med. | Requisitos / Limitaciones |
|---|----------------|--|
| PULMICORT FLEXHALER INHALATION AEROSOL POWDR BREATH ACTIVATED 180 MCG/ACTUATION | 4 | QL (2 EA per 30 days) |
| PULMICORT FLEXHALER INHALATION AEROSOL POWDR BREATH ACTIVATED 90 MCG/ACTUATION | 4 | QL (3 EA per 30 days) |
| PULMOZYME INHALATION SOLUTION 1 MG/ML | 5^ | B/D |
| <i>roflumilast oral tablet 250 mcg, 500 mcg</i> | 2 | GC |
| <i>sajazir subcutaneous syringe 30 mg/3 ml</i> | 5^ | PA; LA; QL (27 ML per 30 days) |
| SEREVENT DISKUS INHALATION BLISTER WITH DEVICE 50 MCG/DOSE | 3 | QL (60 EA per 30 days) |
| <i>sildenafil (pulm.hypertension) oral tablet 20 mg</i> | 2 | generic for Revatio; PA-NS; QL (90 EA per 30 days); GC |
| SYMDEKO ORAL TABLETS, SEQUENTIAL 100-150 MG (D)/ 150 MG (N), 50-75 MG (D)/ 75 MG (N) | 5^ | PA; LA; QL (56 EA per 28 days) |
| <i>tadalafil (pulm. hypertension) oral tablet 20 mg</i> | 5^ | generic for Adcirca; PA-NS; QL (60 EA per 30 days) |
| TADLIQ ORAL SUSPENSION 20 MG/5 ML (4 MG/ML) | 5^ | PA-NS; QL (300 ML per 30 days) |
| <i>terbutaline oral tablet 2.5 mg, 5 mg</i> | 2 | GC |
| THEO-24 ORAL CAPSULE, EXTENDED RELEASE 24HR 100 MG, 200 MG, 300 MG, 400 MG | 4 | |
| <i>theophylline oral elixir 80 mg/15 ml</i> | 2 | GC |
| <i>theophylline oral solution 80 mg/15 ml</i> | 2 | GC |
| <i>theophylline oral tablet extended release 12 hr 100 mg, 200 mg, 300 mg, 450 mg</i> | 2 | GC |
| <i>theophylline oral tablet extended release 24 hr 400 mg, 600 mg</i> | 2 | GC |
| TRELEGY ELLIPTA INHALATION BLISTER WITH DEVICE 100-62.5-25 MCG, 200-62.5-25 MCG | 3 | QL (60 EA per 30 days) |
| TRIKAFTA ORAL GRANULES IN PACKET, SEQUENTIAL 100-50-75MG (D) /75 MG (N), 80-40-60 MG (D) /59.5 MG (N) | 5^ | PA; QL (56 EA per 28 days) |
| TRIKAFTA ORAL TABLETS, SEQUENTIAL 100-50-75 MG(D) /150 MG (N), 50-25-37.5 MG (D)/75 MG (N) | 5^ | PA; LA; QL (84 EA per 28 days) |
| VENTAVIS INHALATION SOLUTION FOR NEBULIZATION 10 MCG/ML, 20 MCG/ML | 5^ | B/D; LA |
| VENTOLIN HFA INHALATION HFA AEROSOL INHALER 90 MCG/ACTUATION | 3 | QL (36 GM per 30 days) |
| XHANCE NASAL AEROSOL BREATH ACTIVATED 93 MCG/ACTUATION | 4 | PA; QL (32 ML per 30 days) |

Puede encontrar información sobre lo que significan los símbolos y las abreviaturas de esta tabla al principio de esta.

06/01/2024

| Nombre del medicamento | Nivel del med. | Requisitos / Limitaciones |
|--|----------------|---------------------------------|
| XOLAIR SUBCUTANEOUS AUTO-INJECTOR 150 MG/ML, 300 MG/2 ML | 5^ | PA; LA; QL (8 ML per 28 days) |
| XOLAIR SUBCUTANEOUS AUTO-INJECTOR 75 MG/0.5 ML | 5^ | PA; LA; QL (1 ML per 28 days) |
| XOLAIR SUBCUTANEOUS RECON SOLN 150 MG | 5^ | PA; LA; QL (8 EA per 28 days) |
| XOLAIR SUBCUTANEOUS SYRINGE 150 MG/ML, 300 MG/2 ML | 5^ | PA; LA; QL (8 ML per 28 days) |
| XOLAIR SUBCUTANEOUS SYRINGE 75 MG/0.5 ML | 5^ | PA; LA; QL (1 ML per 28 days) |
| <i>zafirlukast oral tablet 10 mg, 20 mg</i> | 2 | GC |
| GASTROENTEROLOGÍA | | |
| AGENTES GASTROINTESTINALES DIVERSOS | | |
| <i>alose tron oral tablet 0.5 mg</i> | 4 | PA; QL (60 EA per 30 days) |
| <i>alose tron oral tablet 1 mg</i> | 5^ | PA; QL (60 EA per 30 days) |
| <i>aprepitant oral capsule 125 mg, 40 mg, 80 mg</i> | 2 | B/D; GC |
| <i>aprepitant oral capsule, dose pack 125 mg (1)- 80 mg (2)</i> | 2 | B/D; GC |
| <i>balsalazide oral capsule 750 mg</i> | 2 | GC |
| <i>betaine oral powder 1 gram/scoop</i> | 5^ | LA |
| <i>budesonide oral capsule, delayed, extend. release 3 mg</i> | 2 | PA; QL (90 EA per 30 days); GC |
| <i>budesonide oral tablet, delayed and ext. release 9 mg</i> | 5^ | PA; QL (30 EA per 30 days) |
| <i>compro rectal suppository 25 mg</i> | 2 | GC |
| <i>constulose oral solution 10 gram/15 ml</i> | 2 | GC |
| CREON ORAL CAPSULE, DELAYED RELEASE (DR/EC) 12,000-38,000 -60,000 UNIT, 24,000-76,000 -120,000 UNIT, 3,000-9,500- 15,000 UNIT, 36,000-114,000- 180,000 UNIT, 6,000-19,000 -30,000 UNIT | 3 | |
| <i>cromolyn oral concentrate 100 mg/5 ml</i> | 2 | GC |
| <i>dronabinol oral capsule 10 mg, 2.5 mg, 5 mg</i> | 2 | B/D; QL (60 EA per 30 days); GC |
| <i>enulose oral solution 10 gram/15 ml</i> | 2 | GC |
| GATTEX 30-VIAL SUBCUTANEOUS KIT 5 MG | 5^ | PA; LA |
| GATTEX ONE-VIAL SUBCUTANEOUS KIT 5 MG | 5^ | PA; LA |
| <i>gavilyte-c oral recon soln 240-22.72-6.72 -5.84 gram</i> | 1 | GC |
| <i>gavilyte-g oral recon soln 236-22.74-6.74 -5.86 gram</i> | 1 | GC |
| <i>generlac oral solution 10 gram/15 ml</i> | 2 | GC |
| GOLYTELY ORAL RECON SOLN 236-22.74-6.74 -5.86 GRAM | 3 | |
| <i>granisetron (pf) intravenous solution 1 mg/ml (1 ml)</i> | 2 | GC |

Puede encontrar información sobre lo que significan los símbolos y las abreviaturas de esta tabla al principio de esta.

06/01/2024

| Nombre del medicamento | Nivel del med. | Requisitos / Limitaciones |
|--|----------------|--------------------------------|
| <i>granisetron hcl intravenous solution 1 mg/ml, 1 mg/ml (1 ml)</i> | 2 | GC |
| <i>granisetron hcl oral tablet 1 mg</i> | 2 | B/D; GC |
| <i>hydrocortisone rectal enema 100 mg/60 ml</i> | 2 | GC |
| <i>hydrocortisone topical cream with perineal applicator 1 %, 2.5 %</i> | 1 | GC |
| <i>lactulose oral solution 10 gram/15 ml, 10 gram/15 ml (15 ml), 20 gram/30 ml</i> | 2 | GC |
| LINZESS ORAL CAPSULE 145 MCG, 290 MCG, 72 MCG | 4 | QL (30 EA per 30 days) |
| <i>lubiprostone oral capsule 24 mcg, 8 mcg</i> | 4 | QL (60 EA per 30 days) |
| <i>meclizine oral tablet 12.5 mg, 25 mg</i> | 2 | GC |
| <i>mesalamine oral capsule (with del rel tablets) 400 mg</i> | 2 | QL (180 EA per 30 days); GC |
| <i>mesalamine oral capsule,extended release 24hr 0.375 gram</i> | 2 | QL (120 EA per 30 days); GC |
| <i>mesalamine oral tablet,delayed release (dr/ec) 1.2 gram</i> | 2 | GC |
| <i>mesalamine oral tablet,delayed release (dr/ec) 800 mg</i> | 4 | |
| <i>mesalamine rectal enema 4 gram/60 ml</i> | 2 | GC |
| <i>mesalamine rectal suppository 1,000 mg</i> | 2 | GC |
| <i>mesalamine with cleansing wipe rectal enema kit 4 gram/60 ml</i> | 2 | GC |
| <i>metoclopramide hcl injection solution 5 mg/ml</i> | 2 | GC |
| <i>metoclopramide hcl injection syringe 5 mg/ml</i> | 2 | GC |
| <i>metoclopramide hcl oral solution 5 mg/5 ml</i> | 2 | GC |
| <i>metoclopramide hcl oral tablet 10 mg, 5 mg</i> | 1 | GC |
| MOVANTIK ORAL TABLET 12.5 MG, 25 MG | 3 | QL (30 EA per 30 days) |
| OALIVA ORAL TABLET 10 MG, 5 MG | 5^ | PA; LA; QL (30 EA per 30 days) |
| <i>ondansetron hcl (pf) injection solution 4 mg/2 ml</i> | 2 | GC |
| <i>ondansetron hcl (pf) injection syringe 4 mg/2 ml</i> | 3 | |
| <i>ondansetron hcl intravenous solution 2 mg/ml</i> | 2 | GC |
| <i>ondansetron hcl oral solution 4 mg/5 ml</i> | 2 | GC |
| <i>ondansetron hcl oral tablet 4 mg, 8 mg</i> | 2 | GC |
| <i>ondansetron oral tablet,disintegrating 4 mg, 8 mg</i> | 2 | GC |
| <i>peg 3350-electrolytes oral recon soln 236-22.74-6.74 -5.86 gram</i> | 1 | GC |
| <i>peg-electrolyte soln oral recon soln 420 gram</i> | 1 | GC |

Puede encontrar información sobre lo que significan los símbolos y las abreviaturas de esta tabla al principio de esta.

06/01/2024

| Nombre del medicamento | Nivel del med. | Requisitos / Limitaciones |
|--|----------------|-----------------------------|
| PLENVU ORAL POWDER IN PACKET, SEQUENTIAL 140-9-5.2 GRAM | 4 | |
| <i>prochlorperazine edisylate injection solution 10 mg/2 ml (5 mg/ml)</i> | 2 | GC |
| <i>prochlorperazine maleate oral tablet 10 mg, 5 mg</i> | 2 | GC |
| <i>prochlorperazine rectal suppository 25 mg</i> | 2 | GC |
| <i>procto-med hc topical cream with perineal applicator 2.5 %</i> | 2 | GC |
| <i>proctosol hc topical cream with perineal applicator 2.5 %</i> | 2 | GC |
| <i>proctozone-hc topical cream with perineal applicator 2.5 %</i> | 2 | GC |
| RECTIV RECTAL OINTMENT 0.4 % (W/W) | 4 | QL (30 GM per 30 days) |
| RELISTOR SUBCUTANEOUS SOLUTION 12 MG/0.6 ML | 5^ | PA |
| RELISTOR SUBCUTANEOUS SYRINGE 12 MG/0.6 ML, 8 MG/0.4 ML | 5^ | PA |
| REMICADE INTRAVENOUS RECON SOLN 100 MG | 5^ | PA |
| <i>scopolamine base transdermal patch 3 day 1 mg over 3 days</i> | 4 | PA; QL (10 EA per 30 days) |
| SKYRIZI INTRAVENOUS SOLUTION 60 MG/ML | 5^ | PA; QL (30 ML per 135 days) |
| SKYRIZI SUBCUTANEOUS WEARABLE INJECTOR 180 MG/1.2 ML (150 MG/ML) | 5^ | PA; QL (1.2 ML per 56 days) |
| SKYRIZI SUBCUTANEOUS WEARABLE INJECTOR 360 MG/2.4 ML (150 MG/ML) | 5^ | PA; QL (2.4 ML per 56 days) |
| <i>sodium,potassium,mag sulfates oral recon soln 17.5-3.13-1.6 gram, 17.5-3.13-1.6 gram 2 pack (480ml)</i> | 2 | GC |
| SUCRAID ORAL SOLUTION 8,500 UNIT/ML | 5^ | PA |
| <i>sulfasalazine oral tablet 500 mg</i> | 2 | GC |
| <i>sulfasalazine oral tablet,delayed release (dr/ec) 500 mg</i> | 2 | GC |
| SUPREP BOWEL PREP KIT ORAL RECON SOLN 17.5-3.13-1.6 GRAM | 4 | |
| <i>ursodiol oral capsule 300 mg</i> | 3 | |
| <i>ursodiol oral tablet 250 mg, 500 mg</i> | 3 | |
| ZENPEP ORAL CAPSULE,DELAYED RELEASE(DR/EC) 10,000-32,000 -42,000 UNIT, 15,000-47,000 -63,000 UNIT, 20,000-63,000- 84,000 UNIT, 25,000-79,000- 105,000 UNIT, 3,000-10,000 -14,000-UNIT, 40,000-126,000- 168,000 UNIT, 5,000-17,000- 24,000 UNIT, 60,000-189,600- 252,600 UNIT | 4 | |

Puede encontrar información sobre lo que significan los símbolos y las abreviaturas de esta tabla al principio de esta.

06/01/2024

| Nombre del medicamento | Nivel del med. | Requisitos / Limitaciones |
|---|----------------|-----------------------------|
| ANTIDIARREICOS/ANTIESPASMÓDICOS | | |
| <i>dicyclomine oral capsule 10 mg</i> | 3 | |
| <i>dicyclomine oral solution 10 mg/5 ml</i> | 4 | |
| <i>dicyclomine oral tablet 20 mg</i> | 3 | |
| <i>diphenoxylate-atropine oral liquid 2.5-0.025 mg/5 ml</i> | 4 | |
| <i>diphenoxylate-atropine oral tablet 2.5-0.025 mg</i> | 3 | |
| <i>glycopyrrolate oral tablet 1 mg, 2 mg</i> | 2 | GC |
| <i>loperamide oral capsule 2 mg</i> | 2 | GC |
| TRATAMIENTO PARA LAS ÚLCERAS | | |
| CARAFATE ORAL SUSPENSION 100 MG/ML | 4 | |
| <i>dexlansoprazole oral capsule,biphase delayed releas 30 mg, 60 mg</i> | 2 | GC |
| <i>esomeprazole magnesium oral capsule,delayed release(dr/ec) 20 mg</i> | 2 | GC |
| <i>esomeprazole magnesium oral capsule,delayed release(dr/ec) 40 mg</i> | 2 | QL (60 EA per 30 days); GC |
| <i>famotidine (pf) intravenous solution 20 mg/2 ml</i> | 2 | GC |
| <i>famotidine (pf)-nacl (iso-os) intravenous piggyback 20 mg/50 ml</i> | 3 | |
| <i>famotidine intravenous solution 10 mg/ml</i> | 2 | GC |
| <i>famotidine oral suspension for reconstitution 40 mg/5 ml (8 mg/ml)</i> | 2 | QL (300 ML per 30 days); GC |
| <i>famotidine oral tablet 20 mg</i> | 1 | QL (120 EA per 30 days); GC |
| <i>famotidine oral tablet 40 mg</i> | 1 | QL (60 EA per 30 days); GC |
| <i>lansoprazole oral capsule,delayed release(dr/ec) 15 mg</i> | 2 | GC |
| <i>lansoprazole oral capsule,delayed release(dr/ec) 30 mg</i> | 2 | QL (60 EA per 30 days); GC |
| <i>lansoprazole oral tablet,disintegrat, delay rel 15 mg, 30 mg</i> | 4 | |
| <i>misoprostol oral tablet 100 mcg, 200 mcg</i> | 2 | GC |
| <i>nizatidine oral capsule 150 mg, 300 mg</i> | 2 | GC |
| <i>omeprazole oral capsule,delayed release(dr/ec) 10 mg, 20 mg</i> | 1 | GC |
| <i>omeprazole oral capsule,delayed release(dr/ec) 40 mg</i> | 1 | QL (60 EA per 30 days); GC |
| <i>pantoprazole intravenous recon soln 40 mg</i> | 2 | GC |
| <i>pantoprazole oral tablet,delayed release (dr/ec) 20 mg</i> | 1 | GC |
| <i>pantoprazole oral tablet,delayed release (dr/ec) 40 mg</i> | 1 | QL (60 EA per 30 days); GC |

Puede encontrar información sobre lo que significan los símbolos y las abreviaturas de esta tabla al principio de esta.

06/01/2024

| Nombre del medicamento | Nivel del med. | Requisitos / Limitaciones |
|--|----------------|---------------------------------------|
| <i>rabeprazole oral tablet, delayed release (dr/ec) 20 mg</i> | 2 | GC |
| <i>sucralfate oral suspension 100 mg/ml</i> | 4 | |
| <i>sucralfate oral tablet 1 gram</i> | 2 | GC |
| INMUNOLOGÍA, VACUNAS/BIOTECNOLOGÍA | | |
| MEDICAMENTOS BIOTECNOLÓGICOS | | |
| ACTIMMUNE SUBCUTANEOUS SOLUTION 100 MCG/0.5 ML | 5^ | PA-NS; LA |
| ARCALYST SUBCUTANEOUS RECON SOLN 220 MG | 5^ | PA; LA |
| BESREMI SUBCUTANEOUS SYRINGE 500 MCG/ML | 5^ | PA-NS; LA |
| BETASERON SUBCUTANEOUS KIT 0.3 MG | 5^ | PA-NS; QL (14 EA per 28 days) |
| GENOTROPIN MINIQUICK SUBCUTANEOUS SYRINGE 0.2 MG/0.25 ML, 0.4 MG/0.25 ML, 0.6 MG/0.25 ML, 0.8 MG/0.25 ML, 1 MG/0.25 ML, 1.2 MG/0.25 ML, 1.4 MG/0.25 ML, 1.6 MG/0.25 ML, 1.8 MG/0.25 ML, 2 MG/0.25 ML | 5^ | PA |
| GENOTROPIN SUBCUTANEOUS CARTRIDGE 12 MG/ML (36 UNIT/ML), 5 MG/ML (15 UNIT/ML) | 5^ | PA |
| PEGASYS SUBCUTANEOUS SOLUTION 180 MCG/ML | 5^ | PA; QL (4 ML per 28 days) |
| PEGASYS SUBCUTANEOUS SYRINGE 180 MCG/0.5 ML | 5^ | PA; QL (2 ML per 28 days) |
| PROCRIT INJECTION SOLUTION 10,000 UNIT/ML, 2,000 UNIT/ML, 3,000 UNIT/ML, 4,000 UNIT/ML | 3 | PA |
| PROCRIT INJECTION SOLUTION 20,000 UNIT/ML, 40,000 UNIT/ML | 5^ | PA |
| ZARXIO INJECTION SYRINGE 300 MCG/0.5 ML, 480 MCG/0.8 ML | 5^ | PA |
| ZIEXTENZO SUBCUTANEOUS SYRINGE 6 MG/0.6 ML | 5^ | PA |
| VACUNAS/MEDICAMENTOS INMUNOLÓGICOS DIVERSOS | | |
| ABRYSSVO INTRAMUSCULAR RECON SOLN 120 MCG/0.5 ML | 6 | IRA \$0 for age 19 and older; NM |
| ACTHIB (PF) INTRAMUSCULAR RECON SOLN 10 MCG/0.5 ML | 6 | NM |
| ADACEL(TDAP ADOLESN/ADULT)(PF) INTRAMUSCULAR SUSPENSION 2 LF-(2.5-5-3-5 MCG)-5LF/0.5 ML | 6 | NM |
| ADACEL(TDAP ADOLESN/ADULT)(PF) INTRAMUSCULAR SYRINGE 2 LF-(2.5-5-3-5 MCG)-5LF/0.5 ML | 6 | NM |
| AREXVY (PF) INTRAMUSCULAR SUSPENSION FOR RECONSTITUTION 120 MCG/0.5 ML | 6 | IRA \$0 for age 60 and older only; NM |
| BCG VACCINE, LIVE (PF) PERCUTANEOUS SUSPENSION FOR RECONSTITUTION 50 MG | 3 | NM |

Puede encontrar información sobre lo que significan los símbolos y las abreviaturas de esta tabla al principio de esta.

06/01/2024

| Nombre del medicamento | Nivel del med. | Requisitos / Limitaciones |
|---|----------------|---------------------------|
| BEXSERO INTRAMUSCULAR SYRINGE 50-50-50-25 MCG/0.5 ML | 6 | NM |
| BIVIGAM INTRAVENOUS SOLUTION 10 % | 5^ | PA; NM; LA |
| BOOSTRIX TDAP INTRAMUSCULAR SUSPENSION 2.5-8-5 LF-MCG-LF/0.5ML | 6 | NM |
| BOOSTRIX TDAP INTRAMUSCULAR SYRINGE 2.5-8-5 LF-MCG-LF/0.5ML | 6 | NM |
| DAPTACEL (DTAP PEDIATRIC) (PF) INTRAMUSCULAR SUSPENSION 15-10-5 LF-MCG-LF/0.5ML | 6 | NM |
| DENGVAXIA (PF) SUBCUTANEOUS SUSPENSION FOR RECONSTITUTION 10EXP4.5-6 CCID50/0.5 ML | 6 | NM |
| ENGERIX-B (PF) INTRAMUSCULAR SUSPENSION 20 MCG/ML | 6 | B/D; NM |
| ENGERIX-B (PF) INTRAMUSCULAR SYRINGE 20 MCG/ML | 6 | B/D; NM |
| ENGERIX-B PEDIATRIC (PF) INTRAMUSCULAR SYRINGE 10 MCG/0.5 ML | 6 | B/D; NM |
| FLEBOGAMMA DIF INTRAVENOUS SOLUTION 10 %, 5 % | 5^ | PA; NM |
| GAMASTAN INTRAMUSCULAR SOLUTION 15-18 % RANGE | 4 | NM |
| GAMMAGARD LIQUID INJECTION SOLUTION 10 % | 5^ | PA; NM |
| GAMMAGARD S-D (IGA < 1 MCG/ML) INTRAVENOUS RECON SOLN 10 GRAM, 5 GRAM | 5^ | PA; NM |
| GAMMAKED INJECTION SOLUTION 1 GRAM/10 ML (10 %), 10 GRAM/100 ML (10 %), 20 GRAM/200 ML (10 %), 5 GRAM/50 ML (10 %) | 5^ | PA; NM |
| GAMMAPLEX (WITH SORBITOL) INTRAVENOUS SOLUTION 5 % | 5^ | PA; NM; LA |
| GAMMAPLEX INTRAVENOUS SOLUTION 10 %, 10 % (100 ML), 10 % (200 ML) | 5^ | PA; NM; LA |
| GAMUNEX-C INJECTION SOLUTION 1 GRAM/10 ML (10 %), 10 GRAM/100 ML (10 %), 2.5 GRAM/25 ML (10 %), 20 GRAM/200 ML (10 %), 40 GRAM/400 ML (10 %), 5 GRAM/50 ML (10 %) | 5^ | PA; NM |
| GARDASIL 9 (PF) INTRAMUSCULAR SUSPENSION 0.5 ML | 6 | NM |
| GARDASIL 9 (PF) INTRAMUSCULAR SYRINGE 0.5 ML | 6 | NM |
| HAVRIX (PF) INTRAMUSCULAR SYRINGE 1,440 ELISA UNIT/ML, 720 ELISA UNIT/0.5 ML | 6 | NM |
| HEPLISAV-B (PF) INTRAMUSCULAR SYRINGE 20 MCG/0.5 ML | 6 | B/D; NM |

Puede encontrar información sobre lo que significan los símbolos y las abreviaturas de esta tabla al principio de esta.

06/01/2024

| Nombre del medicamento | Nivel del med. | Requisitos / Limitaciones |
|--|----------------|---------------------------|
| HIBERIX (PF) INTRAMUSCULAR RECON SOLN 10 MCG/0.5 ML | 6 | NM |
| IMOVAX RABIES VACCINE (PF) INTRAMUSCULAR RECON SOLN 2.5 UNIT | 6 | B/D; NM |
| INFANRIX (DTAP) (PF) INTRAMUSCULAR SYRINGE 25-58-10 LF-MCG-LF/0.5ML | 6 | NM |
| IPOL INJECTION SUSPENSION 40-8-32 UNIT/0.5 ML | 6 | NM |
| IXCHIQ INTRAMUSCULAR RECON SOLN 1,000 TCID50/0.5 ML | 6 | NM |
| IXIARO (PF) INTRAMUSCULAR SYRINGE 6 MCG/0.5 ML | 6 | NM |
| JYNNEOS (PF) SUBCUTANEOUS SUSPENSION 0.5X TO 3.95X 10EXP8 UNIT/0.5 | 6 | NM |
| KINRIX (PF) INTRAMUSCULAR SYRINGE 25 LF-58 MCG-10 LF/0.5 ML | 6 | NM |
| MENACTRA (PF) INTRAMUSCULAR SOLUTION 4 MCG/0.5 ML | 6 | NM |
| MENQUADFI (PF) INTRAMUSCULAR SOLUTION 10 MCG/0.5 ML | 6 | NM |
| MENVEO A-C-Y-W-135-DIP (PF) INTRAMUSCULAR KIT 10-5 MCG/0.5 ML | 6 | NM |
| MENVEO A-C-Y-W-135-DIP (PF) INTRAMUSCULAR SOLUTION 10-5 MCG/0.5 ML | 6 | NM |
| M-M-R II (PF) SUBCUTANEOUS RECON SOLN 1,000-12,500 TCID50/0.5 ML | 6 | NM |
| OCTAGAM INTRAVENOUS SOLUTION 10 %, 5 % | 5^ | PA; NM |
| PANZYGA INTRAVENOUS SOLUTION 10 %, 10 % (100 ML), 10 % (200 ML), 10 % (25 ML), 10 % (300 ML), 10 % (50 ML) | 5^ | PA; NM |
| PEDIARIX (PF) INTRAMUSCULAR SYRINGE 10 MCG-25LF-25 MCG-10LF/0.5 ML | 6 | NM |
| PEDVAX HIB (PF) INTRAMUSCULAR SOLUTION 7.5 MCG/0.5 ML | 6 | NM |
| PENBRAYA (PF) INTRAMUSCULAR KIT 5-120 MCG/0.5 ML | 6 | NM |
| PENTACEL (PF) INTRAMUSCULAR KIT 15LF-48MCG-62DU - 10 MCG/0.5ML | 6 | NM |
| PREHEVBRIO (PF) INTRAMUSCULAR SUSPENSION 10 MCG/ML | 6 | B/D; NM |

Puede encontrar información sobre lo que significan los símbolos y las abreviaturas de esta tabla al principio de esta.

06/01/2024

| Nombre del medicamento | Nivel del med. | Requisitos / Limitaciones |
|--|----------------|--|
| PRIORIX (PF) SUBCUTANEOUS SUSPENSION FOR RECONSTITUTION 10EXP3.4-4.2- 3.3CCID50/0.5ML | 6 | NM |
| PRIVIGEN INTRAVENOUS SOLUTION 10 % | 5^ | PA; NM |
| PROQUAD (PF) SUBCUTANEOUS SUSPENSION FOR RECONSTITUTION 10EXP3-4.3-3- 3.99 TCID50/0.5 | 6 | NM |
| QUADRACEL (PF) INTRAMUSCULAR SUSPENSION 15 LF-48 MCG- 5 LF UNIT/0.5ML, 15 LF-48 MCG- 5 LF UNIT/0.5ML (58 UNT/ML) | 6 | NM |
| QUADRACEL (PF) INTRAMUSCULAR SYRINGE 15 LF-48 MCG- 5 LF UNIT/0.5ML | 6 | NM |
| RABAVERT (PF) INTRAMUSCULAR SUSPENSION FOR RECONSTITUTION 2.5 UNIT | 6 | B/D; NM |
| RECOMBIVAX HB (PF) INTRAMUSCULAR SUSPENSION 10 MCG/ML, 40 MCG/ML, 5 MCG/0.5 ML | 6 | B/D; NM |
| RECOMBIVAX HB (PF) INTRAMUSCULAR SYRINGE 10 MCG/ML, 5 MCG/0.5 ML | 6 | B/D; NM |
| ROTARIX ORAL SUSPENSION 10EXP6 CCID50 /1.5 ML | 6 | NM |
| ROTARIX ORAL SUSPENSION FOR RECONSTITUTION 10EXP6 CCID50/ML | 6 | NM |
| ROTATEQ VACCINE ORAL SOLUTION 2 ML | 6 | NM |
| SHINGRIX (PF) INTRAMUSCULAR SUSPENSION FOR RECONSTITUTION 50 MCG/0.5 ML | 6 | A third dose may be considered in post-transplant members (PA required).; NM; QL (2 EA per 999 days) |
| STAMARIL (PF) SUBCUTANEOUS SUSPENSION FOR RECONSTITUTION 1,000 UNIT/0.5 ML | 6 | NM |
| TDVAX INTRAMUSCULAR SUSPENSION 2-2 LF UNIT/0.5 ML | 6 | B/D; NM |
| TENIVAC (PF) INTRAMUSCULAR SUSPENSION 5 LF UNIT- 2 LF UNIT/0.5ML | 6 | B/D; NM |
| TENIVAC (PF) INTRAMUSCULAR SYRINGE 5-2 LF UNIT/0.5 ML | 6 | B/D; NM |
| TETANUS,DIPHTHERIA TOX PED(PF) INTRAMUSCULAR SUSPENSION 5-25 LF UNIT/0.5 ML | 6 | B/D; NM |
| TICOVAC INTRAMUSCULAR SYRINGE 1.2 MCG/0.25 ML, 2.4 MCG/0.5 ML | 6 | NM |
| TRUMENBA INTRAMUSCULAR SYRINGE 120 MCG/0.5 ML | 6 | NM |
| TWINRIX (PF) INTRAMUSCULAR SYRINGE 720 ELISA UNIT- 20 MCG/ML | 6 | NM |

Puede encontrar información sobre lo que significan los símbolos y las abreviaturas de esta tabla al principio de esta.

06/01/2024

| Nombre del medicamento | Nivel del med. | Requisitos / Limitaciones |
|---|----------------|---------------------------|
| TYPHIM VI INTRAMUSCULAR SOLUTION 25 MCG/0.5 ML | 6 | NM |
| TYPHIM VI INTRAMUSCULAR SYRINGE 25 MCG/0.5 ML | 6 | NM |
| VAQTA (PF) INTRAMUSCULAR SUSPENSION 25 UNIT/0.5 ML, 50 UNIT/ML | 6 | NM |
| VAQTA (PF) INTRAMUSCULAR SYRINGE 25 UNIT/0.5 ML, 50 UNIT/ML | 6 | NM |
| VARIVAX (PF) SUBCUTANEOUS SUSPENSION FOR RECONSTITUTION 1,350 UNIT/0.5 ML | 6 | NM |
| YF-VAX (PF) SUBCUTANEOUS SUSPENSION FOR RECONSTITUTION 10 EXP4.74 UNIT/0.5 ML, 10 EXP4.74 UNIT/0.5 ML(2.5 ML IN 1 VIAL) | 6 | NM |

MEDICAMENTOS

ANTINEOPLÁSICOS/INMUNOSUPRESORES

AGENTES COMPLEMENTARIOS

| | | |
|---|----|-------|
| <i>leucovorin calcium oral tablet 10 mg, 15 mg, 25 mg, 5 mg</i> | 2 | GC |
| MESNEX ORAL TABLET 400 MG | 5^ | |
| XGEVA SUBCUTANEOUS SOLUTION 120 MG/1.7 ML (70 MG/ML) | 5^ | PA-NS |

MEDICAMENTOS

ANTINEOPLÁSICOS/INMUNOSUPRESORES

| | | |
|--|----|------------------------------------|
| <i>abiraterone oral tablet 250 mg</i> | 4 | PA-NS; QL (120 EA per 30 days) |
| <i>abiraterone oral tablet 500 mg</i> | 4 | PA-NS; QL (60 EA per 30 days) |
| AKEEGA ORAL TABLET 100-500 MG, 50-500 MG | 5^ | PA-NS; LA; QL (60 EA per 30 days) |
| ALECENSA ORAL CAPSULE 150 MG | 5^ | PA-NS; LA; QL (240 EA per 30 days) |
| ALUNBRIG ORAL TABLET 180 MG, 90 MG | 5^ | PA-NS; LA; QL (30 EA per 30 days) |
| ALUNBRIG ORAL TABLET 30 MG | 5^ | PA-NS; LA; QL (60 EA per 30 days) |
| ALUNBRIG ORAL TABLETS,DOSE PACK 90 MG (7)- 180 MG (23) | 5^ | PA-NS; LA; QL (30 EA per 180 days) |
| <i>anastrozole oral tablet 1 mg</i> | 1 | GC |
| AUGTYRO ORAL CAPSULE 40 MG | 5^ | PA-NS; QL (240 EA per 30 days) |
| AYVAKIT ORAL TABLET 100 MG, 200 MG, 25 MG, 300 MG, 50 MG | 5^ | PA-NS; LA; QL (30 EA per 30 days) |
| <i>azacitidine injection recon soln 100 mg</i> | 5^ | B/D |
| <i>azathioprine oral tablet 50 mg</i> | 2 | B/D; GC |
| BALVERSA ORAL TABLET 3 MG, 4 MG, 5 MG | 5^ | PA-NS; LA |
| BENDEKA INTRAVENOUS SOLUTION 25 MG/ML | 5^ | B/D |

Puede encontrar información sobre lo que significan los símbolos y las abreviaturas de esta tabla al principio de esta.

06/01/2024

| Nombre del medicamento | Nivel del med. | Requisitos / Limitaciones |
|---|----------------|------------------------------------|
| <i>bexarotene oral capsule 75 mg</i> | 5^ | PA-NS |
| <i>bexarotene topical gel 1 %</i> | 5^ | PA-NS; QL (60 GM per 30 days) |
| <i>bicalutamide oral tablet 50 mg</i> | 2 | GC |
| BORTEZOMIB INJECTION RECON SOLN 1 MG, 2.5 MG | 5^ | PA-NS |
| <i>bortezomib injection recon soln 3.5 mg</i> | 5^ | PA-NS |
| BOSULIF ORAL CAPSULE 100 MG | 5^ | PA-NS; QL (90 EA per 30 days) |
| BOSULIF ORAL CAPSULE 50 MG | 5^ | PA-NS; QL (30 EA per 30 days) |
| BOSULIF ORAL TABLET 100 MG | 5^ | PA-NS; QL (90 EA per 30 days) |
| BOSULIF ORAL TABLET 400 MG, 500 MG | 5^ | PA-NS; QL (30 EA per 30 days) |
| BRAFTOVI ORAL CAPSULE 75 MG | 5^ | PA-NS; LA; QL (180 EA per 30 days) |
| BRUKINSA ORAL CAPSULE 80 MG | 5^ | PA-NS; LA; QL (120 EA per 30 days) |
| CABOMETYX ORAL TABLET 20 MG, 40 MG, 60 MG | 5^ | PA-NS; LA; QL (30 EA per 30 days) |
| CALQUENCE (ACALABRUTINIB MAL) ORAL TABLET 100 MG | 5^ | PA-NS; LA; QL (60 EA per 30 days) |
| CALQUENCE ORAL CAPSULE 100 MG | 5^ | PA-NS; LA; QL (60 EA per 30 days) |
| CAPRELSA ORAL TABLET 100 MG | 5^ | PA-NS; LA; QL (60 EA per 30 days) |
| CAPRELSA ORAL TABLET 300 MG | 5^ | PA-NS; LA; QL (30 EA per 30 days) |
| <i>carboplatin intravenous solution 10 mg/ml</i> | 2 | B/D; GC |
| <i>cisplatin intravenous solution 1 mg/ml</i> | 2 | B/D; GC |
| COLUMVI INTRAVENOUS SOLUTION 1 MG/ML | 5^ | B/D |
| COMETRIQ ORAL CAPSULE 100 MG/DAY(80 MG X1-20 MG X1) | 5^ | PA-NS; LA; QL (56 EA per 28 days) |
| COMETRIQ ORAL CAPSULE 140 MG/DAY(80 MG X1-20 MG X3) | 5^ | PA-NS; LA; QL (112 EA per 28 days) |
| COMETRIQ ORAL CAPSULE 60 MG/DAY (20 MG X 3/DAY) | 5^ | PA-NS; LA; QL (84 EA per 28 days) |
| COPIKTRA ORAL CAPSULE 15 MG, 25 MG | 5^ | PA-NS; LA; QL (60 EA per 30 days) |
| COTELLIC ORAL TABLET 20 MG | 5^ | PA-NS; LA; QL (63 EA per 28 days) |
| <i>cyclophosphamide intravenous recon soln 1 gram, 2 gram, 500 mg</i> | 5^ | B/D |
| CYCLOPHOSPHAMIDE INTRAVENOUS SOLUTION 200 MG/ML | 5^ | B/D |
| <i>cyclophosphamide oral capsule 25 mg, 50 mg</i> | 2 | B/D; GC |
| CYCLOPHOSPHAMIDE ORAL TABLET 25 MG, 50 MG | 4 | B/D |
| <i>cyclosporine intravenous solution 250 mg/5 ml</i> | 2 | GC |
| <i>cyclosporine modified oral capsule 100 mg, 25 mg, 50 mg</i> | 2 | B/D; GC |

Puede encontrar información sobre lo que significan los símbolos y las abreviaturas de esta tabla al principio de esta.

06/01/2024

| Nombre del medicamento | Nivel del med. | Requisitos / Limitaciones |
|---|----------------|------------------------------------|
| <i>cyclosporine modified oral solution 100 mg/ml</i> | 2 | B/D; GC |
| <i>cyclosporine oral capsule 100 mg, 25 mg</i> | 2 | B/D; GC |
| <i>cytarabine injection solution 20 mg/ml</i> | 2 | GC |
| DAURISMO ORAL TABLET 100 MG | 5^ | PA-NS; LA; QL (30 EA per 30 days) |
| DAURISMO ORAL TABLET 25 MG | 5^ | PA-NS; LA; QL (60 EA per 30 days) |
| <i>docetaxel intravenous solution 160 mg/16 ml (10 mg/ml), 160 mg/8 ml (20 mg/ml), 20 mg/2 ml (10 mg/ml), 20 mg/ml (1 ml), 80 mg/4 ml (20 mg/ml), 80 mg/8 ml (10 mg/ml)</i> | 5^ | B/D |
| <i>doxorubicin intravenous solution 10 mg/5 ml, 2 mg/ml, 20 mg/10 ml, 50 mg/25 ml</i> | 2 | B/D; GC |
| <i>doxorubicin, peg-liposomal intravenous suspension 2 mg/ml</i> | 5^ | B/D |
| DROXIA ORAL CAPSULE 200 MG, 300 MG, 400 MG | 3 | |
| ELIGARD (3 MONTH) SUBCUTANEOUS SYRINGE 22.5 MG | 4 | PA-NS |
| ELIGARD (4 MONTH) SUBCUTANEOUS SYRINGE 30 MG | 4 | PA-NS |
| ELIGARD (6 MONTH) SUBCUTANEOUS SYRINGE 45 MG | 4 | PA-NS |
| ELIGARD SUBCUTANEOUS SYRINGE 7.5 MG (1 MONTH) | 4 | PA-NS |
| ELLENCEN INTRAVENOUS SOLUTION 200 MG/100 ML, 50 MG/25 ML | 4 | B/D |
| ELREXFO SUBCUTANEOUS SOLUTION 40 MG/ML | 5^ | PA-NS |
| EMCYT ORAL CAPSULE 140 MG | 4 | |
| ENVARBUS XR ORAL TABLET EXTENDED RELEASE 24 HR 0.75 MG, 1 MG, 4 MG | 4 | B/D |
| EPKINLY SUBCUTANEOUS SOLUTION 4 MG/0.8 ML, 48 MG/0.8 ML | 5^ | B/D |
| ERIVEDGE ORAL CAPSULE 150 MG | 5^ | PA-NS; LA; QL (30 EA per 30 days) |
| ERLEADA ORAL TABLET 240 MG | 5^ | PA-NS; QL (30 EA per 30 days) |
| ERLEADA ORAL TABLET 60 MG | 5^ | PA-NS; LA; QL (120 EA per 30 days) |
| <i>erlotinib oral tablet 100 mg, 150 mg</i> | 5^ | PA-NS; QL (30 EA per 30 days) |
| <i>erlotinib oral tablet 25 mg</i> | 5^ | PA-NS; QL (90 EA per 30 days) |
| <i>etoposide intravenous solution 20 mg/ml</i> | 2 | B/D; GC |
| EULEXIN ORAL CAPSULE 125 MG | 5^ | |
| <i>everolimus (antineoplastic) oral tablet 10 mg, 2.5 mg, 5 mg, 7.5 mg</i> | 5^ | PA-NS; QL (30 EA per 30 days) |
| <i>everolimus (antineoplastic) oral tablet for suspension 2 mg</i> | 5^ | PA-NS; QL (150 EA per 30 days) |
| <i>everolimus (antineoplastic) oral tablet for suspension 3 mg</i> | 5^ | PA-NS; QL (90 EA per 30 days) |

Puede encontrar información sobre lo que significan los símbolos y las abreviaturas de esta tabla al principio de esta.

06/01/2024

| Nombre del medicamento | Nivel del med. | Requisitos / Limitaciones |
|---|----------------|------------------------------------|
| <i>everolimus (antineoplastic) oral tablet for suspension 5 mg</i> | 5^ | PA-NS; QL (60 EA per 30 days) |
| <i>everolimus (immunosuppressive) oral tablet 0.25 mg</i> | 4 | B/D |
| <i>everolimus (immunosuppressive) oral tablet 0.5 mg, 0.75 mg, 1 mg</i> | 5^ | B/D |
| <i>exemestane oral tablet 25 mg</i> | 2 | GC |
| EXKIVITY ORAL CAPSULE 40 MG | 5^ | PA-NS; LA; QL (120 EA per 30 days) |
| FIRMAGON KIT W DILUENT SYRINGE SUBCUTANEOUS RECON SOLN 120 MG | 5^ | PA-NS |
| FIRMAGON KIT W DILUENT SYRINGE SUBCUTANEOUS RECON SOLN 80 MG | 4 | PA-NS |
| <i>fluorouracil intravenous solution 1 gram/20 ml, 2.5 gram/50 ml, 5 gram/100 ml, 500 mg/10 ml</i> | 2 | GC |
| FOTIVDA ORAL CAPSULE 0.89 MG, 1.34 MG | 5^ | PA-NS; LA; QL (21 EA per 28 days) |
| FRUZAQLA ORAL CAPSULE 1 MG | 5^ | PA-NS; QL (84 EA per 28 days) |
| FRUZAQLA ORAL CAPSULE 5 MG | 5^ | PA-NS; QL (21 EA per 28 days) |
| <i>fulvestrant intramuscular syringe 250 mg/5 ml</i> | 5^ | B/D |
| GAVRETO ORAL CAPSULE 100 MG | 5^ | PA-NS; LA; QL (120 EA per 30 days) |
| <i>gefitinib oral tablet 250 mg</i> | 5^ | PA-NS; QL (30 EA per 30 days) |
| <i>gemcitabine intravenous recon soln 1 gram, 2 gram, 200 mg</i> | 2 | B/D; GC |
| <i>gemcitabine intravenous solution 1 gram/26.3 ml (38 mg/ml), 2 gram/52.6 ml (38 mg/ml), 200 mg/5.26 ml (38 mg/ml)</i> | 2 | B/D; GC |
| GEMCITABINE INTRAVENOUS SOLUTION 100 MG/ML | 2 | B/D; GC |
| <i>gengraf oral capsule 100 mg, 25 mg</i> | 2 | B/D; GC |
| <i>gengraf oral solution 100 mg/ml</i> | 2 | B/D; GC |
| GILOTRIF ORAL TABLET 20 MG, 30 MG, 40 MG | 5^ | PA-NS; LA; QL (30 EA per 30 days) |
| GLEOSTINE ORAL CAPSULE 10 MG, 40 MG | 4 | |
| GLEOSTINE ORAL CAPSULE 100 MG | 5^ | |
| <i>hydroxyurea oral capsule 500 mg</i> | 2 | GC |
| IBRANCE ORAL CAPSULE 100 MG, 125 MG, 75 MG | 5^ | PA-NS; LA; QL (21 EA per 28 days) |
| IBRANCE ORAL TABLET 100 MG, 125 MG, 75 MG | 5^ | PA-NS; LA; QL (21 EA per 28 days) |
| ICLUSIG ORAL TABLET 10 MG, 15 MG, 30 MG, 45 MG | 5^ | PA-NS; LA; QL (30 EA per 30 days) |
| IDHIFA ORAL TABLET 100 MG, 50 MG | 5^ | PA-NS; LA; QL (30 EA per 30 days) |
| <i>imatinib oral tablet 100 mg</i> | 5^ | PA-NS; QL (180 EA per 30 days) |
| <i>imatinib oral tablet 400 mg</i> | 5^ | PA-NS; QL (60 EA per 30 days) |

Puede encontrar información sobre lo que significan los símbolos y las abreviaturas de esta tabla al principio de esta.

06/01/2024

| Nombre del medicamento | Nivel del med. | Requisitos / Limitaciones |
|---|----------------|------------------------------------|
| IMBRUVICA ORAL CAPSULE 140 MG | 5^ | PA-NS; LA; QL (120 EA per 30 days) |
| IMBRUVICA ORAL CAPSULE 70 MG | 5^ | PA-NS; LA; QL (30 EA per 30 days) |
| IMBRUVICA ORAL SUSPENSION 70 MG/ML | 5^ | PA-NS; LA; QL (216 ML per 27 days) |
| IMBRUVICA ORAL TABLET 420 MG, 560 MG | 5^ | PA-NS; LA; QL (30 EA per 30 days) |
| INLYTA ORAL TABLET 1 MG | 5^ | PA-NS; LA; QL (180 EA per 30 days) |
| INLYTA ORAL TABLET 5 MG | 5^ | PA-NS; LA; QL (120 EA per 30 days) |
| INQOVI ORAL TABLET 35-100 MG | 5^ | PA-NS; LA; QL (5 EA per 28 days) |
| INREBIC ORAL CAPSULE 100 MG | 5^ | PA-NS; LA; QL (120 EA per 30 days) |
| <i>irinotecan intravenous solution 100 mg/5 ml, 300 mg/15 ml, 40 mg/2 ml, 500 mg/25 ml</i> | 4 | B/D |
| IWILFIN ORAL TABLET 192 MG | 5^ | PA-NS; LA; QL (240 EA per 30 days) |
| JAKAFI ORAL TABLET 10 MG, 15 MG, 20 MG, 25 MG, 5 MG | 5^ | PA-NS; LA; QL (60 EA per 30 days) |
| JAYPIRCA ORAL TABLET 100 MG | 5^ | PA-NS; QL (60 EA per 30 days) |
| JAYPIRCA ORAL TABLET 50 MG | 5^ | PA-NS; QL (30 EA per 30 days) |
| KADCYLA INTRAVENOUS RECON SOLN 100 MG, 160 MG | 5^ | B/D |
| KEYTRUDA INTRAVENOUS SOLUTION 25 MG/ML | 5^ | PA-NS |
| KISQALI FEMARA CO-PACK ORAL TABLET 200 MG/DAY(200 MG X 1)-2.5 MG | 5^ | PA-NS; QL (49 EA per 28 days) |
| KISQALI FEMARA CO-PACK ORAL TABLET 400 MG/DAY(200 MG X 2)-2.5 MG | 5^ | PA-NS; QL (70 EA per 28 days) |
| KISQALI FEMARA CO-PACK ORAL TABLET 600 MG/DAY(200 MG X 3)-2.5 MG | 5^ | PA-NS; QL (91 EA per 28 days) |
| KISQALI ORAL TABLET 200 MG/DAY (200 MG X 1) | 5^ | PA-NS; QL (21 EA per 28 days) |
| KISQALI ORAL TABLET 400 MG/DAY (200 MG X 2) | 5^ | PA-NS; QL (42 EA per 28 days) |
| KISQALI ORAL TABLET 600 MG/DAY (200 MG X 3) | 5^ | PA-NS; QL (63 EA per 28 days) |
| KOSELUGO ORAL CAPSULE 10 MG, 25 MG | 5^ | PA |
| KRAZATI ORAL TABLET 200 MG | 5^ | PA-NS; QL (180 EA per 30 days) |
| <i>lapatinib oral tablet 250 mg</i> | 5^ | PA-NS; QL (180 EA per 30 days) |
| <i>lenalidomide oral capsule 10 mg, 15 mg, 2.5 mg, 20 mg, 25 mg, 5 mg</i> | 5^ | PA-NS; LA; QL (28 EA per 28 days) |
| LENVIMA ORAL CAPSULE 10 MG/DAY (10 MG X 1), 4 MG | 5^ | PA-NS; LA; QL (30 EA per 30 days) |
| LENVIMA ORAL CAPSULE 12 MG/DAY (4 MG X 3), 18 MG/DAY (10 MG X 1-4 MG X2), 24 MG/DAY(10 MG X 2-4 MG X 1) | 5^ | PA-NS; LA; QL (90 EA per 30 days) |

Puede encontrar información sobre lo que significan los símbolos y las abreviaturas de esta tabla al principio de esta.

06/01/2024

| Nombre del medicamento | Nivel del med. | Requisitos / Limitaciones |
|--|----------------|------------------------------------|
| LENVIMA ORAL CAPSULE 14 MG/DAY(10 MG X 1-4 MG X 1), 20 MG/DAY (10 MG X 2), 8 MG/DAY (4 MG X 2) | 5^ | PA-NS; LA; QL (60 EA per 30 days) |
| <i>letrozole oral tablet 2.5 mg</i> | 1 | GC |
| LEUKERAN ORAL TABLET 2 MG | 4 | |
| <i>leuprolide subcutaneous kit 1 mg/0.2 ml</i> | 2 | PA-NS; GC |
| LONSURF ORAL TABLET 15-6.14 MG, 20-8.19 MG | 5^ | PA-NS; LA |
| LORBRENA ORAL TABLET 100 MG | 5^ | PA-NS; LA; QL (30 EA per 30 days) |
| LORBRENA ORAL TABLET 25 MG | 5^ | PA-NS; LA; QL (90 EA per 30 days) |
| LUMAKRAS ORAL TABLET 120 MG | 5^ | PA-NS; LA |
| LUMAKRAS ORAL TABLET 320 MG | 5^ | PA-NS |
| LUPRON DEPOT INTRAMUSCULAR SYRINGE KIT 3.75 MG, 7.5 MG | 5^ | PA-NS |
| LYNPARZA ORAL TABLET 100 MG, 150 MG | 5^ | PA-NS; LA; QL (120 EA per 30 days) |
| LYSODREN ORAL TABLET 500 MG | 5^ | |
| LYTGOBI ORAL TABLET 4 MG, 4 MG (4X 4 MG TB), 4 MG (5X 4 MG TB) | 5^ | PA-NS |
| MATULANE ORAL CAPSULE 50 MG | 5^ | LA |
| <i>megestrol oral suspension 400 mg/10 ml (10 ml), 400 mg/10 ml (40 mg/ml)</i> | 3 | |
| <i>megestrol oral suspension 625 mg/5 ml (125 mg/ml)</i> | 4 | PA |
| <i>megestrol oral tablet 20 mg, 40 mg</i> | 3 | |
| MEKINIST ORAL RECON SOLN 0.05 MG/ML | 5^ | PA-NS; QL (1200 ML per 30 days) |
| MEKINIST ORAL TABLET 0.5 MG | 5^ | PA-NS; LA; QL (90 EA per 30 days) |
| MEKINIST ORAL TABLET 2 MG | 5^ | PA-NS; LA; QL (30 EA per 30 days) |
| MEKTOVI ORAL TABLET 15 MG | 5^ | PA-NS; LA; QL (180 EA per 30 days) |
| <i>mercaptopurine oral tablet 50 mg</i> | 2 | GC |
| <i>methotrexate sodium (pf) injection recon soln 1 gram</i> | 2 | B/D; GC |
| <i>methotrexate sodium (pf) injection solution 25 mg/ml</i> | 2 | B/D; GC |
| <i>methotrexate sodium injection solution 25 mg/ml</i> | 2 | B/D; GC |
| <i>methotrexate sodium oral tablet 2.5 mg</i> | 1 | GC |
| MONJUVI INTRAVENOUS RECON SOLN 200 MG | 5^ | PA-NS |
| <i>mycophenolate mofetil oral capsule 250 mg</i> | 2 | B/D; GC |
| <i>mycophenolate mofetil oral suspension for reconstitution 200 mg/ml</i> | 5^ | B/D |
| <i>mycophenolate mofetil oral tablet 500 mg</i> | 2 | B/D; GC |

Puede encontrar información sobre lo que significan los símbolos y las abreviaturas de esta tabla al principio de esta.

06/01/2024

| Nombre del medicamento | Nivel del med. | Requisitos / Limitaciones |
|--|----------------|--|
| <i>mycophenolate sodium oral tablet, delayed release (dr/ec)</i> 180 mg, 360 mg | 2 | B/D; GC |
| <i>mycophenolic acid dr 180 mg tb</i> | 2 | mycophenolate sodium = mycophenolic acid; B/D; GC |
| <i>mycophenolic acid dr 360 mg tb</i> | 2 | mycophenolate sodium = mycophenolic acid; B/D; GC |
| NERLYNX ORAL TABLET 40 MG | 5^ | PA-NS; LA |
| <i>nilutamide oral tablet 150 mg</i> | 5^ | |
| NINLARO ORAL CAPSULE 2.3 MG, 3 MG, 4 MG | 5^ | PA-NS; QL (3 EA per 28 days) |
| NUBEQA ORAL TABLET 300 MG | 5^ | PA-NS; LA; QL (120 EA per 30 days) |
| NULOJIX INTRAVENOUS RECON SOLN 250 MG | 5^ | |
| <i>octreotide acetate injection solution 1,000 mcg/ml, 500 mcg/ml</i> | 5^ | PA |
| <i>octreotide acetate injection solution 100 mcg/ml, 200 mcg/ml, 50 mcg/ml</i> | 4 | PA |
| <i>octreotide acetate injection syringe 100 mcg/ml (1 ml), 50 mcg/ml (1 ml), 500 mcg/ml (1 ml)</i> | 4 | PA |
| ODOMZO ORAL CAPSULE 200 MG | 5^ | PA-NS; LA; QL (30 EA per 30 days) |
| OJJAARA ORAL TABLET 100 MG, 150 MG, 200 MG | 5^ | PA-NS; QL (30 EA per 30 days) |
| ONUREG ORAL TABLET 200 MG, 300 MG | 4 | PA-NS; LA; QL (14 EA per 28 days) |
| ORGOVYX ORAL TABLET 120 MG | 5^ | PA-NS; LA; QL (30 EA per 28 days) |
| ORSERDU ORAL TABLET 345 MG | 5^ | PA-NS; QL (30 EA per 30 days) |
| ORSERDU ORAL TABLET 86 MG | 5^ | PA-NS; QL (90 EA per 30 days) |
| <i>oxaliplatin intravenous recon soln 100 mg, 50 mg</i> | 5^ | B/D |
| <i>oxaliplatin intravenous solution 100 mg/20 ml, 200 mg/40 ml, 50 mg/10 ml (5 mg/ml)</i> | 4 | B/D |
| <i>paclitaxel intravenous concentrate 6 mg/ml</i> | 2 | B/D; GC |
| PACLITAXEL PROTEIN-BOUND INTRAVENOUS SUSPENSION FOR RECONSTITUTION 100 MG | 5^ | B/D |
| <i>paraplatin intravenous solution 10 mg/ml</i> | 3 | B/D |
| <i>pazopanib oral tablet 200 mg</i> | 5^ | PA-NS; QL (120 EA per 30 days) |
| PEMAZYRE ORAL TABLET 13.5 MG, 4.5 MG, 9 MG | 5^ | PA-NS; LA |
| <i>pemetrexed disodium 750 mg vl</i> | 5^ | B/D |
| <i>pemetrexed disodium intravenous recon soln 1,000 mg, 500 mg</i> | 5^ | B/D |
| <i>pemetrexed disodium intravenous recon soln 100 mg</i> | 4 | B/D |

Puede encontrar información sobre lo que significan los símbolos y las abreviaturas de esta tabla al principio de esta.

06/01/2024

| Nombre del medicamento | Nivel del med. | Requisitos / Limitaciones |
|--|----------------|------------------------------------|
| PEMETREXED DISODIUM INTRAVENOUS RECON SOLN 750 MG | 5^ | B/D |
| PIQRAY ORAL TABLET 200 MG/DAY (200 MG X 1), 250 MG/DAY (200 MG X1-50 MG X1), 300 MG/DAY (150 MG X 2) | 5^ | PA-NS |
| POMALYST ORAL CAPSULE 1 MG, 2 MG, 3 MG, 4 MG | 5^ | PA-NS; LA; QL (21 EA per 28 days) |
| PROGRAF ORAL GRANULES IN PACKET 0.2 MG, 1 MG | 4 | B/D |
| PURIXAN ORAL SUSPENSION 20 MG/ML | 5^ | |
| QINLOCK ORAL TABLET 50 MG | 5^ | PA-NS; LA; QL (90 EA per 30 days) |
| RETEVMO ORAL CAPSULE 40 MG | 5^ | PA-NS; LA; QL (180 EA per 30 days) |
| RETEVMO ORAL CAPSULE 80 MG | 5^ | PA-NS; LA; QL (120 EA per 30 days) |
| REZLIDHIA ORAL CAPSULE 150 MG | 5^ | PA-NS; QL (60 EA per 30 days) |
| REZUROCK ORAL TABLET 200 MG | 5^ | PA; LA; QL (30 EA per 30 days) |
| ROZLYTREK ORAL CAPSULE 100 MG | 5^ | PA-NS; LA; QL (150 EA per 30 days) |
| ROZLYTREK ORAL CAPSULE 200 MG | 5^ | PA-NS; LA; QL (90 EA per 30 days) |
| ROZLYTREK ORAL PELLETS IN PACKET 50 MG | 5^ | PA-NS; QL (336 EA per 28 days) |
| RUBRACA ORAL TABLET 200 MG, 250 MG, 300 MG | 5^ | PA-NS; LA; QL (120 EA per 30 days) |
| RYDAPT ORAL CAPSULE 25 MG | 5^ | PA-NS; QL (224 EA per 28 days) |
| SANDIMMUNE ORAL SOLUTION 100 MG/ML | 4 | B/D |
| SCEMBLIX ORAL TABLET 20 MG | 5^ | PA-NS; QL (60 EA per 30 days) |
| SCEMBLIX ORAL TABLET 40 MG | 5^ | PA-NS; QL (300 EA per 30 days) |
| SIGNIFOR SUBCUTANEOUS SOLUTION 0.3 MG/ML (1 ML), 0.6 MG/ML (1 ML), 0.9 MG/ML (1 ML) | 5^ | PA; LA |
| <i>sirolimus oral solution 1 mg/ml</i> | 5^ | B/D |
| <i>sirolimus oral tablet 0.5 mg, 1 mg, 2 mg</i> | 2 | B/D; GC |
| SOLTAMOX ORAL SOLUTION 20 MG/10 ML | 4 | |
| SOMATULINE DEPOT SUBCUTANEOUS SYRINGE 120 MG/0.5 ML, 60 MG/0.2 ML, 90 MG/0.3 ML | 5^ | PA-NS |
| <i>sorafenib oral tablet 200 mg</i> | 5^ | PA-NS; QL (120 EA per 30 days) |
| SPRYCEL ORAL TABLET 100 MG, 140 MG, 50 MG, 80 MG | 5^ | PA-NS; QL (30 EA per 30 days) |
| SPRYCEL ORAL TABLET 20 MG, 70 MG | 5^ | PA-NS; QL (60 EA per 30 days) |
| STIVARGA ORAL TABLET 40 MG | 5^ | PA-NS; LA; QL (84 EA per 28 days) |
| <i>sunitinib malate oral capsule 12.5 mg, 25 mg, 37.5 mg, 50 mg</i> | 5^ | PA-NS; QL (30 EA per 30 days) |
| TABLOID ORAL TABLET 40 MG | 4 | |

Puede encontrar información sobre lo que significan los símbolos y las abreviaturas de esta tabla al principio de esta.

06/01/2024

| Nombre del medicamento | Nivel del med. | Requisitos / Limitaciones |
|---|----------------|------------------------------------|
| TABRECTA ORAL TABLET 150 MG, 200 MG | 5^ | PA-NS |
| <i>tacrolimus oral capsule 0.5 mg, 1 mg, 5 mg</i> | 2 | B/D; GC |
| TAFINLAR ORAL CAPSULE 50 MG, 75 MG | 5^ | PA-NS; LA; QL (120 EA per 30 days) |
| TAFINLAR ORAL TABLET FOR SUSPENSION 10 MG | 5^ | PA-NS; QL (840 EA per 28 days) |
| TAGRISSE ORAL TABLET 40 MG, 80 MG | 5^ | PA-NS; LA; QL (30 EA per 30 days) |
| TALVEY SUBCUTANEOUS SOLUTION 2 MG/ML, 40 MG/ML | 5^ | PA-NS |
| TALZENNA ORAL CAPSULE 0.1 MG, 0.35 MG | 5^ | PA-NS; QL (30 EA per 30 days) |
| TALZENNA ORAL CAPSULE 0.25 MG, 0.5 MG, 0.75 MG, 1 MG | 5^ | PA-NS; LA; QL (30 EA per 30 days) |
| <i>tamoxifen oral tablet 10 mg, 20 mg</i> | 2 | GC |
| TASIGNA ORAL CAPSULE 150 MG, 200 MG | 5^ | PA-NS; QL (112 EA per 28 days) |
| TASIGNA ORAL CAPSULE 50 MG | 5^ | PA-NS; QL (120 EA per 30 days) |
| TAZVERIK ORAL TABLET 200 MG | 5^ | PA-NS; LA |
| TECENTRIQ INTRAVENOUS SOLUTION 1,200 MG/20 ML (60 MG/ML), 840 MG/14 ML (60 MG/ML) | 5^ | PA-NS |
| TEPMETKO ORAL TABLET 225 MG | 5^ | PA-NS; LA |
| THALOMID ORAL CAPSULE 100 MG, 50 MG | 5^ | PA-NS; LA; QL (28 EA per 28 days) |
| THALOMID ORAL CAPSULE 150 MG, 200 MG | 5^ | PA-NS; LA; QL (56 EA per 28 days) |
| TIBSOVO ORAL TABLET 250 MG | 5^ | PA-NS; LA |
| <i>toremifene oral tablet 60 mg</i> | 4 | |
| TRAZIMERA INTRAVENOUS RECON SOLN 150 MG, 420 MG | 5^ | PA-NS |
| <i>tretinoin (antineoplastic) oral capsule 10 mg</i> | 5^ | |
| TREXALL ORAL TABLET 10 MG, 15 MG, 5 MG, 7.5 MG | 4 | |
| TRUQAP ORAL TABLET 160 MG, 200 MG | 5^ | PA-NS; QL (64 EA per 28 days) |
| TRUXIMA INTRAVENOUS SOLUTION 10 MG/ML | 5^ | PA-NS |
| TUKYSA ORAL TABLET 150 MG | 5^ | PA-NS; LA; QL (120 EA per 30 days) |
| TUKYSA ORAL TABLET 50 MG | 5^ | PA-NS; LA; QL (300 EA per 30 days) |
| TURALIO ORAL CAPSULE 125 MG | 5^ | PA-NS; LA; QL (120 EA per 30 days) |
| VANFLYTA ORAL TABLET 17.7 MG, 26.5 MG | 5^ | PA-NS; QL (56 EA per 28 days) |
| VENCLEXTA ORAL TABLET 10 MG | 4 | PA-NS; LA; QL (112 EA per 28 days) |
| VENCLEXTA ORAL TABLET 100 MG | 5^ | PA-NS; LA; QL (180 EA per 30 days) |
| VENCLEXTA ORAL TABLET 50 MG | 5^ | PA-NS; LA; QL (112 EA per 28 days) |
| VENCLEXTA STARTING PACK ORAL TABLETS,DOSE PACK 10 MG-50 MG- 100 MG | 5^ | PA-NS; LA; QL (42 EA per 28 days) |

Puede encontrar información sobre lo que significan los símbolos y las abreviaturas de esta tabla al principio de esta.

06/01/2024

| Nombre del medicamento | Nivel del med. | Requisitos / Limitaciones |
|--|----------------|------------------------------------|
| VERZENIO ORAL TABLET 100 MG, 150 MG, 200 MG, 50 MG | 5^ | PA-NS; LA; QL (60 EA per 30 days) |
| <i>vincristine intravenous solution 1 mg/ml, 2 mg/2 ml</i> | 2 | GC |
| <i>vinorelbine intravenous solution 10 mg/ml, 50 mg/5 ml</i> | 2 | B/D; GC |
| VITRAKVI ORAL CAPSULE 100 MG | 5^ | PA-NS; LA; QL (60 EA per 30 days) |
| VITRAKVI ORAL CAPSULE 25 MG | 5^ | PA-NS; LA; QL (180 EA per 30 days) |
| VITRAKVI ORAL SOLUTION 20 MG/ML | 5^ | PA-NS; LA; QL (300 ML per 30 days) |
| VIZIMPRO ORAL TABLET 15 MG, 30 MG, 45 MG | 5^ | PA-NS; LA; QL (30 EA per 30 days) |
| VONJO ORAL CAPSULE 100 MG | 5^ | PA-NS; LA; QL (120 EA per 30 days) |
| VOTRIENT ORAL TABLET 200 MG | 5^ | PA-NS; LA; QL (120 EA per 30 days) |
| WELIREG ORAL TABLET 40 MG | 5^ | PA-NS; LA |
| XALKORI ORAL CAPSULE 200 MG, 250 MG | 5^ | PA-NS; LA; QL (60 EA per 30 days) |
| XALKORI ORAL PELLETT 150 MG | 5^ | PA-NS; QL (180 EA per 30 days) |
| XALKORI ORAL PELLETT 20 MG, 50 MG | 5^ | PA-NS; QL (120 EA per 30 days) |
| XATMEP ORAL SOLUTION 2.5 MG/ML | 4 | |
| XERMELO ORAL TABLET 250 MG | 5^ | PA; LA; QL (84 EA per 28 days) |
| XOSPATA ORAL TABLET 40 MG | 5^ | PA-NS; LA; QL (90 EA per 30 days) |
| XPOVIO ORAL TABLET 100 MG/WEEK (20 MG X 5), 100 MG/WEEK (50 MG X 2), 40MG TWICE WEEK (40 MG X 2), 40MG TWICE WEEK (80 MG/WEEK), 80 MG/WEEK (20 MG X 4), 80 MG/WEEK (40 MG X 2) | 5^ | PA-NS; LA; QL (8 EA per 28 days) |
| XPOVIO ORAL TABLET 40 MG/WEEK (20 MG X 2), 40 MG/WEEK (40 MG X 1), 60 MG/WEEK (20 MG X 3), 60 MG/WEEK (60 MG X 1) | 5^ | PA-NS; LA; QL (4 EA per 28 days) |
| XPOVIO ORAL TABLET 60MG TWICE WEEK (120 MG/WEEK) | 5^ | PA-NS; LA; QL (24 EA per 28 days) |
| XPOVIO ORAL TABLET 80MG TWICE WEEK (160 MG/WEEK) | 5^ | PA-NS; LA; QL (32 EA per 28 days) |
| XTANDI ORAL CAPSULE 40 MG | 5^ | PA-NS; LA; QL (120 EA per 30 days) |
| XTANDI ORAL TABLET 40 MG | 5^ | PA-NS; LA; QL (120 EA per 30 days) |
| XTANDI ORAL TABLET 80 MG | 5^ | PA-NS; LA; QL (60 EA per 30 days) |
| ZEJULA ORAL CAPSULE 100 MG | 5^ | PA-NS; LA; QL (90 EA per 30 days) |
| ZEJULA ORAL TABLET 100 MG | 5^ | PA-NS; LA; QL (90 EA per 30 days) |
| ZEJULA ORAL TABLET 200 MG, 300 MG | 5^ | PA-NS; LA; QL (30 EA per 30 days) |
| ZELBORAF ORAL TABLET 240 MG | 5^ | PA-NS; LA; QL (240 EA per 30 days) |
| ZIRABEV INTRAVENOUS SOLUTION 25 MG/ML | 5^ | PA-NS |
| ZOLINZA ORAL CAPSULE 100 MG | 5^ | PA-NS; QL (120 EA per 30 days) |
| ZYDELIG ORAL TABLET 100 MG, 150 MG | 5^ | PA-NS; LA; QL (60 EA per 30 days) |

Puede encontrar información sobre lo que significan los símbolos y las abreviaturas de esta tabla al principio de esta.

06/01/2024

| Nombre del medicamento | Nivel del med. | Requisitos / Limitaciones |
|---|----------------|-----------------------------------|
| ZYKADIA ORAL TABLET 150 MG | 5^ | PA-NS; LA; QL (90 EA per 30 days) |
| MEDICAMENTOS AUTONÓMICOS/PARA EL SISTEMA NERVIOSO CENTRAL, NEUROLOGÍA/PSIQUIATRÍA | | |
| AGENTES ANTIPARKINSONIANOS | | |
| APOKYN SUBCUTANEOUS CARTRIDGE 10 MG/ML | 5^ | PA; LA; QL (90 ML per 30 days) |
| <i>apomorphine subcutaneous cartridge 10 mg/ml</i> | 5^ | PA; QL (90 ML per 30 days) |
| <i>benztropine injection solution 1 mg/ml</i> | 2 | GC |
| <i>benztropine oral tablet 0.5 mg, 1 mg, 2 mg</i> | 4 | PA |
| <i>bromocriptine oral capsule 5 mg</i> | 2 | GC |
| <i>bromocriptine oral tablet 2.5 mg</i> | 2 | GC |
| <i>carbidopa oral tablet 25 mg</i> | 2 | GC |
| <i>carbidopa-levodopa oral tablet 10-100 mg, 25-100 mg, 25-250 mg</i> | 2 | GC |
| <i>carbidopa-levodopa oral tablet extended release 25-100 mg, 50-200 mg</i> | 2 | GC |
| <i>carbidopa-levodopa oral tablet, disintegrating 10-100 mg, 25-100 mg, 25-250 mg</i> | 2 | GC |
| <i>carbidopa-levodopa-entacapone oral tablet 12.5-50-200 mg, 18.75-75-200 mg, 25-100-200 mg, 31.25-125-200 mg, 37.5-150-200 mg, 50-200-200 mg</i> | 2 | GC |
| <i>entacapone oral tablet 200 mg</i> | 2 | GC |
| NEUPRO TRANSDERMAL PATCH 24 HOUR 1 MG/24 HOUR, 2 MG/24 HOUR, 3 MG/24 HOUR, 4 MG/24 HOUR, 6 MG/24 HOUR, 8 MG/24 HOUR | 4 | |
| <i>pramipexole oral tablet 0.125 mg, 0.25 mg, 0.5 mg, 0.75 mg, 1 mg, 1.5 mg</i> | 1 | GC |
| <i>pramipexole oral tablet extended release 24 hr 0.375 mg, 0.75 mg, 1.5 mg, 2.25 mg, 3 mg</i> | 2 | GC |
| <i>rasagiline oral tablet 0.5 mg, 1 mg</i> | 2 | QL (30 EA per 30 days); GC |
| <i>ropinirole oral tablet 0.25 mg, 0.5 mg, 1 mg, 2 mg, 3 mg, 4 mg, 5 mg</i> | 1 | GC |
| <i>ropinirole oral tablet extended release 24 hr 12 mg, 2 mg, 4 mg, 6 mg, 8 mg</i> | 2 | GC |
| <i>selegiline hcl oral capsule 5 mg</i> | 2 | GC |
| <i>selegiline hcl oral tablet 5 mg</i> | 2 | GC |
| <i>trihexyphenidyl oral tablet 2 mg, 5 mg</i> | 3 | PA |

Puede encontrar información sobre lo que significan los símbolos y las abreviaturas de esta tabla al principio de esta.

06/01/2024

| Nombre del medicamento | Nivel del med. | Requisitos / Limitaciones |
|---|----------------|------------------------------|
| ANALGÉSICOS NO OPIOIDES | | |
| <i>buprenorphine-naloxone sublingual film 12-3 mg</i> | 2 | QL (60 EA per 30 days); GC |
| <i>buprenorphine-naloxone sublingual film 2-0.5 mg, 4-1 mg, 8-2 mg</i> | 2 | QL (90 EA per 30 days); GC |
| <i>buprenorphine-naloxone sublingual tablet 2-0.5 mg, 8-2 mg</i> | 2 | QL (90 EA per 30 days); GC |
| <i>butorphanol injection solution 1 mg/ml, 2 mg/ml</i> | 4 | |
| <i>butorphanol nasal spray,non-aerosol 10 mg/ml</i> | 2 | QL (10 ML per 28 days); GC |
| <i>celecoxib oral capsule 100 mg, 200 mg, 50 mg</i> | 2 | QL (60 EA per 30 days); GC |
| <i>celecoxib oral capsule 400 mg</i> | 2 | QL (30 EA per 30 days); GC |
| <i>diclofenac potassium oral tablet 50 mg</i> | 2 | QL (120 EA per 30 days); GC |
| <i>diclofenac sodium oral tablet extended release 24 hr 100 mg</i> | 2 | GC |
| <i>diclofenac sodium oral tablet, delayed release (dr/ec) 25 mg, 50 mg, 75 mg</i> | 2 | GC |
| <i>diclofenac sodium topical gel 1 %</i> | 2 | QL (1000 GM per 28 days); GC |
| <i>diclofenac-misoprostol oral tablet,ir, delayed rel,biphasic 50-200 mg-mcg, 75-200 mg-mcg</i> | 2 | GC |
| <i>diflunisal oral tablet 500 mg</i> | 2 | GC |
| <i>ec-naproxen oral tablet, delayed release (dr/ec) 375 mg</i> | 2 | QL (120 EA per 30 days); GC |
| <i>ec-naproxen oral tablet, delayed release (dr/ec) 500 mg</i> | 2 | QL (90 EA per 30 days); GC |
| <i>etodolac oral capsule 200 mg, 300 mg</i> | 2 | GC |
| <i>etodolac oral tablet 400 mg, 500 mg</i> | 2 | GC |
| <i>etodolac oral tablet extended release 24 hr 400 mg, 500 mg, 600 mg</i> | 2 | GC |
| <i>flurbiprofen oral tablet 100 mg</i> | 2 | GC |
| <i>ibu oral tablet 600 mg, 800 mg</i> | 1 | GC |
| <i>ibuprofen oral suspension 100 mg/5 ml</i> | 2 | GC |
| <i>ibuprofen oral tablet 400 mg, 600 mg, 800 mg</i> | 1 | GC |
| <i>meloxicam oral tablet 15 mg</i> | 1 | QL (30 EA per 30 days); GC |
| <i>meloxicam oral tablet 7.5 mg</i> | 1 | GC |
| <i>nabumetone oral tablet 500 mg, 750 mg</i> | 1 | GC |
| <i>nalbuphine injection solution 10 mg/ml, 20 mg/ml</i> | 4 | |
| <i>naloxone injection solution 0.4 mg/ml</i> | 2 | GC |
| <i>naloxone injection syringe 0.4 mg/ml, 1 mg/ml</i> | 2 | GC |
| <i>naloxone nasal spray,non-aerosol 4 mg/actuation</i> | 2 | GC |

Puede encontrar información sobre lo que significan los símbolos y las abreviaturas de esta tabla al principio de esta.

06/01/2024

| Nombre del medicamento | Nivel del med. | Requisitos / Limitaciones |
|---|----------------|--------------------------------|
| <i>naltrexone oral tablet 50 mg</i> | 2 | GC |
| <i>naproxen oral tablet 250 mg, 375 mg, 500 mg</i> | 1 | GC |
| <i>naproxen oral tablet, delayed release (dr/ec) 375 mg</i> | 2 | QL (120 EA per 30 days); GC |
| <i>naproxen oral tablet, delayed release (dr/ec) 500 mg</i> | 2 | QL (90 EA per 30 days); GC |
| <i>naproxen sodium oral tablet 275 mg, 550 mg</i> | 2 | GC |
| <i>oxaprozin oral tablet 600 mg</i> | 2 | GC |
| <i>piroxicam oral capsule 10 mg, 20 mg</i> | 2 | GC |
| <i>sulindac oral tablet 150 mg, 200 mg</i> | 2 | GC |
| <i>tramadol oral tablet 50 mg</i> | 2 | QL (240 EA per 30 days); GC |
| <i>tramadol-acetaminophen oral tablet 37.5-325 mg</i> | 2 | QL (240 EA per 30 days); GC |
| VIVITROL INTRAMUSCULAR SUSPENSION, EXTENDED REL RECON 380 MG | 4 | |
| ANALGÉSICOS OPIOIDES | | |
| <i>acetaminophen-codeine oral solution 120 mg-12 mg /5 ml (5 ml), 120-12 mg/5 ml, 300 mg-30 mg /12.5 ml</i> | 2 | QL (2700 ML per 30 days); GC |
| <i>acetaminophen-codeine oral tablet 300-15 mg</i> | 2 | QL (400 EA per 30 days); GC |
| <i>acetaminophen-codeine oral tablet 300-30 mg</i> | 2 | QL (360 EA per 30 days); GC |
| <i>acetaminophen-codeine oral tablet 300-60 mg</i> | 2 | QL (180 EA per 30 days); GC |
| <i>buprenorphine hcl sublingual tablet 2 mg, 8 mg</i> | 2 | PA; QL (90 EA per 30 days); GC |
| <i>endocet oral tablet 10-325 mg</i> | 2 | QL (180 EA per 30 days); GC |
| <i>endocet oral tablet 2.5-325 mg, 5-325 mg</i> | 2 | QL (360 EA per 30 days); GC |
| <i>endocet oral tablet 7.5-325 mg</i> | 2 | QL (240 EA per 30 days); GC |
| <i>fentanyl citrate buccal lozenge on a handle 1,200 mcg, 1,600 mcg, 400 mcg, 600 mcg, 800 mcg</i> | 5^ | PA; QL (120 EA per 30 days) |
| <i>fentanyl citrate buccal lozenge on a handle 200 mcg</i> | 4 | PA; QL (120 EA per 30 days) |
| <i>fentanyl transdermal patch 72 hour 100 mcg/hr, 12 mcg/hr, 25 mcg/hr, 50 mcg/hr, 75 mcg/hr</i> | 4 | PA; QL (10 EA per 30 days) |
| <i>hydrocodone-acetaminophen oral solution 7.5-325 mg/15 ml</i> | 4 | QL (2700 ML per 30 days) |
| <i>hydrocodone-acetaminophen oral tablet 10-325 mg, 7.5- 325 mg</i> | 4 | QL (180 EA per 30 days) |
| <i>hydrocodone-acetaminophen oral tablet 5-325 mg</i> | 4 | QL (240 EA per 30 days) |
| <i>hydrocodone-ibuprofen oral tablet 7.5-200 mg</i> | 3 | QL (150 EA per 30 days) |
| <i>hydromorphone oral liquid 1 mg/ml</i> | 2 | QL (600 ML per 30 days); GC |
| <i>hydromorphone oral tablet 2 mg, 4 mg, 8 mg</i> | 2 | QL (180 EA per 30 days); GC |

Puede encontrar información sobre lo que significan los símbolos y las abreviaturas de esta tabla al principio de esta.

06/01/2024

| Nombre del medicamento | Nivel del med. | Requisitos / Limitaciones |
|---|----------------|---------------------------------|
| HYSINGLA ER ORAL TABLET,ORAL ONLY,EXT.REL.24 HR 100 MG, 120 MG, 20 MG, 30 MG, 40 MG, 60 MG, 80 MG | 3 | PA; QL (30 EA per 30 days) |
| <i>methadone intensol oral concentrate 10 mg/ml</i> | 2 | PA; QL (90 ML per 30 days); GC |
| <i>methadone oral concentrate 10 mg/ml</i> | 2 | PA; QL (90 ML per 30 days); GC |
| <i>methadone oral solution 10 mg/5 ml, 5 mg/5 ml</i> | 2 | PA; QL (450 ML per 30 days); GC |
| <i>methadone oral tablet 10 mg, 5 mg</i> | 2 | PA; QL (90 EA per 30 days); GC |
| <i>morphine (pf) intravenous patient control.analgesia soln 30 mg/30 ml (1 mg/ml)</i> | 4 | |
| <i>morphine concentrate oral solution 100 mg/5 ml (20 mg/ml)</i> | 2 | QL (180 ML per 30 days); GC |
| MORPHINE INJECTION SOLUTION 10 MG/ML, 2 MG/ML, 4 MG/ML, 5 MG/ML | 4 | |
| MORPHINE INJECTION SYRINGE 2 MG/ML | 4 | |
| <i>morphine injection syringe 4 mg/ml</i> | 4 | |
| <i>morphine intravenous solution 10 mg/ml, 50 mg/ml</i> | 4 | |
| MORPHINE INTRAVENOUS SOLUTION 4 MG/ML | 4 | B/D |
| MORPHINE INTRAVENOUS SOLUTION 8 MG/ML | 4 | |
| <i>morphine intravenous syringe 10 mg/ml, 2 mg/ml, 4 mg/ml</i> | 4 | |
| MORPHINE INTRAVENOUS SYRINGE 8 MG/ML | 4 | |
| <i>morphine oral solution 10 mg/5 ml, 20 mg/5 ml (4 mg/ml)</i> | 2 | QL (900 ML per 30 days); GC |
| <i>morphine oral tablet 15 mg, 30 mg</i> | 2 | QL (180 EA per 30 days); GC |
| <i>morphine oral tablet extended release 100 mg, 15 mg, 200 mg, 30 mg, 60 mg</i> | 2 | PA; QL (90 EA per 30 days); GC |
| <i>morphine sulfate 4 mg/ml vial inner, sub</i> | 4 | B/D |
| <i>oxycodone oral capsule 5 mg</i> | 2 | QL (180 EA per 30 days); GC |
| <i>oxycodone oral concentrate 20 mg/ml</i> | 2 | QL (180 ML per 30 days); GC |
| <i>oxycodone oral solution 5 mg/5 ml</i> | 2 | QL (900 ML per 30 days); GC |
| <i>oxycodone oral tablet 10 mg, 15 mg, 20 mg, 30 mg, 5 mg</i> | 2 | QL (180 EA per 30 days); GC |
| <i>oxycodone-acetaminophen oral tablet 10-325 mg</i> | 2 | QL (180 EA per 30 days); GC |
| <i>oxycodone-acetaminophen oral tablet 2.5-325 mg, 5-325 mg</i> | 2 | QL (360 EA per 30 days); GC |
| <i>oxycodone-acetaminophen oral tablet 7.5-325 mg</i> | 2 | QL (240 EA per 30 days); GC |
| ANTICONVULSIVOS | | |
| APTOM ORAL TABLET 200 MG, 400 MG | 4 | QL (30 EA per 30 days) |
| APTOM ORAL TABLET 600 MG, 800 MG | 4 | QL (60 EA per 30 days) |

Puede encontrar información sobre lo que significan los símbolos y las abreviaturas de esta tabla al principio de esta.

06/01/2024

| Nombre del medicamento | Nivel del med. | Requisitos / Limitaciones |
|--|----------------|------------------------------------|
| BRIVIACT INTRAVENOUS SOLUTION 50 MG/5 ML | 4 | PA-NS; QL (600 ML per 30 days) |
| BRIVIACT ORAL SOLUTION 10 MG/ML | 5^ | PA-NS; QL (600 ML per 30 days) |
| BRIVIACT ORAL TABLET 10 MG, 100 MG, 25 MG, 50 MG, 75 MG | 5^ | PA-NS; QL (60 EA per 30 days) |
| <i>carbamazepine oral capsule, er multiphase 12 hr 100 mg, 200 mg, 300 mg</i> | 2 | GC |
| <i>carbamazepine oral suspension 100 mg/5 ml, 200 mg/10 ml</i> | 2 | GC |
| <i>carbamazepine oral tablet 200 mg</i> | 2 | GC |
| <i>carbamazepine oral tablet extended release 12 hr 100 mg, 200 mg, 400 mg</i> | 2 | GC |
| <i>carbamazepine oral tablet, chewable 100 mg</i> | 2 | GC |
| <i>clobazam oral suspension 2.5 mg/ml</i> | 2 | PA-NS; QL (480 ML per 30 days); GC |
| <i>clobazam oral tablet 10 mg, 20 mg</i> | 2 | PA-NS; QL (60 EA per 30 days); GC |
| <i>clonazepam oral tablet 0.5 mg, 1 mg</i> | 2 | QL (90 EA per 30 days); GC |
| <i>clonazepam oral tablet 2 mg</i> | 2 | QL (300 EA per 30 days); GC |
| <i>clonazepam oral tablet, disintegrating 0.125 mg, 0.25 mg, 0.5 mg, 1 mg</i> | 2 | QL (90 EA per 30 days); GC |
| <i>clonazepam oral tablet, disintegrating 2 mg</i> | 2 | QL (300 EA per 30 days); GC |
| DIACOMIT ORAL CAPSULE 250 MG | 5^ | PA-NS; LA; QL (360 EA per 30 days) |
| DIACOMIT ORAL CAPSULE 500 MG | 5^ | PA-NS; LA; QL (180 EA per 30 days) |
| DIACOMIT ORAL POWDER IN PACKET 250 MG | 5^ | PA-NS; LA; QL (360 EA per 30 days) |
| DIACOMIT ORAL POWDER IN PACKET 500 MG | 5^ | PA-NS; LA; QL (180 EA per 30 days) |
| <i>diazepam rectal kit 12.5-15-17.5-20 mg, 2.5 mg, 5-7.5-10 mg</i> | 2 | GC |
| DILANTIN EXTENDED ORAL CAPSULE 100 MG | 4 | |
| DILANTIN INFATABS ORAL TABLET, CHEWABLE 50 MG | 4 | |
| DILANTIN ORAL CAPSULE 30 MG | 4 | |
| DILANTIN-125 ORAL SUSPENSION 125 MG/5 ML | 4 | |
| <i>divalproex oral capsule, delayed rel sprinkle 125 mg</i> | 2 | GC |
| <i>divalproex oral tablet extended release 24 hr 250 mg, 500 mg</i> | 2 | GC |
| <i>divalproex oral tablet, delayed release (dr/ec) 125 mg, 250 mg, 500 mg</i> | 2 | GC |
| EPIDIOLEX ORAL SOLUTION 100 MG/ML | 4 | PA-NS; LA; QL (600 ML per 30 days) |
| <i>epitol oral tablet 200 mg</i> | 2 | GC |

Puede encontrar información sobre lo que significan los símbolos y las abreviaturas de esta tabla al principio de esta.

06/01/2024

| Nombre del medicamento | Nivel del med. | Requisitos / Limitaciones |
|---|----------------|------------------------------------|
| EPRONTIA ORAL SOLUTION 25 MG/ML | 4 | PA-NS; QL (480 ML per 30 days) |
| <i>ethosuximide oral capsule 250 mg</i> | 2 | GC |
| <i>ethosuximide oral solution 250 mg/5 ml</i> | 2 | GC |
| <i>felbamate oral suspension 600 mg/5 ml</i> | 5^ | |
| <i>felbamate oral tablet 400 mg, 600 mg</i> | 2 | GC |
| FINTEPLA ORAL SOLUTION 2.2 MG/ML | 5^ | PA-NS; LA; QL (360 ML per 30 days) |
| FYCOMPA ORAL SUSPENSION 0.5 MG/ML | 5^ | PA-NS; QL (720 ML per 30 days) |
| FYCOMPA ORAL TABLET 10 MG, 12 MG, 4 MG, 6 MG, 8 MG | 5^ | PA-NS; QL (30 EA per 30 days) |
| FYCOMPA ORAL TABLET 2 MG | 4 | PA-NS; QL (60 EA per 30 days) |
| <i>gabapentin oral capsule 100 mg, 400 mg</i> | 1 | QL (270 EA per 30 days); GC |
| <i>gabapentin oral capsule 300 mg</i> | 1 | QL (360 EA per 30 days); GC |
| <i>gabapentin oral solution 250 mg/5 ml, 250 mg/5 ml (5 ml), 300 mg/6 ml (6 ml)</i> | 2 | QL (2160 ML per 30 days); GC |
| <i>gabapentin oral tablet 600 mg</i> | 2 | QL (180 EA per 30 days); GC |
| <i>gabapentin oral tablet 800 mg</i> | 2 | QL (120 EA per 30 days); GC |
| GRALISE ORAL TABLET EXTENDED RELEASE 24 HR 300 MG | 4 | PA; QL (180 EA per 30 days) |
| GRALISE ORAL TABLET EXTENDED RELEASE 24 HR 450 MG, 750 MG, 900 MG | 4 | PA; QL (60 EA per 30 days) |
| GRALISE ORAL TABLET EXTENDED RELEASE 24 HR 600 MG | 4 | PA; QL (90 EA per 30 days) |
| <i>lacosamide intravenous solution 200 mg/20 ml</i> | 5^ | QL (1200 ML per 30 days) |
| <i>lacosamide oral solution 10 mg/ml</i> | 2 | QL (1200 ML per 30 days); GC |
| <i>lacosamide oral tablet 100 mg, 150 mg, 200 mg</i> | 2 | QL (60 EA per 30 days); GC |
| <i>lacosamide oral tablet 50 mg</i> | 2 | QL (120 EA per 30 days); GC |
| <i>lamotrigine oral tablet 100 mg, 150 mg, 200 mg, 25 mg</i> | 1 | GC |
| <i>lamotrigine oral tablet extended release 24hr 100 mg, 200 mg, 25 mg, 250 mg, 300 mg, 50 mg</i> | 2 | GC |
| <i>lamotrigine oral tablet, chewable dispersible 25 mg, 5 mg</i> | 2 | GC |
| <i>lamotrigine oral tablet, disintegrating 100 mg, 200 mg, 25 mg, 50 mg</i> | 2 | GC |
| <i>levetiracetam in nacl (iso-os) intravenous piggyback 1,000 mg/100 ml, 1,500 mg/100 ml, 500 mg/100 ml</i> | 2 | GC |
| <i>levetiracetam intravenous solution 500 mg/5 ml</i> | 2 | GC |
| <i>levetiracetam oral solution 100 mg/ml, 500 mg/5 ml (5 ml)</i> | 2 | GC |
| <i>levetiracetam oral tablet 1,000 mg, 250 mg, 500 mg, 750 mg</i> | 2 | GC |

Puede encontrar información sobre lo que significan los símbolos y las abreviaturas de esta tabla al principio de esta.

06/01/2024

| Nombre del medicamento | Nivel del med. | Requisitos / Limitaciones |
|--|----------------|------------------------------------|
| <i>levetiracetam oral tablet extended release 24 hr 500 mg, 750 mg</i> | 2 | GC |
| LYRICA CR ORAL TABLET EXTENDED RELEASE 24 HR 165 MG, 82.5 MG | 3 | PA; QL (90 EA per 30 days) |
| LYRICA CR ORAL TABLET EXTENDED RELEASE 24 HR 330 MG | 3 | PA; QL (60 EA per 30 days) |
| <i>methsuximide oral capsule 300 mg</i> | 4 | |
| NAYZILAM NASAL SPRAY, NON-AEROSOL 5 MG/SPRAY (0.1 ML) | 4 | |
| <i>oxcarbazepine oral suspension 300 mg/5 ml (60 mg/ml)</i> | 2 | GC |
| <i>oxcarbazepine oral tablet 150 mg, 300 mg, 600 mg</i> | 2 | GC |
| <i>phenobarbital oral elixir 20 mg/5 ml (4 mg/ml)</i> | 4 | PA-NS |
| <i>phenobarbital oral tablet 100 mg, 15 mg, 16.2 mg, 30 mg, 32.4 mg, 60 mg, 64.8 mg, 97.2 mg</i> | 3 | PA-NS |
| <i>phenobarbital sodium injection solution 130 mg/ml, 65 mg/ml</i> | 4 | PA-NS |
| PHENYTEK ORAL CAPSULE 200 MG, 300 MG | 4 | |
| <i>phenytoin oral suspension 100 mg/4 ml, 125 mg/5 ml</i> | 2 | GC |
| <i>phenytoin oral tablet, chewable 50 mg</i> | 2 | GC |
| <i>phenytoin sodium extended oral capsule 100 mg, 200 mg, 300 mg</i> | 2 | GC |
| <i>phenytoin sodium intravenous solution 50 mg/ml</i> | 2 | GC |
| <i>pregabalin oral capsule 100 mg, 150 mg, 25 mg, 50 mg, 75 mg</i> | 2 | QL (120 EA per 30 days); GC |
| <i>pregabalin oral capsule 200 mg</i> | 2 | QL (90 EA per 30 days); GC |
| <i>pregabalin oral capsule 225 mg, 300 mg</i> | 2 | QL (60 EA per 30 days); GC |
| <i>pregabalin oral solution 20 mg/ml</i> | 2 | QL (900 ML per 30 days); GC |
| PRIMIDONE ORAL TABLET 125 MG | 4 | |
| <i>primidone oral tablet 250 mg, 50 mg</i> | 1 | GC |
| <i>roweepra oral tablet 500 mg</i> | 2 | GC |
| <i>rufinamide oral suspension 40 mg/ml</i> | 5^ | PA-NS; QL (2400 ML per 30 days) |
| <i>rufinamide oral tablet 200 mg</i> | 2 | PA-NS; QL (480 EA per 30 days); GC |
| <i>rufinamide oral tablet 400 mg</i> | 5^ | PA-NS; QL (240 EA per 30 days) |
| SPRITAM ORAL TABLET FOR SUSPENSION 1,000 MG | 4 | QL (90 EA per 30 days) |
| SPRITAM ORAL TABLET FOR SUSPENSION 250 MG | 4 | QL (360 EA per 30 days) |
| SPRITAM ORAL TABLET FOR SUSPENSION 500 MG | 4 | QL (180 EA per 30 days) |

Puede encontrar información sobre lo que significan los símbolos y las abreviaturas de esta tabla al principio de esta.

06/01/2024

| Nombre del medicamento | Nivel del med. | Requisitos / Limitaciones |
|--|----------------|------------------------------------|
| SPRITAM ORAL TABLET FOR SUSPENSION 750 MG | 4 | QL (120 EA per 30 days) |
| SYMPAZAN ORAL FILM 10 MG, 20 MG | 5^ | PA-NS; QL (60 EA per 30 days) |
| SYMPAZAN ORAL FILM 5 MG | 4 | PA-NS; QL (60 EA per 30 days) |
| <i>tiagabine oral tablet 12 mg, 16 mg, 2 mg, 4 mg</i> | 2 | GC |
| <i>topiramate oral capsule, sprinkle 15 mg, 25 mg</i> | 2 | GC |
| <i>topiramate oral tablet 100 mg, 200 mg, 25 mg, 50 mg</i> | 1 | GC |
| <i>valproate sodium intravenous solution 500 mg/5 ml (100 mg/ml)</i> | 2 | GC |
| <i>valproic acid (as sodium salt) oral solution 250 mg/5 ml, 250 mg/5 ml (5 ml), 500 mg/10 ml (10 ml)</i> | 2 | GC |
| <i>valproic acid oral capsule 250 mg</i> | 2 | GC |
| VALTOCO NASAL SPRAY, NON-AEROSOL 10 MG/SPRAY (0.1 ML), 15 MG/2 SPRAY (7.5/0.1ML X 2), 20 MG/2 SPRAY (10MG/0.1ML X2), 5 MG/SPRAY (0.1 ML) | 4 | |
| <i>vigabatrin oral powder in packet 500 mg</i> | 5^ | PA-NS; LA; QL (180 EA per 30 days) |
| <i>vigabatrin oral tablet 500 mg</i> | 5^ | PA-NS; LA; QL (180 EA per 30 days) |
| <i>vigadrone oral powder in packet 500 mg</i> | 5^ | PA-NS; LA; QL (180 EA per 30 days) |
| <i>vigadrone oral tablet 500 mg</i> | 5^ | PA-NS; LA; QL (180 EA per 30 days) |
| <i>vigpoder oral powder in packet 500 mg</i> | 5^ | PA-NS; LA; QL (180 EA per 30 days) |
| XCOPRI MAINTENANCE PACK ORAL TABLET 250MG/DAY(150 MG X1-100MG X1), 350 MG/DAY (200 MG X1-150MG X1) | 5^ | QL (56 EA per 28 days) |
| XCOPRI ORAL TABLET 100 MG, 25 MG, 50 MG | 5^ | QL (30 EA per 30 days) |
| XCOPRI ORAL TABLET 150 MG, 200 MG | 5^ | QL (60 EA per 30 days) |
| XCOPRI TITRATION PACK ORAL TABLETS, DOSE PACK 12.5 MG (14)- 25 MG (14) | 4 | QL (28 EA per 28 days) |
| XCOPRI TITRATION PACK ORAL TABLETS, DOSE PACK 150 MG (14)- 200 MG (14), 50 MG (14)- 100 MG (14) | 5^ | QL (28 EA per 28 days) |
| ZONISADE ORAL SUSPENSION 100 MG/5 ML | 4 | PA-NS; QL (900 ML per 30 days) |
| <i>zonisamide oral capsule 100 mg, 25 mg, 50 mg</i> | 2 | GC |
| ZTALMY ORAL SUSPENSION 50 MG/ML | 5^ | PA-NS; QL (1100 ML per 30 days) |
| MEDICAMENTOS PSICOTERAPÉUTICOS | | |
| ABILIFY MAINTENA INTRAMUSCULAR SUSPENSION, EXTENDED REL RECON 300 MG, 400 MG | 4 | QL (1 EA per 28 days) |
| ABILIFY MAINTENA INTRAMUSCULAR SUSPENSION, EXTENDED REL SYRING 300 MG, 400 MG | 4 | QL (1 EA per 28 days) |

Puede encontrar información sobre lo que significan los símbolos y las abreviaturas de esta tabla al principio de esta.

06/01/2024

| Nombre del medicamento | Nivel del med. | Requisitos / Limitaciones |
|---|----------------|--------------------------------|
| <i>alprazolam oral tablet 0.25 mg, 0.5 mg, 1 mg, 2 mg</i> | 2 | QL (150 EA per 30 days); GC |
| <i>amitriptyline oral tablet 10 mg, 100 mg, 150 mg, 25 mg, 50 mg, 75 mg</i> | 4 | |
| <i>amoxapine oral tablet 100 mg, 150 mg, 25 mg, 50 mg</i> | 3 | |
| <i>aripiprazole oral solution 1 mg/ml</i> | 4 | QL (900 ML per 30 days) |
| <i>aripiprazole oral tablet 10 mg, 15 mg, 2 mg, 20 mg, 30 mg, 5 mg</i> | 4 | QL (30 EA per 30 days) |
| <i>aripiprazole oral tablet, disintegrating 10 mg, 15 mg</i> | 4 | QL (60 EA per 30 days) |
| ARISTADA INITIO INTRAMUSCULAR SUSPENSION, EXTENDED REL SYRING 675 MG/2.4 ML | 4 | |
| ARISTADA INTRAMUSCULAR SUSPENSION, EXTENDED REL SYRING 1,064 MG/3.9 ML | 4 | QL (3.9 ML per 56 days) |
| ARISTADA INTRAMUSCULAR SUSPENSION, EXTENDED REL SYRING 441 MG/1.6 ML | 4 | QL (1.6 ML per 28 days) |
| ARISTADA INTRAMUSCULAR SUSPENSION, EXTENDED REL SYRING 662 MG/2.4 ML | 4 | QL (2.4 ML per 28 days) |
| ARISTADA INTRAMUSCULAR SUSPENSION, EXTENDED REL SYRING 882 MG/3.2 ML | 4 | QL (3.2 ML per 28 days) |
| <i>armodafinil oral tablet 150 mg, 200 mg, 250 mg</i> | 2 | PA; QL (30 EA per 30 days); GC |
| <i>armodafinil oral tablet 50 mg</i> | 2 | PA; QL (60 EA per 30 days); GC |
| <i>asenapine maleate sublingual tablet 10 mg, 2.5 mg, 5 mg</i> | 2 | QL (60 EA per 30 days); GC |
| <i>atomoxetine oral capsule 10 mg, 18 mg, 25 mg, 40 mg</i> | 2 | QL (60 EA per 30 days); GC |
| <i>atomoxetine oral capsule 100 mg, 60 mg, 80 mg</i> | 2 | QL (30 EA per 30 days); GC |
| AUVELITY ORAL TABLET, IR AND ER, BIPHASIC 45-105 MG | 4 | PA-NS; QL (60 EA per 30 days) |
| BELSOMRA ORAL TABLET 10 MG, 15 MG, 20 MG, 5 MG | 3 | QL (30 EA per 30 days) |
| <i>bupropion hcl oral tablet 100 mg, 75 mg</i> | 2 | GC |
| <i>bupropion hcl oral tablet extended release 24 hr 150 mg</i> | 2 | QL (90 EA per 30 days); GC |
| <i>bupropion hcl oral tablet extended release 24 hr 300 mg</i> | 2 | QL (30 EA per 30 days); GC |
| <i>bupropion hcl oral tablet sustained-release 12 hr 100 mg, 150 mg, 200 mg</i> | 2 | QL (60 EA per 30 days); GC |
| <i>buspirone oral tablet 10 mg, 15 mg, 5 mg</i> | 1 | GC |
| <i>buspirone oral tablet 30 mg, 7.5 mg</i> | 2 | GC |
| CAPLYTA ORAL CAPSULE 10.5 MG, 21 MG | 4 | QL (30 EA per 30 days) |
| CAPLYTA ORAL CAPSULE 42 MG | 5^ | QL (30 EA per 30 days) |
| <i>chlorpromazine injection solution 25 mg/ml</i> | 2 | GC |

Puede encontrar información sobre lo que significan los símbolos y las abreviaturas de esta tabla al principio de esta.

06/01/2024

| Nombre del medicamento | Nivel del med. | Requisitos / Limitaciones |
|--|-----------------------|-------------------------------------|
| <i>chlorpromazine oral concentrate 100 mg/ml, 30 mg/ml</i> | 4 | |
| <i>chlorpromazine oral tablet 10 mg, 50 mg</i> | 2 | GC |
| <i>chlorpromazine oral tablet 100 mg, 200 mg, 25 mg</i> | 4 | |
| <i>citalopram oral solution 10 mg/5 ml</i> | 2 | GC |
| <i>citalopram oral tablet 10 mg, 20 mg, 40 mg</i> | 1 | GC |
| <i>clomipramine oral capsule 25 mg, 50 mg, 75 mg</i> | 4 | PA-NS |
| <i>clorazepate dipotassium oral tablet 15 mg, 3.75 mg, 7.5 mg</i> | 2 | PA-NS; QL (180 EA per 30 days); GC |
| <i>clozapine oral tablet 100 mg</i> | 2 | QL (270 EA per 30 days); GC |
| <i>clozapine oral tablet 200 mg</i> | 2 | QL (120 EA per 30 days); GC |
| <i>clozapine oral tablet 25 mg, 50 mg</i> | 2 | GC |
| <i>clozapine oral tablet, disintegrating 100 mg</i> | 2 | QL (270 EA per 30 days); GC |
| <i>clozapine oral tablet, disintegrating 12.5 mg, 25 mg</i> | 2 | GC |
| <i>clozapine oral tablet, disintegrating 150 mg</i> | 2 | QL (180 EA per 30 days); GC |
| <i>clozapine oral tablet, disintegrating 200 mg</i> | 4 | QL (120 EA per 30 days) |
| <i>desipramine oral tablet 10 mg, 100 mg, 150 mg, 25 mg, 50 mg, 75 mg</i> | 4 | |
| <i>desvenlafaxine succinate oral tablet extended release 24 hr 100 mg, 25 mg, 50 mg</i> | 2 | QL (30 EA per 30 days); GC |
| <i>dexmethylphenidate oral tablet 10 mg</i> | 2 | PA; QL (60 EA per 30 days); GC |
| <i>dexmethylphenidate oral tablet 2.5 mg, 5 mg</i> | 2 | PA; QL (120 EA per 30 days); GC |
| <i>dextroamphetamine-amphetamine oral capsule, extended release 24hr 10 mg, 15 mg, 20 mg, 25 mg, 30 mg, 5 mg</i> | 2 | PA; QL (30 EA per 30 days); GC |
| <i>dextroamphetamine-amphetamine oral tablet 10 mg, 12.5 mg, 15 mg, 30 mg, 5 mg, 7.5 mg</i> | 2 | PA; QL (60 EA per 30 days); GC |
| <i>dextroamphetamine-amphetamine oral tablet 20 mg</i> | 2 | PA; QL (90 EA per 30 days); GC |
| <i>diazepam injection solution 5 mg/ml</i> | 2 | PA-NS; GC |
| <i>diazepam injection syringe 5 mg/ml</i> | 2 | PA-NS; GC |
| <i>diazepam intensol oral concentrate 5 mg/ml</i> | 2 | PA-NS; QL (240 ML per 30 days); GC |
| <i>diazepam oral concentrate 5 mg/ml</i> | 2 | PA-NS; QL (240 ML per 30 days); GC |
| <i>diazepam oral solution 5 mg/5 ml (1 mg/ml), 5 mg/5 ml (1 mg/ml, 5 ml)</i> | 2 | PA-NS; QL (1200 ML per 30 days); GC |
| <i>diazepam oral tablet 10 mg, 2 mg, 5 mg</i> | 2 | PA-NS; QL (120 EA per 30 days); GC |
| <i>doxepin oral capsule 10 mg, 100 mg, 25 mg, 50 mg, 75 mg</i> | 3 | |
| <i>doxepin oral capsule 150 mg</i> | 4 | |
| <i>doxepin oral concentrate 10 mg/ml</i> | 3 | |

Puede encontrar información sobre lo que significan los símbolos y las abreviaturas de esta tabla al principio de esta.

06/01/2024

| Nombre del medicamento | Nivel del med. | Requisitos / Limitaciones |
|--|----------------|-------------------------------|
| <i>doxepin oral tablet 3 mg, 6 mg</i> | 2 | QL (30 EA per 30 days); GC |
| DRIZALMA SPRINKLE ORAL CAPSULE, DELAYED REL SPRINKLE 20 MG, 30 MG, 40 MG, 60 MG | 4 | PA-NS; QL (60 EA per 30 days) |
| <i>duloxetine oral capsule, delayed release(dr/ec) 20 mg, 30 mg, 40 mg, 60 mg</i> | 2 | QL (60 EA per 30 days); GC |
| EMSAM TRANSDERMAL PATCH 24 HOUR 12 MG/24 HR, 6 MG/24 HR, 9 MG/24 HR | 5^ | QL (30 EA per 30 days) |
| <i>escitalopram oxalate oral solution 5 mg/5 ml</i> | 2 | GC |
| <i>escitalopram oxalate oral tablet 10 mg, 20 mg, 5 mg</i> | 1 | GC |
| FANAPT ORAL TABLET 1 MG, 10 MG, 12 MG, 2 MG, 4 MG, 6 MG, 8 MG | 5^ | PA-NS; QL (60 EA per 30 days) |
| FANAPT ORAL TABLETS, DOSE PACK 1MG(2)-2MG(2)-4MG(2)-6MG(2) | 4 | PA-NS |
| FETZIMA ORAL CAPSULE, EXT REL 24HR DOSE PACK 20 MG (2)- 40 MG (26) | 4 | |
| FETZIMA ORAL CAPSULE, EXTENDED RELEASE 24 HR 120 MG, 20 MG, 40 MG, 80 MG | 4 | QL (30 EA per 30 days) |
| <i>fluoxetine oral capsule 10 mg, 20 mg, 40 mg</i> | 1 | GC |
| <i>fluoxetine oral solution 20 mg/5 ml (4 mg/ml)</i> | 2 | GC |
| <i>fluphenazine decanoate injection solution 25 mg/ml</i> | 2 | GC |
| <i>fluphenazine hcl injection solution 2.5 mg/ml</i> | 2 | GC |
| <i>fluphenazine hcl oral concentrate 5 mg/ml</i> | 2 | GC |
| <i>fluphenazine hcl oral elixir 2.5 mg/5 ml</i> | 2 | GC |
| <i>fluphenazine hcl oral tablet 1 mg, 10 mg, 2.5 mg, 5 mg</i> | 2 | GC |
| <i>fluvoxamine oral tablet 100 mg, 25 mg, 50 mg</i> | 2 | GC |
| <i>guanfacine oral tablet extended release 24 hr 1 mg, 2 mg, 4 mg</i> | 3 | PA; QL (30 EA per 30 days) |
| <i>guanfacine oral tablet extended release 24 hr 3 mg</i> | 3 | PA; QL (60 EA per 30 days) |
| <i>haloperidol decanoate intramuscular solution 100 mg/ml, 100 mg/ml (1 ml), 50 mg/ml, 50 mg/ml(1ml)</i> | 2 | GC |
| <i>haloperidol lactate injection solution 5 mg/ml</i> | 2 | GC |
| <i>haloperidol lactate oral concentrate 2 mg/ml</i> | 2 | GC |
| <i>haloperidol oral tablet 0.5 mg, 1 mg, 10 mg, 2 mg, 20 mg, 5 mg</i> | 2 | GC |
| <i>imipramine hcl oral tablet 10 mg, 25 mg, 50 mg</i> | 2 | GC |

Puede encontrar información sobre lo que significan los símbolos y las abreviaturas de esta tabla al principio de esta.

06/01/2024

| Nombre del medicamento | Nivel del med. | Requisitos / Limitaciones |
|--|----------------|-----------------------------|
| INVEGA HAFYERA INTRAMUSCULAR SYRINGE 1,092 MG/3.5 ML | 4 | QL (3.5 ML per 180 days) |
| INVEGA HAFYERA INTRAMUSCULAR SYRINGE 1,560 MG/5 ML | 4 | QL (5 ML per 180 days) |
| INVEGA SUSTENNA INTRAMUSCULAR SYRINGE 117 MG/0.75 ML | 4 | QL (0.75 ML per 28 days) |
| INVEGA SUSTENNA INTRAMUSCULAR SYRINGE 156 MG/ML | 4 | QL (1 ML per 28 days) |
| INVEGA SUSTENNA INTRAMUSCULAR SYRINGE 234 MG/1.5 ML | 4 | QL (1.5 ML per 28 days) |
| INVEGA SUSTENNA INTRAMUSCULAR SYRINGE 39 MG/0.25 ML | 4 | QL (0.25 ML per 28 days) |
| INVEGA SUSTENNA INTRAMUSCULAR SYRINGE 78 MG/0.5 ML | 4 | QL (0.5 ML per 28 days) |
| INVEGA TRINZA INTRAMUSCULAR SYRINGE 273 MG/0.88 ML | 4 | QL (0.88 ML per 90 days) |
| INVEGA TRINZA INTRAMUSCULAR SYRINGE 410 MG/1.32 ML | 4 | QL (1.32 ML per 90 days) |
| INVEGA TRINZA INTRAMUSCULAR SYRINGE 546 MG/1.75 ML | 4 | QL (1.75 ML per 90 days) |
| INVEGA TRINZA INTRAMUSCULAR SYRINGE 819 MG/2.63 ML | 4 | QL (2.63 ML per 90 days) |
| <i>lisdexamfetamine oral capsule 10 mg, 20 mg, 30 mg</i> | 4 | PA; QL (60 EA per 30 days) |
| <i>lisdexamfetamine oral capsule 40 mg, 50 mg, 60 mg, 70 mg</i> | 4 | PA; QL (30 EA per 30 days) |
| <i>lisdexamfetamine oral tablet, chewable 10 mg, 20 mg, 30 mg</i> | 4 | PA; QL (60 EA per 30 days) |
| <i>lisdexamfetamine oral tablet, chewable 40 mg, 50 mg, 60 mg</i> | 4 | PA; QL (30 EA per 30 days) |
| <i>lithium carbonate oral capsule 150 mg, 300 mg, 600 mg</i> | 1 | GC |
| <i>lithium carbonate oral tablet 300 mg</i> | 1 | GC |
| <i>lithium carbonate oral tablet extended release 300 mg, 450 mg</i> | 2 | GC |
| <i>lithium citrate oral solution 8 meq/5 ml</i> | 2 | GC |
| <i>lorazepam injection solution 2 mg/ml, 4 mg/ml</i> | 2 | GC |
| <i>lorazepam injection syringe 2 mg/ml</i> | 2 | GC |
| <i>lorazepam intensol oral concentrate 2 mg/ml</i> | 2 | QL (150 ML per 30 days); GC |
| <i>lorazepam oral concentrate 2 mg/ml</i> | 2 | QL (150 ML per 30 days); GC |
| <i>lorazepam oral tablet 0.5 mg, 1 mg, 2 mg</i> | 2 | QL (150 EA per 30 days); GC |

Puede encontrar información sobre lo que significan los símbolos y las abreviaturas de esta tabla al principio de esta.

06/01/2024

| Nombre del medicamento | Nivel del med. | Requisitos / Limitaciones |
|--|----------------|-----------------------------------|
| <i>loxapine succinate oral capsule 10 mg, 25 mg, 5 mg, 50 mg</i> | 2 | GC |
| <i>lurasidone oral tablet 120 mg, 20 mg, 40 mg, 60 mg</i> | 5^ | QL (30 EA per 30 days) |
| <i>lurasidone oral tablet 80 mg</i> | 5^ | QL (60 EA per 30 days) |
| MARPLAN ORAL TABLET 10 MG | 4 | QL (180 EA per 30 days) |
| <i>methylphenidate hcl oral solution 10 mg/5 ml</i> | 2 | PA; QL (900 ML per 30 days); GC |
| <i>methylphenidate hcl oral solution 5 mg/5 ml</i> | 2 | PA; QL (1800 ML per 30 days); GC |
| <i>methylphenidate hcl oral tablet 10 mg, 5 mg</i> | 2 | PA; QL (180 EA per 30 days); GC |
| <i>methylphenidate hcl oral tablet 20 mg</i> | 2 | PA; QL (90 EA per 30 days); GC |
| <i>methylphenidate hcl oral tablet extended release 10 mg, 20 mg</i> | 2 | PA; QL (90 EA per 30 days); GC |
| <i>methylphenidate hcl oral tablet, chewable 10 mg, 2.5 mg, 5 mg</i> | 2 | PA; QL (180 EA per 30 days); GC |
| <i>mirtazapine oral tablet 15 mg, 30 mg, 45 mg</i> | 1 | GC |
| <i>mirtazapine oral tablet 7.5 mg</i> | 2 | GC |
| <i>mirtazapine oral tablet, disintegrating 15 mg, 30 mg, 45 mg</i> | 2 | GC |
| <i>modafinil oral tablet 100 mg</i> | 2 | PA; QL (30 EA per 30 days); GC |
| <i>modafinil oral tablet 200 mg</i> | 2 | PA; QL (60 EA per 30 days); GC |
| <i>molindone oral tablet 10 mg, 25 mg, 5 mg</i> | 2 | GC |
| <i>nefazodone oral tablet 100 mg, 150 mg, 200 mg, 250 mg, 50 mg</i> | 2 | GC |
| <i>nortriptyline oral capsule 10 mg, 25 mg, 50 mg, 75 mg</i> | 2 | GC |
| <i>nortriptyline oral solution 10 mg/5 ml</i> | 4 | |
| NUPLAZID ORAL CAPSULE 34 MG | 5^ | PA-NS; LA; QL (30 EA per 30 days) |
| NUPLAZID ORAL TABLET 10 MG | 5^ | PA-NS; LA; QL (30 EA per 30 days) |
| <i>olanzapine intramuscular recon soln 10 mg</i> | 2 | QL (3 EA per 1 day); GC |
| <i>olanzapine oral tablet 10 mg, 2.5 mg, 5 mg</i> | 2 | QL (60 EA per 30 days); GC |
| <i>olanzapine oral tablet 15 mg, 20 mg, 7.5 mg</i> | 2 | QL (30 EA per 30 days); GC |
| <i>olanzapine oral tablet, disintegrating 10 mg</i> | 2 | QL (60 EA per 30 days); GC |
| <i>olanzapine oral tablet, disintegrating 15 mg, 20 mg, 5 mg</i> | 2 | QL (30 EA per 30 days); GC |
| <i>paliperidone oral tablet extended release 24hr 1.5 mg, 3 mg, 9 mg</i> | 4 | QL (30 EA per 30 days) |
| <i>paliperidone oral tablet extended release 24hr 6 mg</i> | 4 | QL (60 EA per 30 days) |
| <i>paroxetine hcl oral suspension 10 mg/5 ml</i> | 4 | QL (900 ML per 30 days) |
| <i>paroxetine hcl oral tablet 10 mg, 20 mg, 40 mg</i> | 2 | QL (30 EA per 30 days); GC |

Puede encontrar información sobre lo que significan los símbolos y las abreviaturas de esta tabla al principio de esta.

06/01/2024

| Nombre del medicamento | Nivel del med. | Requisitos / Limitaciones |
|---|----------------|-----------------------------------|
| <i>paroxetine hcl oral tablet 30 mg</i> | 2 | QL (60 EA per 30 days); GC |
| <i>paroxetine hcl oral tablet extended release 24 hr 12.5 mg, 25 mg, 37.5 mg</i> | 3 | QL (60 EA per 30 days) |
| <i>perphenazine oral tablet 16 mg, 2 mg, 4 mg, 8 mg</i> | 2 | GC |
| PERSERIS SUBCUTANEOUS SUSPENSION,EXTENDED REL SYRING 120 MG, 90 MG | 4 | QL (1 EA per 30 days) |
| <i>phenelzine oral tablet 15 mg</i> | 2 | GC |
| <i>pimozide oral tablet 1 mg, 2 mg</i> | 2 | GC |
| <i>protriptyline oral tablet 10 mg, 5 mg</i> | 4 | |
| <i>quetiapine oral tablet 100 mg, 200 mg, 25 mg, 300 mg, 400 mg, 50 mg</i> | 2 | GC |
| QUETIAPINE ORAL TABLET 150 MG | 2 | GC |
| <i>quetiapine oral tablet extended release 24 hr 150 mg, 200 mg</i> | 2 | PA-NS; QL (30 EA per 30 days); GC |
| <i>quetiapine oral tablet extended release 24 hr 300 mg, 400 mg, 50 mg</i> | 2 | PA-NS; QL (60 EA per 30 days); GC |
| REXULTI ORAL TABLET 0.25 MG, 0.5 MG, 1 MG, 2 MG, 3 MG, 4 MG | 5^ | QL (30 EA per 30 days) |
| RISPERDAL CONSTA INTRAMUSCULAR SUSPENSION,EXTENDED REL RECON 12.5 MG/2 ML, 25 MG/2 ML, 37.5 MG/2 ML, 50 MG/2 ML | 4 | QL (2 EA per 28 days) |
| <i>risperidone oral solution 1 mg/ml</i> | 2 | QL (240 ML per 30 days); GC |
| <i>risperidone oral tablet 0.25 mg, 0.5 mg, 1 mg, 2 mg, 3 mg, 4 mg</i> | 1 | GC |
| <i>risperidone oral tablet,disintegrating 0.25 mg, 0.5 mg</i> | 2 | QL (90 EA per 30 days); GC |
| <i>risperidone oral tablet,disintegrating 1 mg, 2 mg, 3 mg</i> | 2 | QL (60 EA per 30 days); GC |
| <i>risperidone oral tablet,disintegrating 4 mg</i> | 2 | QL (120 EA per 30 days); GC |
| SECUADO TRANSDERMAL PATCH 24 HOUR 3.8 MG/24 HOUR, 5.7 MG/24 HOUR, 7.6 MG/24 HOUR | 4 | QL (30 EA per 30 days) |
| <i>sertraline oral concentrate 20 mg/ml</i> | 2 | GC |
| <i>sertraline oral tablet 100 mg, 25 mg, 50 mg</i> | 1 | GC |
| SODIUM OXYBATE ORAL SOLUTION 500 MG/ML | 5^ | PA; LA; QL (540 ML per 30 days) |
| <i>temazepam oral capsule 15 mg</i> | 2 | PA; QL (60 EA per 30 days); GC |
| <i>temazepam oral capsule 30 mg, 7.5 mg</i> | 2 | PA; QL (30 EA per 30 days); GC |
| <i>thioridazine oral tablet 10 mg, 100 mg, 25 mg, 50 mg</i> | 2 | GC |
| <i>thiothixene oral capsule 1 mg, 10 mg, 2 mg, 5 mg</i> | 2 | GC |

Puede encontrar información sobre lo que significan los símbolos y las abreviaturas de esta tabla al principio de esta.

06/01/2024

| Nombre del medicamento | Nivel del med. | Requisitos / Limitaciones |
|--|----------------|---------------------------------|
| <i>tranylcypromine oral tablet 10 mg</i> | 2 | GC |
| <i>trazodone oral tablet 100 mg, 150 mg, 50 mg</i> | 1 | GC |
| <i>trifluoperazine oral tablet 1 mg, 10 mg, 2 mg, 5 mg</i> | 2 | GC |
| <i>trimipramine oral capsule 100 mg</i> | 4 | QL (60 EA per 30 days) |
| <i>trimipramine oral capsule 25 mg, 50 mg</i> | 4 | QL (120 EA per 30 days) |
| TRINTELLIX ORAL TABLET 10 MG, 20 MG, 5 MG | 4 | QL (30 EA per 30 days) |
| <i>venlafaxine oral capsule,extended release 24hr 150 mg, 37.5 mg, 75 mg</i> | 1 | GC |
| <i>venlafaxine oral tablet 100 mg, 25 mg, 37.5 mg, 50 mg, 75 mg</i> | 2 | GC |
| VERSACLOZ ORAL SUSPENSION 50 MG/ML | 5^ | PA-NS; QL (600 ML per 30 days) |
| <i>vilazodone oral tablet 10 mg, 20 mg, 40 mg</i> | 2 | QL (30 EA per 30 days); GC |
| VRAYLAR ORAL CAPSULE 1.5 MG, 3 MG, 4.5 MG, 6 MG | 5^ | QL (30 EA per 30 days) |
| VRAYLAR ORAL CAPSULE,DOSE PACK 1.5 MG (1)- 3 MG (6) | 4 | |
| VYVANSE ORAL CAPSULE 10 MG, 20 MG, 30 MG | 4 | PA; QL (60 EA per 30 days) |
| VYVANSE ORAL CAPSULE 40 MG, 50 MG, 60 MG, 70 MG | 4 | PA; QL (30 EA per 30 days) |
| VYVANSE ORAL TABLET,CHEWABLE 10 MG, 20 MG, 30 MG | 4 | PA; QL (60 EA per 30 days) |
| VYVANSE ORAL TABLET,CHEWABLE 40 MG, 50 MG, 60 MG | 4 | PA; QL (30 EA per 30 days) |
| <i>ziprasidone hcl oral capsule 20 mg, 40 mg, 60 mg, 80 mg</i> | 2 | QL (60 EA per 30 days); GC |
| <i>ziprasidone mesylate intramuscular recon soln 20 mg/ml (final conc.)</i> | 2 | QL (6 EA per 3 days); GC |
| <i>zolpidem oral tablet 10 mg, 5 mg</i> | 2 | PA; QL (30 EA per 30 days); GC |
| ZURZUVAE ORAL CAPSULE 20 MG, 25 MG, 30 MG | 5^ | PA-NS |
| ZYPREXA RELPREVV INTRAMUSCULAR SUSPENSION FOR RECONSTITUTION 210 MG | 4 | PA-NS; QL (2 EA per 28 days) |
| ZYPREXA RELPREVV INTRAMUSCULAR SUSPENSION FOR RECONSTITUTION 300 MG | 5^ | PA-NS; QL (2.4 EA per 30 days) |
| ZYPREXA RELPREVV INTRAMUSCULAR SUSPENSION FOR RECONSTITUTION 405 MG | 5^ | PA-NS; QL (1.2 EA per 30 days) |
| PRODUCTOS DIVERSOS PARA EL TRATAMIENTO NEUROLÓGICO | | |
| AUSTEDO ORAL TABLET 12 MG, 9 MG | 5^ | PA; LA; QL (120 EA per 30 days) |
| AUSTEDO ORAL TABLET 6 MG | 5^ | PA; LA; QL (60 EA per 30 days) |
| AUSTEDO XR ORAL TABLET EXTENDED RELEASE 24 HR 12 MG | 5^ | PA; QL (120 EA per 30 days) |

Puede encontrar información sobre lo que significan los símbolos y las abreviaturas de esta tabla al principio de esta.

06/01/2024

| Nombre del medicamento | Nivel del med. | Requisitos / Limitaciones |
|--|----------------|--------------------------------|
| AUSTEDO XR ORAL TABLET EXTENDED RELEASE 24 HR 24 MG | 5^ | PA; QL (60 EA per 30 days) |
| AUSTEDO XR ORAL TABLET EXTENDED RELEASE 24 HR 6 MG | 5^ | PA; QL (90 EA per 30 days) |
| AUSTEDO XR TITRATION KT(WK1-4) ORAL TABLET, EXT REL 24HR DOSE PACK 6 MG (14)-12 MG (14)-24 MG (14) | 5^ | PA; QL (42 EA per 28 days) |
| <i>dalfampridine oral tablet extended release 12 hr 10 mg</i> | 2 | PA; QL (60 EA per 30 days); GC |
| <i>donepezil oral tablet 10 mg</i> | 1 | GC |
| <i>donepezil oral tablet 5 mg</i> | 1 | QL (30 EA per 30 days); GC |
| <i>donepezil oral tablet, disintegrating 10 mg</i> | 1 | GC |
| <i>donepezil oral tablet, disintegrating 5 mg</i> | 1 | QL (30 EA per 30 days); GC |
| <i>fingolimod oral capsule 0.5 mg</i> | 5^ | PA-NS; QL (28 EA per 28 days) |
| <i>galantamine oral capsule, ext rel. pellets 24 hr 16 mg, 24 mg, 8 mg</i> | 2 | QL (30 EA per 30 days); GC |
| <i>galantamine oral solution 4 mg/ml</i> | 2 | GC |
| <i>galantamine oral tablet 12 mg, 4 mg, 8 mg</i> | 2 | QL (60 EA per 30 days); GC |
| <i>glatiramer subcutaneous syringe 20 mg/ml</i> | 5^ | PA-NS; QL (30 ML per 30 days) |
| <i>glatiramer subcutaneous syringe 40 mg/ml</i> | 5^ | PA-NS; QL (12 ML per 28 days) |
| <i>glatopa subcutaneous syringe 20 mg/ml</i> | 5^ | PA-NS; QL (30 ML per 30 days) |
| <i>glatopa subcutaneous syringe 40 mg/ml</i> | 5^ | PA-NS; QL (12 ML per 28 days) |
| <i>memantine oral capsule, sprinkle, er 24hr 14 mg, 21 mg, 28 mg, 7 mg</i> | 2 | PA; GC |
| <i>memantine oral solution 2 mg/ml</i> | 2 | PA; GC |
| <i>memantine oral tablet 10 mg, 5 mg</i> | 2 | PA; GC |
| NAMZARIC ORAL CAP, SPRINKLE, ER 24HR DOSE PACK 7/14/21/28 MG-10 MG | 4 | |
| NAMZARIC ORAL CAPSULE, SPRINKLE, ER 24HR 14-10 MG, 21-10 MG, 28-10 MG, 7-10 MG | 4 | |
| NUDEXTA ORAL CAPSULE 20-10 MG | 5^ | PA; QL (60 EA per 30 days) |
| OCREVUS INTRAVENOUS SOLUTION 30 MG/ML | 5^ | PA-NS; QL (20 ML per 135 days) |
| RADICAVA ORS ORAL SUSPENSION 105 MG/5 ML | 5^ | PA |
| RADICAVA ORS STARTER KIT SUSP ORAL SUSPENSION 105 MG/5 ML | 5^ | PA |
| <i>rivastigmine tartrate oral capsule 1.5 mg, 3 mg, 4.5 mg, 6 mg</i> | 2 | QL (60 EA per 30 days); GC |
| <i>rivastigmine transdermal patch 24 hour 13.3 mg/24 hour, 4.6 mg/24 hour, 9.5 mg/24 hour</i> | 2 | QL (30 EA per 30 days); GC |

Puede encontrar información sobre lo que significan los símbolos y las abreviaturas de esta tabla al principio de esta.

06/01/2024

| Nombre del medicamento | Nivel del med. | Requisitos / Limitaciones |
|---|----------------|------------------------------------|
| TECFIDERA ORAL CAPSULE,DELAYED RELEASE(DR/EC) 120 MG | 5^ | PA-NS; LA; QL (14 EA per 7 days) |
| TECFIDERA ORAL CAPSULE,DELAYED RELEASE(DR/EC) 120 MG (14)- 240 MG (46) | 5^ | PA-NS; LA |
| TECFIDERA ORAL CAPSULE,DELAYED RELEASE(DR/EC) 240 MG | 5^ | PA-NS; LA; QL (60 EA per 30 days) |
| <i>teriflunomide oral tablet 14 mg, 7 mg</i> | 5^ | PA-NS; QL (30 EA per 30 days) |
| <i>tetrabenazine oral tablet 12.5 mg</i> | 5^ | PA; QL (90 EA per 30 days) |
| <i>tetrabenazine oral tablet 25 mg</i> | 5^ | PA; QL (120 EA per 30 days) |
| VUMERITY ORAL CAPSULE,DELAYED RELEASE(DR/EC) 231 MG | 5^ | PA-NS; LA; QL (120 EA per 30 days) |
| RELAJANTES MUSCULARES/TRATAMIENTO ANTIESPASMÓDICO | | |
| <i>baclofen oral tablet 10 mg, 20 mg, 5 mg</i> | 2 | GC |
| <i>cyclobenzaprine oral tablet 10 mg, 5 mg</i> | 2 | PA; GC |
| <i>dantrolene oral capsule 100 mg, 25 mg, 50 mg</i> | 2 | GC |
| <i>pyridostigmine bromide oral tablet 60 mg</i> | 2 | GC |
| <i>tizanidine oral tablet 2 mg, 4 mg</i> | 2 | GC |
| TRATAMIENTO PARA LA MIGRAÑA/CEFALEA EN BROTES | | |
| AIMOVIG AUTOINJECTOR SUBCUTANEOUS AUTO-INJECTOR 140 MG/ML, 70 MG/ML | 3 | PA; QL (1 ML per 30 days) |
| <i>dihydroergotamine injection solution 1 mg/ml</i> | 5^ | |
| <i>dihydroergotamine nasal spray,non-aerosol 0.5 mg/pump act. (4 mg/ml)</i> | 4 | PA; QL (8 ML per 28 days) |
| EMGALITY PEN SUBCUTANEOUS PEN INJECTOR 120 MG/ML | 3 | PA; QL (2 ML per 30 days) |
| EMGALITY SYRINGE SUBCUTANEOUS SYRINGE 120 MG/ML | 3 | PA; QL (2 ML per 30 days) |
| EMGALITY SYRINGE SUBCUTANEOUS SYRINGE 300 MG/3 ML (100 MG/ML X 3) | 5^ | PA; QL (3 ML per 30 days) |
| <i>ergotamine-caffeine oral tablet 1-100 mg</i> | 2 | PA; QL (40 EA per 28 days); GC |
| <i>naratriptan oral tablet 1 mg, 2.5 mg</i> | 2 | QL (12 EA per 30 days); GC |
| NURTEC ODT ORAL TABLET,DISINTEGRATING 75 MG | 5^ | PA; QL (16 EA per 30 days) |
| <i>rizatriptan oral tablet 10 mg, 5 mg</i> | 2 | QL (18 EA per 30 days); GC |
| <i>rizatriptan oral tablet,disintegrating 10 mg, 5 mg</i> | 2 | QL (18 EA per 30 days); GC |
| <i>sumatriptan nasal spray,non-aerosol 20 mg/actuation</i> | 2 | QL (12 EA per 30 days); GC |
| <i>sumatriptan nasal spray,non-aerosol 5 mg/actuation</i> | 2 | QL (24 EA per 30 days); GC |

Puede encontrar información sobre lo que significan los símbolos y las abreviaturas de esta tabla al principio de esta.

06/01/2024

| Nombre del medicamento | Nivel del med. | Requisitos / Limitaciones |
|--|-----------------------|----------------------------------|
| <i>sumatriptan succinate oral tablet 100 mg, 25 mg, 50 mg</i> | 2 | QL (12 EA per 30 days); GC |
| <i>sumatriptan succinate subcutaneous cartridge 4 mg/0.5 ml</i> | 2 | QL (9 ML per 30 days); GC |
| <i>sumatriptan succinate subcutaneous cartridge 6 mg/0.5 ml</i> | 2 | QL (6 ML per 30 days); GC |
| <i>sumatriptan succinate subcutaneous pen injector 4 mg/0.5 ml</i> | 2 | QL (9 ML per 30 days); GC |
| <i>sumatriptan succinate subcutaneous pen injector 6 mg/0.5 ml</i> | 2 | QL (6 ML per 30 days); GC |
| <i>sumatriptan succinate subcutaneous solution 6 mg/0.5 ml</i> | 2 | QL (6 ML per 30 days); GC |
| <i>zolmitriptan oral tablet 2.5 mg, 5 mg</i> | 2 | QL (12 EA per 30 days); GC |
| <i>zolmitriptan oral tablet, disintegrating 2.5 mg, 5 mg</i> | 2 | QL (12 EA per 30 days); GC |
| MEDICAMENTOS PARA EL OÍDO, LA NARIZ/LA GARGANTA | | |
| AGENTES VARIOS | | |
| <i>azelastine nasal aerosol, spray 137 mcg (0.1 %)</i> | 2 | QL (60 ML per 30 days); GC |
| <i>azelastine nasal spray, non-aerosol 205.5 mcg (0.15 %)</i> | 2 | QL (60 ML per 30 days); GC |
| <i>chlorhexidine gluconate mucous membrane mouthwash 0.12 %</i> | 1 | GC |
| <i>ipratropium bromide nasal spray, non-aerosol 21 mcg (0.03 %), 42 mcg (0.06 %)</i> | 2 | GC |
| <i>kourzeq dental paste 0.1 %</i> | 3 | |
| <i>olopatadine nasal spray, non-aerosol 0.6 %</i> | 2 | GC |
| <i>periogard mucous membrane mouthwash 0.12 %</i> | 1 | GC |
| <i>triamcinolone acetonide dental paste 0.1 %</i> | 3 | |
| CORTICOIDE/ANTIBIÓTICO ÓTICO | | |
| <i>CIPRO HC OTIC (EAR) DROPS, SUSPENSION 0.2-1 %</i> | 4 | |
| <i>ciprofloxacin-dexamethasone otic (ear) drops, suspension 0.3-0.1 %</i> | 3 | QL (7.5 ML per 7 days) |
| <i>neomycin-polymyxin-hc otic (ear) drops, suspension 3.5-10,000-1 mg/ml-unit/ml-%</i> | 2 | GC |
| <i>neomycin-polymyxin-hc otic (ear) solution 3.5-10,000-1 mg/ml-unit/ml-%</i> | 2 | GC |
| PREPARACIONES ÓTICAS DIVERSAS | | |
| <i>acetic acid otic (ear) solution 2 %</i> | 2 | GC |
| <i>flac otic oil otic (ear) drops 0.01 %</i> | 2 | GC |
| <i>fluocinolone acetonide oil otic (ear) drops 0.01 %</i> | 2 | GC |
| <i>ofloxacin otic (ear) drops 0.3 %</i> | 2 | GC |

Puede encontrar información sobre lo que significan los símbolos y las abreviaturas de esta tabla al principio de esta.

06/01/2024

| Nombre del medicamento | Nivel del med. | Requisitos / Limitaciones |
|---|----------------|--------------------------------|
| MEDICAMENTOS UROLÓGICOS | | |
| ANTICOLINÉRGICOS/ANTIESPASMÓDICOS | | |
| <i>darifenacin oral tablet extended release 24 hr 15 mg, 7.5 mg</i> | 2 | ST; QL (30 EA per 30 days); GC |
| <i>fesoterodine oral tablet extended release 24 hr 4 mg, 8 mg</i> | 2 | QL (30 EA per 30 days); GC |
| GEMTESA ORAL TABLET 75 MG | 4 | QL (30 EA per 30 days) |
| MYRBETRIQ ORAL SUSPENSION,EXTENDED REL RECON 8 MG/ML | 4 | QL (300 ML per 28 days) |
| MYRBETRIQ ORAL TABLET EXTENDED RELEASE 24 HR 25 MG, 50 MG | 4 | QL (30 EA per 30 days) |
| <i>oxybutynin chloride oral syrup 5 mg/5 ml</i> | 2 | GC |
| <i>oxybutynin chloride oral tablet 5 mg</i> | 2 | GC |
| <i>oxybutynin chloride oral tablet extended release 24hr 10 mg, 15 mg</i> | 2 | QL (60 EA per 30 days); GC |
| <i>oxybutynin chloride oral tablet extended release 24hr 5 mg</i> | 2 | QL (30 EA per 30 days); GC |
| <i>solifenacin oral tablet 10 mg, 5 mg</i> | 2 | QL (30 EA per 30 days); GC |
| <i>tolterodine oral capsule,extended release 24hr 2 mg, 4 mg</i> | 2 | ST; QL (30 EA per 30 days); GC |
| <i>tolterodine oral tablet 1 mg, 2 mg</i> | 2 | QL (60 EA per 30 days); GC |
| <i>tropium oral capsule,extended release 24hr 60 mg</i> | 2 | QL (30 EA per 30 days); GC |
| <i>tropium oral tablet 20 mg</i> | 2 | QL (60 EA per 30 days); GC |
| MEDICAMENTOS UROLÓGICOS DIVERSOS | | |
| <i>bethanechol chloride oral tablet 10 mg, 25 mg, 5 mg, 50 mg</i> | 2 | GC |
| CYSTAGON ORAL CAPSULE 150 MG, 50 MG | 4 | PA; LA |
| ELMIRON ORAL CAPSULE 100 MG | 4 | PA |
| <i>potassium citrate oral tablet extended release 10 meq (1,080 mg), 15 meq, 5 meq (540 mg)</i> | 2 | GC |
| <i>sildenafil oral tablet 100 mg, 25 mg, 50 mg</i> | 1 | QL (6 EA per 30 days); NT |
| <i>vardenafil oral tablet 10 mg, 2.5 mg, 20 mg, 5 mg</i> | 1 | QL (6 EA per 30 days); NT |
| TRATAMIENTO PARA LA HIPERPLASIA PROSTÁTICA BENIGNA (BPH) | | |
| <i>alfuzosin oral tablet extended release 24 hr 10 mg</i> | 1 | QL (30 EA per 30 days); GC |
| <i>dutasteride oral capsule 0.5 mg</i> | 2 | QL (30 EA per 30 days); GC |
| <i>dutasteride-tamsulosin oral capsule, er multiphase 24 hr 0.5-0.4 mg</i> | 2 | QL (30 EA per 30 days); GC |
| <i>finasteride oral tablet 5 mg</i> | 1 | GC |

Puede encontrar información sobre lo que significan los símbolos y las abreviaturas de esta tabla al principio de esta.

06/01/2024

| Nombre del medicamento | Nivel del med. | Requisitos / Limitaciones |
|---|----------------|--|
| <i>silodosin oral capsule 4 mg, 8 mg</i> | 2 | QL (30 EA per 30 days); GC |
| <i>tamsulosin oral capsule 0.4 mg</i> | 1 | GC |
| MUSCULOESQUELÉTICO/REUMATOLOGÍA | | |
| OTROS MEDICAMENTOS REUMATOLÓGICOS | | |
| ACTEMRA ACTPEN SUBCUTANEOUS PEN INJECTOR 162 MG/0.9 ML | 5^ | PA; QL (3.6 ML per 28 days) |
| ACTEMRA SUBCUTANEOUS SYRINGE 162 MG/0.9 ML | 5^ | PA; QL (3.6 ML per 28 days) |
| BENLYSTA INTRAVENOUS RECON SOLN 120 MG, 400 MG | 5^ | PA; LA |
| BENLYSTA SUBCUTANEOUS AUTO-INJECTOR 200 MG/ML | 5^ | PA; LA; QL (8 ML per 28 days) |
| BENLYSTA SUBCUTANEOUS SYRINGE 200 MG/ML | 5^ | PA; LA; QL (8 ML per 28 days) |
| CYLTEZO(CF) PEN CROHN'S-UC-HS SUBCUTANEOUS PEN INJECTOR KIT 40 MG/0.8 ML | 5^ | PA; QL (6 EA per 180 days) |
| CYLTEZO(CF) PEN PSORIASIS-UV SUBCUTANEOUS PEN INJECTOR KIT 40 MG/0.8 ML | 5^ | PA; QL (4 EA per 180 days) |
| CYLTEZO(CF) PEN SUBCUTANEOUS PEN INJECTOR KIT 40 MG/0.4 ML | 5^ | PA |
| CYLTEZO(CF) PEN SUBCUTANEOUS PEN INJECTOR KIT 40 MG/0.8 ML | 5^ | PA; QL (4 EA per 28 days) |
| CYLTEZO(CF) SUBCUTANEOUS SYRINGE KIT 10 MG/0.2 ML, 20 MG/0.4 ML | 5^ | PA; QL (2 EA per 28 days) |
| CYLTEZO(CF) SUBCUTANEOUS SYRINGE KIT 40 MG/0.8 ML | 5^ | PA; QL (4 EA per 28 days) |
| ENBREL MINI SUBCUTANEOUS CARTRIDGE 50 MG/ML (1 ML) | 5^ | PA; QL (8 ML per 28 days) |
| ENBREL SUBCUTANEOUS SOLUTION 25 MG/0.5 ML | 5^ | PA; QL (8 ML per 28 days) |
| ENBREL SUBCUTANEOUS SYRINGE 25 MG/0.5 ML (0.5), 50 MG/ML (1 ML) | 5^ | PA; QL (8 ML per 28 days) |
| ENBREL SURECLICK SUBCUTANEOUS PEN INJECTOR 50 MG/ML (1 ML) | 5^ | PA; QL (8 ML per 28 days) |
| HUMIRA PEN PSOR-UEVITS-ADOL HS SUBCUTANEOUS PEN INJECTOR KIT 40 MG/0.8 ML | 5^ | Only Humira NDCs starting 00074 are covered; PA |
| HUMIRA PEN SUBCUTANEOUS PEN INJECTOR KIT 40 MG/0.8 ML | 5^ | Only Humira NDCs starting 00074 are covered; PA; QL (6 EA per 28 days) |
| HUMIRA SUBCUTANEOUS SYRINGE KIT 40 MG/0.8 ML | 5^ | Only Humira NDCs starting 00074 are covered; PA; QL (6 EA per 28 days) |
| HUMIRA(CF) PEDI CROHNS STARTER SUBCUTANEOUS SYRINGE KIT 80 MG/0.8 ML, 80 MG/0.8 ML-40 MG/0.4 ML | 5^ | Only Humira NDCs starting 00074 are covered; PA |

Puede encontrar información sobre lo que significan los símbolos y las abreviaturas de esta tabla al principio de esta.

06/01/2024

| Nombre del medicamento | Nivel del med. | Requisitos / Limitaciones |
|--|----------------|--|
| HUMIRA(CF) PEN CROHNS-UC-HS SUBCUTANEOUS PEN INJECTOR KIT 80 MG/0.8 ML | 5^ | Only Humira NDCs starting 00074 are covered; PA |
| HUMIRA(CF) PEN PEDIATRIC UC SUBCUTANEOUS PEN INJECTOR KIT 80 MG/0.8 ML | 5^ | Only Humira NDCs starting 00074 are covered; PA |
| HUMIRA(CF) PEN PSOR-UV-ADOL HS SUBCUTANEOUS PEN INJECTOR KIT 80 MG/0.8 ML-40 MG/0.4 ML | 5^ | Only Humira NDCs starting 00074 are covered; PA |
| HUMIRA(CF) PEN SUBCUTANEOUS PEN INJECTOR KIT 40 MG/0.4 ML | 5^ | Only Humira NDCs starting 00074 are covered; PA; QL (6 EA per 28 days) |
| HUMIRA(CF) PEN SUBCUTANEOUS PEN INJECTOR KIT 80 MG/0.8 ML | 5^ | Only Humira NDCs starting 00074 are covered; PA; QL (4 EA per 28 days) |
| HUMIRA(CF) SUBCUTANEOUS SYRINGE KIT 10 MG/0.1 ML, 20 MG/0.2 ML | 5^ | Only Humira NDCs starting 00074 are covered; PA; QL (2 EA per 28 days) |
| HUMIRA(CF) SUBCUTANEOUS SYRINGE KIT 40 MG/0.4 ML | 5^ | Only Humira NDCs starting 00074 are covered; PA; QL (6 EA per 28 days) |
| IDACIO(CF) PEN CROHN-UC STARTR SUBCUTANEOUS PEN INJECTOR KIT 40 MG/0.8 ML | 5^ | PA; QL (6 EA per 180 days) |
| IDACIO(CF) PEN PSORIASIS START SUBCUTANEOUS PEN INJECTOR KIT 40 MG/0.8 ML | 5^ | PA; QL (4 EA per 28 days) |
| IDACIO(CF) PEN SUBCUTANEOUS PEN INJECTOR KIT 40 MG/0.8 ML | 5^ | PA; QL (4 EA per 180 days) |
| IDACIO(CF) SUBCUTANEOUS SYRINGE KIT 40 MG/0.8 ML | 5^ | PA; QL (4 EA per 28 days) |
| <i>leflunomide oral tablet 10 mg, 20 mg</i> | 2 | QL (30 EA per 30 days); GC |
| OTEZLA ORAL TABLET 30 MG | 5^ | PA; QL (60 EA per 30 days) |
| OTEZLA STARTER ORAL TABLETS,DOSE PACK 10 MG (4)-20 MG (4)-30 MG (47) | 5^ | PA; QL (55 EA per 180 days) |
| <i>penicillamine oral tablet 250 mg</i> | 5^ | |
| RINVOQ ORAL TABLET EXTENDED RELEASE 24 HR 15 MG, 30 MG | 5^ | PA; QL (30 EA per 30 days) |
| RINVOQ ORAL TABLET EXTENDED RELEASE 24 HR 45 MG | 5^ | PA; QL (84 EA per 180 days) |
| SAVELLA ORAL TABLET 100 MG, 12.5 MG, 25 MG, 50 MG | 4 | PA; QL (60 EA per 30 days) |
| SAVELLA ORAL TABLETS,DOSE PACK 12.5 MG (5)-25 MG(8)-50 MG(42) | 4 | PA |
| XELJANZ ORAL SOLUTION 1 MG/ML | 5^ | PA; QL (480 ML per 24 days) |
| XELJANZ ORAL TABLET 10 MG, 5 MG | 5^ | PA; QL (60 EA per 30 days) |
| XELJANZ XR ORAL TABLET EXTENDED RELEASE 24 HR 11 MG, 22 MG | 5^ | PA; QL (30 EA per 30 days) |

Puede encontrar información sobre lo que significan los símbolos y las abreviaturas de esta tabla al principio de esta.

06/01/2024

| Nombre del medicamento | Nivel del med. | Requisitos / Limitaciones |
|---|----------------|--|
| TRATAMIENTO PARA LA GOTA | | |
| <i>allopurinol oral tablet 100 mg, 300 mg</i> | 1 | GC |
| <i>colchicine oral tablet 0.6 mg</i> | 4 | QL (120 EA per 30 days) |
| <i>febuxostat oral tablet 40 mg, 80 mg</i> | 2 | GC |
| MITIGARE ORAL CAPSULE 0.6 MG | 3 | QL (60 EA per 30 days) |
| <i>probenecid oral tablet 500 mg</i> | 2 | GC |
| <i>probenecid-colchicine oral tablet 500-0.5 mg</i> | 2 | GC |
| TRATAMIENTO PARA LA OSTEOPOROSIS | | |
| <i>alendronate oral solution 70 mg/75 ml</i> | 2 | QL (300 ML per 28 days); GC |
| <i>alendronate oral tablet 10 mg</i> | 1 | QL (30 EA per 30 days); GC |
| <i>alendronate oral tablet 35 mg, 70 mg</i> | 1 | QL (4 EA per 28 days); GC |
| FORTEO SUBCUTANEOUS PEN INJECTOR 20 MCG/DOSE (600MCG/2.4ML) | 5^ | PA |
| FOSAMAX PLUS D ORAL TABLET 70 MG- 2,800 UNIT, 70 MG- 5,600 UNIT | 4 | ST; QL (4 EA per 28 days) |
| <i>ibandronate intravenous solution 3 mg/3 ml</i> | 2 | QL (3 ML per 68 days); GC |
| <i>ibandronate intravenous syringe 3 mg/3 ml</i> | 2 | QL (3 ML per 68 days); GC |
| <i>ibandronate oral tablet 150 mg</i> | 2 | QL (1 EA per 30 days); GC |
| PROLIA SUBCUTANEOUS SYRINGE 60 MG/ML | 4 | QL (1 ML per 180 days) |
| <i>raloxifene oral tablet 60 mg</i> | 2 | GC |
| <i>risedronate oral tablet 150 mg</i> | 2 | QL (1 EA per 30 days); GC |
| <i>risedronate oral tablet 35 mg, 35 mg (12 pack), 35 mg (4 pack)</i> | 2 | QL (4 EA per 28 days); GC |
| <i>risedronate oral tablet 5 mg</i> | 2 | QL (30 EA per 30 days); GC |
| <i>risedronate oral tablet, delayed release (dr/ec) 35 mg</i> | 2 | QL (4 EA per 28 days); GC |
| TERIPARATIDE SUBCUTANEOUS PEN INJECTOR 20 MCG/DOSE (620MCG/2.48ML) | 5^ | Only Teriparatide NDC 47781065289 is covered; PA; QL (2.48 ML per 28 days) |
| TYMLOS SUBCUTANEOUS PEN INJECTOR 80 MCG (3,120 MCG/1.56 ML) | 5^ | PA |
| OBSTETRICIA/GINECOLOGÍA | | |
| ANTICONCEPTIVOS ORALES/AGENTES RELACIONADOS | | |
| <i>altavera (28) oral tablet 0.15-0.03 mg</i> | 2 | GC |
| <i>alyacen 1/35 (28) oral tablet 1-35 mg-mcg</i> | 2 | GC |
| <i>alyacen 7/7/7 (28) oral tablet 0.5/0.75/1 mg- 35 mcg</i> | 2 | GC |
| <i>apri oral tablet 0.15-0.03 mg</i> | 2 | GC |

Puede encontrar información sobre lo que significan los símbolos y las abreviaturas de esta tabla al principio de esta.

06/01/2024

| Nombre del medicamento | Nivel del med. | Requisitos / Limitaciones |
|---|-----------------------|----------------------------------|
| <i>aranelle (28) oral tablet 0.5/1/0.5-35 mg-mcg</i> | 2 | GC |
| <i>abra eq oral tablet 0.1-20 mg-mcg</i> | 2 | GC |
| <i>aurovela fe 1.5/30 (28) oral tablet 1.5 mg-30 mcg (21)/75 mg (7)</i> | 2 | GC |
| <i>aurovela fe 1-20 (28) oral tablet 1 mg-20 mcg (21)/75 mg (7)</i> | 2 | GC |
| <i>aviane oral tablet 0.1-20 mg-mcg</i> | 2 | GC |
| <i>azurette (28) oral tablet 0.15-0.02 mgx21 /0.01 mg x 5</i> | 2 | GC |
| <i>blisovi fe 1.5/30 (28) oral tablet 1.5 mg-30 mcg (21)/75 mg (7)</i> | 2 | GC |
| <i>blisovi fe 1/20 (28) oral tablet 1 mg-20 mcg (21)/75 mg (7)</i> | 2 | GC |
| <i>cryelle (28) oral tablet 0.3-30 mg-mcg</i> | 2 | GC |
| <i>cyred eq oral tablet 0.15-0.03 mg</i> | 2 | GC |
| <i>dasetta 1/35 (28) oral tablet 1-35 mg-mcg</i> | 2 | GC |
| <i>dasetta 7/7/7 (28) oral tablet 0.5/0.75/1 mg- 35 mcg</i> | 2 | GC |
| <i>desog-e.estradiol/e.estradiol oral tablet 0.15-0.02 mgx21 /0.01 mg x 5</i> | 2 | GC |
| <i>desogestrel-ethinyl estradiol oral tablet 0.15-0.03 mg</i> | 2 | GC |
| <i>drospirenone-ethinyl estradiol oral tablet 3-0.02 mg, 3-0.03 mg</i> | 2 | GC |
| <i>elinst oral tablet 0.3-30 mg-mcg</i> | 2 | GC |
| <i>emoquette oral tablet 0.15-0.03 mg</i> | 2 | GC |
| <i>enpresse oral tablet 50-30 (6)/75-40 (5)/125-30(10)</i> | 2 | GC |
| <i>enskyce oral tablet 0.15-0.03 mg</i> | 2 | GC |
| <i>estarylla oral tablet 0.25-35 mg-mcg</i> | 2 | GC |
| <i>ethynodiol diac-eth estradiol oral tablet 1-35 mg-mcg, 1-50 mg-mcg</i> | 2 | GC |
| <i>falmina (28) oral tablet 0.1-20 mg-mcg</i> | 2 | GC |
| <i>introvale oral tablets,dose pack,3 month 0.15 mg-30 mcg (91)</i> | 2 | GC |
| <i>isibloom oral tablet 0.15-0.03 mg</i> | 2 | GC |
| <i>jasmiel (28) oral tablet 3-0.02 mg</i> | 2 | GC |
| <i>jolessa oral tablets,dose pack,3 month 0.15 mg-30 mcg (91)</i> | 2 | GC |
| <i>juleber oral tablet 0.15-0.03 mg</i> | 2 | GC |

Puede encontrar información sobre lo que significan los símbolos y las abreviaturas de esta tabla al principio de esta.

06/01/2024

| Nombre del medicamento | Nivel del med. | Requisitos / Limitaciones |
|---|-----------------------|----------------------------------|
| <i>junel fe 1.5/30 (28) oral tablet 1.5 mg-30 mcg (21)/75 mg (7)</i> | 2 | GC |
| <i>junel fe 1/20 (28) oral tablet 1 mg-20 mcg (21)/75 mg (7)</i> | 2 | GC |
| <i>kariva (28) oral tablet 0.15-0.02 mgx21 /0.01 mg x 5</i> | 2 | GC |
| <i>kelnor 1/35 (28) oral tablet 1-35 mg-mcg</i> | 2 | GC |
| <i>kelnor 1-50 (28) oral tablet 1-50 mg-mcg</i> | 2 | GC |
| <i>kurvelo (28) oral tablet 0.15-0.03 mg</i> | 2 | GC |
| <i>larin 1.5/30 (21) oral tablet 1.5-30 mg-mcg</i> | 2 | GC |
| <i>larin 1/20 (21) oral tablet 1-20 mg-mcg</i> | 2 | GC |
| <i>larin fe 1.5/30 (28) oral tablet 1.5 mg-30 mcg (21)/75 mg (7)</i> | 2 | GC |
| <i>larin fe 1/20 (28) oral tablet 1 mg-20 mcg (21)/75 mg (7)</i> | 2 | GC |
| <i>lessina oral tablet 0.1-20 mg-mcg</i> | 2 | GC |
| <i>levonest (28) oral tablet 50-30 (6)/75-40 (5)/125-30(10)</i> | 2 | GC |
| <i>levonorgestrel-ethinyl estrad oral tablet 0.1-20 mg-mcg, 0.15-0.03 mg</i> | 2 | GC |
| <i>levonorgestrel-ethinyl estrad oral tablets,dose pack,3 month 0.15 mg-30 mcg (91)</i> | 2 | GC |
| <i>levonorg-eth estrad triphasic oral tablet 50-30 (6)/75-40 (5)/125-30(10)</i> | 2 | GC |
| <i>levora-28 oral tablet 0.15-0.03 mg</i> | 2 | GC |
| <i>loryna (28) oral tablet 3-0.02 mg</i> | 2 | GC |
| <i>low-ogestrel (28) oral tablet 0.3-30 mg-mcg</i> | 2 | GC |
| <i>lutera (28) oral tablet 0.1-20 mg-mcg</i> | 2 | GC |
| <i>marlissa (28) oral tablet 0.15-0.03 mg</i> | 2 | GC |
| <i>microgestin 1.5/30 (21) oral tablet 1.5-30 mg-mcg</i> | 2 | GC |
| <i>microgestin 1/20 (21) oral tablet 1-20 mg-mcg</i> | 2 | GC |
| <i>microgestin fe 1.5/30 (28) oral tablet 1.5 mg-30 mcg (21)/75 mg (7)</i> | 2 | GC |
| <i>microgestin fe 1/20 (28) oral tablet 1 mg-20 mcg (21)/75 mg (7)</i> | 2 | GC |
| <i>mili oral tablet 0.25-35 mg-mcg</i> | 2 | GC |
| <i>mono-linyah oral tablet 0.25-35 mg-mcg</i> | 2 | GC |
| <i>nikki (28) oral tablet 3-0.02 mg</i> | 2 | GC |

Puede encontrar información sobre lo que significan los símbolos y las abreviaturas de esta tabla al principio de esta.

06/01/2024

| Nombre del medicamento | Nivel del med. | Requisitos / Limitaciones |
|---|-----------------------|----------------------------------|
| <i>norethindrone ac-eth estradiol oral tablet 1-20 mg-mcg, 1.5-30 mg-mcg</i> | 2 | GC |
| <i>norethindrone-e.estradiol-iron oral tablet 1 mg-20 mcg (21)/75 mg (7), 1.5 mg-30 mcg (21)/75 mg (7)</i> | 2 | GC |
| <i>norgestimate-ethinyl estradiol oral tablet 0.18/0.215/0.25 mg-25 mcg, 0.18/0.215/0.25 mg-35 mcg (28), 0.25-35 mg-mcg</i> | 2 | GC |
| <i>nortrel 0.5/35 (28) oral tablet 0.5-35 mg-mcg</i> | 2 | GC |
| <i>nortrel 1/35 (21) oral tablet 1-35 mg-mcg (21)</i> | 2 | GC |
| <i>nortrel 1/35 (28) oral tablet 1-35 mg-mcg</i> | 2 | GC |
| <i>nortrel 7/7/7 (28) oral tablet 0.5/0.75/1 mg- 35 mcg</i> | 2 | GC |
| <i>philith oral tablet 0.4-35 mg-mcg</i> | 2 | GC |
| <i>pimtrex (28) oral tablet 0.15-0.02 mgx21 /0.01 mg x 5</i> | 2 | GC |
| <i>pirmella oral tablet 1-35 mg-mcg</i> | 2 | GC |
| <i>portia 28 oral tablet 0.15-0.03 mg</i> | 2 | GC |
| <i>reclipsen (28) oral tablet 0.15-0.03 mg</i> | 2 | GC |
| <i>setlakin oral tablets,dose pack,3 month 0.15 mg-30 mcg (91)</i> | 2 | GC |
| <i>sprintec (28) oral tablet 0.25-35 mg-mcg</i> | 2 | GC |
| <i>sronyx oral tablet 0.1-20 mg-mcg</i> | 2 | GC |
| <i>syeda oral tablet 3-0.03 mg</i> | 2 | GC |
| <i>tarina fe 1-20 eq (28) oral tablet 1 mg-20 mcg (21)/75 mg (7)</i> | 2 | GC |
| <i>tilia fe oral tablet 1-20(5)/1-30(7) /1mg-35mcg (9)</i> | 2 | GC |
| <i>tri-estarylla oral tablet 0.18/0.215/0.25 mg-35 mcg (28)</i> | 2 | GC |
| <i>tri-legest fe oral tablet 1-20(5)/1-30(7) /1mg-35mcg (9)</i> | 2 | GC |
| <i>tri-linyah oral tablet 0.18/0.215/0.25 mg-35 mcg (28)</i> | 2 | GC |
| <i>tri-lo-estarylla oral tablet 0.18/0.215/0.25 mg-25 mcg</i> | 2 | GC |
| <i>tri-lo-marzia oral tablet 0.18/0.215/0.25 mg-25 mcg</i> | 2 | GC |
| <i>tri-lo-mili oral tablet 0.18/0.215/0.25 mg-25 mcg</i> | 2 | GC |
| <i>tri-lo-sprintec oral tablet 0.18/0.215/0.25 mg-25 mcg</i> | 2 | GC |
| <i>tri-sprintec (28) oral tablet 0.18/0.215/0.25 mg-35 mcg (28)</i> | 2 | GC |
| <i>trivora (28) oral tablet 50-30 (6)/75-40 (5)/125-30(10)</i> | 2 | GC |
| <i>turqoz (28) oral tablet 0.3-30 mg-mcg</i> | 2 | GC |

Puede encontrar información sobre lo que significan los símbolos y las abreviaturas de esta tabla al principio de esta.

06/01/2024

| Nombre del medicamento | Nivel del med. | Requisitos / Limitaciones |
|---|----------------|---------------------------|
| <i>velivet triphasic regimen (28) oral tablet 0.1/.125/.15-25 mg-mcg</i> | 2 | GC |
| <i>vestura (28) oral tablet 3-0.02 mg</i> | 2 | GC |
| <i>vienva oral tablet 0.1-20 mg-mcg</i> | 2 | GC |
| <i>viorele (28) oral tablet 0.15-0.02 mgx21 /0.01 mg x 5</i> | 2 | GC |
| <i>wera (28) oral tablet 0.5-35 mg-mcg</i> | 2 | GC |
| <i>zovia 1-35 (28) oral tablet 1-35 mg-mcg</i> | 2 | GC |
| <i>zumandimine (28) oral tablet 3-0.03 mg</i> | 2 | GC |
| ESTRÓGENOS/PROGESTERONA | | |
| <i>amabelz oral tablet 0.5-0.1 mg, 1-0.5 mg</i> | 3 | |
| <i>camila oral tablet 0.35 mg</i> | 2 | GC |
| <i>deblitane oral tablet 0.35 mg</i> | 2 | GC |
| DELESTROGEN INTRAMUSCULAR OIL 10 MG/ML | 4 | |
| DEPO-SUBQ PROVERA 104 SUBCUTANEOUS SYRINGE 104 MG/0.65 ML | 4 | |
| <i>dotti transdermal patch semiweekly 0.025 mg/24 hr, 0.0375 mg/24 hr, 0.05 mg/24 hr, 0.075 mg/24 hr, 0.1 mg/24 hr</i> | 3 | |
| <i>errin oral tablet 0.35 mg</i> | 2 | GC |
| <i>estradiol oral tablet 0.5 mg, 1 mg, 2 mg</i> | 2 | GC |
| <i>estradiol transdermal patch semiweekly 0.025 mg/24 hr, 0.0375 mg/24 hr, 0.05 mg/24 hr, 0.075 mg/24 hr, 0.1 mg/24 hr</i> | 3 | |
| <i>estradiol transdermal patch weekly 0.025 mg/24 hr, 0.0375 mg/24 hr, 0.05 mg/24 hr, 0.06 mg/24 hr, 0.075 mg/24 hr, 0.1 mg/24 hr</i> | 3 | |
| <i>estradiol vaginal cream 0.01 % (0.1 mg/gram)</i> | 2 | GC |
| <i>estradiol vaginal tablet 10 mcg</i> | 2 | GC |
| <i>estradiol valerate intramuscular oil 20 mg/ml, 40 mg/ml</i> | 2 | GC |
| <i>estradiol-norethindrone acet oral tablet 0.5-0.1 mg, 1-0.5 mg</i> | 3 | |
| <i>fyavolv oral tablet 0.5-2.5 mg-mcg, 1-5 mg-mcg</i> | 3 | |
| <i>heather oral tablet 0.35 mg</i> | 2 | GC |
| IMVEXXY MAINTENANCE PACK VAGINAL INSERT 10 MCG, 4 MCG | 3 | |
| IMVEXXY STARTER PACK VAGINAL INSERT, DOSE PACK 10 MCG, 4 MCG | 3 | |

Puede encontrar información sobre lo que significan los símbolos y las abreviaturas de esta tabla al principio de esta.

06/01/2024

| Nombre del medicamento | Nivel del med. | Requisitos / Limitaciones |
|--|----------------|---------------------------|
| <i>incassia oral tablet 0.35 mg</i> | 2 | GC |
| <i>jinteli oral tablet 1-5 mg-mcg</i> | 3 | |
| <i>lyleq oral tablet 0.35 mg</i> | 2 | GC |
| <i>lyllana transdermal patch semiweekly 0.025 mg/24 hr, 0.0375 mg/24 hr, 0.05 mg/24 hr, 0.075 mg/24 hr, 0.1 mg/24 hr</i> | 3 | |
| <i>lyza oral tablet 0.35 mg</i> | 2 | GC |
| <i>medroxyprogesterone intramuscular suspension 150 mg/ml</i> | 2 | GC |
| <i>medroxyprogesterone intramuscular syringe 150 mg/ml</i> | 2 | GC |
| <i>medroxyprogesterone oral tablet 10 mg, 2.5 mg, 5 mg</i> | 1 | GC |
| <i>mimvey oral tablet 1-0.5 mg</i> | 3 | |
| <i>nora-be oral tablet 0.35 mg</i> | 2 | GC |
| <i>norethindrone (contraceptive) oral tablet 0.35 mg</i> | 2 | GC |
| <i>norethindrone acetate oral tablet 5 mg</i> | 2 | GC |
| <i>norethindrone ac-eth estradiol oral tablet 0.5-2.5 mg-mcg, 1-5 mg-mcg</i> | 3 | |
| <i>norlyda oral tablet 0.35 mg</i> | 2 | GC |
| PREMARIN VAGINAL CREAM 0.625 MG/GRAM | 3 | |
| <i>progesterone intramuscular oil 50 mg/ml</i> | 2 | GC |
| <i>progesterone micronized oral capsule 100 mg, 200 mg</i> | 2 | GC |
| <i>sharobel oral tablet 0.35 mg</i> | 2 | GC |
| <i>yuvafem vaginal tablet 10 mcg</i> | 2 | GC |
| PRODUCTOS DE OBSTETRICIA/GINECOLOGÍA DIVERSOS | | |
| <i>clindamycin phosphate vaginal cream 2 %</i> | 3 | |
| <i>eluryng vaginal ring 0.12-0.015 mg/24 hr</i> | 2 | GC |
| <i>etonogestrel-ethinyl estradiol vaginal ring 0.12-0.015 mg/24 hr</i> | 2 | GC |
| <i>metronidazole vaginal gel 0.75 % (37.5mg/5 gram)</i> | 2 | GC |
| NEXPLANON SUBDERMAL IMPLANT 68 MG | 4 | |
| <i>terconazole vaginal cream 0.4 %, 0.8 %</i> | 2 | GC |
| <i>terconazole vaginal suppository 80 mg</i> | 3 | |
| <i>tranexamic acid oral tablet 650 mg</i> | 2 | GC |
| <i>xulane transdermal patch weekly 150-35 mcg/24 hr</i> | 2 | GC |
| <i>zafemy transdermal patch weekly 150-35 mcg/24 hr</i> | 2 | GC |

Puede encontrar información sobre lo que significan los símbolos y las abreviaturas de esta tabla al principio de esta.

06/01/2024

| Nombre del medicamento | Nivel del med. | Requisitos / Limitaciones |
|--|----------------|---------------------------|
| OFTALMOLOGÍA | | |
| ANTIBIÓTICOS | | |
| <i>ak-poly-bac ophthalmic (eye) ointment 500-10,000 unit/gram</i> | 1 | GC |
| <i>bacitracin ophthalmic (eye) ointment 500 unit/gram</i> | 2 | GC |
| <i>bacitracin-polymyxin b ophthalmic (eye) ointment 500-10,000 unit/gram</i> | 1 | GC |
| BESIVANCE OPHTHALMIC (EYE) DROPS,SUSPENSION 0.6 % | 3 | |
| CILOXAN OPHTHALMIC (EYE) OINTMENT 0.3 % | 3 | |
| <i>ciprofloxacin hcl ophthalmic (eye) drops 0.3 %</i> | 1 | GC |
| <i>erythromycin ophthalmic (eye) ointment 5 mg/gram (0.5 %)</i> | 1 | GC |
| <i>gatifloxacin ophthalmic (eye) drops 0.5 %</i> | 2 | GC |
| <i>gentak ophthalmic (eye) ointment 0.3 % (3 mg/gram)</i> | 2 | GC |
| <i>gentamicin ophthalmic (eye) drops 0.3 %</i> | 1 | GC |
| <i>moxifloxacin ophthalmic (eye) drops 0.5 %</i> | 2 | GC |
| <i>moxifloxacin ophthalmic (eye) drops, viscous 0.5 %</i> | 2 | GC |
| NATACYN OPHTHALMIC (EYE) DROPS,SUSPENSION 5 % | 4 | |
| <i>neomycin-bacitracin-polymyxin ophthalmic (eye) ointment 3.5-400-10,000 mg-unit-unit/g</i> | 2 | GC |
| <i>neomycin-polymyxin-gramicidin ophthalmic (eye) drops 1.75 mg-10,000 unit-0.025mg/ml</i> | 2 | GC |
| <i>ofloxacin ophthalmic (eye) drops 0.3 %</i> | 2 | GC |
| <i>polymyxin b sulf-trimethoprim ophthalmic (eye) drops 10,000 unit- 1 mg/ml</i> | 1 | GC |
| <i>tobramycin ophthalmic (eye) drops 0.3 %</i> | 1 | GC |
| ANTIINFLAMATORIOS NO ESTEROIDEOS | | |
| <i>bromfenac ophthalmic (eye) drops 0.09 %</i> | 4 | |
| BROMSITE OPHTHALMIC (EYE) DROPS 0.075 % | 4 | |
| <i>diclofenac sodium ophthalmic (eye) drops 0.1 %</i> | 2 | GC |
| <i>flurbiprofen sodium ophthalmic (eye) drops 0.03 %</i> | 2 | GC |
| ILEVRO OPHTHALMIC (EYE) DROPS,SUSPENSION 0.3 % | 3 | |
| <i>ketorolac ophthalmic (eye) drops 0.4 %, 0.5 %</i> | 2 | GC |
| PROLENSA OPHTHALMIC (EYE) DROPS 0.07 % | 3 | |
| ANTIVIRALES | | |
| <i>trifluridine ophthalmic (eye) drops 1 %</i> | 2 | GC |

Puede encontrar información sobre lo que significan los símbolos y las abreviaturas de esta tabla al principio de esta.

06/01/2024

| Nombre del medicamento | Nivel del med. | Requisitos / Limitaciones |
|--|----------------|---------------------------|
| ZIRGAN OPHTHALMIC (EYE) GEL 0.15 % | 4 | |
| BLOQUEADORES BETA | | |
| <i>betaxolol ophthalmic (eye) drops 0.5 %</i> | 2 | GC |
| <i>carteolol ophthalmic (eye) drops 1 %</i> | 2 | GC |
| <i>levobunolol ophthalmic (eye) drops 0.5 %</i> | 2 | GC |
| <i>timolol maleate ophthalmic (eye) drops 0.25 %, 0.5 %</i> | 1 | GC |
| <i>timolol maleate ophthalmic (eye) gel forming solution 0.25 %, 0.5 %</i> | 2 | GC |
| COMBINACIONES DE ESTEROIDES Y ANTIBIÓTICOS | | |
| <i>neomycin-bacitracin-poly-hc ophthalmic (eye) ointment 3.5-400-10,000 mg-unit/g-1%</i> | 2 | GC |
| <i>neomycin-polymyxin b-dexameth ophthalmic (eye) drops,suspension 3.5mg/ml-10,000 unit/ml-0.1 %</i> | 2 | GC |
| <i>neomycin-polymyxin b-dexameth ophthalmic (eye) ointment 3.5 mg/g-10,000 unit/g-0.1 %</i> | 1 | GC |
| <i>neomycin-polymyxin-hc ophthalmic (eye) drops,suspension 3.5-10,000-10 mg-unit-mg/ml</i> | 2 | GC |
| TOBRADEX OPHTHALMIC (EYE) OINTMENT 0.3-0.1 % | 3 | |
| TOBRADEX ST OPHTHALMIC (EYE) DROPS,SUSPENSION 0.3-0.05 % | 3 | |
| <i>tobramycin-dexamethasone ophthalmic (eye) drops,suspension 0.3-0.1 %</i> | 3 | |
| ZYLET OPHTHALMIC (EYE) DROPS,SUSPENSION 0.3-0.5 % | 3 | |
| ESTEROIDES | | |
| ALREX OPHTHALMIC (EYE) DROPS,SUSPENSION 0.2 % | 3 | |
| <i>dexamethasone sodium phosphate ophthalmic (eye) drops 0.1 %</i> | 3 | |
| <i>difluprednate ophthalmic (eye) drops 0.05 %</i> | 4 | |
| FLAREX OPHTHALMIC (EYE) DROPS,SUSPENSION 0.1 % | 4 | |
| <i>fluorometholone ophthalmic (eye) drops,suspension 0.1 %</i> | 3 | |
| LOTEMAX OPHTHALMIC (EYE) OINTMENT 0.5 % | 3 | |
| <i>prednisolone acetate ophthalmic (eye) drops,suspension 1 %</i> | 2 | GC |
| <i>prednisolone sodium phosphate ophthalmic (eye) drops 1 %</i> | 3 | |
| MEDICAMENTOS ORALES PARA EL GLAUCOMA | | |
| <i>acetazolamide oral capsule, extended release 500 mg</i> | 2 | GC |

Puede encontrar información sobre lo que significan los símbolos y las abreviaturas de esta tabla al principio de esta.

06/01/2024

| Nombre del medicamento | Nivel del med. | Requisitos / Limitaciones |
|---|----------------|----------------------------|
| <i>acetazolamide oral tablet 125 mg, 250 mg</i> | 2 | GC |
| <i>methazolamide oral tablet 25 mg, 50 mg</i> | 2 | GC |
| OTROS MEDICAMENTOS PARA EL GLAUCOMA | | |
| <i>brinzolamide ophthalmic (eye) drops,suspension 1 %</i> | 2 | GC |
| COMBIGAN OPHTHALMIC (EYE) DROPS 0.2-0.5 % | 3 | |
| <i>dorzolamide ophthalmic (eye) drops 2 %</i> | 1 | GC |
| <i>dorzolamide-timolol ophthalmic (eye) drops 22.3-6.8 mg/ml</i> | 1 | GC |
| <i>latanoprost ophthalmic (eye) drops 0.005 %</i> | 1 | GC |
| LUMIGAN OPHTHALMIC (EYE) DROPS 0.01 % | 3 | |
| RHOPRESSA OPHTHALMIC (EYE) DROPS 0.02 % | 3 | |
| ROCKLATAN OPHTHALMIC (EYE) DROPS 0.02-0.005 % | 4 | |
| SIMBRINZA OPHTHALMIC (EYE) DROPS,SUSPENSION 1-0.2 % | 4 | |
| <i>travoprost ophthalmic (eye) drops 0.004 %</i> | 2 | GC |
| VYZULTA OPHTHALMIC (EYE) DROPS 0.024 % | 4 | |
| PRODUCTOS OFTALMOLÓGICOS DIVERSOS | | |
| <i>atropine ophthalmic (eye) drops 1 %</i> | 2 | GC |
| ATROPINE SULFATE (PF) OPHTHALMIC (EYE) DROPPERETTE 1 % | 2 | GC |
| <i>azelastine ophthalmic (eye) drops 0.05 %</i> | 2 | GC |
| <i>cromolyn ophthalmic (eye) drops 4 %</i> | 1 | GC |
| CYSTADROPS OPHTHALMIC (EYE) DROPS 0.37 % | 5^ | PA; LA |
| CYSTARAN OPHTHALMIC (EYE) DROPS 0.44 % | 5^ | PA; LA |
| <i>olopatadine ophthalmic (eye) drops 0.1 %</i> | 2 | GC |
| <i>pilocarpine hcl ophthalmic (eye) drops 1 %, 2 %, 4 %</i> | 2 | GC |
| RESTASIS MULTIDOSE OPHTHALMIC (EYE) DROPS 0.05 % | 3 | QL (5.5 ML per 30 days) |
| RESTASIS OPHTHALMIC (EYE) DROPPERETTE 0.05 % | 3 | QL (60 EA per 30 days) |
| <i>sulfacetamide sodium ophthalmic (eye) drops 10 %</i> | 2 | GC |
| <i>sulfacetamide sodium ophthalmic (eye) ointment 10 %</i> | 2 | GC |
| <i>sulfacetamide-prednisolone ophthalmic (eye) drops 10 %-0.23 % (0.25 %)</i> | 2 | GC |
| TYRVAYA NASAL SPRAY, METERED, NON-AEROSOL 0.03 MG/SPRAY | 4 | |
| XDEMVI OPHTHALMIC (EYE) DROPS 0.25 % | 5^ | PA; QL (10 ML per 42 days) |

Puede encontrar información sobre lo que significan los símbolos y las abreviaturas de esta tabla al principio de esta.

06/01/2024

| Nombre del medicamento | Nivel del med. | Requisitos / Limitaciones |
|---|----------------|---------------------------|
| ZERVIAE OPHTHALMIC (EYE) DROPPERETTE 0.24 % | 4 | |
| SIMPATICOMIMÉTICOS | | |
| ALPHAGAN P OPHTHALMIC (EYE) DROPS 0.1 % | 3 | |
| <i>apraclonidine ophthalmic (eye) drops 0.5 %</i> | 3 | |
| <i>brimonidine ophthalmic (eye) drops 0.15 %</i> | 2 | GC |
| <i>brimonidine ophthalmic (eye) drops 0.2 %</i> | 1 | GC |
| SISTEMA ENDOCRINO/DIABETES | | |
| AGENTES ANTITIROIDEOS | | |
| <i>methimazole oral tablet 10 mg, 5 mg</i> | 1 | GC |
| <i>propylthiouracil oral tablet 50 mg</i> | 2 | GC |
| HORMONAS DE LA TIROIDE | | |
| <i>euthyrox oral tablet 100 mcg, 112 mcg, 125 mcg, 137 mcg, 150 mcg, 175 mcg, 200 mcg, 25 mcg, 50 mcg, 75 mcg, 88 mcg</i> | 1 | GC |
| <i>levo-t oral tablet 100 mcg, 112 mcg, 125 mcg, 137 mcg, 150 mcg, 175 mcg, 200 mcg, 25 mcg, 300 mcg, 50 mcg, 75 mcg, 88 mcg</i> | 1 | GC |
| <i>levothyroxine oral tablet 100 mcg, 112 mcg, 125 mcg, 137 mcg, 150 mcg, 175 mcg, 200 mcg, 25 mcg, 300 mcg, 50 mcg, 75 mcg, 88 mcg</i> | 1 | GC |
| <i>levoxyl oral tablet 100 mcg, 112 mcg, 125 mcg, 137 mcg, 150 mcg, 175 mcg, 200 mcg, 25 mcg, 50 mcg, 75 mcg, 88 mcg</i> | 1 | GC |
| <i>liothyronine oral tablet 25 mcg, 5 mcg, 50 mcg</i> | 2 | GC |
| SYNTHROID ORAL TABLET 100 MCG, 112 MCG, 125 MCG, 137 MCG, 150 MCG, 175 MCG, 200 MCG, 25 MCG, 300 MCG, 50 MCG, 75 MCG, 88 MCG | 3 | |
| <i>unithroid oral tablet 100 mcg, 112 mcg, 125 mcg, 137 mcg, 150 mcg, 175 mcg, 200 mcg, 25 mcg, 300 mcg, 50 mcg, 75 mcg, 88 mcg</i> | 1 | GC |
| HORMONAS SUPRARRENALES | | |
| <i>dexamethasone intensol oral drops 1 mg/ml</i> | 4 | |
| <i>dexamethasone oral elixir 0.5 mg/5 ml</i> | 2 | GC |
| <i>dexamethasone oral solution 0.5 mg/5 ml</i> | 2 | GC |
| <i>dexamethasone oral tablet 0.5 mg, 0.75 mg, 1 mg, 1.5 mg, 2 mg, 4 mg, 6 mg</i> | 2 | GC |

Puede encontrar información sobre lo que significan los símbolos y las abreviaturas de esta tabla al principio de esta.

06/01/2024

| Nombre del medicamento | Nivel del med. | Requisitos / Limitaciones |
|--|----------------|---------------------------|
| <i>dexamethasone sodium phos (pf) injection solution 10 mg/ml</i> | 2 | GC |
| <i>dexamethasone sodium phosphate injection solution 10 mg/ml, 4 mg/ml</i> | 2 | GC |
| <i>dexamethasone sodium phosphate injection syringe 4 mg/ml</i> | 2 | GC |
| <i>fludrocortisone oral tablet 0.1 mg</i> | 2 | GC |
| <i>hydrocortisone oral tablet 10 mg, 20 mg, 5 mg</i> | 2 | GC |
| <i>methylprednisolone acetate injection suspension 40 mg/ml, 80 mg/ml</i> | 2 | GC |
| <i>methylprednisolone oral tablet 16 mg, 32 mg, 4 mg, 8 mg</i> | 2 | B/D; GC |
| <i>methylprednisolone oral tablets,dose pack 4 mg</i> | 2 | GC |
| <i>methylprednisolone sodium succ injection recon soln 125 mg, 40 mg</i> | 2 | GC |
| <i>methylprednisolone sodium succ intravenous recon soln 1,000 mg, 500 mg</i> | 2 | GC |
| <i>prednisolone oral solution 15 mg/5 ml</i> | 2 | GC |
| <i>prednisolone sodium phosphate oral solution 15 mg/5 ml (3 mg/ml), 15 mg/5 ml (5 ml), 25 mg/5 ml (5 mg/ml), 5 mg base/5 ml (6.7 mg/5 ml)</i> | 2 | GC |
| <i>prednisone intensol oral concentrate 5 mg/ml</i> | 4 | |
| <i>prednisone oral solution 5 mg/5 ml</i> | 3 | |
| <i>prednisone oral tablet 1 mg, 10 mg, 2.5 mg, 20 mg, 5 mg, 50 mg</i> | 1 | GC |
| <i>prednisone oral tablets,dose pack 10 mg, 10 mg (48 pack), 5 mg, 5 mg (48 pack)</i> | 2 | GC |
| SOLU-CORTEF ACT-O-VIAL (PF) INJECTION RECON SOLN 1,000 MG/8 ML, 100 MG/2 ML, 250 MG/2 ML, 500 MG/4 ML | 4 | |
| HORMONAS VARIAS | | |
| ALDURAZYME INTRAVENOUS SOLUTION 2.9 MG/5 ML | 5^ | PA |
| <i>cabergoline oral tablet 0.5 mg</i> | 2 | GC |
| <i>calcitonin (salmon) nasal spray,non-aerosol 200 unit/actuation</i> | 2 | GC |
| <i>calcitriol intravenous solution 1 mcg/ml</i> | 2 | B/D; GC |
| <i>calcitriol oral capsule 0.25 mcg, 0.5 mcg</i> | 2 | B/D; GC |
| <i>calcitriol oral solution 1 mcg/ml</i> | 2 | B/D; GC |

Puede encontrar información sobre lo que significan los símbolos y las abreviaturas de esta tabla al principio de esta.

06/01/2024

| Nombre del medicamento | Nivel del med. | Requisitos / Limitaciones |
|---|----------------|---------------------------------|
| CERDELGA ORAL CAPSULE 84 MG | 5^ | PA; LA |
| CEREZYME INTRAVENOUS RECON SOLN 400 UNIT | 5^ | PA |
| <i>cinacalcet oral tablet 30 mg</i> | 2 | B/D; QL (60 EA per 30 days); GC |
| <i>cinacalcet oral tablet 60 mg</i> | 4 | B/D; QL (60 EA per 30 days) |
| <i>cinacalcet oral tablet 90 mg</i> | 4 | B/D; QL (120 EA per 30 days) |
| <i>danazol oral capsule 100 mg, 200 mg, 50 mg</i> | 2 | GC |
| <i>desmopressin injection solution 4 mcg/ml</i> | 5^ | |
| <i>desmopressin nasal spray with pump 10 mcg/spray (0.1 ml)</i> | 2 | GC |
| <i>desmopressin nasal spray, non-aerosol 10 mcg/spray (0.1 ml)</i> | 2 | GC |
| <i>desmopressin oral tablet 0.1 mg, 0.2 mg</i> | 2 | GC |
| <i>doxercalciferol oral capsule 0.5 mcg, 1 mcg, 2.5 mcg</i> | 2 | B/D; GC |
| FABRAZYME INTRAVENOUS RECON SOLN 35 MG, 5 MG | 5^ | PA |
| KORLYM ORAL TABLET 300 MG | 5^ | PA; LA |
| LUMIZYME INTRAVENOUS RECON SOLN 50 MG | 5^ | PA |
| <i>mifepristone oral tablet 300 mg</i> | 5^ | PA |
| NAGLAZYME INTRAVENOUS SOLUTION 5 MG/5 ML | 5^ | PA |
| <i>pamidronate intravenous solution 30 mg/10 ml (3 mg/ml), 60 mg/10 ml (6 mg/ml), 90 mg/10 ml (9 mg/ml)</i> | 3 | B/D |
| <i>paricalcitol oral capsule 1 mcg, 2 mcg, 4 mcg</i> | 2 | B/D; GC |
| RAYALDEE ORAL CAPSULE, EXTENDED RELEASE 24 HR 30 MCG | 5^ | |
| <i>sapropterin oral powder in packet 100 mg, 500 mg</i> | 5^ | PA |
| <i>sapropterin oral tablet, soluble 100 mg</i> | 5^ | PA |
| SOMAVERT SUBCUTANEOUS RECON SOLN 10 MG, 15 MG, 20 MG, 25 MG, 30 MG | 4 | PA; LA |
| <i>testosterone cypionate intramuscular oil 100 mg/ml, 200 mg/ml, 200 mg/ml (1 ml)</i> | 2 | GC |
| <i>testosterone enanthate intramuscular oil 200 mg/ml</i> | 2 | GC |
| <i>testosterone transdermal gel 50 mg/5 gram (1 %)</i> | 2 | PA; QL (300 GM per 30 days); GC |
| <i>testosterone transdermal gel in metered-dose pump 12.5 mg/1.25 gram (1 %)</i> | 2 | PA; QL (300 GM per 30 days); GC |
| <i>testosterone transdermal gel in metered-dose pump 20.25 mg/1.25 gram (1.62 %)</i> | 2 | PA; QL (150 GM per 30 days); GC |

Puede encontrar información sobre lo que significan los símbolos y las abreviaturas de esta tabla al principio de esta.

06/01/2024

| Nombre del medicamento | Nivel del med. | Requisitos / Limitaciones |
|---|----------------|---------------------------------|
| <i>testosterone transdermal gel in packet 1 % (25 mg/2.5gram), 1 % (50 mg/5 gram)</i> | 2 | PA; QL (300 GM per 30 days); GC |
| <i>tolvaptan oral tablet 15 mg, 30 mg</i> | 5^ | PA |
| <i>zoledronic acid intravenous solution 4 mg/5 ml</i> | 2 | B/D; GC |
| <i>zoledronic acid-mannitol-water intravenous piggyback 4 mg/100 ml</i> | 2 | B/D; GC |
| TRATAMIENTO PARA LA DIABETES | | |
| <i>acarbose oral tablet 100 mg</i> | 6 | QL (90 EA per 30 days); GC |
| <i>acarbose oral tablet 25 mg</i> | 6 | QL (360 EA per 30 days); GC |
| <i>acarbose oral tablet 50 mg</i> | 6 | QL (180 EA per 30 days); GC |
| <i>alcohol pads topical pads, medicated</i> | 3 | |
| BASAGLAR KWIKPEN U-100 INSULIN SUBCUTANEOUS INSULIN PEN 100 UNIT/ML (3 ML) | 3 | |
| BYDUREON BCISE SUBCUTANEOUS AUTO-INJECTOR 2 MG/0.85 ML | 3 | PA; QL (3.4 ML per 28 days) |
| <i>diazoxide oral suspension 50 mg/ml</i> | 4 | |
| FARXIGA ORAL TABLET 10 MG, 5 MG | 3 | QL (30 EA per 30 days) |
| FIASP FLEXTOUCH U-100 INSULIN SUBCUTANEOUS INSULIN PEN 100 UNIT/ML (3 ML) | 3 | |
| FIASP PENFILL U-100 INSULIN SUBCUTANEOUS CARTRIDGE 100 UNIT/ML (3 ML) | 3 | |
| FIASP U-100 INSULIN SUBCUTANEOUS SOLUTION 100 UNIT/ML | 3 | |
| <i>glimepiride oral tablet 1 mg, 2 mg</i> | 6 | QL (90 EA per 30 days); GC |
| <i>glimepiride oral tablet 4 mg</i> | 6 | QL (60 EA per 30 days); GC |
| <i>glipizide oral tablet 10 mg</i> | 6 | QL (120 EA per 30 days); GC |
| <i>glipizide oral tablet 5 mg</i> | 6 | QL (240 EA per 30 days); GC |
| <i>glipizide oral tablet extended release 24hr 10 mg</i> | 6 | QL (60 EA per 30 days); GC |
| <i>glipizide oral tablet extended release 24hr 2.5 mg, 5 mg</i> | 6 | QL (90 EA per 30 days); GC |
| <i>glipizide-metformin oral tablet 2.5-250 mg</i> | 6 | QL (240 EA per 30 days); GC |
| <i>glipizide-metformin oral tablet 2.5-500 mg, 5-500 mg</i> | 6 | QL (120 EA per 30 days); GC |
| GLYXAMBI ORAL TABLET 10-5 MG, 25-5 MG | 3 | QL (30 EA per 30 days) |
| GVOKE HYPOPEN 1-PACK SUBCUTANEOUS AUTO-INJECTOR 0.5 MG/0.1 ML, 1 MG/0.2 ML | 3 | |
| GVOKE HYPOPEN 2-PACK SUBCUTANEOUS AUTO-INJECTOR 0.5 MG/0.1 ML, 1 MG/0.2 ML | 3 | |

Puede encontrar información sobre lo que significan los símbolos y las abreviaturas de esta tabla al principio de esta.

06/01/2024

| Nombre del medicamento | Nivel del med. | Requisitos / Limitaciones |
|--|----------------|--|
| GVOKE PFS 1-PACK SYRINGE SUBCUTANEOUS SYRINGE 1 MG/0.2 ML | 3 | |
| GVOKE PFS 2-PACK SYRINGE SUBCUTANEOUS SYRINGE 1 MG/0.2 ML | 3 | |
| GVOKE SUBCUTANEOUS SOLUTION 1 MG/0.2 ML | 3 | |
| HUMULIN R U-500 (CONC) INSULIN SUBCUTANEOUS SOLUTION 500 UNIT/ML | 5 [^] | B/D |
| HUMULIN R U-500 (CONC) KWIKPEN SUBCUTANEOUS INSULIN PEN 500 UNIT/ML (3 ML) | 5 [^] | |
| INVOKAMET ORAL TABLET 150-1,000 MG, 150-500 MG, 50-1,000 MG | 4 | QL (60 EA per 30 days) |
| INVOKAMET ORAL TABLET 50-500 MG | 4 | QL (120 EA per 30 days) |
| INVOKAMET XR ORAL TABLET, IR - ER, BIPHASIC 24HR 150-1,000 MG, 150-500 MG, 50-1,000 MG | 4 | QL (60 EA per 30 days) |
| INVOKAMET XR ORAL TABLET, IR - ER, BIPHASIC 24HR 50-500 MG | 4 | QL (120 EA per 30 days) |
| INVOKANA ORAL TABLET 100 MG | 4 | QL (60 EA per 30 days) |
| INVOKANA ORAL TABLET 300 MG | 4 | QL (30 EA per 30 days) |
| JANUMET ORAL TABLET 50-1,000 MG, 50-500 MG | 3 | QL (60 EA per 30 days) |
| JANUMET XR ORAL TABLET, ER MULTIPHASE 24 HR 100-1,000 MG | 3 | QL (30 EA per 30 days) |
| JANUMET XR ORAL TABLET, ER MULTIPHASE 24 HR 50-1,000 MG, 50-500 MG | 3 | QL (60 EA per 30 days) |
| JANUVIA ORAL TABLET 100 MG, 25 MG, 50 MG | 3 | QL (30 EA per 30 days) |
| JARDIANCE ORAL TABLET 10 MG, 25 MG | 3 | QL (30 EA per 30 days) |
| JENTADUETO ORAL TABLET 2.5-1,000 MG, 2.5-500 MG, 2.5-850 MG | 3 | QL (60 EA per 30 days) |
| JENTADUETO XR ORAL TABLET, IR - ER, BIPHASIC 24HR 2.5-1,000 MG | 3 | QL (60 EA per 30 days) |
| JENTADUETO XR ORAL TABLET, IR - ER, BIPHASIC 24HR 5-1,000 MG | 3 | QL (30 EA per 30 days) |
| <i>metformin oral tablet 1,000 mg</i> | 6 | QL (75 EA per 30 days); GC |
| <i>metformin oral tablet 500 mg</i> | 6 | QL (150 EA per 30 days); GC |
| <i>metformin oral tablet 850 mg</i> | 6 | QL (90 EA per 30 days); GC |
| <i>metformin oral tablet extended release 24 hr 500 mg</i> | 6 | Generic for Glucophage XR; QL (120 EA per 30 days); GC |

Puede encontrar información sobre lo que significan los símbolos y las abreviaturas de esta tabla al principio de esta.

06/01/2024

| Nombre del medicamento | Nivel del med. | Requisitos / Limitaciones |
|--|----------------|---|
| <i>metformin oral tablet extended release 24 hr 750 mg</i> | 6 | Generic for Glucophage XR; QL (60 EA per 30 days); GC |
| MOUNJARO SUBCUTANEOUS PEN INJECTOR 10 MG/0.5 ML, 12.5 MG/0.5 ML, 15 MG/0.5 ML, 2.5 MG/0.5 ML, 5 MG/0.5 ML, 7.5 MG/0.5 ML | 3 | PA; QL (2 ML per 28 days) |
| <i>nateglinide oral tablet 120 mg, 60 mg</i> | 6 | QL (90 EA per 30 days); GC |
| NOVOLIN 70/30 U-100 INSULIN SUBCUTANEOUS SUSPENSION 100 UNIT/ML (70-30) | 3 | (brand RELION not covered) |
| NOVOLIN 70-30 FLEXPEN U-100 SUBCUTANEOUS INSULIN PEN 100 UNIT/ML (70-30) | 3 | (brand RELION not covered) |
| NOVOLIN N FLEXPEN SUBCUTANEOUS INSULIN PEN 100 UNIT/ML (3 ML) | 3 | (brand RELION not covered) |
| NOVOLIN N NPH U-100 INSULIN SUBCUTANEOUS SUSPENSION 100 UNIT/ML | 3 | (brand RELION not covered) |
| NOVOLIN R FLEXPEN SUBCUTANEOUS INSULIN PEN 100 UNIT/ML (3 ML) | 3 | (brand RELION not covered) |
| NOVOLIN R REGULAR U100 INSULIN INJECTION SOLUTION 100 UNIT/ML | 3 | (brand RELION not covered) |
| NOVOLOG FLEXPEN U-100 INSULIN SUBCUTANEOUS INSULIN PEN 100 UNIT/ML (3 ML) | 3 | (brand RELION not covered) |
| NOVOLOG MIX 70-30 U-100 INSULIN SUBCUTANEOUS SOLUTION 100 UNIT/ML (70-30) | 3 | (brand RELION not covered) |
| NOVOLOG MIX 70-30FLEXPEN U-100 SUBCUTANEOUS INSULIN PEN 100 UNIT/ML (70-30) | 3 | (brand RELION not covered) |
| NOVOLOG PENFILL U-100 INSULIN SUBCUTANEOUS CARTRIDGE 100 UNIT/ML | 3 | (brand RELION not covered) |
| NOVOLOG U-100 INSULIN ASPART SUBCUTANEOUS SOLUTION 100 UNIT/ML | 3 | (brand RELION not covered) |
| OZEMPIC SUBCUTANEOUS PEN INJECTOR 0.25 MG OR 0.5 MG (2 MG/3 ML), 1 MG/DOSE (4 MG/3 ML), 2 MG/DOSE (8 MG/3 ML) | 3 | PA; QL (3 ML per 28 days) |
| OZEMPIC SUBCUTANEOUS PEN INJECTOR 0.25 MG OR 0.5 MG(2 MG/1.5 ML) | 3 | PA; QL (1.8 ML per 30 days) |
| <i>pioglitazone oral tablet 15 mg, 30 mg, 45 mg</i> | 6 | QL (30 EA per 30 days); GC |
| <i>pioglitazone-glimepiride oral tablet 30-2 mg, 30-4 mg</i> | 6 | QL (30 EA per 30 days); GC |
| <i>pioglitazone-metformin oral tablet 15-500 mg, 15-850 mg</i> | 6 | QL (90 EA per 30 days); GC |
| <i>repaglinide oral tablet 0.5 mg, 1 mg</i> | 6 | QL (120 EA per 30 days); GC |

Puede encontrar información sobre lo que significan los símbolos y las abreviaturas de esta tabla al principio de esta.

06/01/2024

| Nombre del medicamento | Nivel del med. | Requisitos / Limitaciones |
|---|----------------|-----------------------------|
| <i>repaglinide oral tablet 2 mg</i> | 6 | QL (240 EA per 30 days); GC |
| RYBELSUS ORAL TABLET 14 MG, 3 MG, 7 MG | 3 | PA; QL (30 EA per 30 days) |
| SOLIQUA 100/33 SUBCUTANEOUS INSULIN PEN 100 UNIT-33 MCG/ML | 3 | QL (15 ML per 25 days) |
| SYNJARDY ORAL TABLET 12.5-1,000 MG, 12.5-500 MG, 5-1,000 MG | 3 | QL (60 EA per 30 days) |
| SYNJARDY ORAL TABLET 5-500 MG | 3 | QL (120 EA per 30 days) |
| SYNJARDY XR ORAL TABLET, IR - ER, BIPHASIC 24HR 10-1,000 MG, 25-1,000 MG | 3 | QL (30 EA per 30 days) |
| SYNJARDY XR ORAL TABLET, IR - ER, BIPHASIC 24HR 12.5-1,000 MG, 5-1,000 MG | 3 | QL (60 EA per 30 days) |
| TOUJEO MAX U-300 SOLOSTAR SUBCUTANEOUS INSULIN PEN 300 UNIT/ML (3 ML) | 3 | |
| TOUJEO SOLOSTAR U-300 INSULIN SUBCUTANEOUS INSULIN PEN 300 UNIT/ML (1.5 ML) | 3 | |
| TRADJENTA ORAL TABLET 5 MG | 3 | QL (30 EA per 30 days) |
| TRESIBA FLEXTOUCH U-100 SUBCUTANEOUS INSULIN PEN 100 UNIT/ML (3 ML) | 3 | |
| TRESIBA FLEXTOUCH U-200 SUBCUTANEOUS INSULIN PEN 200 UNIT/ML (3 ML) | 3 | |
| TRESIBA U-100 INSULIN SUBCUTANEOUS SOLUTION 100 UNIT/ML | 3 | |
| TRIJARDY XR ORAL TABLET, IR - ER, BIPHASIC 24HR 10-5-1,000 MG, 25-5-1,000 MG | 3 | QL (30 EA per 30 days) |
| TRIJARDY XR ORAL TABLET, IR - ER, BIPHASIC 24HR 12.5-2.5-1,000 MG, 5-2.5-1,000 MG | 3 | QL (60 EA per 30 days) |
| TRULICITY SUBCUTANEOUS PEN INJECTOR 0.75 MG/0.5 ML, 1.5 MG/0.5 ML, 3 MG/0.5 ML, 4.5 MG/0.5 ML | 3 | PA; QL (2 ML per 28 days) |
| XIGDUO XR ORAL TABLET, IR - ER, BIPHASIC 24HR 10-1,000 MG, 10-500 MG | 3 | QL (30 EA per 30 days) |
| XIGDUO XR ORAL TABLET, IR - ER, BIPHASIC 24HR 2.5-1,000 MG, 5-1,000 MG, 5-500 MG | 3 | QL (60 EA per 30 days) |
| XULTOPHY 100/3.6 SUBCUTANEOUS INSULIN PEN 100 UNIT-3.6 MG /ML (3 ML) | 3 | QL (15 ML per 30 days) |
| SUMINISTROS VARIOS | | |
| <i>SUMINISTROS VARIOS</i> | | |
| ASSURE ID INSULIN SAFETY SYRINGE 1 ML 29 GAUGE X 1/2" | 2 | GC |

Puede encontrar información sobre lo que significan los símbolos y las abreviaturas de esta tabla al principio de esta.

06/01/2024

| Nombre del medicamento | Nivel del med. | Requisitos / Limitaciones |
|---|----------------|----------------------------|
| GAUZE PAD TOPICAL BANDAGE 2 X 2 " | 3 | |
| INSULIN SYRINGE-NEEDLE U-100 SYRINGE 0.3 ML 29 GAUGE, 1 ML 29 GAUGE X 1/2", 1/2 ML 28 GAUGE | 2 | BD Preferred; GC |
| OMNIPOD 5 G6 INTRO KIT (GEN 5) SUBCUTANEOUS CARTRIDGE | 4 | PA; QL (1 EA per 365 days) |
| OMNIPOD 5 G6 PODS (GEN 5) SUBCUTANEOUS CARTRIDGE | 4 | PA; QL (15 EA per 30 days) |
| OMNIPOD CLASSIC PDM KIT(GEN 3) | 4 | PA; QL (1 EA per 365 days) |
| OMNIPOD CLASSIC PODS (GEN 3) SUBCUTANEOUS CARTRIDGE | 4 | PA; QL (15 EA per 30 days) |
| OMNIPOD DASH INTRO KIT (GEN 4) SUBCUTANEOUS CARTRIDGE | 4 | PA; QL (1 EA per 365 days) |
| OMNIPOD DASH PODS (GEN 4) SUBCUTANEOUS CARTRIDGE | 4 | PA; QL (15 EA per 30 days) |
| OMNIPOD GO PODS 10 UNITS/DAY SUBCUTANEOUS CARTRIDGE | 4 | PA; QL (15 EA per 30 days) |
| OMNIPOD GO PODS 15 UNITS/DAY SUBCUTANEOUS CARTRIDGE | 4 | PA; QL (15 EA per 30 days) |
| OMNIPOD GO PODS 20 UNITS/DAY SUBCUTANEOUS CARTRIDGE | 4 | PA; QL (15 EA per 30 days) |
| OMNIPOD GO PODS 25 UNITS/DAY SUBCUTANEOUS CARTRIDGE | 4 | PA; QL (15 EA per 30 days) |
| OMNIPOD GO PODS 30 UNITS/DAY SUBCUTANEOUS CARTRIDGE | 4 | PA; QL (15 EA per 30 days) |
| OMNIPOD GO PODS SUBCUTANEOUS CARTRIDGE | 4 | PA; QL (15 EA per 30 days) |
| PEN NEEDLE, DIABETIC NEEDLE 29 GAUGE X 1/2" | 2 | BD Preferred; GC |
| V-GO 30 DEVICE | 4 | PA; QL (30 EA per 30 days) |
| V-GO 40 DEVICE | 4 | PA; QL (30 EA per 30 days) |
| TRATAMIENTOS DERMATOLÓGICOS/TÓPICOS | | |
| ANTIBACTERIANOS TÓPICOS | | |
| <i>gentamicin topical cream 0.1 %</i> | 2 | QL (30 GM per 30 days); GC |
| <i>gentamicin topical ointment 0.1 %</i> | 3 | QL (30 GM per 30 days) |
| <i>mupirocin topical ointment 2 %</i> | 1 | QL (44 GM per 30 days); GC |
| <i>sulfacetamide sodium (acne) topical suspension 10 %</i> | 4 | QL (118 ML per 30 days) |
| SULFAMYLON TOPICAL CREAM 85 MG/G | 4 | QL (453.6 GM per 30 days) |
| ANTIFÚNGICOS TÓPICOS | | |
| <i>ciclopirox topical cream 0.77 %</i> | 2 | QL (90 GM per 30 days); GC |

Puede encontrar información sobre lo que significan los símbolos y las abreviaturas de esta tabla al principio de esta.

06/01/2024

| Nombre del medicamento | Nivel del med. | Requisitos / Limitaciones |
|---|-----------------------|----------------------------------|
| <i>ciclopirox topical suspension 0.77 %</i> | 3 | QL (60 ML per 30 days) |
| <i>clotrimazole topical cream 1 %</i> | 2 | QL (45 GM per 28 days); GC |
| <i>clotrimazole topical solution 1 %</i> | 2 | QL (30 ML per 28 days); GC |
| <i>clotrimazole-betamethasone topical cream 1-0.05 %</i> | 2 | QL (45 GM per 30 days); GC |
| <i>ketoconazole topical cream 2 %</i> | 2 | QL (60 GM per 28 days); GC |
| <i>ketoconazole topical shampoo 2 %</i> | 1 | QL (120 ML per 28 days); GC |
| <i>klayesta topical powder 100,000 unit/gram</i> | 2 | QL (60 GM per 30 days); GC |
| <i>nyamyc topical powder 100,000 unit/gram</i> | 2 | QL (60 GM per 30 days); GC |
| <i>nystatin topical cream 100,000 unit/gram</i> | 2 | QL (30 GM per 30 days); GC |
| <i>nystatin topical ointment 100,000 unit/gram</i> | 2 | QL (30 GM per 30 days); GC |
| <i>nystatin topical powder 100,000 unit/gram</i> | 2 | QL (60 GM per 30 days); GC |
| <i>nystop topical powder 100,000 unit/gram</i> | 2 | QL (60 GM per 30 days); GC |
| CORTICOESTEROIDES TÓPICOS | | |
| <i>ala-cort topical cream 1 %, 2.5 %</i> | 1 | GC |
| <i>alclometasone topical cream 0.05 %</i> | 3 | QL (60 GM per 30 days) |
| <i>alclometasone topical ointment 0.05 %</i> | 3 | QL (60 GM per 30 days) |
| <i>betamethasone dipropionate topical cream 0.05 %</i> | 2 | QL (120 GM per 30 days); GC |
| <i>betamethasone dipropionate topical lotion 0.05 %</i> | 2 | QL (120 ML per 30 days); GC |
| <i>betamethasone dipropionate topical ointment 0.05 %</i> | 3 | QL (120 GM per 30 days) |
| <i>betamethasone valerate topical cream 0.1 %</i> | 2 | QL (120 GM per 30 days); GC |
| <i>betamethasone valerate topical lotion 0.1 %</i> | 3 | QL (120 ML per 30 days) |
| <i>betamethasone valerate topical ointment 0.1 %</i> | 2 | QL (120 GM per 30 days); GC |
| <i>betamethasone, augmented topical cream 0.05 %</i> | 2 | QL (120 GM per 30 days); GC |
| <i>betamethasone, augmented topical gel 0.05 %</i> | 2 | QL (120 GM per 30 days); GC |
| <i>betamethasone, augmented topical lotion 0.05 %</i> | 2 | QL (120 ML per 30 days); GC |
| <i>betamethasone, augmented topical ointment 0.05 %</i> | 2 | QL (120 GM per 30 days); GC |
| <i>clobetasol scalp solution 0.05 %</i> | 2 | QL (50 ML per 30 days); GC |
| <i>clobetasol topical cream 0.05 %</i> | 2 | QL (60 GM per 30 days); GC |
| <i>clobetasol topical gel 0.05 %</i> | 4 | QL (60 GM per 30 days) |
| <i>clobetasol topical ointment 0.05 %</i> | 2 | QL (60 GM per 30 days); GC |
| <i>clobetasol-emollient topical cream 0.05 %</i> | 3 | QL (60 GM per 30 days) |
| <i>desonide topical cream 0.05 %</i> | 2 | QL (60 GM per 30 days); GC |
| <i>desonide topical ointment 0.05 %</i> | 2 | QL (60 GM per 30 days); GC |
| <i>fluocinolone and shower cap scalp oil 0.01 %</i> | 2 | QL (118.28 ML per 30 days); GC |

Puede encontrar información sobre lo que significan los símbolos y las abreviaturas de esta tabla al principio de esta.

06/01/2024

| Nombre del medicamento | Nivel del med. | Requisitos / Limitaciones |
|---|-----------------------|----------------------------------|
| <i>fluocinolone topical cream 0.01 %</i> | 4 | QL (60 GM per 30 days) |
| <i>fluocinolone topical cream 0.025 %</i> | 4 | QL (120 GM per 30 days) |
| <i>fluocinolone topical oil 0.01 %</i> | 2 | QL (118.28 ML per 30 days); GC |
| <i>fluocinolone topical ointment 0.025 %</i> | 3 | QL (120 GM per 30 days) |
| <i>fluocinolone topical solution 0.01 %</i> | 2 | QL (90 ML per 30 days); GC |
| <i>fluocinonide topical cream 0.05 %</i> | 3 | QL (120 GM per 30 days) |
| <i>fluocinonide topical gel 0.05 %</i> | 4 | QL (60 GM per 30 days) |
| <i>fluocinonide topical ointment 0.05 %</i> | 2 | QL (60 GM per 30 days); GC |
| <i>fluocinonide topical solution 0.05 %</i> | 2 | QL (60 ML per 30 days); GC |
| <i>fluocinonide-e topical cream 0.05 %</i> | 4 | QL (120 GM per 30 days) |
| <i>fluocinonide-emollient topical cream 0.05 %</i> | 4 | QL (120 GM per 30 days) |
| <i>fluticasone propionate topical cream 0.05 %</i> | 2 | GC |
| <i>halobetasol propionate topical cream 0.05 %</i> | 2 | QL (50 GM per 30 days); GC |
| <i>halobetasol propionate topical ointment 0.05 %</i> | 4 | QL (50 GM per 30 days) |
| <i>hydrocortisone topical cream 1 %, 2.5 %</i> | 1 | GC |
| <i>hydrocortisone topical lotion 2.5 %</i> | 2 | GC |
| <i>hydrocortisone topical ointment 2.5 %</i> | 2 | GC |
| <i>mometasone topical cream 0.1 %</i> | 2 | GC |
| <i>mometasone topical ointment 0.1 %</i> | 2 | GC |
| <i>mometasone topical solution 0.1 %</i> | 2 | GC |
| <i>triamcinolone acetonide topical cream 0.025 %, 0.5 %</i> | 1 | GC |
| <i>triamcinolone acetonide topical cream 0.1 %</i> | 1 | QL (454 GM per 30 days); GC |
| <i>triamcinolone acetonide topical lotion 0.025 %, 0.1 %</i> | 2 | GC |
| <i>triamcinolone acetonide topical ointment 0.025 %, 0.1 %, 0.5 %</i> | 1 | GC |
| ESCABICIDAS TÓPICOS/PEDICULICIDAS | | |
| <i>malathion topical lotion 0.5 %</i> | 2 | QL (59 ML per 30 days); GC |
| <i>permethrin topical cream 5 %</i> | 2 | QL (60 GM per 30 days); GC |
| MEDICAMENTOS ANTIPSORIÁSICOS/ANTISEBORREICOS | | |
| <i>acitretin oral capsule 10 mg, 17.5 mg, 25 mg</i> | 4 | PA |
| <i>calcipotriene scalp solution 0.005 %</i> | 3 | PA; QL (120 ML per 30 days) |
| <i>calcipotriene topical ointment 0.005 %</i> | 4 | PA; QL (120 GM per 30 days) |
| ENSTILAR TOPICAL FOAM 0.005-0.064 % | 4 | PA; QL (120 GM per 30 days) |
| <i>selenium sulfide topical lotion 2.5 %</i> | 2 | GC |

Puede encontrar información sobre lo que significan los símbolos y las abreviaturas de esta tabla al principio de esta.

06/01/2024

| Nombre del medicamento | Nivel del med. | Requisitos / Limitaciones |
|--|----------------|--------------------------------|
| SKYRIZI SUBCUTANEOUS PEN INJECTOR 150 MG/ML | 5^ | PA; QL (6 ML per 365 days) |
| SKYRIZI SUBCUTANEOUS SYRINGE 150 MG/ML | 5^ | PA; QL (6 ML per 365 days) |
| STELARA SUBCUTANEOUS SOLUTION 45 MG/0.5 ML | 5^ | PA; QL (0.5 ML per 28 days) |
| STELARA SUBCUTANEOUS SYRINGE 45 MG/0.5 ML | 5^ | PA; QL (0.5 ML per 28 days) |
| STELARA SUBCUTANEOUS SYRINGE 90 MG/ML | 5^ | PA; QL (1 ML per 28 days) |
| TALTZ AUTOINJECTOR (2 PACK) SUBCUTANEOUS AUTO-INJECTOR 80 MG/ML | 5^ | PA; QL (3 ML per 28 days) |
| TALTZ AUTOINJECTOR (3 PACK) SUBCUTANEOUS AUTO-INJECTOR 80 MG/ML | 5^ | PA; QL (3 ML per 28 days) |
| TALTZ AUTOINJECTOR SUBCUTANEOUS AUTO-INJECTOR 80 MG/ML | 5^ | PA; LA; QL (3 ML per 28 days) |
| TALTZ SYRINGE SUBCUTANEOUS SYRINGE 80 MG/ML | 5^ | PA; LA; QL (3 ML per 28 days) |
| PRODUCTOS DERMATOLÓGICOS DIVERSOS | | |
| <i>ammonium lactate topical cream 12 %</i> | 2 | GC |
| <i>ammonium lactate topical lotion 12 %</i> | 2 | GC |
| <i>dermacinrx lidocan topical adhesive patch, medicated 5 %</i> | 4 | PA; QL (90 EA per 30 days) |
| DUPIXENT PEN SUBCUTANEOUS PEN INJECTOR 200 MG/1.14 ML | 5^ | PA; QL (4.56 ML per 28 days) |
| DUPIXENT PEN SUBCUTANEOUS PEN INJECTOR 300 MG/2 ML | 5^ | PA; QL (8 ML per 28 days) |
| DUPIXENT SYRINGE SUBCUTANEOUS SYRINGE 100 MG/0.67 ML | 5^ | PA; QL (1.34 ML per 28 days) |
| DUPIXENT SYRINGE SUBCUTANEOUS SYRINGE 200 MG/1.14 ML | 5^ | PA; QL (4.56 ML per 28 days) |
| DUPIXENT SYRINGE SUBCUTANEOUS SYRINGE 300 MG/2 ML | 5^ | PA; QL (8 ML per 28 days) |
| <i>fluorouracil topical cream 5 %</i> | 3 | QL (40 GM per 30 days) |
| <i>fluorouracil topical solution 2 %, 5 %</i> | 2 | QL (10 ML per 30 days); GC |
| <i>glydo mucous membrane jelly in applicator 2 %</i> | 2 | PA; QL (60 ML per 30 days); GC |
| <i>imiquimod topical cream in packet 5 %</i> | 2 | QL (24 EA per 30 days); GC |
| <i>lidocaine (pf) injection solution 10 mg/ml (1 %), 15 mg/ml (1.5 %), 20 mg/ml (2 %), 40 mg/ml (4 %), 5 mg/ml (0.5 %)</i> | 2 | B/D; GC |
| <i>lidocaine hcl injection solution 10 mg/ml (1 %), 20 mg/ml (2 %), 5 mg/ml (0.5 %)</i> | 2 | B/D; GC |
| <i>lidocaine hcl laryngotracheal solution 4 %</i> | 3 | PA; QL (50 ML per 30 days) |
| <i>lidocaine hcl mucous membrane jelly 2 %</i> | 4 | PA; QL (30 ML per 30 days) |

Puede encontrar información sobre lo que significan los símbolos y las abreviaturas de esta tabla al principio de esta.

06/01/2024

| Nombre del medicamento | Nivel del med. | Requisitos / Limitaciones |
|--|----------------|-----------------------------------|
| <i>lidocaine hcl mucous membrane solution 2 %</i> | 2 | GC |
| <i>lidocaine hcl mucous membrane solution 4 % (40 mg/ml)</i> | 3 | PA; QL (50 ML per 30 days) |
| <i>lidocaine topical adhesive patch,medicated 5 %</i> | 4 | PA; QL (90 EA per 30 days) |
| <i>lidocaine topical ointment 5 %</i> | 2 | PA; QL (50 GM per 30 days); GC |
| <i>lidocaine viscous mucous membrane solution 2 %</i> | 2 | GC |
| <i>lidocaine-prilocaine topical cream 2.5-2.5 %</i> | 2 | PA; QL (30 GM per 30 days); GC |
| <i>lidocan iii topical adhesive patch,medicated 5 %</i> | 4 | PA; QL (90 EA per 30 days) |
| <i>lidocan iv topical adhesive patch,medicated 5 %</i> | 4 | PA; QL (90 EA per 30 days) |
| <i>lidocan v topical adhesive patch,medicated 5 %</i> | 4 | PA; QL (90 EA per 30 days) |
| PANRETIN TOPICAL GEL 0.1 % | 5^ | PA-NS; QL (60 GM per 30 days) |
| <i>podofilox topical solution 0.5 %</i> | 3 | QL (7 ML per 28 days) |
| REGRANEX TOPICAL GEL 0.01 % | 5^ | QL (15 GM per 30 days) |
| SANTYL TOPICAL OINTMENT 250 UNIT/GRAM | 4 | QL (180 GM per 30 days) |
| <i>silver sulfadiazine topical cream 1 %</i> | 2 | GC |
| <i>ssd topical cream 1 %</i> | 2 | GC |
| <i>tacrolimus topical ointment 0.03 %, 0.1 %</i> | 4 | QL (100 GM per 30 days) |
| VALCHLOR TOPICAL GEL 0.016 % | 5^ | PA-NS; LA; QL (60 GM per 30 days) |
| ZYCLARA TOPICAL CREAM IN METERED-DOSE PUMP 2.5 % | 5^ | QL (7.5 GM per 28 days) |
| TRATAMIENTO CONTRA EL ACNÉ | | |
| <i>acutane oral capsule 10 mg, 20 mg, 30 mg, 40 mg</i> | 2 | GC |
| <i>amnestem oral capsule 10 mg, 20 mg, 40 mg</i> | 2 | GC |
| <i>azelaic acid topical gel 15 %</i> | 4 | QL (50 GM per 30 days) |
| <i>claravis oral capsule 10 mg, 20 mg, 30 mg, 40 mg</i> | 2 | GC |
| <i>clindamycin phosphate topical gel 1 %</i> | 3 | QL (75 GM per 30 days) |
| <i>clindamycin phosphate topical gel, once daily 1 %</i> | 3 | QL (75 GM per 30 days) |
| <i>clindamycin phosphate topical lotion 1 %</i> | 3 | QL (60 ML per 30 days) |
| <i>clindamycin phosphate topical solution 1 %</i> | 2 | QL (60 ML per 30 days); GC |
| <i>ery pads topical swab 2 %</i> | 3 | QL (60 EA per 30 days) |
| <i>erythromycin with ethanol topical solution 2 %</i> | 2 | QL (60 ML per 30 days); GC |
| FINACEA TOPICAL FOAM 15 % | 4 | QL (50 GM per 30 days) |
| <i>isotretinoin oral capsule 10 mg, 20 mg, 30 mg, 40 mg</i> | 4 | |
| <i>metronidazole topical cream 0.75 %</i> | 4 | QL (45 GM per 30 days) |
| <i>metronidazole topical gel 0.75 %</i> | 3 | QL (45 GM per 30 days) |
| <i>metronidazole topical lotion 0.75 %</i> | 4 | QL (59 ML per 30 days) |

Puede encontrar información sobre lo que significan los símbolos y las abreviaturas de esta tabla al principio de esta.

06/01/2024

| Nombre del medicamento | Nivel del med. | Requisitos / Limitaciones |
|---|----------------|-----------------------------|
| <i>myorisan oral capsule 10 mg, 20 mg, 30 mg, 40 mg</i> | 2 | GC |
| NORITATE TOPICAL CREAM 1 % | 5^ | QL (60 GM per 30 days) |
| <i>tazarotene topical cream 0.1 %</i> | 4 | PA; QL (60 GM per 30 days) |
| <i>tazarotene topical gel 0.05 %, 0.1 %</i> | 4 | PA |
| TAZORAC TOPICAL CREAM 0.05 % | 4 | PA; QL (60 GM per 30 days) |
| <i>tretinoin topical cream 0.025 %, 0.05 %, 0.1 %</i> | 4 | PA; QL (45 GM per 30 days) |
| <i>tretinoin topical gel 0.01 %, 0.025 %</i> | 4 | PA; QL (45 GM per 30 days) |
| <i>zenatane oral capsule 10 mg, 20 mg, 30 mg, 40 mg</i> | 2 | GC |
| VITAMINAS, MINERALES/ELECTROLITOS | | |
| ELECTROLITOS | | |
| <i>calcium acetate(phosphat bind) oral capsule 667 mg</i> | 2 | QL (360 EA per 30 days); GC |
| <i>calcium acetate(phosphat bind) oral tablet 667 mg</i> | 2 | QL (360 EA per 30 days); GC |
| <i>klor-con 10 oral tablet extended release 10 meq</i> | 1 | GC |
| <i>klor-con 8 oral tablet extended release 8 meq</i> | 1 | GC |
| <i>klor-con m10 oral tablet,er particles/crystals 10 meq</i> | 1 | GC |
| <i>klor-con m15 oral tablet,er particles/crystals 15 meq</i> | 2 | GC |
| <i>klor-con m20 oral tablet,er particles/crystals 20 meq</i> | 1 | GC |
| <i>klor-con oral packet 20 meq</i> | 2 | GC |
| <i>lactated ringers intravenous parenteral solution</i> | 4 | |
| MAGNESIUM SULFATE IN D5W INTRAVENOUS PIGGYBACK 1 GRAM/100 ML | 3 | |
| <i>magnesium sulfate in water intravenous parenteral solution 20 gram/500 ml (4 %), 40 gram/1,000 ml (4 %)</i> | 3 | |
| <i>magnesium sulfate in water intravenous piggyback 2 gram/50 ml (4 %), 4 gram/100 ml (4 %), 4 gram/50 ml (8 %)</i> | 4 | |
| <i>magnesium sulfate injection solution 500 mg/ml (50 %)</i> | 3 | |
| <i>magnesium sulfate injection syringe 500 mg/ml (50 %)</i> | 3 | |
| <i>potassium chlorid-d5-0.45%nacl intravenous parenteral solution 10 meq/l, 20 meq/l, 30 meq/l, 40 meq/l</i> | 2 | GC |
| <i>potassium chloride in 0.9%nacl intravenous parenteral solution 20 meq/l, 40 meq/l</i> | 2 | GC |
| <i>potassium chloride in 5 % dex intravenous parenteral solution 20 meq/l</i> | 2 | GC |
| <i>potassium chloride in water intravenous piggyback 10 meq/50 ml, 20 meq/50 ml</i> | 4 | |

Puede encontrar información sobre lo que significan los símbolos y las abreviaturas de esta tabla al principio de esta.

06/01/2024

| Nombre del medicamento | Nivel del med. | Requisitos / Limitaciones |
|--|----------------|---------------------------|
| <i>potassium chloride intravenous solution 2 meq/ml, 2 meq/ml (20 ml)</i> | 2 | GC |
| <i>potassium chloride oral capsule, extended release 10 meq, 8 meq</i> | 2 | GC |
| <i>potassium chloride oral liquid 20 meq/15 ml, 40 meq/15 ml</i> | 2 | GC |
| <i>potassium chloride oral packet 20 meq</i> | 2 | GC |
| <i>potassium chloride oral tablet extended release 10 meq, 20 meq, 8 meq</i> | 1 | GC |
| <i>potassium chloride oral tablet, er particles/crystals 10 meq, 20 meq</i> | 1 | GC |
| <i>potassium chloride oral tablet, er particles/crystals 15 meq</i> | 2 | GC |
| <i>potassium chloride-0.45 % nacl intravenous parenteral solution 20 meq/l</i> | 2 | GC |
| <i>potassium chloride-d5-0.2%nacl intravenous parenteral solution 20 meq/l</i> | 2 | GC |
| <i>potassium chloride-d5-0.9%nacl intravenous parenteral solution 20 meq/l</i> | 2 | GC |
| <i>potassium chloride-d5-0.9%nacl intravenous parenteral solution 40 meq/l</i> | 4 | |
| <i>sodium chloride 0.45 % intravenous parenteral solution 0.45 %</i> | 2 | GC |
| <i>sodium chloride 3 % hypertonic intravenous parenteral solution 3 %</i> | 2 | GC |
| <i>sodium chloride 5 % hypertonic intravenous parenteral solution 5 %</i> | 2 | GC |
| <i>sodium chloride intravenous solution 2.5 meq/ml, 4 meq/ml</i> | 4 | |
| TPN ELECTROLYTES INTRAVENOUS SOLUTION 35-20-5 MEQ/20 ML | 4 | |
| PRODUCTOS NUTRICIONALES DIVERSOS | | |
| CLINIMIX 5%/D15W SULFITE FREE INTRAVENOUS PARENTERAL SOLUTION 5 % | 4 | B/D |
| CLINIMIX 4.25%/D10W SULF FREE INTRAVENOUS PARENTERAL SOLUTION 4.25 % | 4 | B/D |
| CLINIMIX 5%-D20W(SULFITE-FREE) INTRAVENOUS PARENTERAL SOLUTION 5 % | 4 | B/D |
| CLINIMIX 6%-D5W (SULFITE-FREE) INTRAVENOUS PARENTERAL SOLUTION 6-5 % | 4 | B/D |

Puede encontrar información sobre lo que significan los símbolos y las abreviaturas de esta tabla al principio de esta.

06/01/2024

| Nombre del medicamento | Nivel del med. | Requisitos / Limitaciones |
|--|----------------|---------------------------|
| CLINIMIX 8%-D10W(SULFITE-FREE) INTRAVENOUS PARENTERAL SOLUTION 8-10 % | 4 | B/D |
| CLINIMIX 8%-D14W(SULFITE-FREE) INTRAVENOUS PARENTERAL SOLUTION 8-14 % | 4 | B/D |
| CLINOLIPID INTRAVENOUS EMULSION 20 % | 4 | B/D |
| <i>electrolyte-148 intravenous parenteral solution</i> | 2 | GC |
| <i>electrolyte-48 in d5w intravenous parenteral solution</i> | 4 | |
| <i>electrolyte-a intravenous parenteral solution</i> | 2 | GC |
| <i>intralipid intravenous emulsion 20 %</i> | 4 | B/D |
| INTRALIPID INTRAVENOUS EMULSION 30 % | 4 | B/D |
| ISOLYTE S PH 7.4 INTRAVENOUS PARENTERAL SOLUTION | 4 | |
| ISOLYTE-P IN 5 % DEXTROSE INTRAVENOUS PARENTERAL SOLUTION 5 % | 4 | |
| ISOLYTE-S INTRAVENOUS PARENTERAL SOLUTION | 4 | |
| NUTRILIPID INTRAVENOUS EMULSION 20 % | 4 | B/D |
| PLASMA-LYTE A INTRAVENOUS PARENTERAL SOLUTION | 4 | |
| PLENAMINE INTRAVENOUS PARENTERAL SOLUTION 15 % | 2 | B/D; GC |
| <i>premasol 10 % intravenous parenteral solution 10 %</i> | 4 | B/D |
| PROSOL 20 % INTRAVENOUS PARENTERAL SOLUTION | 4 | B/D |
| <i>travasol 10 % intravenous parenteral solution 10 %</i> | 4 | B/D |
| TROPHAMINE 10 % INTRAVENOUS PARENTERAL SOLUTION 10 % | 4 | B/D |
| VITAMINAS/MINERALES | | |
| <i>cyanocobalamin (vitamin b-12) injection solution</i> | 1 | NT |
| <i>dodex injection solution 1,000 mcg/ml</i> | 1 | NT |
| <i>ergocalciferol (vitamin d2) oral capsule 1,250 mcg (50,000 unit)</i> | 1 | NT |
| <i>fluoride (sodium) oral tablet 1 mg (2.2 mg sod. fluoride)</i> | 2 | GC |
| <i>fluoride (sodium) oral tablet, chewable 1 mg (2.2 mg sod. fluoride)</i> | 2 | GC |
| <i>folic acid oral tablet 1 mg</i> | 1 | NT |
| <i>prenatal vitamin plus low iron oral tablet 27 mg iron- 1 mg</i> | 3 | |

Puede encontrar información sobre lo que significan los símbolos y las abreviaturas de esta tabla al principio de esta.

06/01/2024

Índice de medicamentos

| | | | | | |
|------------------------------------|--------|--|----|--|--------|
| <i>abacavir</i> | 6 | ALTOPREV..... | 18 | <i>armodafinil</i> | 56 |
| <i>abacavir-lamivudine</i> | 6 | ALUNBRIG..... | 38 | ARNUIITY ELLIPTA..... | 27 |
| ABELCET..... | 5 | <i>alyacen 1/35 (28)</i> | 69 | <i>asenapine maleate</i> | 56 |
| ABILIFY MAINTENA..... | 55 | <i>alyacen 7/7/7 (28)</i> | 69 | <i>aspirin-dipyridamole</i> | 24 |
| <i>abiraterone</i> | 38 | <i>alyq</i> | 27 | ASSURE ID INSULIN SAFETY..... | 84 |
| ABRYSVO..... | 34 | <i>amabelz</i> | 73 | <i>atazanavir</i> | 7 |
| <i>acamprosate</i> | 3 | <i>amantadine hcl</i> | 7 | <i>atenolol</i> | 20 |
| <i>acarbose</i> | 81 | <i>ambrisentan</i> | 27 | <i>atenolol-chlorthalidone</i> | 20 |
| <i>accutane</i> | 89 | <i>amikacin</i> | 12 | <i>atomoxetine</i> | 56 |
| <i>acebutolol</i> | 20 | <i>amiloride</i> | 20 | <i>atorvastatin</i> | 18 |
| <i>acetaminophen-codeine</i> | 50 | <i>amiloride-hydrochlorothiazide</i> ... | 20 | <i>atovaquone</i> | 12 |
| <i>acetazolamide</i> | 76, 77 | <i>amiodarone</i> | 17 | <i>atovaquone-proguanil</i> | 12 |
| <i>acetic acid</i> | 3, 65 | <i>amitriptyline</i> | 56 | <i>atropine</i> | 77 |
| <i>acetylcysteine</i> | 26 | <i>amlodipine</i> | 20 | ATROPINE SULFATE (PF)..... | 77 |
| <i>acitretin</i> | 87 | <i>amlodipine-atorvastatin</i> | 18 | ATROVENT HFA..... | 27 |
| ACTEMRA..... | 67 | <i>amlodipine-benazepril</i> | 20 | <i>aubra eq</i> | 70 |
| ACTEMRA ACTPEN..... | 67 | <i>amlodipine-olmesartan</i> | 20 | AUGTYRO..... | 38 |
| ACTHIB (PF)..... | 34 | <i>amlodipine-valsartan</i> | 20 | <i>aurovela fe 1.5/30 (28)</i> | 70 |
| ACTIMMUNE..... | 34 | <i>amlodipine-valsartan-hcthiazyd</i> .. | 20 | <i>aurovela fe 1-20 (28)</i> | 70 |
| <i>acyclovir</i> | 6 | <i>ammonium lactate</i> | 88 | AUSTEDO..... | 62 |
| <i>acyclovir sodium</i> | 7 | <i>amnesteem</i> | 89 | AUSTEDO XR..... | 62, 63 |
| ADACEL(TDAP | | <i>amoxapine</i> | 56 | AUSTEDO XR TITRATION | |
| ADOLESN/ADULT)(PF)..... | 34 | <i>amoxicillin</i> | 15 | KT(WK1-4)..... | 63 |
| <i>adefovir</i> | 7 | <i>amoxicillin-pot clavulanate</i> | 15 | AUVELITY..... | 56 |
| ADEMPAS..... | 26 | <i>amphotericin b</i> | 5 | <i>aviane</i> | 70 |
| <i>adrenalin</i> | 26 | <i>ampicillin</i> | 15 | AYVAKIT..... | 38 |
| ADVAIR HFA..... | 26 | <i>ampicillin sodium</i> | 15 | <i>azacitidine</i> | 38 |
| AIMOVIG AUTOINJECTOR..... | 64 | <i>ampicillin-sulbactam</i> | 16 | <i>azathioprine</i> | 38 |
| AKEEGA..... | 38 | <i>anagrelide</i> | 3 | <i>azelaic acid</i> | 89 |
| <i>ak-poly-bac</i> | 75 | <i>anastrozole</i> | 38 | <i>azelastine</i> | 65, 77 |
| <i>ala-cort</i> | 86 | ANORO ELLIPTA..... | 27 | <i>azithromycin</i> | 12 |
| <i>albendazole</i> | 12 | APOKYN..... | 48 | <i>aztreonam</i> | 12 |
| <i>albuterol sulfate</i> | 26, 27 | <i>apomorphine</i> | 48 | <i>azurette (28)</i> | 70 |
| ALBUTEROL SULFATE..... | 26 | <i>apraclonidine</i> | 78 | <i>bacitracin</i> | 75 |
| <i>alclometasone</i> | 86 | <i>aprepitant</i> | 30 | <i>bacitracin-polymyxin b</i> | 75 |
| <i>alcohol pads</i> | 81 | <i>apri</i> | 69 | <i>baclofen</i> | 64 |
| ALDURAZYME..... | 79 | APTIOM..... | 51 | <i>balsalazide</i> | 30 |
| ALECENSA..... | 38 | APTIVUS..... | 7 | BALVERSA..... | 38 |
| <i>alendronate</i> | 69 | ARALAST NP..... | 3 | BARACLUDGE..... | 7 |
| <i>alfuzosin</i> | 66 | <i>aranelle (28)</i> | 70 | BASAGLAR KWIKPEN U-100 | |
| <i>aliskiren</i> | 20 | ARCALYST..... | 34 | INSULIN..... | 81 |
| <i>allopurinol</i> | 69 | AREXVY (PF)..... | 34 | BCG VACCINE, LIVE (PF)..... | 34 |
| <i>alosetron</i> | 30 | <i>arformoterol</i> | 27 | BELSOMRA..... | 56 |
| ALPHAGAN P..... | 78 | ARIKAYCE..... | 12 | <i>benazepril</i> | 20 |
| <i>alprazolam</i> | 56 | <i>aripiprazole</i> | 56 | <i>benazepril-hydrochlorothiazide</i> .. | 20 |
| ALREX..... | 76 | ARISTADA..... | 56 | BENDEKA..... | 38 |
| <i>altavera (28)</i> | 69 | ARISTADA INITIO..... | 56 | BENLYSTA..... | 67 |

| | | | | | |
|---|--------|---|----|--|------------|
| <i>benztropine</i> | 48 | <i>cabergoline</i> | 79 | <i>cefuroxime axetil</i> | 11 |
| BERINERT..... | 27 | CABOMETYX..... | 39 | <i>cefuroxime sodium</i> | 11 |
| BESIVANCE..... | 75 | <i>calcipotriene</i> | 87 | <i>celecoxib</i> | 49 |
| BESREMI..... | 34 | <i>calcitonin (salmon)</i> | 79 | <i>cephalexin</i> | 11 |
| <i>betaine</i> | 30 | <i>calcitriol</i> | 79 | CERDELGA..... | 80 |
| <i>betamethasone dipropionate</i> | 86 | <i>calcium acetate(phosphat bind)</i> | 90 | CEREZYME..... | 80 |
| <i>betamethasone valerate</i> | 86 | CALQUENCE..... | 39 | <i>cetirizine</i> | 26 |
| <i>betamethasone, augmented</i> | 86 | CALQUENCE (ACALABRUTINIB | | <i>cevimeline</i> | 3 |
| BETASERON..... | 34 | MAL)..... | 39 | CHEMET..... | 3 |
| <i>betaxolol</i> | 76 | <i>camila</i> | 73 | <i>chlorhexidine gluconate</i> | 65 |
| <i>bethanechol chloride</i> | 66 | <i>candesartan</i> | 20 | <i>chloroquine phosphate</i> | 13 |
| BEVESPI AEROSPHERE..... | 27 | <i>candesartan-hydrochlorothiazid</i> | 20 | <i>chlorpromazine</i> | 56, 57 |
| <i>bexarotene</i> | 39 | CAPLYTA..... | 56 | <i>chlorthalidone</i> | 21 |
| BEXSERO..... | 35 | CAPRELSA..... | 39 | <i>cholestyramine (with sugar)</i> | 18 |
| <i>bicalutamide</i> | 39 | <i>captopril</i> | 20 | <i>cholestyramine light</i> | 18 |
| BICILLIN L-A..... | 16 | <i>captopril-hydrochlorothiazide</i> | 20 | <i>cholestyramine-aspartame</i> | 18 |
| BIKTARVY..... | 7 | CARAFATE..... | 33 | <i>ciclopirox</i> | 85, 86 |
| <i>bisoprolol fumarate</i> | 20 | <i>carbamazepine</i> | 52 | <i>cilostazol</i> | 24 |
| <i>bisoprolol-hydrochlorothiazide</i> | 20 | <i>carbidopa</i> | 48 | CILOXAN..... | 75 |
| BIVIGAM..... | 35 | <i>carbidopa-levodopa</i> | 48 | CIMDUO..... | 7 |
| <i>blisovi fe 1.5/30 (28)</i> | 70 | <i>carbidopa-levodopa-</i> | | <i>cinacalcet</i> | 80 |
| <i>blisovi fe 1/20 (28)</i> | 70 | <i>entacapone</i> | 48 | CIPRO..... | 16 |
| BOOSTRIX TDAP..... | 35 | <i>carboplatin</i> | 39 | CIPRO HC..... | 65 |
| BORTEZOMIB..... | 39 | <i>carglumic acid</i> | 3 | <i>ciprofloxacin</i> | 17 |
| <i>bortezomib</i> | 39 | <i>carteolol</i> | 76 | <i>ciprofloxacin hcl</i> | 16, 75 |
| <i>bosentan</i> | 27 | <i>cartia xt</i> | 21 | <i>ciprofloxacin in 5 % dextrose</i> | 16, 17 |
| BOSULIF..... | 39 | <i>carvedilol</i> | 21 | <i>ciprofloxacin-dexamethasone</i> | 65 |
| BRAFTOVI..... | 39 | <i>caspofungin</i> | 5 | <i>cisplatin</i> | 39 |
| BREO ELLIPTA..... | 27 | CAYSTON..... | 13 | <i>citalopram</i> | 57 |
| <i>breyana</i> | 27 | <i>cefaclor</i> | 10 | <i>claravis</i> | 89 |
| BREZTRI AEROSPHERE..... | 27 | <i>cefadroxil</i> | 10 | <i>clarithromycin</i> | 12 |
| BRILINTA..... | 24 | <i>cefazolin</i> | 10 | <i>clindamycin hcl</i> | 13 |
| <i>brimonidine</i> | 78 | <i>cefazolin in dextrose (iso-os)</i> | 10 | CLINDAMYCIN IN 0.9 % SOD | |
| <i>brinzolamide</i> | 77 | CEFAZOLIN IN DEXTROSE (ISO- | | CHLOR..... | 13 |
| BRIVIACT..... | 52 | OS)..... | 10 | <i>clindamycin in 5 % dextrose</i> | 13 |
| <i>bromfenac</i> | 75 | <i>cefdinir</i> | 10 | <i>clindamycin phosphate</i> | 13, 74, 89 |
| <i>bromocriptine</i> | 48 | <i>cefepime</i> | 11 | CLINIMIX 5%/D15W SULFITE | |
| BROMSITE..... | 75 | CEFEPIME IN DEXTROSE 5 %..... | 11 | FREE..... | 91 |
| BRUKINSA..... | 39 | <i>cefepime in dextrose,iso-osm</i> | 11 | CLINIMIX 4.25%/D10W SULF | |
| <i>budesonide</i> | 27, 30 | <i>cefixime</i> | 11 | FREE..... | 91 |
| <i>bumetanide</i> | 20 | <i>cefoxitin</i> | 11 | CLINIMIX 4.25%/D5W SULFIT | |
| <i>buprenorphine hcl</i> | 50 | <i>cefoxitin in dextrose, iso-osm</i> | 11 | FREE..... | 3 |
| <i>buprenorphine-naloxone</i> | 49 | <i>cefpodoxime</i> | 11 | CLINIMIX 5%-D20W(SULFITE- | |
| <i>bupropion hcl</i> | 56 | <i>cefprozil</i> | 11 | FREE)..... | 91 |
| <i>bupropion hcl (smoking deter)</i> | 5 | <i>ceftazidime</i> | 11 | CLINIMIX 6%-D5W (SULFITE- | |
| <i>buspiron</i> | 56 | <i>ceftriaxone</i> | 11 | FREE)..... | 91 |
| <i>butorphanol</i> | 49 | CEFTRIAZONE..... | 11 | CLINIMIX 8%-D10W(SULFITE- | |
| BYDUREON BCISE..... | 81 | <i>ceftriaxone in dextrose,iso-os</i> | 11 | FREE)..... | 92 |

| | | | | | |
|--|------------|--|--------|--|--------|
| CLINIMIX 8%-D14W(SULFITE-FREE)..... | 92 | CYSTAGON..... | 66 | <i>dextrose 5 %-lactated ringers.....</i> | 3 |
| CLINOLIPID..... | 92 | CYSTARAN..... | 77 | <i>dextrose 5%-0.2 % sod chloride</i> | 3 |
| <i>clobazam.....</i> | 52 | <i>cytarabine.....</i> | 40 | <i>dextrose 5%-0.3 % sod.chloride</i> | 4 |
| <i>clobetasol.....</i> | 86 | <i>d10 %-0.45 % sodium chloride.....</i> | 3 | <i>dextrose 50 % in water (d50w).....</i> | 4 |
| <i>clobetasol-emollient.....</i> | 86 | <i>d2.5 %-0.45 % sodium chloride.....</i> | 3 | <i>dextrose 70 % in water (d70w).....</i> | 4 |
| <i>clomipramine.....</i> | 57 | <i>d5 % and 0.9 % sodium chloride... </i> | 3 | DIACOMIT..... | 52 |
| <i>clonazepam.....</i> | 52 | <i>d5 %-0.45 % sodium chloride.....</i> | 3 | <i>diazepam.....</i> | 52, 57 |
| <i>clonidine.....</i> | 21 | <i>dabigatran etexilate.....</i> | 24 | <i>diazepam intensol.....</i> | 57 |
| <i>clonidine hcl.....</i> | 21 | <i>dalfampridine.....</i> | 63 | <i>diazoxide.....</i> | 81 |
| <i>clopidogrel.....</i> | 24 | <i>danazol.....</i> | 80 | <i>diclofenac potassium.....</i> | 49 |
| <i>clorazepate dipotassium.....</i> | 57 | <i>dantrolene.....</i> | 64 | <i>diclofenac sodium.....</i> | 49, 75 |
| <i>clotrimazole.....</i> | 5, 86 | <i>dapsone.....</i> | 13 | <i>diclofenac-misoprostol.....</i> | 49 |
| <i>clotrimazole-betamethasone.....</i> | 86 | DAPTACEL (DTAP PEDIATRIC) (PF)..... | 35 | <i>dicloxacillin.....</i> | 16 |
| <i>clozapine.....</i> | 57 | <i>daptomycin.....</i> | 13 | <i>dicyclomine.....</i> | 33 |
| COARTEM..... | 13 | <i>darifenacin.....</i> | 66 | DIFICID..... | 12 |
| <i>colchicine.....</i> | 69 | <i>darunavir.....</i> | 7 | <i>diflunisal.....</i> | 49 |
| <i>colesevelam.....</i> | 18 | <i>dasetta 1/35 (28).....</i> | 70 | <i>difluprednate.....</i> | 76 |
| <i>colestipol.....</i> | 19 | <i>dasetta 7/7/7 (28).....</i> | 70 | <i>digoxin.....</i> | 18 |
| <i>colistin (colistimethate na).....</i> | 13 | DAURISMO..... | 40 | <i>dihydroergotamine.....</i> | 64 |
| COLUMVI..... | 39 | <i>deblitane.....</i> | 73 | DILANTIN..... | 52 |
| COMBIGAN..... | 77 | <i>deferasirox.....</i> | 3 | DILANTIN EXTENDED..... | 52 |
| COMBIVENT RESPIMAT..... | 27 | DELESTROGEN..... | 73 | DILANTIN INFATABS..... | 52 |
| COMETRIQ..... | 39 | DELSTRIGO..... | 7 | DILANTIN-125..... | 52 |
| COMPLERA..... | 7 | DENGVAXIA (PF)..... | 35 | <i>diltiazem hcl.....</i> | 21 |
| <i>compro.....</i> | 30 | DEPO-SUBQ PROVERA 104..... | 73 | <i>dilt-xr.....</i> | 21 |
| <i>constulose.....</i> | 30 | <i>dermacinrx lidocan.....</i> | 88 | <i>diphenhydramine hcl.....</i> | 26 |
| COPIKTRA..... | 39 | DESCOVY..... | 7 | <i>diphenoxylate-atropine.....</i> | 33 |
| CORLANOR..... | 18 | <i>desipramine.....</i> | 57 | <i>dipyridamole.....</i> | 24 |
| COTELLIC..... | 39 | <i>desloratadine.....</i> | 26 | <i>disopyramide phosphate.....</i> | 17 |
| CREON..... | 30 | <i>desmopressin.....</i> | 80 | <i>disulfiram.....</i> | 4 |
| CRESEMBA..... | 5 | <i>desog-e.estradiol/e.estradiol.....</i> | 70 | <i>divalproex.....</i> | 52 |
| <i>cromolyn.....</i> | 27, 30, 77 | <i>desogestrel-ethinyl estradiol.....</i> | 70 | <i>docetaxel.....</i> | 40 |
| <i>cryselle (28).....</i> | 70 | <i>desonide.....</i> | 86 | <i>dodex.....</i> | 92 |
| <i>cyanocobalamin (vitamin b-12)..</i> | 92 | <i>desvenlafaxine succinate.....</i> | 57 | <i>dofetilide.....</i> | 17 |
| <i>cyclobenzaprine.....</i> | 64 | <i>dexamethasone.....</i> | 78 | <i>donepezil.....</i> | 63 |
| <i>cyclophosphamide.....</i> | 39 | <i>dexamethasone intensol.....</i> | 78 | DOPTELET (10 TAB PACK)..... | 24 |
| CYCLOPHOSPHAMIDE..... | 39 | <i>dexamethasone sodium phos (pf).....</i> | 79 | DOPTELET (15 TAB PACK)..... | 24 |
| <i>cyclosporine.....</i> | 39, 40 | <i>dexamethasone sodium phosphate.....</i> | 76, 79 | DOPTELET (30 TAB PACK)..... | 25 |
| <i>cyclosporine modified.....</i> | 39, 40 | <i>dexlansoprazole.....</i> | 33 | <i>dorzolamide.....</i> | 77 |
| CYLTEZO(CF)..... | 67 | <i>dexmethylphenidate.....</i> | 57 | <i>dorzolamide-timolol.....</i> | 77 |
| CYLTEZO(CF) PEN..... | 67 | <i>dextroamphetamine-amphetamine.....</i> | 57 | <i>dotti.....</i> | 73 |
| CYLTEZO(CF) PEN CROHN'S-UC-HS..... | 67 | <i>dextrose 10 % and 0.2 % nacl.....</i> | 3 | DOVATO..... | 7 |
| CYLTEZO(CF) PEN PSORIASIS-UV..... | 67 | <i>dextrose 10 % in water (d10w).....</i> | 3 | <i>doxazosin.....</i> | 21 |
| <i>cyproheptadine.....</i> | 26 | <i>dextrose 5 % in water (d5w).....</i> | 3 | <i>doxepin.....</i> | 57, 58 |
| <i>cyred eq.....</i> | 70 | | | <i>doxercalciferol.....</i> | 80 |
| CYSTADROPS..... | 77 | | | <i>doxorubicin.....</i> | 40 |
| | | | | <i>doxorubicin, peg-liposomal.....</i> | 40 |
| | | | | <i>doxy-100.....</i> | 17 |

| | | | | | |
|--|----|--|--------|--|--------|
| <i>doxycycline hyclate</i> | 17 | ENBREL SURECLICK..... | 67 | <i>etoposide</i> | 40 |
| <i>doxycycline monohydrate</i> | 17 | ENDARI..... | 4 | <i>etravirine</i> | 7 |
| DRIZALMA SPRINKLE..... | 58 | <i>endocet</i> | 50 | EULEXIN..... | 40 |
| <i>dronabinol</i> | 30 | ENGERIX-B (PF)..... | 35 | <i>euthyrox</i> | 78 |
| <i>drospirenone-ethinyl estradiol</i> | 70 | ENGERIX-B PEDIATRIC (PF)..... | 35 | <i>everolimus (antineoplastic)</i> .. | 40, 41 |
| DROXIA..... | 40 | <i>enoxaparin</i> | 25 | <i>everolimus</i> | |
| <i>droxidopa</i> | 4 | <i>enpresse</i> | 70 | <i>(immunosuppressive)</i> | 41 |
| <i>duloxetine</i> | 58 | <i>enskyce</i> | 70 | EVOTAZ..... | 8 |
| DUPIXENT PEN..... | 88 | ENSTILAR..... | 87 | <i>exemestane</i> | 41 |
| DUPIXENT SYRINGE..... | 88 | <i>entacapone</i> | 48 | EXKIVITY..... | 41 |
| <i>dutasteride</i> | 66 | <i>entecavir</i> | 7 | EZALLOR SPRINKLE..... | 19 |
| <i>dutasteride-tamsulosin</i> | 66 | ENTRESTO..... | 18 | <i>ezetimibe</i> | 19 |
| <i>e.e.s. 400</i> | 12 | <i>enulose</i> | 30 | <i>ezetimibe-simvastatin</i> | 19 |
| <i>ec-naproxen</i> | 49 | ENVARBUS XR..... | 40 | FABRAZYME..... | 80 |
| EDARBI..... | 21 | EPCLUSA..... | 7 | <i>falmina (28)</i> | 70 |
| EDARBYCLOR..... | 21 | EPIDIOLEX..... | 52 | <i>famciclovir</i> | 8 |
| EDURANT..... | 7 | <i>epinephrine</i> | 26 | <i>famotidine</i> | 33 |
| <i>efavirenz</i> | 7 | EPINEPHRINE..... | 26 | <i>famotidine (pf)</i> | 33 |
| <i>efavirenz-emtricitabin-tenofov</i> | 7 | <i>epitol</i> | 52 | <i>famotidine (pf)-nacl (iso-os)</i> | 33 |
| <i>efavirenz-lamivu-tenofov disop</i> | 7 | EPIVIR HBV..... | 7 | FANAPT..... | 58 |
| <i>electrolyte-148</i> | 92 | EPKINLY..... | 40 | FARXIGA..... | 81 |
| <i>electrolyte-48 in d5w</i> | 92 | <i>eplerenone</i> | 21 | FASENRA..... | 27 |
| <i>electrolyte-a</i> | 92 | EPRONTIA..... | 53 | FASENRA PEN..... | 27 |
| ELIGARD..... | 40 | <i>ergocalciferol (vitamin d2)</i> | 92 | <i>febuxostat</i> | 69 |
| ELIGARD (3 MONTH)..... | 40 | <i>ergotamine-caffeine</i> | 64 | <i>felbamate</i> | 53 |
| ELIGARD (4 MONTH)..... | 40 | ERIVEDGE..... | 40 | <i>felodipine</i> | 21 |
| ELIGARD (6 MONTH)..... | 40 | ERLEADA..... | 40 | <i>fenofibrate</i> | 19 |
| <i>elinest</i> | 70 | <i>erlotinib</i> | 40 | <i>fenofibrate micronized</i> | 19 |
| ELIQUIS..... | 25 | <i>errin</i> | 73 | <i>fenofibrate nanocrystallized</i> | 19 |
| ELIQUIS DVT-PE TREAT 30D | | <i>ertapenem</i> | 13 | <i>fenofibric acid (choline)</i> | 19 |
| START..... | 25 | <i>ery pads</i> | 89 | <i>fentanyl</i> | 50 |
| ELLECE..... | 40 | <i>ery-tab</i> | 12 | <i>fentanyl citrate</i> | 50 |
| ELMIRON..... | 66 | ERYTHROCIN..... | 12 | <i>fesoterodine</i> | 66 |
| ELREXFIO..... | 40 | <i>erythrocin (as stearate)</i> | 12 | FETZIMA..... | 58 |
| <i>eluryng</i> | 74 | <i>erythromycin</i> | 12, 75 | FIASP FLEXTOUCH U-100 | |
| EMCYT..... | 40 | <i>erythromycin ethylsuccinate</i> | 12 | INSULIN..... | 81 |
| EMGALITY PEN..... | 64 | <i>erythromycin with ethanol</i> | 89 | FIASP PENFILL U-100 INSULIN.... | 81 |
| EMGALITY SYRINGE..... | 64 | <i>escitalopram oxalate</i> | 58 | FIASP U-100 INSULIN..... | 81 |
| <i>emoquette</i> | 70 | <i>esomeprazole magnesium</i> | 33 | FINACEA..... | 89 |
| EMSAM..... | 58 | <i>estarylla</i> | 70 | <i>finasteride</i> | 66 |
| <i>emtricitabine</i> | 7 | <i>estradiol</i> | 73 | <i>finingolimod</i> | 63 |
| <i>emtricitabine-tenofov (tdf)</i> | 7 | <i>estradiol valerate</i> | 73 | FINTEPLA..... | 53 |
| EMTRIVA..... | 7 | <i>estradiol-norethindrone acet</i> | 73 | FIRMAGON KIT W DILUENT | |
| EMVERM..... | 13 | <i>ethambutol</i> | 13 | SYRINGE..... | 41 |
| <i>enalapril maleate</i> | 21 | <i>ethosuximide</i> | 53 | <i>flac otic oil</i> | 65 |
| <i>enalapril-hydrochlorothiazide</i> | 21 | <i>ethynodiol diac-eth estradiol</i> | 70 | FLAREX..... | 76 |
| ENBREL..... | 67 | <i>etodolac</i> | 49 | FLEBOGAMMA DIF..... | 35 |
| ENBREL MINI..... | 67 | <i>etonogestrel-ethinyl estradiol</i> | 74 | <i>flecainide</i> | 17 |

| | | | | | |
|--|--------|--|------------|---|------------|
| <i>fluconazole</i> | 5 | <i>ganciclovir sodium</i> | 8 | <i>haloperidol decanoate</i> | 58 |
| <i>fluconazole in nacl (iso-osm)</i> | 5 | GARDASIL 9 (PF)..... | 35 | <i>haloperidol lactate</i> | 58 |
| <i>flucytosine</i> | 5 | <i>gatifloxacin</i> | 75 | HARVONI..... | 8 |
| <i>fludrocortisone</i> | 79 | GATTEX 30-VIAL..... | 30 | HAVRIX (PF)..... | 35 |
| <i>flunisolide</i> | 27 | GATTEX ONE-VIAL..... | 30 | <i>heather</i> | 73 |
| <i>fluocinolone</i> | 87 | GAUZE PAD..... | 85 | <i>heparin (porcine)</i> | 25 |
| <i>fluocinolone acetonide oil</i> | 65 | <i>gavilyte-c</i> | 30 | <i>heparin (porcine) in 5 % dex</i> | 25 |
| <i>fluocinolone and shower cap</i> | 86 | <i>gavilyte-g</i> | 30 | HEPARIN(PORCINE) IN 0.45% NACL..... | 25 |
| <i>fluocinonide</i> | 87 | GAVRETO..... | 41 | <i>heparin(porcine) in 0.45% nacl</i> ... | 25 |
| <i>fluocinonide-e</i> | 87 | <i>gefitinib</i> | 41 | HEPLISAV-B (PF)..... | 35 |
| <i>fluocinonide-emollient</i> | 87 | <i>gemcitabine</i> | 41 | HIBERIX (PF)..... | 36 |
| <i>fluoride (sodium)</i> | 92 | GEMCITABINE..... | 41 | HUMIRA..... | 67 |
| <i>fluorometholone</i> | 76 | <i>gemfibrozil</i> | 19 | HUMIRA PEN..... | 67 |
| <i>fluorouracil</i> | 41, 88 | GEMTESA..... | 66 | HUMIRA PEN PSOR-UVEITS- ADOL HS..... | 67 |
| <i>fluoxetine</i> | 58 | <i>generlac</i> | 30 | HUMIRA(CF)..... | 68 |
| <i>fluphenazine decanoate</i> | 58 | <i>gengraf</i> | 41 | HUMIRA(CF) PEDI CROHNS STARTER..... | 67 |
| <i>fluphenazine hcl</i> | 58 | GENOTROPIN..... | 34 | HUMIRA(CF) PEN..... | 68 |
| <i>flurbiprofen</i> | 49 | GENOTROPIN MINIQUICK..... | 34 | HUMIRA(CF) PEN CROHNS-UC- HS..... | 68 |
| <i>flurbiprofen sodium</i> | 75 | <i>gentak</i> | 75 | HUMIRA(CF) PEN PEDIATRIC UC..... | 68 |
| <i>fluticasone propionate</i> | 28, 87 | <i>gentamicin</i> | 13, 75, 85 | HUMIRA(CF) PEN PSOR-UV- ADOL HS..... | 68 |
| <i>fluticasone propion-salmeterol</i> ... | 28 | <i>gentamicin in nacl (iso-osm)</i> | 13 | HUMULIN R U-500 (CONC) INSULIN..... | 82 |
| <i>fluvastatin</i> | 19 | <i>gentamicin sulfate (ped) (pf)</i> | 13 | HUMULIN R U-500 (CONC) KWIKPEN..... | 82 |
| <i>fluvoxamine</i> | 58 | GENVOYA..... | 8 | <i>hydralazine</i> | 22 |
| <i>folic acid</i> | 92 | GILOTRIF..... | 41 | <i>hydrochlorothiazide</i> | 22 |
| <i>fondaparinux</i> | 25 | <i>glatiramer</i> | 63 | <i>hydrocodone-acetaminophen</i> | 50 |
| <i>formoterol fumarate</i> | 28 | <i>glatopa</i> | 63 | <i>hydrocodone-ibuprofen</i> | 50 |
| FORTEO..... | 69 | GLEOSTINE..... | 41 | <i>hydrocortisone</i> | 31, 79, 87 |
| FOSAMAX PLUS D..... | 69 | <i>glimepiride</i> | 81 | <i>hydromorphone</i> | 50 |
| <i>fosamprenavir</i> | 8 | <i>glipizide</i> | 81 | <i>hydroxychloroquine</i> | 13 |
| <i>fosinopril</i> | 21 | <i>glipizide-metformin</i> | 81 | <i>hydroxyurea</i> | 41 |
| <i>fosinopril-hydrochlorothiazide</i> ... | 21 | <i>glycopyrrolate</i> | 33 | <i>hydroxyzine hcl</i> | 26 |
| FOTIVDA..... | 41 | <i>glydo</i> | 88 | <i>hydroxyzine pamoate</i> | 26 |
| FRUZAQLA..... | 41 | GLYXAMBI..... | 81 | HYSINGLA ER..... | 51 |
| <i>fulvestrant</i> | 41 | GOLYTELY..... | 30 | <i>ibandronate</i> | 69 |
| <i>furosemide</i> | 21 | GRALISE..... | 53 | IBRANCE..... | 41 |
| FUZEON..... | 8 | <i>granisetron (pf)</i> | 30 | <i>ibu</i> | 49 |
| <i>fyavolv</i> | 73 | <i>granisetron hcl</i> | 31 | <i>ibuprofen</i> | 49 |
| FYCOMPA..... | 53 | <i>griseofulvin microsize</i> | 5 | <i>icatibant</i> | 28 |
| <i>gabapentin</i> | 53 | <i>griseofulvin ultramicrosize</i> | 5 | ICLUSIG..... | 41 |
| <i>galantamine</i> | 63 | <i>guanfacine</i> | 22, 58 | IDACIO(CF)..... | 68 |
| GAMASTAN..... | 35 | GVOKE..... | 82 | IDACIO(CF) PEN..... | 68 |
| GAMMAGARD LIQUID..... | 35 | GVOKE HYOPEN 1-PACK..... | 81 | | |
| GAMMAGARD S-D (IGA < 1 MCG/ML)..... | 35 | GVOKE HYOPEN 2-PACK..... | 81 | | |
| GAMMAKED..... | 35 | GVOKE PFS 1-PACK SYRINGE..... | 82 | | |
| GAMMAPLEX..... | 35 | GVOKE PFS 2-PACK SYRINGE..... | 82 | | |
| GAMMAPLEX (WITH SORBITOL)..... | 35 | HAEGARDA..... | 28 | | |
| GAMUNEX-C..... | 35 | <i>halobetasol propionate</i> | 87 | | |
| | | <i>haloperidol</i> | 58 | | |

| | | | | |
|--|-------------------------------------|-------|---|--------|
| IDACIO(CF) PEN CROHN-UC | <i>isosorbide mononitrate</i> | 19 | <i>kurvelo (28)</i> | 71 |
| STARTR..... | <i>isotretinoin</i> | 89 | <i>labetalol</i> | 22 |
| IDACIO(CF) PEN PSORIASIS | <i>isradipine</i> | 22 | <i>lacosamide</i> | 53 |
| START..... | <i>itraconazole</i> | 6 | <i>lactated ringers</i> | 90 |
| IDHIFA..... | <i>ivermectin</i> | 13 | <i>lactulose</i> | 31 |
| ILEVRO..... | IWILFIN..... | 42 | LAGEVRIO (EUA)..... | 8 |
| <i>imatinib</i> | IXCHIQ..... | 36 | <i>lamivudine</i> | 8 |
| IMBRUVICA..... | IXIARO (PF)..... | 36 | <i>lamivudine-zidovudine</i> | 8 |
| <i>imipenem-cilastatin</i> | JAKAFI..... | 42 | <i>lamotrigine</i> | 53 |
| <i>imipramine hcl</i> | <i>jantoven</i> | 25 | <i>lansoprazole</i> | 33 |
| <i>imiquimod</i> | JANUMET..... | 82 | <i>lapatinib</i> | 42 |
| IMOVAX RABIES VACCINE (PF).... | JANUMET XR..... | 82 | <i>larin 1.5/30 (21)</i> | 71 |
| IMVEXXY MAINTENANCE PACK.. | JANUVIA..... | 82 | <i>larin 1/20 (21)</i> | 71 |
| IMVEXXY STARTER PACK..... | JARDIANCE..... | 82 | <i>larin fe 1.5/30 (28)</i> | 71 |
| <i>incassia</i> | <i>jasmiel (28)</i> | 70 | <i>larin fe 1/20 (28)</i> | 71 |
| INCRELEX..... | JAYPIRCA..... | 42 | <i>latanoprost</i> | 77 |
| INCRUSE ELLIPTA..... | JENTADUETO..... | 82 | <i>leflunomide</i> | 68 |
| <i>indapamide</i> | JENTADUETO XR..... | 82 | <i>lenalidomide</i> | 42 |
| INFANRIX (DTAP) (PF)..... | <i>jinteli</i> | 74 | LENVIMA..... | 42, 43 |
| INLYTA..... | <i>jolessa</i> | 70 | <i>lessina</i> | 71 |
| INQOVI..... | <i>juleber</i> | 70 | <i>letrozole</i> | 43 |
| INREBIC..... | JULUCA..... | 8 | <i>leucovorin calcium</i> | 38 |
| INSULIN SYRINGE-NEEDLE U- | <i>junel fe 1.5/30 (28)</i> | 71 | LEUKERAN..... | 43 |
| 100..... | <i>junel fe 1/20 (28)</i> | 71 | <i>leuprolide</i> | 43 |
| INTELENCE..... | JYNNEOS (PF)..... | 36 | <i>levalbuterol hcl</i> | 28 |
| <i>intralipid</i> | KADCYLA..... | 42 | LEVALBUTEROL TARTRATE..... | 28 |
| INTRALIPID..... | KALYDECO..... | 28 | <i>levetiracetam</i> | 53, 54 |
| <i>introvale</i> | <i>kariva (28)</i> | 71 | <i>levetiracetam in nacl (iso-os)</i> | 53 |
| INVEGA HAFYERA..... | <i>kelnor 1/35 (28)</i> | 71 | <i>levobunolol</i> | 76 |
| INVEGA SUSTENNA..... | <i>kelnor 1-50 (28)</i> | 71 | <i>levocarnitine</i> | 4 |
| INVEGA TRINZA..... | KERENDIA..... | 22 | <i>levocarnitine (with sugar)</i> | 4 |
| INVOKAMET..... | <i>ketoconazole</i> | 6, 86 | <i>levocetirizine</i> | 26 |
| INVOKAMET XR..... | <i>ketorolac</i> | 75 | <i>levofloxacin</i> | 17 |
| INVOKANA..... | KEYTRUDA..... | 42 | <i>levofloxacin in d5w</i> | 17 |
| IPOL..... | KINRIX (PF)..... | 36 | <i>levonest (28)</i> | 71 |
| <i>ipratropium bromide</i> | KISQALI..... | 42 | <i>levonorgestrel-ethinyl estrad</i> | 71 |
| <i>ipratropium-albuterol</i> | KISQALI FEMARA CO-PACK..... | 42 | <i>levonorg-eth estrad triphasic</i> | 71 |
| <i>irbesartan</i> | <i>klayesta</i> | 86 | <i>levora-28</i> | 71 |
| <i>irbesartan-hydrochlorothiazide</i> .. | <i>klor-con</i> | 90 | <i>levo-t</i> | 78 |
| <i>irinotecan</i> | <i>klor-con 10</i> | 90 | <i>levothyroxine</i> | 78 |
| ISENTRESS..... | <i>klor-con 8</i> | 90 | <i>levoxyl</i> | 78 |
| ISENTRESS HD..... | <i>klor-con m10</i> | 90 | LEXIVA..... | 8 |
| <i>isibloom</i> | <i>klor-con m15</i> | 90 | <i>lidocaine</i> | 89 |
| ISOLYTE S PH 7.4..... | <i>klor-con m20</i> | 90 | <i>lidocaine (pf)</i> | 88 |
| ISOLYTE-P IN 5 % DEXTROSE..... | KORLYM..... | 80 | <i>lidocaine hcl</i> | 88, 89 |
| ISOLYTE-S..... | KOSELUGO..... | 42 | <i>lidocaine viscous</i> | 89 |
| <i>isoniazid</i> | <i>kourzeq</i> | 65 | <i>lidocaine-prilocaine</i> | 89 |
| <i>isosorbide dinitrate</i> | KRAZATI..... | 42 | <i>lidocan iii</i> | 89 |

| | | | | | |
|--|----|--|------------|---|--------|
| <i>lidocan iv</i> | 89 | <i>marlissa (28)</i> | 71 | <i>microgestin 1/20 (21)</i> | 71 |
| <i>lidocan v</i> | 89 | MARPLAN..... | 60 | <i>microgestin fe 1.5/30 (28)</i> | 71 |
| <i>linezolid</i> | 13 | MATULANE..... | 43 | <i>microgestin fe 1/20 (28)</i> | 71 |
| <i>linezolid in dextrose 5%</i> | 13 | <i>matzim la</i> | 22 | <i>midodrine</i> | 4 |
| <i>linezolid-0.9% sodium chloride</i> ... | 13 | <i>meclizine</i> | 31 | <i>mifepristone</i> | 80 |
| LINEZOLID-0.9% SODIUM | | <i>medroxyprogesterone</i> | 74 | <i>mili</i> | 71 |
| CHLORIDE..... | 14 | <i>mefloquine</i> | 14 | <i>mimvey</i> | 74 |
| LINZESS..... | 31 | <i>megestrol</i> | 43 | <i>minocycline</i> | 17 |
| <i>liothyronine</i> | 78 | MEKINIST..... | 43 | <i>minoxidil</i> | 22 |
| <i>lisdexamfetamine</i> | 59 | MEKTOVI..... | 43 | <i>mirtazapine</i> | 60 |
| <i>lisinopril</i> | 22 | <i>meloxicam</i> | 49 | <i>misoprostol</i> | 33 |
| <i>lisinopril-hydrochlorothiazide</i> | 22 | <i>memantine</i> | 63 | MITIGARE..... | 69 |
| <i>lithium carbonate</i> | 59 | MENACTRA (PF)..... | 36 | M-M-R II (PF)..... | 36 |
| <i>lithium citrate</i> | 59 | MENQUADFI (PF)..... | 36 | <i>modafinil</i> | 60 |
| LIVALO..... | 19 | MENVEO A-C-Y-W-135-DIP (PF).. | 36 | <i>moexipril</i> | 22 |
| LOKELMA..... | 4 | <i>mercaptapurine</i> | 43 | <i>molindone</i> | 60 |
| LONSURF..... | 43 | <i>meropenem</i> | 14 | <i>mometasone</i> | 28, 87 |
| <i>loperamide</i> | 33 | MEROPENEM-0.9% SODIUM | | MONJUVI..... | 43 |
| <i>lopinavir-ritonavir</i> | 8 | CHLORIDE..... | 14 | <i>mono-linyah</i> | 71 |
| <i>lorazepam</i> | 59 | <i>mesalamine</i> | 31 | <i>montelukast</i> | 28 |
| <i>lorazepam intensol</i> | 59 | <i>mesalamine with cleansing</i> | | MORPHINE..... | 51 |
| LORBRENA..... | 43 | <i>wipe</i> | 31 | <i>morphine</i> | 51 |
| <i>loryna (28)</i> | 71 | MESNEX..... | 38 | <i>morphine (pf)</i> | 51 |
| <i>losartan</i> | 22 | <i>metformin</i> | 82, 83 | <i>morphine concentrate</i> | 51 |
| <i>losartan-hydrochlorothiazide</i> | 22 | <i>methadone</i> | 51 | MOUNJARO..... | 83 |
| LOTEMAX..... | 76 | <i>methadone intensol</i> | 51 | MOVANTIK..... | 31 |
| <i>lovastatin</i> | 19 | <i>methazolamide</i> | 77 | <i>moxifloxacin</i> | 17, 75 |
| <i>low-ogestrel (28)</i> | 71 | <i>methenamine hippurate</i> | 6 | MOXIFLOXACIN-SOD.ACE,SUL- | |
| <i>loxapine succinate</i> | 60 | <i>methimazole</i> | 78 | WATER..... | 17 |
| <i>lubiprostone</i> | 31 | <i>methotrexate sodium</i> | 43 | <i>moxifloxacin-sod.chloride(iso)</i> | 17 |
| LUMAKRAS..... | 43 | <i>methotrexate sodium (pf)</i> | 43 | MULTAQ..... | 17 |
| LUMIGAN..... | 77 | <i>methsuximide</i> | 54 | <i>mupirocin</i> | 85 |
| LUMIZYME..... | 80 | <i>methylphenidate hcl</i> | 60 | <i>mycophenolate mofetil</i> | 43 |
| LUPRON DEPOT..... | 43 | <i>methylprednisolone</i> | 79 | <i>mycophenolate sodium</i> | 44 |
| <i>lurasidone</i> | 60 | <i>methylprednisolone acetate</i> | 79 | <i>myorisan</i> | 90 |
| <i>lutera (28)</i> | 71 | <i>methylprednisolone sodium</i> | | MYRBETRIQ..... | 66 |
| <i>lyleq</i> | 74 | <i>succ</i> | 79 | <i>nabumetone</i> | 49 |
| <i>lyllana</i> | 74 | <i>metoclopramide hcl</i> | 31 | <i>nadolol</i> | 22 |
| LYNPARZA..... | 43 | <i>metolazone</i> | 22 | <i>nafacillin</i> | 16 |
| LYRICA CR..... | 54 | <i>metoprolol succinate</i> | 22 | <i>nafacillin in dextrose iso-osm</i> | 16 |
| LYSODREN..... | 43 | <i>metoprolol ta-hydrochlorothiaz</i> .. | 22 | NAGLAZYME..... | 80 |
| LYTGOBI..... | 43 | <i>metoprolol tartrate</i> | 22 | <i>nalbuphine</i> | 49 |
| <i>lyza</i> | 74 | <i>metro i.v.</i> | 14 | <i>naloxone</i> | 49 |
| <i>magnesium sulfate</i> | 90 | <i>metronidazole</i> | 14, 74, 89 | <i>naltrexone</i> | 50 |
| MAGNESIUM SULFATE IN D5W .. | 90 | <i>metronidazole in nacl (iso-os)</i> | 14 | NAMZARIC..... | 63 |
| <i>magnesium sulfate in water</i> | 90 | <i>metyrosine</i> | 22 | <i>naproxen</i> | 50 |
| <i>malathion</i> | 87 | <i>micafungin</i> | 6 | <i>naproxen sodium</i> | 50 |
| <i>maraviroc</i> | 8 | <i>microgestin 1.5/30 (21)</i> | 71 | <i>naratriptan</i> | 64 |

| | | | | | |
|---|--------|---|--------|--------------------------------------|----|
| NATACYN..... | 75 | <i>nortriptyline</i> | 60 | OMNIPOD CLASSIC PDM | |
| <i>nateglinide</i> | 83 | NORVIR..... | 8 | KIT(GEN 3)..... | 85 |
| NAYZILAM..... | 54 | NOVOLIN 70/30 U-100 INSULIN. | 83 | OMNIPOD CLASSIC PODS (GEN | |
| <i>nebivolol</i> | 22 | NOVOLIN 70-30 FLEXPEN U-100. | 83 | 3)..... | 85 |
| <i>nefazodone</i> | 60 | NOVOLIN N FLEXPEN..... | 83 | OMNIPOD DASH INTRO KIT | |
| <i>neomycin</i> | 14 | NOVOLIN N NPH U-100 INSULIN | 83 | (GEN 4)..... | 85 |
| <i>neomycin-bacitracin-poly-hc</i> | 76 | NOVOLIN R FLEXPEN..... | 83 | OMNIPOD DASH PODS (GEN 4).. | 85 |
| <i>neomycin-bacitracin-polymyxin</i> .. | 75 | NOVOLIN R REGULAR U100 | | OMNIPOD GO PODS..... | 85 |
| <i>neomycin-polymyxin b-</i> | | INSULIN..... | 83 | OMNIPOD GO PODS 10 | |
| <i>dexameth</i> | 76 | NOVOLOG FLEXPEN U-100 | | UNITS/DAY..... | 85 |
| <i>neomycin-polymyxin-gramicidin</i> . | 75 | INSULIN..... | 83 | OMNIPOD GO PODS 15 | |
| <i>neomycin-polymyxin-hc</i> | 65, 76 | NOVOLOG MIX 70-30 U-100 | | UNITS/DAY..... | 85 |
| NERLYNX..... | 44 | INSULN..... | 83 | OMNIPOD GO PODS 20 | |
| NEUPRO..... | 48 | NOVOLOG MIX 70-30FLEXPEN | | UNITS/DAY..... | 85 |
| <i>nevirapine</i> | 8 | U-100..... | 83 | OMNIPOD GO PODS 25 | |
| NEXPLANON..... | 74 | NOVOLOG PENFILL U-100 | | UNITS/DAY..... | 85 |
| <i>niacin</i> | 19 | INSULIN..... | 83 | OMNIPOD GO PODS 30 | |
| <i>nicardipine</i> | 22 | NOVOLOG U-100 INSULIN | | UNITS/DAY..... | 85 |
| NICOTROL..... | 5 | ASPART..... | 83 | <i>ondansetron</i> | 31 |
| NICOTROL NS..... | 5 | NOXAFIL..... | 6 | <i>ondansetron hcl</i> | 31 |
| <i>nifedipine</i> | 23 | NUBEQA..... | 44 | <i>ondansetron hcl (pf)</i> | 31 |
| <i>nikki (28)</i> | 71 | NUDEXTA..... | 63 | ONUREG..... | 44 |
| <i>nilutamide</i> | 44 | NULOJIX..... | 44 | OPSUMIT..... | 28 |
| <i>nimodipine</i> | 23 | NUPLAZID..... | 60 | ORGOVYX..... | 44 |
| NINLARO..... | 44 | NURTEC ODT..... | 64 | ORKAMBI..... | 28 |
| <i>nisoldipine</i> | 23 | NUTRILIPID..... | 92 | ORSERDU..... | 44 |
| <i>nitazoxanide</i> | 14 | <i>nyamyc</i> | 86 | <i>oseltamivir</i> | 8 |
| <i>nitisinone</i> | 4 | NYMALIZE..... | 23 | OTEZLA..... | 68 |
| <i>nitro-bid</i> | 19 | <i>nystatin</i> | 6, 86 | OTEZLA STARTER..... | 68 |
| <i>nitrofurantoin macrocrystal</i> | 6 | <i>nystop</i> | 86 | <i>oxacillin</i> | 16 |
| <i>nitrofurantoin monohyd/m-</i> | | OCALIVA..... | 31 | <i>oxaliplatin</i> | 44 |
| <i>cryst</i> | 6 | OCREVUS..... | 63 | <i>oxaprozin</i> | 50 |
| <i>nitroglycerin</i> | 20 | OCTAGAM..... | 36 | <i>oxcarbazepine</i> | 54 |
| <i>nizatidine</i> | 33 | <i>octreotide acetate</i> | 44 | <i>oxybutynin chloride</i> | 66 |
| <i>nora-be</i> | 74 | ODEFSEY..... | 8 | <i>oxycodone</i> | 51 |
| <i>norethindrone (contraceptive)</i> | 74 | ODOMZO..... | 44 | <i>oxycodone-acetaminophen</i> | 51 |
| <i>norethindrone acetate</i> | 74 | OFEV..... | 28 | OZEMPIC..... | 83 |
| <i>norethindrone ac-eth estradiol</i> | | <i>ofloxacin</i> | 65, 75 | <i>pacerone</i> | 18 |
| | 72, 74 | OJJAARA..... | 44 | <i>paclitaxel</i> | 44 |
| <i>norethindrone-e.estradiol-iron</i> ... | 72 | <i>olanzapine</i> | 60 | PACLITAXEL PROTEIN-BOUND.... | 44 |
| <i>norgestimate-ethinyl estradiol</i> ... | 72 | <i>olmesartan</i> | 23 | <i>paliperidone</i> | 60 |
| NORITATE..... | 90 | <i>olmesartan-amlodipin-hcthiazyd</i> . | 23 | <i>pamidronate</i> | 80 |
| <i>norlyda</i> | 74 | <i>olmesartan-hydrochlorothiazide</i> | 23 | PANRETIN..... | 89 |
| NORPACE CR..... | 18 | <i>olopatadine</i> | 65, 77 | <i>pantoprazole</i> | 33 |
| <i>nortrel 0.5/35 (28)</i> | 72 | <i>omeprazole</i> | 33 | PANZYGA..... | 36 |
| <i>nortrel 1/35 (21)</i> | 72 | OMNIPOD 5 G6 INTRO KIT (GEN | | <i>paraplatin</i> | 44 |
| <i>nortrel 1/35 (28)</i> | 72 | 5)..... | 85 | <i>paricalcitol</i> | 80 |
| <i>nortrel 7/7/7 (28)</i> | 72 | OMNIPOD 5 G6 PODS (GEN 5).... | 85 | <i>paromomycin</i> | 14 |

| | | | | | |
|--|--------|---|--------|--|----|
| <i>paroxetine hcl</i> | 60, 61 | PIRFENIDONE..... | 28 | <i>probenecid</i> | 69 |
| PAXLOVID..... | 9 | <i>pirmella</i> | 72 | <i>probenecid-colchicine</i> | 69 |
| <i>pazopanib</i> | 44 | <i>piroxicam</i> | 50 | <i>prochlorperazine</i> | 32 |
| PEDIARIX (PF)..... | 36 | PLASMA-LYTE A..... | 92 | <i>prochlorperazine edisylate</i> | 32 |
| PEDVAX HIB (PF)..... | 36 | PLENAMINE..... | 92 | <i>prochlorperazine maleate</i> | 32 |
| <i>peg 3350-electrolytes</i> | 31 | PLENVU..... | 32 | PROCRIT..... | 34 |
| PEGASYS..... | 34 | <i>podofilox</i> | 89 | <i>procto-med hc</i> | 32 |
| <i>peg-electrolyte soln</i> | 31 | <i>polymyxin b sulf-trimethoprim</i> ... 75 | | <i>proctosol hc</i> | 32 |
| PEMAZYRE..... | 44 | POMALYST..... | 45 | <i>proctozone-hc</i> | 32 |
| <i>pemetrexed disodium</i> | 44 | <i>portia 28</i> | 72 | <i>progesterone</i> | 74 |
| PEMETREXED DISODIUM..... | 45 | <i>posaconazole</i> | 6 | <i>progesterone micronized</i> | 74 |
| PEN NEEDLE, DIABETIC..... | 85 | <i>potassium chlorid-d5-0.45%nacl</i> 90 | | PROGRAF..... | 45 |
| PENBRAYA (PF)..... | 36 | <i>potassium chloride</i> | 91 | PROLASTIN-C..... | 4 |
| <i>penicillamine</i> | 68 | <i>potassium chloride in 0.9%nacl</i> .. 90 | | PROLENSA..... | 75 |
| PENICILLIN G POT IN DEXTROSE. 16 | | <i>potassium chloride in 5 % dex</i>90 | | PROLIA..... | 69 |
| <i>penicillin g potassium</i> | 16 | <i>potassium chloride in water</i> | 90 | PROMACTA..... | 25 |
| <i>penicillin g procaine</i> | 16 | <i>potassium chloride-0.45 % nacl</i> .. 91 | | <i>promethazine</i> | 26 |
| <i>penicillin g sodium</i> | 16 | <i>potassium chloride-d5-0.2%nacl</i> .91 | | <i>propafenone</i> | 18 |
| <i>penicillin v potassium</i> | 16 | <i>potassium chloride-d5-0.9%nacl</i> .91 | | <i>propranolol</i> | 23 |
| PENTACEL (PF)..... | 36 | <i>potassium citrate</i> | 66 | <i>propylthiouracil</i> | 78 |
| <i>pentamidine</i> | 14 | PRADAXA..... | 25 | PROQUAD (PF)..... | 37 |
| <i>pentoxifylline</i> | 25 | PRALUENT PEN..... | 19 | PROSOL 20 %..... | 92 |
| <i>perindopril erbumine</i> | 23 | <i>pramipexole</i> | 48 | <i>protriptyline</i> | 61 |
| <i>periogard</i> | 65 | <i>prasugrel</i> | 25 | PULMICORT FLEXHALER..... | 29 |
| <i>permethrin</i> | 87 | <i>pravastatin</i> | 19 | PULMOZYME..... | 29 |
| <i>perphenazine</i> | 61 | <i>praziquantel</i> | 14 | PURIXAN..... | 45 |
| PERSERIS..... | 61 | <i>prazosin</i> | 23 | <i>pyrazinamide</i> | 14 |
| <i>pfizerpen-g</i> | 16 | <i>prednisolone</i> | 79 | <i>pyridostigmine bromide</i> | 64 |
| <i>phenelzine</i> | 61 | <i>prednisolone acetate</i> | 76 | QINLOCK..... | 45 |
| <i>phenobarbital</i> | 54 | <i>prednisolone sodium phosphate</i> | 76, 79 | QUADRACEL (PF)..... | 37 |
| <i>phenobarbital sodium</i> | 54 | <i>prednisone</i> | 79 | <i>quetiapine</i> | 61 |
| PHENYTEK..... | 54 | <i>prednisone intensol</i> | 79 | QUETIAPINE..... | 61 |
| <i>phenytoin</i> | 54 | <i>pregabalin</i> | 54 | <i>quinapril</i> | 23 |
| <i>phenytoin sodium</i> | 54 | PREHEVBRIO (PF)..... | 36 | <i>quinapril-hydrochlorothiazide</i> 23 | |
| <i>phenytoin sodium extended</i> | 54 | PREMARIN..... | 74 | <i>quinidine sulfate</i> | 18 |
| <i>philith</i> | 72 | <i>premasol 10 %</i> | 92 | <i>quinine sulfate</i> | 14 |
| PIFELTRO..... | 9 | <i>prenatal vitamin plus low iron</i> ... 92 | | RABAVERT (PF)..... | 37 |
| <i>pilocarpine hcl</i> | 4, 77 | <i>prevalite</i> | 19 | <i>rabeprazole</i> | 34 |
| <i>pimozide</i> | 61 | PREVYMIS..... | 9 | RADICAVA ORS..... | 63 |
| <i>pimtreea (28)</i> | 72 | PREZCOBIX..... | 9 | RADICAVA ORS STARTER KIT SUSP..... | 63 |
| <i>pindolol</i> | 23 | PREZISTA..... | 9 | <i>raloxifene</i> | 69 |
| <i>pioglitazone</i> | 83 | PRIFTIN..... | 14 | <i>ramipril</i> | 23 |
| <i>pioglitazone-glimepiride</i> | 83 | PRIMAQUINE..... | 14 | <i>ranolazine</i> | 18 |
| <i>pioglitazone-metformin</i> | 83 | PRIMIDONE..... | 54 | <i>rasagiline</i> | 48 |
| PIPERACILLIN-TAZOBACTAM..... 16 | | <i>primidone</i> | 54 | RAYALDEE..... | 80 |
| <i>piperacillin-tazobactam</i> | 16 | PRIORIX (PF)..... | 37 | <i>reclipsen (28)</i> | 72 |
| PIQRAY..... | 45 | PRIVIGEN..... | 37 | RECOMBIVAX HB (PF)..... | 37 |
| <i>pirfenidone</i> | 28 | | | | |

| | | | | | |
|------------------------------------|--------|--|--------|--|--------|
| RECTIV..... | 32 | <i>selegiline hcl</i> | 48 | STIVARGA..... | 45 |
| REGRANEX..... | 89 | <i>selenium sulfide</i> | 87 | STREPTOMYCIN..... | 14 |
| RELENZA DISKHALER..... | 9 | SELZENTRY..... | 9 | STRIBILD..... | 9 |
| RELISTOR..... | 32 | SEREVENT DISKUS..... | 29 | SUCRAID..... | 32 |
| REMICADE..... | 32 | <i>sertraline</i> | 61 | <i>sucralfate</i> | 34 |
| <i>repaglinide</i> | 83, 84 | <i>setlakin</i> | 72 | <i>sulfacetamide sodium</i> | 77 |
| RESTASIS..... | 77 | <i>sevelamer carbonate</i> | 4 | <i>sulfacetamide sodium (acne)</i> | 85 |
| RESTASIS MULTIDOSE..... | 77 | <i>sharobel</i> | 74 | <i>sulfacetamide-prednisolone</i> | 77 |
| RETEVMO..... | 45 | SHINGRIX (PF)..... | 37 | <i>sulfadiazine</i> | 6 |
| REXULTI..... | 61 | SIGNIFOR..... | 45 | <i>sulfamethoxazole-trimethoprim</i> ...6 | |
| REYATAZ..... | 9 | <i>sildenafil</i> | 66 | SULFAMYLON..... | 85 |
| REZLIDHIA..... | 45 | <i>sildenafil (pulm.hypertension)</i> | 29 | <i>sulfasalazine</i> | 32 |
| REZUROCK..... | 45 | <i>sildenafil</i> | 67 | <i>sulindac</i> | 50 |
| RHOPRESSA..... | 77 | <i>silver sulfadiazine</i> | 89 | <i>sumatriptan</i> | 64 |
| <i>ribavirin</i> | 9 | SIMBRINZA..... | 77 | <i>sumatriptan succinate</i> | 65 |
| <i>rifabutin</i> | 14 | <i>simvastatin</i> | 19 | <i>sunitinib malate</i> | 45 |
| <i>rifampin</i> | 14 | <i>sirolimus</i> | 45 | SUNLENCA..... | 9 |
| <i>riluzole</i> | 4 | SIRTURO..... | 14 | SUPREP BOWEL PREP KIT..... | 32 |
| <i>rimantadine</i> | 9 | SKYRIZI..... | 32, 88 | <i>syeda</i> | 72 |
| RINVOQ..... | 68 | <i>sodium chloride</i> | 4, 91 | SYMDEKO..... | 29 |
| <i>risedronate</i> | 4, 69 | <i>sodium chloride 0.45 %</i> | 91 | SYMPAZAN..... | 55 |
| RISPERDAL CONSTA..... | 61 | <i>sodium chloride 0.9 %</i> | 4 | SYMTUZA..... | 9 |
| <i>risperidone</i> | 61 | <i>sodium chloride 3 % hypertonic</i> .. | 91 | SYNERCID..... | 14 |
| <i>ritonavir</i> | 9 | <i>sodium chloride 5 % hypertonic</i> .. | 91 | SYNJARDY..... | 84 |
| <i>rivastigmine</i> | 63 | SODIUM OXYBATE..... | 61 | SYNJARDY XR..... | 84 |
| <i>rivastigmine tartrate</i> | 63 | <i>sodium phenylbutyrate</i> | 4 | SYNTHROID..... | 78 |
| <i>rizatriptan</i> | 64 | <i>sodium polystyrene sulfonate</i> | 4 | TABLOID..... | 45 |
| ROCKLATAN..... | 77 | <i>sodium,potassium,mag sulfates</i> .. | 32 | TABRECTA..... | 46 |
| <i>roflumilast</i> | 29 | <i>solifenacin</i> | 66 | <i>tacrolimus</i> | 46, 89 |
| <i>ropinirole</i> | 48 | SOLQUA 100/33..... | 84 | <i>tadalafil (pulm. hypertension)</i> | 29 |
| <i>rosuvastatin</i> | 19 | SOLTAMOX..... | 45 | TADLIQ..... | 29 |
| ROTARIX..... | 37 | SOLU-CORTEF ACT-O-VIAL (PF).... | 79 | TAFINLAR..... | 46 |
| ROTATEQ VACCINE..... | 37 | SOMATULINE DEPOT..... | 45 | TAGRISSO..... | 46 |
| <i>roweepira</i> | 54 | SOMAVERT..... | 80 | TALTZ AUTOINJECTOR..... | 88 |
| ROZLYTREK..... | 45 | <i>sorafenib</i> | 45 | TALTZ AUTOINJECTOR (2 PACK) .. | 88 |
| RUBRACA..... | 45 | <i>sorine</i> | 18 | TALTZ AUTOINJECTOR (3 PACK) .. | 88 |
| <i>rufinamide</i> | 54 | <i>sotalol</i> | 18 | TALTZ SYRINGE..... | 88 |
| RUKOBIA..... | 9 | <i>sotalol af</i> | 18 | TALVEY..... | 46 |
| RYBELSUS..... | 84 | <i>spironolactone</i> | 23 | TALZENNA..... | 46 |
| RYDAPT..... | 45 | <i>spironolacton-hydrochlorothiaz</i> .. | 23 | <i>tamoxifen</i> | 46 |
| <i>sajazir</i> | 29 | <i>sprintec (28)</i> | 72 | <i>tamsulosin</i> | 67 |
| SANDIMMUNE..... | 45 | SPRITAM..... | 54, 55 | <i>tarina fe 1-20 eq (28)</i> | 72 |
| SANTYL..... | 89 | SPRYCEL..... | 45 | TASIGNA..... | 46 |
| <i>sapropterin</i> | 80 | <i>sps (with sorbitol)</i> | 4, 5 | <i>tazarotene</i> | 90 |
| SAVELLA..... | 68 | <i>sronyx</i> | 72 | <i>tazicef</i> | 11, 12 |
| SCSEMBLIX..... | 45 | <i>ssd</i> | 89 | TAZORAC..... | 90 |
| <i>scopolamine base</i> | 32 | STAMARIL (PF)..... | 37 | <i>taztia xt</i> | 23 |
| SECUADO..... | 61 | STELARA..... | 88 | TAZVERIK..... | 46 |

| | | | | | |
|--|--------|--|--------|---|--------|
| TDVAX..... | 37 | <i>topiramate</i> | 55 | TRIZIVIR..... | 9 |
| TECENTRIQ..... | 46 | <i>toremifene</i> | 46 | TROGARZO..... | 10 |
| TECFIDERA..... | 64 | <i>torseamide</i> | 24 | TROPHAMINE 10 %..... | 92 |
| TEFLARO..... | 12 | TOUJEO MAX U-300 SOLOSTAR.. | 84 | <i>tropium</i> | 66 |
| <i>telmisartan</i> | 23 | TOUJEO SOLOSTAR U-300 | | TRULICITY..... | 84 |
| <i>telmisartan-amlodipine</i> | 23 | INSULIN..... | 84 | TRUMENBA..... | 37 |
| <i>telmisartan-hydrochlorothiazid</i> .. | 23 | TPN ELECTROLYTES..... | 91 | TRUQAP..... | 46 |
| <i>temazepam</i> | 61 | TRADJENTA..... | 84 | TRUXIMA..... | 46 |
| TENIVAC (PF)..... | 37 | <i>tramadol</i> | 50 | TUKYSA..... | 46 |
| <i>tenofovir disoproxil fumarate</i> | 9 | <i>tramadol-acetaminophen</i> | 50 | TURALIO..... | 46 |
| TEPMETKO..... | 46 | <i>trandolapril</i> | 24 | <i>turqoz (28)</i> | 72 |
| <i>terazosin</i> | 24 | <i>tranexamic acid</i> | 74 | TWINRIX (PF)..... | 37 |
| <i>terbinafine hcl</i> | 6 | <i>tranylcypromine</i> | 62 | TYBOST..... | 10 |
| <i>terbutaline</i> | 29 | <i>travasol 10 %</i> | 92 | TYMLOS..... | 69 |
| <i>terconazole</i> | 74 | <i>travoprost</i> | 77 | TYPHIM VI..... | 38 |
| <i>teriflunomide</i> | 64 | TRAZIMERA..... | 46 | TYRVAYA..... | 77 |
| TERIPARATIDE..... | 69 | <i>trazodone</i> | 62 | <i>unithroid</i> | 78 |
| <i>testosterone</i> | 80, 81 | TRECTOR..... | 14 | <i>ursodiol</i> | 32 |
| <i>testosterone cypionate</i> | 80 | TRELEGY ELLIPTA..... | 29 | <i>valacyclovir</i> | 10 |
| <i>testosterone enanthate</i> | 80 | <i>treprostinil sodium</i> | 24 | VALCHLOR..... | 89 |
| TETANUS,DIPHThERIA TOX | | TRESIBA FLEXTOUCH U-100..... | 84 | <i>valganciclovir</i> | 10 |
| PED(PF)..... | 37 | TRESIBA FLEXTOUCH U-200..... | 84 | <i>valproate sodium</i> | 55 |
| <i>tetrabenazine</i> | 64 | TRESIBA U-100 INSULIN..... | 84 | <i>valproic acid</i> | 55 |
| <i>tetracycline</i> | 17 | <i>tretinoin</i> | 90 | <i>valproic acid (as sodium salt)</i> | 55 |
| THALOMID..... | 46 | <i>tretinoin (antineoplastic)</i> | 46 | <i>valsartan</i> | 24 |
| THEO-24..... | 29 | TREXALL..... | 46 | <i>valsartan-hydrochlorothiazide</i> | 24 |
| <i>theophylline</i> | 29 | <i>triamcinolone acetonide</i> | 65, 87 | VALTOCO..... | 55 |
| <i>thioridazine</i> | 61 | <i>triamterene-hydrochlorothiazid</i> .. | 24 | <i>vancomycin</i> | 14, 15 |
| <i>thiothixene</i> | 61 | <i>trientine</i> | 5 | VANCOMYCIN..... | 15 |
| <i>tiadylt er</i> | 24 | <i>tri-estarylla</i> | 72 | VANCOMYCIN IN 0.9 % SODIUM | |
| <i>tiagabine</i> | 55 | <i>trifluoperazine</i> | 62 | CHL..... | 15 |
| TIBSOVO..... | 46 | <i>trifluridine</i> | 75 | VANFLYTA..... | 46 |
| TICOVAC..... | 37 | <i>trihexyphenidyl</i> | 48 | VAQTA (PF)..... | 38 |
| <i>tigecycline</i> | 14 | TRIJARDY XR..... | 84 | <i>vardefafil</i> | 66 |
| <i>tilia fe</i> | 72 | TRIKAFTA..... | 29 | <i>varenicline</i> | 5 |
| <i>timolol maleate</i> | 24, 76 | <i>tri-legest fe</i> | 72 | VARIVAX (PF)..... | 38 |
| <i>tinidazole</i> | 14 | <i>tri-linyah</i> | 72 | VASCEPA..... | 19 |
| TIVICAY..... | 9 | <i>tri-lo-estarylla</i> | 72 | <i>velivet triphasic regimen (28)</i> | 73 |
| TIVICAY PD..... | 9 | <i>tri-lo-marzia</i> | 72 | VELPHORO..... | 5 |
| <i>tizanidine</i> | 64 | <i>tri-lo-mili</i> | 72 | VELTASSA..... | 5 |
| TOBRADEX..... | 76 | <i>tri-lo-sprintec</i> | 72 | VEMLIDY..... | 10 |
| TOBRADEX ST..... | 76 | <i>trimethoprim</i> | 6 | VENCLEXTA..... | 46 |
| <i>tobramycin</i> | 75 | <i>trimipramine</i> | 62 | VENCLEXTA STARTING PACK..... | 46 |
| <i>tobramycin in 0.225 % nacl</i> | 14 | TRINTELLIX..... | 62 | <i>venlafaxine</i> | 62 |
| <i>tobramycin sulfate</i> | 14 | <i>tri-sprintec (28)</i> | 72 | VENTAVIS..... | 29 |
| <i>tobramycin-dexamethasone</i> | 76 | TRIUMEQ..... | 9 | VENTOLIN HFA..... | 29 |
| <i>tolterodine</i> | 66 | TRIUMEQ PD..... | 9 | <i>verapamil</i> | 24 |
| <i>tolvaptan</i> | 81 | <i>trivora (28)</i> | 72 | VERQUVO..... | 18 |

| | | | |
|--|--------|--|-------|
| VERSACLOZ..... | 62 | XOSPATA..... | 47 |
| VERZENIO..... | 47 | XPOVIO..... | 47 |
| <i>vestura (28)</i> | 73 | XTANDI..... | 47 |
| V-GO 30..... | 85 | <i>xulane</i> | 74 |
| V-GO 40..... | 85 | XULTOPHY 100/3.6..... | 84 |
| <i>vienva</i> | 73 | YF-VAX (PF)..... | 38 |
| <i>vigabatrin</i> | 55 | <i>yuvafem</i> | 74 |
| <i>vigadrone</i> | 55 | <i>zafemy</i> | 74 |
| <i>vigpoder</i> | 55 | <i>zafirlukast</i> | 30 |
| <i>vilazodone</i> | 62 | ZARXIO..... | 34 |
| <i>vincristine</i> | 47 | ZEJULA..... | 47 |
| <i>vinorelbine</i> | 47 | ZELBORAF..... | 47 |
| <i>viorele (28)</i> | 73 | ZEMAIRA..... | 5 |
| VIRACEPT..... | 10 | <i>zenatane</i> | 90 |
| VIREAD..... | 10 | ZENPEP..... | 32 |
| VITRAKVI..... | 47 | ZERVIATE..... | 78 |
| VIVITROL..... | 50 | <i>zidovudine</i> | 10 |
| VIZIMPRO..... | 47 | ZIEXTENZO..... | 34 |
| VONJO..... | 47 | <i>ziprasidone hcl</i> | 62 |
| <i>voriconazole</i> | 6 | <i>ziprasidone mesylate</i> | 62 |
| VOSEVI..... | 10 | ZIRABEV..... | 47 |
| VOTRIENT..... | 47 | ZIRGAN..... | 76 |
| VRAYLAR..... | 62 | <i>zoledronic acid</i> | 81 |
| VUMERITY..... | 64 | <i>zoledronic acid-mannitol-water</i> | 5, 81 |
| VYNDAQEL..... | 18 | ZOLINZA..... | 47 |
| VYVANSE..... | 62 | <i>zolmitriptan</i> | 65 |
| VYZULTA..... | 77 | <i>zolpidem</i> | 62 |
| <i>warfarin</i> | 25 | ZONISADE..... | 55 |
| <i>water for irrigation, sterile</i> | 5 | <i>zonisamide</i> | 55 |
| WELIREG..... | 47 | <i>zovia 1-35 (28)</i> | 73 |
| <i>wera (28)</i> | 73 | ZTALMY..... | 55 |
| XALKORI..... | 47 | <i>zumandimine (28)</i> | 73 |
| XARELTO..... | 25, 26 | ZURZUVAE..... | 62 |
| XARELTO DVT-PE TREAT 30D START..... | 25 | ZYCLARA..... | 89 |
| XATMEP..... | 47 | ZYDELIG..... | 47 |
| XCOPRI..... | 55 | ZYKADIA..... | 48 |
| XCOPRI MAINTENANCE PACK..... | 55 | ZYLET..... | 76 |
| XCOPRI TITRATION PACK..... | 55 | ZYPITAMAG..... | 19 |
| XDEMVY..... | 77 | ZYPREXA RELPREVV..... | 62 |
| XELJANZ..... | 68 | | |
| XELJANZ XR..... | 68 | | |
| XERMELO..... | 47 | | |
| XGEVA..... | 38 | | |
| XHANCE..... | 29 | | |
| XIFAXAN..... | 15 | | |
| XIGDUO XR..... | 84 | | |
| XOLAIR..... | 30 | | |

Multi-Language Insert
Multi-language Interpreter Services

Form Approved
OMB# 0938-1421

English: We have free interpreter services to answer any questions you may have about our health or drug plan. To get an interpreter, just call us at the plan numbers on the following pages. Someone who speaks English/Language can help you. This is a free service.

Spanish: Contamos con los servicios gratuitos de un intérprete para responder las preguntas que tenga sobre nuestro plan de salud o de medicamentos. Para solicitar un intérprete, simplemente llámenos a los números del plan que figuran en las siguientes páginas. Alguien que habla español puede ayudarle. Este es un servicio gratuito.

Chinese Mandarin: 我们提供免费的口译服务，可解答您对我们的健康或药物计划的有关疑问。如需译员，请拨打以下页面上的计划号码联系我们。您将获得讲汉语普通话的译员的帮助。这是一项免费服务。

Chinese Cantonese: 我們提供免費的口譯服務，可解答您對我們的健康或藥物計劃可能有的任何疑問。如需口譯員服務，請致電下頁的計劃電話號碼。會說廣東話的人員可以幫助您。此為免費服務。

Tagalog: May mga libre kaming serbisyo ng interpreter para sagutin ang anumang posible ninyong tanong tungkol sa aming planong pangkalusugan o plano sa gamot. Para kumuha ng interpreter, tawagan lang kami sa mga numero ng plano na nasa mga sumusunod na pahina. May makakatulong sa inyo na nagsasalita ng Tagalog. Isa itong libreng serbisyo.

French: Nous proposons des services d'interprètes gratuits pour répondre à toutes vos questions sur notre régime de santé ou de médicaments. Pour obtenir les services d'un interprète, il suffit de nous appeler aux numéros figurant sur les pages suivantes. Quelqu'un parlant français pourra vous aider. Ce service est gratuit.

Vietnamese: Chúng tôi có dịch vụ thông dịch miễn phí để trả lời bất kỳ câu hỏi nào về chương trình sức khỏe hoặc chương trình thuốc của chúng tôi. Để nhận thông dịch viên, chỉ cần gọi chúng tôi theo số điện thoại chương trình ở các trang sau. Một nhân viên nói tiếng Việt có thể giúp quý vị. Dịch vụ này được miễn phí.

German: Wir bieten Ihnen einen kostenlosen Dolmetschservice, wenn Sie Fragen zu unseren Gesundheits- oder Medikamentenplänen haben. Wenn Sie einen Dolmetscher brauchen, rufen Sie eine der Telefonnummern auf den folgenden Seiten an. Ein deutschsprachiger Mitarbeiter wird Ihnen behilflich sein. Dieser Service ist kostenlos.

Korean: 당사의 건강 또는 의약품 플랜과 관련해서 물어볼 수 있는 모든 질문에 답변하기 위한 무료 통역 서비스가 있습니다. 통역사가 필요한 경우 다음 페이지에 있는 플랜 번호로 연락해 주십시오. 한국어를 구사하는 통역사가 도움을 드릴 수 있습니다. 통역 서비스는 무료로 제공됩니다.

Russian: Если у вас возникли какие-либо вопросы о нашем плане медицинского страхования или плане с покрытием лекарственных препаратов, вам доступны бесплатные услуги переводчика. Если вам нужен переводчик, просто позвоните нам по номерам, представленным на следующих страницах. Вам окажет помощь сотрудник, говорящий на русском языке. Данная услуга бесплатна.

Arabic: نوّقر خدمات ترجمة فورية مجانية للإجابة على أي أسئلة قد تكون لديك حول خطة الصحة أو الدواء الخاصة بنا. للحصول على مترجم فوري، ما عليك سوى الاتصال بنا على أرقام الخطة التي تظهر في الصفحات التالية. يمكن أن يساعدك شخص يتحدث العربية. وتتوفر هذه الخدمة بشكل مجاني.

Hindi: हमारे स्वास्थ्य या ड्रग प्लान के बारे में आपके किसी भी सवाल का जवाब देने के लिए, हम मुफ्त में दुभाषिया सेवाएं देते हैं। दुभाषिया सेवा पाने के लिए, बस हमें अगले पेज पर दिए गए प्लान नंबर पर कॉल करें। हिन्दी में बात करने वाला सहायक आपकी मदद करेगा। यह एक निःशुल्क सेवा है।

Italian: Sono disponibili servizi di interpretariato gratuiti per rispondere a qualsiasi domanda possa avere in merito al nostro piano farmacologico o sanitario. Per usufruire di un interprete, è sufficiente contattare i numeri del piano riportati nelle pagine seguenti. Qualcuno la assisterà in lingua italiana. È un servizio gratuito.

Portuguese: Temos serviços de intérprete gratuitos para responder a quaisquer dúvidas que possa ter sobre o nosso plano de saúde ou medicação. Para obter um intérprete, contacte-nos através dos números do plano nas páginas seguintes. Um falante de português poderá ajudá-lo. Este serviço é gratuito.

French Creole: Nou gen sèvis entèprèt gratis pou reponn nenpòt kesyon ou ka genyen sou plan sante oswa plan medikaman nou an. Pou jwenn yon tradiktè nan bouch, annik rele nimewo yo pou plan an ki make sou paj ki annapre yo. Yon moun ki pale Kreyòl Ayisyen ka ede w. Se yon sèvis gratis.

Polish: Oferujemy bezpłatną usługę tłumaczenia ustnego, która pomoże Państwu uzyskać odpowiedzi na ewentualne pytania dotyczące naszego planu leczenia lub planu refundacji leków. Aby skorzystać z usługi tłumaczenia ustnego, wystarczy zadzwonić pod podany na kolejnych stronach numer odnoszący się do planu. Zapewni to Państwu pomoc osoby mówiącej po polsku. Usługa ta jest bezpłatna.

Japanese: 弊社の健康や薬剤計画についてご質問がある場合は、無料の通訳サービスをご利用いただけます。通訳を利用するには、次からのページに記載されている弊社の計画担当の電話番号にお問い合わせください。日本語の通訳担当者が対応します。これは無料のサービスです。

NEVADA

HMO

1-800-977-7522 (TTY: 711)

[wellcare.com/allwellNV](https://www.wellcare.com/allwellNV)

TEXAS

HMO

1-833-444-9088 (TTY: 711)

[wellcare.com/medicare](https://www.wellcare.com/medicare)



Esta lista de medicamentos se actualizó el 06/01/2024.

Para obtener información más reciente o realizar otras preguntas, comuníquese con Servicios para Miembros de Wellcare al número de teléfono o mediante el sitio web de su plan que aparecen en la portada y la contraportada de este formulario. Entre el 1 de octubre y el 31 de marzo, los representantes están disponibles los siete días de la semana, de 8 a.m. a 8 p.m. Entre el 1 de abril y el 30 de septiembre, los representantes están disponibles de lunes a viernes, de 8 a.m. a 8 p.m.

06/01/2024

Medicare_{Rx}
Prescription Drug Coverage